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Summary 
Acute myeloid leukaemia (AML) is an aggressive haematological cancer that remains an unmet medical 
need, with over 70% of patients still succumbing to this disease. Despite this, a deeper understanding of 
AML biology has allowed for the identification of novel agents with efficacy against specific molecular 
subtypes. Recently, a better understanding of aberrant epigenetic control in AML has led to the 
development of promising small molecule inhibitors of epigenetic regulators. The work described in this 
thesis details the results of genetic and pharmacological experiments designed to perturb the histone 
methyltransferase EZH2, a critical regulator of gene silencing during development and cell fate decisions 
and a potential therapeutic target, in the context of AML. The core aims were to assess its role during 
the development and subsequent maintenance of AML both in vitro and in vivo using mouse models, 
and to subsequently determine mechanisms by which its activity may facilitate leukaemia and how 
inhibition may abrogate leukaemic growth.  
 
Through utilising a conditional Ezh2 knock-out murine model together with bone marrow retroviral 
transduction and transplantation assays, Ezh2 was shown to have markedly differing roles during the 
induction and maintenance of three well-characterised subtypes of AML (MLL-AF9, AML1-ETO9a, MOZ-
TIF2) both in vitro and in vivo, serving to highlight its complex nature. Whilst there were no significant 
effects in vitro, prior Ezh2 loss led to a significant acceleration in the induction of MLL-AF9 and AML1-
ETO9a leukaemias in vivo, whilst significantly decelerating induction of MOZ-TIF2 leukaemias in vivo. This 
finding of a single gene demonstrating both tumour-suppressive and oncogenic roles, clearly dependent 
upon subtype of AML during the same induction phase of disease was particularly surprising.  
 
Contrary to the induction experiments, Ezh2 loss in vitro completely abolished the growth of MLL-AF9, 
AML1-ETO9a and MOZ-TIF2 transformed murine cell lines, strongly suggesting that it was an oncogenic 
facilitator of the transformed state. When examined in vivo, Ezh2 loss caused a significant prolongation 
in the latency of disease development of MLL-AF9 and AML1-ETO9a, suggesting that it was required for 
the maintenance of both as per the in vitro assays. Though a similar trend was established for secondary 
MOZ-TIF2 leukaemias in vivo, this was not statistically significant.  
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Thus, completely contrasting, stage-specific requirements of Ezh2 during the evolution of AML were 
demonstrated.  The diametrically opposite effects of Ezh2 loss between the induction and maintenance 
phases of MLL-AF9 and AML1-ETO9a leukaemias in vivo, was a novel finding, suggesting that this gene 
was unexpectedly capable of fulfilling both tumour-suppressive and oncogenic roles within the same 
subtypes of AML, but at different phases of disease. Whilst the maintenance experiments provided 
evidence for targeting EZH2 therapeutically, the acceleration seen upon Ezh2 loss during AML induction 
raised caution over EZH2 inhibition. This prompted a detailed mechanistic analysis to reconcile these 
disparate effects. 
 
Utilising RNA-sequencing, further genomic characterisation of differential gene expression changes 
following Ezh2 loss in murine HSPCs was made. This demonstrated a significant upregulation of genes - 
consistent with its role as a transcriptional repressor. A number of these upregulated genes were known 
oncogenes that were potentially facilitating leukaemia induction. When compared to differential gene 
expression datasets generated from RNA-sequencing of the Ezh2+/+ and Ezh2-/- MLL-AF9 and AML1-
ETO9a leukaemias that had shown a clear acceleration in the induction experiments, the overlaps 
identified Lin28b (a negative regulator of the let-7 microRNA tumour suppressor family and itself 
implicated as an oncogene in a number of other cancer models) and Plag1 (a zinc-finger transcription 
factor also exhibiting oncogenic function in other leukaemia models and cancers) as being significantly 
upregulated. These were common to the Ezh2-null non-transformed, MLL-AF9 and/or AML1-ETO9a 
states, implying they may be functioning as downstream mediators of Ezh2 loss and co-operating with 
these AML oncogenes in accelerating leukaemogenesis.  
 
A more detailed characterisation of the epigenetic changes following Ezh2 loss in the non-transformed 
state was then conducted in order to provide a mechanism at the chromatin level for the de-repression 
of genes seen during induction. ChIP-sequencing of the repressive histone mark, H3K27me3, in the non-
transformed state following Ezh2 loss identified that a significant number of peaks were downregulated 
across the genome.  When compared to the above dataset, it was apparent that a clear subset of the 
genes upregulated following Ezh2 loss (approximately 20%) were associated with a significant 
downregulation of H3K27me3, particularly at their promoter regions. Interestingly, whilst there were no 
significant changes in the activating H3K27Ac mark (typically associated with enhancers) near these 
genes, the majority were also populated with the activating H3K4me3 mark at their promoters, 
suggesting bivalency.  This suggested loss of Ezh2 resulted in the resolution of these two conflicting 
histone marks, in favour of the activating H3K4me3 mark, thus explaining their increase in expression at 
the transcript level. Strikingly, following Ezh2 loss, a few select candidate genes also demonstrated a 
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clear increase in H3K4me3 at their promoters – this included Lin28b and Plag1. Whilst directing further 
scrutiny of these two candidate genes, this detailed characterisation also revealed that loss of Ezh2 was 
interfering with H3K4me3 at highly specific genes, either directly or indirectly through changes in 
H3K27me3, suggesting a significant and active “cross-talk” between H3K27me3 and H3K4me3 in gene 
regulation.  
 
Whilst overexpression of Lin28b in MLL-AF9 driven murine primary leukaemias in vivo showed a trend 
towards acceleration of this aggressive disease, overexpression of Plag1 led to a clear and significant 
acceleration of MLL-AF9 driven primary leukaemias in vivo, functionally validating the genomic data and 
the hypothesis that this candidate gene was cooperating with MLL-AF9 following Ezh2 loss. The 
synergism between Ezh2 loss and MLL-AF9 is likely to be mediated by the concerted action of several 
genes and this data indicates that Plag1 is clearly one of these downstream targets.  
 
To explain the opposing effects of Ezh2 loss between induction and maintenance of MLL-AF9 leukaemias, 
differential gene expression changes were assessed in spleen tumours from wild-type MLL-AF9 primary 
murine leukaemias cultured in vitro, following treatment with either vehicle control or GSK343 (an EZH2 
inhibitor). These cultured tumours showed marked sensitivity to GSK343 in vitro, and following RNA-
sequencing, demonstrated an almost entirely different gene set was being de-repressed following Ezh2 
inhibition of these established leukaemias to that during induction, potentially reconciling the opposite 
effects seen between induction and maintenance following Ezh2 loss. This provided a rationale for 
subsequent experiments designed to assess the preclinical in vitro efficacy of GSK343 in AML.  
 
Lastly, functional in vitro experiments demonstrated clear sensitivity of the Kasumi and KG1 AML cell 
lines, immortalised MLL-AF9 and MOZ-TIF2 murine HSPCs, wild-type MLL-AF9 primary leukaemia spleen 
tumours and importantly, human primary AML samples to GSK343. There was no evidence that 
Ezh2/EZH2 inhibition across these cell types accelerated their proliferative or clonogenic growth. This 
correlated directly with the maintenance in vitro and in vivo experiments where Ezh2 was demonstrated 
to have an oncogenic role, thus providing clear evidence that EZH2 inhibition may be a viable therapeutic 
strategy in AML.  
 
In summary, the work presented herein provides data demonstrating the contrasting, stage-specific 
roles of EZH2 during AML evolution, as well as mechanistic and functional data to potentially explain and 
reconcile these differences, and finally, preclinical data affording confidence that the therapeutic 
targeting of EZH2 in this aggressive haematological cancer is a viable opportunity.  
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Chapter 1 
Introduction 
 
1.1 Acute Myeloid Leukaemia: incidence, aetiology and clinical features 
Acute myeloid leukaemia (AML) is an aggressive cancer infiltrating bone marrow, blood and other 
tissues with a characteristically clonal, abnormally differentiated proliferation of early myeloid cells 
that gain a survival advantage. These rapidly subsume normal bone marrow function through impaired 
haematopoiesis leading to profound bone marrow failure. The majority of patients present with 
combined leucocytosis and anaemia or thrombocytopenia, with fatigue, weight loss and anorexia 
being common symptoms. If untreated, death usually results within months of diagnosis due to 
bleeding or severe infections.  
AML is the most common leukaemia in adults, accounting for a quarter of all leukaemias in adults, with 
an incidence of 6 per 100,000 males and 4 per 100,000 females of the UK population annually. 1 The 
incidence of AML increases with age, from 17 - 25 per 100,000 population between males and females 
at 65 years old, to a peak of 35 per 100,000 in males and 23 per 100,000 in females at 75 years of age. 
In most cases the aetiology is unclear, arising as a de novo malignancy, but many risk factors and several 
pre-leukaemic conditions are known. Myeloproliferative neoplasms and myelodysplasia can transform 
into AML taking on an aggressive course that inevitably leads to death if untreated. Other predisposing 
conditions include Down Syndrome that has a 50-fold increase in AML incidence during the first 5 years 
of life. There is also a degree of genetic predisposition, with first degree relatives of patients with AML 
have a 2-3 fold increased risk of developing AML themselves. Inherited myeloid neoplasms associated 
with germline mutations in a number of genes have also been described, as have SNPs that increase 
the likelihood of AML development. 2,3 
AML can arise in patients as a consequence of prior therapies for other malignancies that often involve 
cytotoxic drugs, other chemotherapy and ionising radiation. As a result of patients surviving longer 
from these therapies the number of therapy-related AML cases is continuing to rise. Alkylating agents 
and ionising radiation are significantly associated with therapy-related AML, commonly occurring as 
advanced therapy-related myelodysplasia progressing to overt AML approximately 5-10 years after 
treatment. Topoisomerase II drugs are strongly associated with overt AML with a latency period of 
about 1-5 years.  
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1.2 AML cytogenetic, molecular heterogeneity and prognostic classification  
AML is a considerably heterogeneous disease with several distinct subgroups characterised by 
cytogenetic, molecular, gene expression and morphological characteristics. The molecular 
heterogeneity of AML in particular has expanded significantly over the past 15 years, yielding better 
insights into prognostic stratification. Conventional cytogenetic testing and, more recently, screening 
for select molecular lesions has allowed for a more detailed classification of AML. The World Health 
Organisation classifies AML according to clinical, morphological cytogenetic and molecular factors. A 
recent revision of the WHO classification of AML was published in 2016 which introduces further 
molecular changes to the section on AML with recurrent genetic abnormalities and identifies new 
provisional entities with characteristic clinicopathological features. The 2016 revised WHO 
classification is shown below (Table 1.1):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 1.1 2016 Revised WHO Classification of Acute Myeloid Leukaemia and its subtypes 
Table adapted from Blood. 2016; 127(20):2391-2405 4 
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The major difference to previously is the inclusion of genetic information with morphology, 
immunophenotyped and clinical presentation. Within ‘AML with recurrent genetic abnormalities’ 
there are 11 subtypes defined according to their chromosomal translocations. The preceding 2008 
classification had introduced AML with mutated NPM1 (nucleophosmin) and AML with mutated 
CEBPA. The latter has been updated to reflect the added prognostic benefit of biallelic CEBPA 
mutations. Additionally, there has been the introduction of two new provisional entities: AML with 
BCR-ABL1 and AML with mutated RUNX1 (de novo cases of AML with RUNX1 mutation that are not 
associated with cytogenetic abnormalities). The former describes rare de novo cases of AML that may 
benefit from tyrosine kinase inhibitor (TKI) therapy whilst the latter classifies de novo AML cases with 
this mutation that are not associated with myelodysplasia-related cytogenetic abnormalities. Finally, 
a section on familial myeloid neoplasms has been included, highlighting subtypes associated with 
germline mutations in at least 10 genes.  
 
In current practice, conventional cytogenetics and results from NPM1, FLT3 and CEBPA mutation 
screening are being used to risk stratify patients newly diagnosed with AML conferring a guide to likely 
prognosis. With the emergence of further molecular markers (detailed in the next section) a revised 
genetic risk stratification has been proposed in the 2017 European LeukemiaNet (ELN) guidelines: 
 
 
 
 
TABLE 1.2 2017 Revised European LeukaemiaNet risk stratification of AML by genetics 
Table adapted from 2017 European LeukaemiaNet guidelines 
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These risk categories are likely to expand further in the future to incorporate more molecular markers 
as more clinical data becomes available regarding their prognostic impact in AML patients. 
 
 
1.3 The molecular landscape of AML 
 
As alluded to above, with the advent of new genomic techniques such as next-generation sequencing 
in recent years, a significant number of new genetic mutations within AML - their variety and 
frequency, co-operative nature or mutual exclusivity, clonal evolution and epigenetic hallmarks -  have 
been described. A landmark study was the analysis of the genomes of 200 patients with AML (25% via 
whole-genome sequencing and the remainder with whole-exome sequencing, RNA and miRNA-
sequencing and DNA-methylation status) provided by The Cancer Genome Atlas Research Network. 5 
Frequently mutated genes in AML were organised into multiple functional categories (Figure 1.1): 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Twenty-three genes were found to be mutated at significantly higher rates than expected, including 
known drivers of AML such as DNMT3A, FLT3, NPM1, IDH1, IDH2, U2AF1, EZH2 and SMC1a. 99.5% of 
all cases had at least one important mutation. Through an analysis of variant-allele frequencies, >50% 
The Cancer Genome Atlas (TCGA) Research Network 
FIGURE 1.1 Circos plot showing a panoramic view of genetic events leading to the 
pathogenesis of AML 
 Adapted from Chen et al. Nature Genetics 2013 6 
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of AML cases were made up of a founding clone and subclones, demonstrating the possibility of clonal 
evolution during disease progression.  
Four new functional classes were identified from analysing this dataset, showing complex patterns of 
association. In particular, mutations in epigenetic pathways including enzymes involved in DNA 
methylation and chromatin modifications were shown to be present in over 70% cases.  
More recently, 1540 patients intensively treated for AML across multi-centre trials were genetically 
profiled through cytogenetic analyses and targeted sequencing.7 Co-mutation patterns emerged and 
segregated AML cases into 11 classes with distinct clinical phenotype and outcome. Three additional 
heterogenous classes appeared from this analysis: AML with mutations in chromatin and RNA-splicing 
regulators, AML with TP53 mutations and/or chromosomal aneuploidies and AML with IDHR172 
mutations. This study categorised driver mutations and identified nonoverlapping subgroups of 
patients, facilitating a fully genomic classification of AML. In addition, it provided further evidence to 
allow mutated TP53, RUNX1 and ASXL1 to be included in the 2017 ELN recommendations adverse risk 
group whilst strongly putting forward the case for other molecular lesions such as DNMT3A, SRSF2, 
IDH2 to be considered for inclusion into risk stratification for AML patients. Through these analyses a 
genetic approach to classifying AML with prognostic implications was furthered, whilst obtaining 
similar results to the TCGA dataset. They also corroborated several epigenetic modifiers that were 
prominent in the TCGA analysis.  
A follow up landmark study by the same authors analysed genetic data across 111 cancer genes, 
cytogenetic profiles and clinical information from the same 1540 AML patients. 8 Even within the 11 
subgroups defined above, there was considerable variability in responses to treatment and clinical 
outcomes between patients. Whilst allowing a prediction for overall patterns such as survival 
outcomes from such data, it did not fully inform at the individual patient level. Through accumulating 
this molecular and clinical data as a knowledge bank, they were able to provide more accurate 
statements about the individual patient’s likely responses through their therapy course for AML and 
compare likelihoods of favourable outcomes in varying treatment scenarios. This allowed for the 
provision of clinical advice regarding treatment that adopted a more personalised approach, 
particularly with respect to recommendations regarding proceeding to allogeneic transplant in first 
complete remission (CR1). Utilising their multistage predictive model generated from all the 
information provided by this detailed analysis of 1540 AML patients, and through knowledge of the 
complement of somatic mutations and karyotype particular to that patient, as an example, they were 
able to predict that an individual’s risk of relapse after CR1 was considerably higher than the favourable 
risk score that would have been estimated by current ELN criteria. This allowed them to suggest that 
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allogeneic transplantation would be indicated as opposed to routine surveillance as had been 
suggested by the current clinical criteria. This move toward deeper characterisation at the molecular 
level, subsequent risk stratification and individual treatment prediction in AML suggests a future where 
therapeutic strategies and courses may be better informed and predicted, in order to suit the 
individual patient better. On a larger scale, this type of modelling also provides additional benefits for 
healthcare economy through being better able to predict the most appropriate therapy courses and 
potentially reducing costs through better resource allocation, for a condition that is also relatively 
expensive to treat.  
The cytogenetic and molecular heterogeneity seen across AML cases has been a significant 
impediment to the development of effective treatments for the condition as whole. The mainstays of 
AML therapy (cytarabine and anthracyclines) have remained unchanged over the past 35 years. There 
are over 2500 deaths in the UK alone from AML each year. Whilst curable in up to 40% of patients <60 
years of age, over 70% of patients diagnosed with AML eventually succumb to the condition. Outcomes 
in older patients remain unacceptable with median survivals of 5 to 10 months due largely to the 
inability to tolerate the aggressive chemotherapy regimens (that centre around the two drugs 
mentioned above) required for remission induction and consolidation. Through large robust studies 
such as those described above, the characterisation of this heterogeneous, difficult-to-treat condition 
is becoming more precise. The identification of critical driver lesions of AML that define subtypes 
followed by specific molecular mutations that may have either a prognostic impact or therapeutic 
implications has become increasingly important in facilitating the development of novel therapies. 
Novel therapeutics with lower toxicities, targeting these molecular lesions that may augment or 
replace standard chemotherapy would go some way to improving abysmal survival outcomes seen in 
older AML patients. Ongoing efforts to understand the molecular biology of several of these recently 
identified molecular drivers within this fascinating condition to a greater degree are most certainly 
required, and are paving the way for the development of important novel therapeutic strategies. As 
discussed above, the TCGA dataset revealed the presence of a significant number of mutations in 
epigenetic modifiers (>70%) in AML which has fuelled further investigation into this area in recent 
years.  
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1.4 Epigenetic regulation 
Histones are a family of scaffolding proteins that associate in octamers (a tetramer of H2A and H2B 
plus two dimers of H3 and H4) with 147bp of DNA in the nucleus to form the nucleosome; the basic 
functional unit of chromatin (Figure 1.2). Chromatin facilitates compact storage of the whole 2 metres 
of eukaryotic cellular DNA within the nucleus and is widely recognised to exist in two states - 
euchromatin or heterochromatin. Euchromatin has a relaxed conformation that provides a permissive 
environment for active transcription, whilst heterochromatin is tightly packaged and contains 
predominantly inactive genes. Nucleosomes package DNA in a finely regulated manner dependent 
upon the cell's requirements for various dynamic DNA-templated processes. Chromatin modifying 
enzymes regulate post-translational modifications of histones through tightly regulated catalytic 
processes. Modifications to chromatin may alter function in two non-mutually exclusive ways: firstly, 
they may enhance or attenuate non-covalent interactions between histones and DNA, thereby 
governing accessibility to specific loci, and secondly the modifications that they regulate may facilitate 
specific recruitment of chromatin regulators to appropriate sites to alter DNA-templated processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 1.2 The structure of histones and a summary of common histone modifications 
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The term ‘epigenetics’ has come to encompass the general study of such chromatin based events and 
their regulation of DNA-based processes9, although it was originally coined by Waddington to describe 
inherited changes in gene expression independent of DNA sequence changes.10 Four different DNA 
modifications and at least 16 different classes of histone modification have been described.11 These 
modifications are inherently malleable – they are laid down by protein complexes with catalytic 
function termed epigenetic “writers” and removed by other catalytic proteins known as epigenetic 
“erasers”. The majority of histone modifications are found on the unstructured N-terminal histone tails 
that emanate from the globular core of the nucleosome and individual modifications include 
acetylation, methylation, biotinylation, citrullination, phosphorylation, ribosylation and 
SUMOylation.12 Their effect is cumulative with the overall state of chromatin being dictated by 
combinations of these modifications. A key advance in our understanding of chromatin regulation was 
the recognition that most chromatin regulators contain specialised domains that confer the ability to 
survey the epigenetic landscape and anchor themselves to specific sites within the genome. These 
epigenetic “readers” can recognise and bind to post-translationally modified sites on histone tails 
“interpreting” the information contained in the modifications to alter locus–specific DNA functions, 
such as transcription, DNA repair, replication and recombination through the recruitment of specific 
proteins.   
Aberrant regulation of these processes through the acquisition of somatic mutations in the proteins 
that mediate them has been increasingly recognised as a typical hallmark of leukaemia and other 
cancer genomes. Equally, the plasticity of the epigenome by comparison with the fixed nature of the 
genome, allows for its potential therapeutic manipulation in pathological conditions. Moreover, 
pathological dysfunction reveals mechanistic insight into the function of chromatin modifier proteins.  
As discussed in Section 1.3, AML is an exemplar condition in which epigenetic dysregulation has 
become increasingly recognised. An increasing number of epigenetic modifier/readers potentially 
relevant to AML pathogenesis e.g. TET2, IDH1/2, DNMT3a, ASXL1, BRD4 have been described. 
Recently, a better understanding of aberrant epigenetic control in AML has led to the development of 
promising small molecule inhibitors of epigenetic regulators. Epigenetic changes are plastic and 
potentially reversible, making them attractive therapeutic targets. Theoretically if a tumour-specific 
epigenetic state was reversible, the cancer cells within that state could re-acquire the ability to 
differentiate normally and surrender their proliferative advantage, restoring the balance with normal 
haematopoiesis. 
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1.5 Polycomb repressive complexes 
The term Polycomb (Pc) referred to a Drosophila mutant with failure of normal body segmentation. 13 
This mutant allowed the identification of the Polycomb Group of genes (PcG) – a group of genes that 
are required for normal body segmentation – their mutations result in phenotypes similar to Polycomb. 
Early embryonic lethality was observed upon deletion of genes encoding some of these proteins (Ezh2, 
Eed, Suz12, Ring1b) in mice. 14 PcG proteins are found in several families of multiproteic complexes, 
the most well defined of these are the Polycomb Repressive Complexes 1 and 2 (PRC1 and PRC2).  
Enhancer of Zeste Homologue 2 (EZH2) functions via a catalytic “Suppressor of variegation 3-9, 
Enhancer of zeste and Tri-thorax” (SET) domain, as a histone di- and tri- methyltransferase for lysine 
27 of histone 3 (H3K27me2/me3). It forms the core of PRC2 with three other obligate members 
(Embryonic Ectoderm Development (EED), Suppressor of Zeste 12 (SUZ12) and RbAp46/48) (Figure 
1.3). Additionally, EZH1 is a non-canonical PRC2 member which complements the role of EZH2. EZH1 
and EZH2 are differentially expressed with PRC2 complexes containing EZH1 instead of EZH2 displaying 
low methyltransferase activity relative to PRC2 containing EZH2.15 PRC2 is well conserved throughout 
evolution and acts via several mechanisms to initiate polycomb-mediated gene repression, utilising 
direct inhibition of RNA polymerase II and chromatin compaction, which at the H3K27me3 mark, blocks 
access to transcription factors, and promotes transcriptional repression of genes. The H3K27me3 mark 
then functions as a docking site to recruit a second polycomb complex PRC1, which assists in 
maintaining gene repression via ubiquitination of H2AK119 (not shown). PRC1 contains 4 core 
components, RING2 (Ring1B in mice), BMI1, HPH, and CBX (one of various CBX proteins), and possesses 
E3 ubiquitin ligase activity for the mono-ubiquitylation of histone H2A at lysine 119 (H2AK119ub1). 
PRC1 and PRC2 occupy a common set of target sites in vivo. Whilst this sequential model of recruitment 
of PRC2 and PRC1 complexes has been well characterised 16, 17, more recently, variant PRC1 complexes 
containing PCGF1/3 proteins have been described - these have been shown to unexpectedly possess 
the ability to be recruited actively to target chromatin sites in a PRC2 independent manner. 
Furthermore KDM2B-mediated targeting of the variant PRC1 complexes to CpG islands was shown to 
be required for normal levels of PRC2 at subsets of target sites, providing an alternate mechanism of 
hierarchical recruitment. 18   
Early purifications of PRC2 allowed for the identification of 3 additional proteins – Aebp2, Pcl and 
Jarid2. AEBP2 serves to enhance enzymatic activity of the PRC2 complex and facilitates DNA binding. 
The PCL group (Pcl1/2/3) share similar motifs and interact with PRC2 through Ezh2 and Suz12 whilst 
Jarid2 belongs to the Jumonji family of proteins and facilitates PRC2 recruitment, though does not 
appear to enhance enzymatic function.19  
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Histone methylation occurs on the tails of arginine, lysine and histidine amino acid residues, and whilst 
it does not alter the overall charge of the histone, the methylation of different residues has varying 
effects. Methylation of H3K4, H3K36 and H3K79 is associated with gene activation in euchromatin, 
whilst methylation of H3K27, H3K9 and H4K20 is associated with heterochromatin formation and gene 
silencing. Lysine residues can be mono-, di- or tri-methylated and each methyltransferase may catalyse 
one or two of the transitions between these three potential states. PRC2 is the only complex that 
possesses enzymatic activity that results in di and tri methylation of H3K27. Enrichment of H3K27me3 
correlates directly with gene silencing 20 
In mammals, binding patterns for H3K27me3 include small domains covering a few kilobases (kb) and 
large domains covering >100kb (e.g. those containing Hox loci).21 H3K27me3 enrichment appears to be 
centred primarily around the transcriptional start site (TSS) at promoters with some found at intergenic 
regions.22 In embryonic stem (ES) cells, chromatin organisation tends to be more open and flexible 
allowing for an overall higher rate of transcription. To corroborate this idea, the H3K4me3 mark 
associated with gene activation and transcriptional activity was found to be present at the vast 
majority of all PRC2 targeted genes in ES cells, demonstrating the so-called ‘Bivalent Domain’. 23  Whilst 
initially believed to be ES-cell specific, this pattern has since been demonstrated in other differentiated 
FIGURE 1.3 The PRC2 complex 
 EZH2; histone methyltransferase responsible for H3K27 di- and tri-methylation 
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somatic cells, highlighting the importance of coexisting histone modifications in the fine tuning of gene 
transcription. 
 
1.6 EZH2 in haematopoiesis and cancer 
EZH2 has been demonstrated to have vital roles in stem cell development and haematopoiesis. It is 
essential for normal foetal haematopoiesis with Ezh2 deficient murine embryos dying of severe 
anaemia.24 In the same study however, Ezh2 deletion in adult murine bone marrow (BM) did not 
significantly compromise haematopoietic stem cell (HSC) function, importantly highlighting its 
potential as a target in haematological disease. EZH2 contributes to the regulation of cell fate decisions 
(as alluded to above), controlling gene expression to settle upon a balance between self-renewal and 
differentiation.25 EZH2 has a predominant role in embryonic tissues and becomes downregulated in 
some adult differentiated tissues. In haematopoiesis, it has been shown to stabilise chromatin 
structure to maintain the long-term self-renewal potential of HSCs through the repression of pro-
differentiation genes.26   
Aberrant EZH2 expression and activity have been linked to tumorigenesis, through its ability to block 
genes necessary for differentiation, allowing retention of a cancer stem cell phenotype. This is 
recognised in several cancer models, including breast and prostate.27-29 These studies demonstrated a 
clear correlation in both transcript and protein levels with poorer outcomes in these malignancies, also 
showing promoted tumour progression and metastasis.  
Outwith its increased expression at both transcript and protein levels, gain-of function mutations of 
EZH2 have been described. Within lymphoma, a landmark study described a cohort of patients with 
diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) with EZH2 variants. 30 Through 
whole genome DNA sequencing of an index case of FL they demonstrated a mutation affecting exon 
15 of the EZH2 gene, encoding part of the catalytic SET domain. This resulted in the substitution of 
tyrosine to histidine at codon 641 (Y641). Upon screening further DLBCL and FL cases, the same point 
mutation was revealed in approximately 21% and 7% of DLBCL (exclusively in the germinal centre 
subtype) and FLs respectively. Data from a subsequent study demonstrated that the Y641 mutation in 
EZH2 conferred an aberrant functional interaction between mutant and WT gene products.31 The 
malignant phenotype arising in Y641 mutated B-cell lymphoma was shown to occur due to an altered 
cooperation between mutated and WT EZH2 with an over-all hyper-trimethylating effect at H3K27, 
resulting in gene repression. In succession to these and other studies, small molecule inhibitors of EZH2 
were developed to target this mutation in lymphoma. Utilising GSK126 (a novel highly selective EZH2 
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methyltransferase inhibitor) McCabe et al. demonstrated reduced global H3K27me3 levels in EZH2 
mutant DLBCL cell lines, which resulted in inhibition of proliferation of these cells.32 Furthermore, the 
compound significantly inhibited growth of EZH2 mutant DLBCL xenografts in mice. This has led to a 
demonstrable reduction of cancer stem cell renewal capability in lymphomas, with this and other 
agents (e.g. EZH2 inhibitors EPZ-6438, CPI-1205) moving into the clinical arena via ongoing early phase 
trials. [NCT Trial numbers: NCT02082977, NCT01897571, NCT02395601 for compounds GSK2816126, 
EPZ-6438 and CPI-1205 respectively]  
 
1.7 EZH2 in myeloid malignancy 
The role of EZH2 in myeloid malignancies, by comparison, is less well-defined. Although loss of function 
mutations have been described at low frequency in myeloid malignancies including myelodysplasia 
(MDS) and AML33, evidence for overactivity of EZH2 in established myeloid leukaemia also exists. 
Another study demonstrated Ezh2 loss contributed to development of a RUNX1 mutant driven MDS in 
mice, however prevented its transformation to AML through PRC1-mediated repression of Hoxa9.34  
AML associated with the rearrangement of the mixed lineage leukaemia (MLL) gene has been 
genetically demonstrated, in two separate studies, to rely on Ezh2 for leukaemia maintenance.35, 36 
AML cases with translocations of the MLL gene occur in around 70% of infantile leukaemias and are 
characterised by aggressive leukaemias often refractory to conventional therapies. MLL is a histone 
methyl-transferase containing a SET (Suppressor variant 3-9, enhancer of Zeste, trithorax) domain and 
is involved in tri-methylation of lysine 4 on histone H3, leading to transcriptional activation. In MLL 
rearranged leukaemias the N-terminus of MLL is fused to one of over 70 fusion partner genes.37 Most 
of these result in loss of activity at the SET domain but activate pro-leukaemogenic changes in gene 
expression.   
In the first study35, conditional deletion of Ezh2 in granulocyte-macrophage progenitors already 
transformed by the MLL-AF9 fusion compromised growth severely in vitro and delayed progression of 
AML in vivo. Through genomic analysis, a significant reduction in H3K27me3 in Ezh2-deficient 
transformed cells was seen at several genes important for developmental and differentiation 
processes. This included the Ink4a/Arf tumor suppressor locus (also known as CDKN2A) which was 
significantly de-repressed upon Ezh2 loss as well as Egr1 (a positive regulator of myeloid 
differentiation), the latter of which was functionally validated through overexpression in vitro 
demonstrating a significant drive toward differentiation of these MLL-AF9 transformed cells. In the 
second study36, conditionally Ezh2-deleted MLL-AF9 driven AMLs failed to accelerate upon secondary 
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transplantation in vivo complementing the findings of the first study, however H3K27me3 levels 
persisted at specific loci, suggesting Ezh1 was likely partially compensating. Ablation of Eed however 
led to a complete ablation of PRC2 function and did not allow leukaemic growth. Both studies 
suggested that Ezh2/PRC2 function is required for the maintenance of MLL-AF9 driven AML.  
More recently, and somewhat contrary to the oncogenic role of Ezh2 in myeloid malignancies 
described above, early Ezh2 loss has been shown to co-operate with Jak2-V617F driven 
myeloproliferative neoplasms, markedly advancing myelofibrosis in vivo and reducing survival.38 
Through further genomic analysis in this study, several highly-upregulated target genes from HSCs in 
the Ezh2 null state were described, including Lin28b and Hmga2. These are well described oncogenes 
(discussed later in this thesis) with a clear association to other advanced human malignancies.39 
Overexpression of the latter (Hmga2), but not the former, partly recapitulated the accelerated 
synergistic myelofibrotic phenotype in vitro and in vivo. A similar study demonstrated synergistic 
effects between Ezh2 loss and Jak2-V617F driven myelofibrosis in vivo with de-repression of several 
other targets, again including Hmga2, in the Ezh2 deficient state.40 Overexpression of these in vitro 
using Jak2-V617F murine bone marrow significantly increased clonogenic output, once again providing 
evidence for its role in mediating the synergism between Ezh2 loss and Jak2-V617F.  
These clearly disparate findings regarding EZH2’s oncogenic or tumour-suppressive function in cancers 
and their subtypes, particularly within myeloid malignancies, suggest that further studies are required 
to delineate its role in greater detail. Being an epigenetic regulator responsible for gene silencing at a 
huge variety of loci, provides an added complexity. This warrants further investigation to try and 
reconcile the protein’s apparent ability to induce both pro-oncogenic and tumour-suppressive effects. 
Given EZH2 inhibitors are currently in pre-clinical and early phase clinical trials, this is particularly 
required as inhibition of this protein could be potentially beneficial or detrimental depending on 
context.  
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1.8 H3K27me3 in AML 
Work relevant to this thesis performed by Drs Mike Chapman and Emma Gudgin in the Huntly lab 
(unpublished data) just prior to this dissertation, has also indirectly suggested EZH2 dysfunction in 
AML. To characterise histone modification patterns across AML patient samples, the repressive 
H3K27me3 (catalysed by EZH2) and the activating mark H3K9/14 acetylation were assessed for 
approximately 300 genes known to be important in leukaemogenesis and haematopoiesis by 
Chromatin Immuno-Precipitation followed by hybridisation to microarrays ("ChIP on CHIP"). The 
rationale was that investigating a combination of activating and inactivating histone modifications in 
the chromatin landscape of AML versus control populations may provide additional information 
regarding patterns/mechanisms of dysregulation compared to the direct readout provided by gene 
expression profiling. Chromatin from 53 AML patients and 7 AML cell lines were examined, using 
normal CD34+ haematopoietic stem and progenitor cells (HSPC), T cells and neutrophils as controls. 
Following bioinformatics analysis, a variety of subpatterns were demonstrated. The most striking 
observation however, was that this analysis dichotomised patients into two groups, one that either 
demonstrated an increased H3K27 methylation and a decreased H3K 9/14 acetylation pattern – a gene 
"repressive" status – and vice versa (a gene "activated" status) (Figure 1.4). This suggested that 
overactivity of EZH2 and an H3K27me3 repressive pattern may be involved in the pathogenesis of 
certain subtypes of AML.  
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FIGURE 1.4 Bioinformatics analysis of chromatin activation/repression states in AML patients 
and AML cell lines suggests patterns of EZH2 overactivity 
 
The prognostic significance of these AML patient epigenetic profiles was assessed (Figure 1.5). Though 
there was no significant overall survival difference between the two curves, there was a difference in 
median survival between the two states, with the “activated” group having a median survival of 21.4 
months versus the “repressive” groups at 12.7 months median survival. This analysis was limited due 
to the small numbers involved (n=43, only patients enrolled in MRC trials were included), but again 
correlated with the hypothesis that EZH2 overactivity may be of pathogenetic relevance in AML. 
 
 FIGURE 1.5 A “repressed” state (upregulated H3K27me3 + downregulated H3K9/14Ac) 
correlates with poorer survival 
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1.9 Thesis aims 
 
The central aim of this project was to define the role of EZH2 in various stages of AML evolution. In 
particular, the aim was to delineate the role of EZH2 in the induction and maintenance of multiple AML 
subtypes through in vitro and in vivo experiments, utilising a conditional Ezh2 knockout system. 
Following this, if any differences in outcomes were demonstrated, a detailed genomic analysis was 
proposed utilising gene expression profiling through RNA-sequencing between Ezh2 wild-type (Ezh2+/+ 
or wt) and Ezh2 null (Ezh2-/-) transformed or leukaemic states at various stages of AML evolution. 
Through Chromatin Immunoprecipitation coupled to next generation sequencing (ChIP-seq) a detailed 
examination of alterations in the H3K27me3 repressive mark, along with other histone activating 
marks and localisation of the PRC2 complex in the above conditions was also planned.  
Through robustly combining these data, the aim was then to identify any targets deregulated between 
the two Ezh2 states that would contribute to phenotype and functionally assess these either in vitro 
or in vivo.  
Lastly through collaboration with GlaxoSmithKline – GSK343, an active novel small molecule inhibitor 
of EZH2 (and its inactive homologue GSK669) were provided to the Huntly lab. The final aim was to 
test this inhibitor across a range of AML cell lines, murine AML tumours in vitro and primary AML 
patient samples, to assess for sensitivity/resistance, with an investigation to delineate mechanism or 
sensitivity through genomic analysis as discussed above.  
This dissertation has thus been divided into five experimental chapters and addresses the following 
questions: 
1. Is Ezh2 genetically required for the induction and maintenance of subtypes of AML in vitro 
and in vivo? 
 
2. What underlying transcriptional programmes are subverted by Ezh2 loss during induction or 
maintenance of AML to account for differences in phenotypic outcomes? 
 
3. Do candidate genes (identified in Aim 2) provide a mechanistic insight to differences seen in 
Aim 1? Can these be functionally validated? 
 
4. Is EZH2 a plausible therapeutic target (as informed by Aims 1-3) and does pharmacological 
inhibition with a novel EZH2 inhibitor have a role in AML? 
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Chapter 2  
Materials and Methods 
 
2.1  Materials 
This chapter contains a description of all materials and protocols for the experimental work described 
in this dissertation. 
 
2.1.1 General laboratory reagents 
β-Mercaptoethanol   Sigma Aldrich   M6250 
5X DNA loading buffer    Bioline    BIO-37045 
Bovine serum albumin    Sigma Aldrich   A2153 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich    276855 
Ethanol     Sigma Aldrich 
Foetal bovine serum   Sigma Aldrich   F6178 
Hexadimethrine bromide (Polybrene) Sigma Aldrich   H9268 
Isopropanol    Sigma Aldrich 
L-glutamine    Sigma Aldrich   59202C 
LymphoprepTM    Axis-Shield, Norway  1114547 
Methanol    Fisher Chemicals 
Methocult Methylcellulose Human Stem Cell Technologies  H4435 
Methocult Methylcellulose Murine Stem Cell Technologies  M3434 
Opti-MEM reduced serum medium ThermoFisher scientific  31985062 
Penicillin/Streptomycin   Sigma Aldrich   P4333 
Propidium iodide   Sigma Aldrich   P4170 
Protease inhibitor   Sigma Aldrich   11 873 580 001 
Puromycin    Thermo ScientifiC  A1113803 
Red cell lysis buffer   5 Prime    2301310 
TransIT-LT1 transfection reagent Mirus Bio   MIR2300 
Trypan Blue    Sigma Aldrich   T8154 
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2.1.2  GSK343: EZH2 inhibitor 
 
 
 
 
 
 
GSK343 was initially provided by GlaxoSmithKline through the specifications of a Materials Transfer 
Agreement (MTA) and later purchased through Sigma Aldrich (Sigma, Catalogue No: SML0766). Both 
were in powder form and this was dissolved in an appropriate volume of dimethyl sulfoxide (DMSO), 
(Sigma, Catalogue No: 276855) to provide a 10mM solution and stored in aliquots at -80oC for use. 
Neat DMSO served as controls in subsequent experiments. GlaxoSmithKline also provided an inactive 
version of GSK343 entitled GSK669 that was again used as an additional control in some experiments. 
Each experiment used a freshly thawed aliquot of compound to avoid potential reduction in efficacy 
from repeated freeze-thawing.  
 
2.2 Tissue Culture  
 
All tissue culture was performed under Category 1 conditions, with cells being incubated at 37oC in 5% 
CO2 unless otherwise specified. 
 
2.2.1 Cell lines 
2.2.1.1 AML Cell lines 
Human AML cells lines detailed below (Table 2.1) were typically maintained at a density of 0.5-
2x106/ml according to optimal conditions set out by DSMZ (Deutsche Sammlung von Mikroorganismen 
und Zellkulturen) GmbH where they were purchased from. 
FIGURE 2.1  GSK343 structure 
GSK343: EZH2 inhibitor 
60-fold selective:  EZH2:EZH1 
1000-fold selective:  other methyltransferases 
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Cell Line Species Disease Mutation/Disease Culture conditions 
Kasumi Human AML AML1-ETO RPMI 20% FCS 
KG1 Human AML FGFR1OP2-FGFR1 RPMI 10% FCS 
K562 Human AML BCR-ABL RPMI 10% FCS 
NB4 Human APML PML-RARa RPMI 20% FCS 
 
 
2.2.1.2 293T cells 
293T Cells were used to produce retroviral supernatant. They are a variant of the human embryonic 
kidney 293 cell line, having been isolated from foetal kidney cells and transformed with type 5 
adenovirus. They contain a temperature sensitive SV40 large T antigen. Routine culture conditions for 
293T cells were at 37 oC, 5% CO2 in DMEM (Life Technologies, Cat No: 11965-084) + 10% heat-
inactivated Fetal Bovine Serum (Sigma, Cat No: 12003C) + L-glutamine (Sigma, Cat No: G75713), being 
maintained at 50-70% confluency across 100mm sterile plates. To ensure no reduction in supernatant 
quality, passages were kept to a minimum by freezing large numbers of vials and thawing as required.  
 
2.2.2  In vitro culture and passage of murine MLL-AF9 AML spleen tumours 
All murine leukaemias generated from the in vivo studies described in this thesis had bone marrow 
and spleen tissues processed into single-cell suspensions and frozen as described in Methods 2.6.10. 
In order to passage these in vitro, they were thawed under sterile conditions as described in (Cell 
Storage). The splenic tumour cells were then resuspended in sterile X-Vivo 20 culture medium (Lonza, 
Cat No: 04-448Q) supplemented with mIL-3, IL-6 and mSCF cytokines, (PeprotechTM, Catalogue 
Numbers: 213-03, 200-06 and 250-03, at final concentrations of 10ng/ml, 10ng/ml and 50ng/ml 
respectively) at approximately 0.2-0.3x106 cells/ml. These tumours were then passaged every 48-72 
hours in vitro under standard tissue culture conditions in 10ml Falcon flasks and expanded. Initial 
GSK343 titration to assess sensitivity to GSK343, cell proliferation and viability quantifications and 
clonogenic methylcellulose assays were performed as described in Methods 2.3.2 to 2.3.3. 
 
TABLE 2.1  Human AML cell lines 
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2.2.3 Primary AML sample collection/processing 
Peripheral blood/bone marrow samples were collected from newly diagnosed/relapsed patients with 
AML by WHO Criteria1 into cytogenetic media (RPMI supplemented with HEPES, lithium heparin and 
gentamicin). This was done as part of “The Causes of Clonal Blood cell disorders” study (Department 
of Haematology, University of Cambridge) approved by the Cambridge and Eastern Region Ethics 
Committee. Patients gave written informed consent and research was carried out in accordance with 
the Declaration of Helsinki. All samples were anonymised and were identifiable only by a tissue bank 
code. The mononuclear fraction was obtained following a 1:1 dilution in PBS and layering onto 1:1 
volume of Lymphoprep (Axis-Shield Norway, Catalogue No: 1114544). Samples were centrifuged for 
45min at 1400rpm and the interface layer between plasma and red cells containing the mononuclear 
fraction was carefully removed using a 1ml pipette. Finally, after washing in MACS buffer (500 ml PBS 
without Ca/Mg, 2.5 g BSA and 2 ml of 0.5 M EDTA, filter sterilised), cells were counted for use/storage. 
 
2.2.4 Cell storage 
2.2.4.1 Freezing 
Human AML cell lines, murine cell lines and tumour cells and primary AML samples were counted and 
then centrifuged for 5 minutes at 1200rpm at 4oC and the supernatant removed. 1x107 – 1x108 cells 
were then resuspended in 1ml of freezing medium (90% FCS + 10% DMSO) and aliquots in cryovials 
were made, placed into Nalgene 1oC/min freezing containers (Sigma) and stored at -80oC until 
completely frozen. These were subsequently transferred to liquid nitrogen tanks for longer term 
freezing at -180oC. 
2.2.4.2 Thawing 
Frozen cells in cryovials were warmed in a 37oC water bath and immediately diluted with 10ml of 
appropriate media. After centrifugation for 5 minutes at 1200rpm, the supernatant was removed and 
the cells resuspended in appropriate media, counted and cultured at 0.5-1x106/ml overnight or plated 
at the appropriate number into semi-solid methylcellulose for functional assays.  
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2.2.5 Cell counting 
Counting was performed using a CASY Counter (Schärfe System GmbH), which generates a cell size 
profile and total viable and dead cell number (cells below average nuclear size indicated death/dying 
and were excluded). This method uses electric current exclusion and pulse area analysis to determine 
viable cell numbers. Under a low voltage field, electric current cannot pass through the intact cell 
membrane of a viable cell, whilst it can through the pores of a dead/dying cell, thereby allowing a 
means of differentiating the two. 
 
2.3 Functional assays utilising tissue culture 
2.3.1 Liquid culture growth assay 
This 12 day protocol required Kasumi and KG1 cell lines maintained in liquid culture media (RPMI + 
20% FCS) to be expanded in the presence of DMSO, GSK343 or GSK669 (refreshed every 72 hours) with 
total cell counts measured every 72 hours.   
At Day 0, 0.5x106/ml of Kasumi and KG1 cells in fresh media (RPMI + 20% FCS) were initially placed in 
a 12 well plate at 1ml/well. To each well either 1ul DMSO, GSK343 or GSK669 (at 10mM) were added. 
By pipetting up and down repeatedly, each well was mixed thoroughly and the plates were incubated 
under standard mammalian cell culture conditions (37oC, 5% CO2).  
At Day 3, each well was pipetted up and down several times to re-establish a single cell suspension and 
the cells were counted. Upon establishing total viable cell count, these were then transferred to 
Eppendorf tubes and centrifuged at 1200rpm for 7 minutes. They were then resuspended in the 
appropriate volume of fresh media (plus the appropriate volume of DMSO, GSK343 or GSK669), to 
return the concentration back to 0.5x106/ml. Where cell growth had occurred, this inevitably resulted 
in an expanded volume after counting and resuspending, therefore the cells were subsequently stored 
in individual BD Falcon 5ml flasks and returned to the incubator. 
This process was repeated at Days 6, 9 and 12, with increasing volumes of media (plus final 
concentrations of DMSO, GSK343 or GSK669 at 10µM). At each time point the total viable cell number 
was recorded and then plotted against time.  
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2.3.2 Clonogenic assays in methylcellulose with GSK343 
Clonogenic potential was assessed through colony growth (colony numbers and total cell numbers) in 
the presence of DMSO, GSK343 or GSK669. The same method was used for human AML cell lines, 
immortalised murine bone marrow (BM) c-kit selected cells, murine MLL-AF9 spleen tumours cultured 
in vitro, and for primary AML samples. An aliquot of each of the AML cell lines or murine MLL-AF9 
leukaemia spleen tumours was thawed (as per Methods 2.2.4.2) and then cultured in appropriate 
media (Table 2.1 for AML cell lines and Section 2.2.2 for murine MLL-AF9 tumours). All primary samples 
were obtained fresh from the patient (the same day) with written consent and the mononuclear cell 
fraction was resuspended in MACS buffer at ~1x106/ml (Section 2.2.3 primary samples).  
The cells were counted and the volume containing the appropriate number of cells for plating (as per 
Table 2.2) was calculated. This was then diluted in RPMI 1640 + 20% FCS media to a final volume of 
300µl and added to 3ml aliquots of freshly thawed and vigorously vortexed methylcellulose (Methocult 
H4435 containing human cytokines or Methocult M3434 containing murine cytokines, Stem Cell 
Technologies). At this stage, either 3µl DMSO and 3µl of 10mM GSK343 or GSK669 were added to each 
3ml mixture of cells + methylcellulose and once again vortexed thoroughly. This achieved a final 
concentration of 10µM of GSK343 in the methylcellulose. The mixture was divided into 1ml aliquots in 
duplicate 35mm gridded tissue culture dishes using a 2ml syringe (BD Biosciences) with a 19G needle. 
These were then placed in a larger 150mm tissue culture dish with an additional 35mm dish containing 
PBS to maintain humidity. They were grown for 7-10 days under standard tissue culture conditions. At 
this stage, the colonies were counted using an inversion microscope, with a colony being reproducibly 
and consistently defined as ≥ 20 cells with a convincing core. 
 
Cell type 
Total number of cells plated per 
3ml methylcellulose 
Methylcellulose type 
AML cell lines 3x104 Methocult H4435 
Murine transformed c-kit+ bone 
marrow cells 
1-1.5x105 
Methocult M3434 
Murine MLL-AF9 leukaemia spleen 
tumour cells cultured in vitro 
1.5x105 
Methocult M3434 
Primary AML samples 2.4x105 Methocult H4435 
 
TABLE 2.2  Numbers of cells plated for clonogenic methylcellulose assays 
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2.3.3 Cell proliferation and viability quantification 
Using CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega G3582), the 
antiproliferative and cytotoxic effects of GSK343 were assayed. This product contains MTS, a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium]. MTS is reduced by viable, metabolically active cells into a coloured, soluble formazan 
product that allows for colorimetric detection. 2x104 cells in 100µl media were seeded into each well 
of a 96-well plate. GSK343 (solubilised in DMSO) was added to the wells at 10 different concentrations 
reducing in a semi-logarithmic manner from 100µM to 100nM. The dilutions were created ensuring a 
final concentration of 1% DMSO within each condition to avoid varying levels of DMSO influencing cell 
proliferation/toxicity. Following 72 hours incubation, 40µl of 96® AQueous One Solution was added to 
each well with further incubation for 3 hours. This was then transferred to an optical plate reader and 
read at 490nm (excitation). Proliferation curves and IC50 values were generated using Prism® 
statistical software.  
 
2.4 Flow cytometry 
All flow cytometry was performed in the Cambridge Institute for Medical Research (CIMR) Flow 
cytometry core facility. 
 
2.4.1 Apoptosis and cell cycle analysis by flow cytometry 
A time course over 96 hours of cellular responses to DMSO, GSK343 and GSK669 (all at 10µM) was set 
up in liquid culture. At each time point of 24, 48, 72 and 96hrs post addition of drug to 2x10^6 cells 
cultured in 4ml media on 6 well plate, 500µl of cells were taken and cellular apoptosis was assessed 
using the Annexin V-FITC kit (Miltenyi Biotec, Catalogue No: 130-092-052), supplemented with 7-AAD 
(BD Bioscience, Catalogue No: 559925) as per manufacturer’s instructions. Another 500µl of cells were 
taken for cell cycle analysis. These were washed in PBS, fixed in 70% ethanol in PBS and kept at -20oC. 
Following this, they were washed in PBS and resuspended in 50µg/ml propidium iodide and 0.1mg/ml 
RNase. Finally the samples were incubated at 37oC for 30 minutes. Flow cytometry was performed on 
a BD LSRFortessa 4-laser machine using FACSDiva analysis software. Data was then analysed with 
FlowJo software (Tree Star Inc.). 
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2.4.2 H3K27me3 assessment by flow cytometry 
To assess for loss of H3K27me3 following Ezh2 inhibition with GSK343, Ezh2fl/fl; Cre wild-type MLL-
AF9 AML spleen tumours (#5340 and #5342) generated from the induction in vivo experiments were 
thawed and passaged as above. 8x106 cells from two MLL-AF9 spleen tumours (biological duplicates) 
were resuspended in pairs in X-Vivo 20 medium supplemented with cytokines (as per Methods 2.2.2) 
at 0.5x106/ml concentrations at Day 0. At 0hr, DMSO and GSK343 (final concentration 10µM) were 
added to each MLL-AF9 tumour. At 24hr, 48hr and 72hrs approximately 2x106 cells were taken from 
each of the DMSO and GSK343 treated conditions – for fixation and staining with: 
a) H3K27me3 antibody conjugated to Alexa Fluor 647 fluorochrome (Abcam, Cat No: ab205729) 
and  
b) Total Histone H3 antibody conjugated to Pacific-Blue fluorochrome (Cell Signaling technology, 
Cat No: 12167) 
At each time point, the remaining cells were washed and returned to 0.5x106/ml concentrations with 
fresh media and DMSO or GSK343 (10µM) 
2.4.2.1 Fixation and permeabilization  
1x106 cells were placed into 1.5ml Eppendorf tubes and centrifuged at 1200rpm for 5 minutes at room 
temperature. They were then resuspended in 100µl of BD Cytofix/Cytoperm solution (BD Biosciences, 
Cat No: 51-2090K2) and incubated for 20 minutes at 4°C. The cells were then washed twice with 500µl 
of a 1:10 dilution of 10x BD Perm/Wash cell permeabilising buffer (BD Biosciences, Cat No: 51-2091K2). 
After two washes, the cells were resuspended in 50µl of BD Perm/Wash buffer containing either 
H3K27me3-Alexa 647 conjugated antibody (1:100 dilution) or Histone H3-Pacific Blue conjugated 
antibody (1:50 dilution) and incubated at 4°C in the dark for 30 minutes. A further two wash steps (as 
already described) were undertaken to remove any excess antibody and the cells were resuspended 
in 200µl of BD Perm/Wash buffer mixed with 1X PBS for flow cytometry.  
Flow cytometry was performed in the CIMR Flow cytometry core, on a BD Biosciences LSRFortessa 4-
laser machine, as already described. Unstained cells were used to gate live cells. The 640 670/14 laser 
was used to detect the Alexa-647 fluorochrome conjugated to H3K27me3 antibody and the 405 450/50 
laser was used for Pacific Blue conjugated to Total H3 antibody. Quantifying a reduction by flow 
cytometry in H3K27me3 following treatment with GSK343 was compared to both lack of reduction in 
H3K27me3 in the DMSO treatment arm and lack of change in both arms in total histone H3 as controls. 
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All flow analyses were done using FACSDiva analysis software. Data was then analysed further with 
FlowJo software (Tree Star Inc.) if required. 
2.4.3 GFP/YFP/mCherry assessment by flow cytometry 
Green and Yellow Fluorescent protein (GFP/YFP) and mCherry were fluorophores used throughout this 
project in several DNA constructs used across the retroviral transduction and overexpression 
experiments. Assessment of these markers by flow cytometry across MLL-AF9 (YFP), AML1-ETO9a 
(GFP) or MOZ-TIF2 (GFP) transformed murine c-kit+ bone marrow cells, mononuclear cells obtained 
from blood samples of mice with these leukaemias and tissues isolated from terminal leukaemic mice, 
allowed an estimation of percentage of transformed cells or leukaemic burden to be made. Both GFP 
and YFP were readily detectable on the same channel 488 530/30 using the BD LSRFortessa machine 
in the CIMR Flow Cytometry Core. The mCherry marker was incorporated into the MSCV-IRES-mCherry 
constructs used to clone candidate genes (Lin28b or Plag1) into for functional assessments. It was used 
to provide a surrogate measure of overexpression of these genes in murine c-kit+ bone marrow cells 
when assessing transduction efficiency, also to track leukaemia development in peripheral blood and 
to assess terminal leukaemia tissue burden. It was readily detectable on the 561 610/20 channel.  
For terminal leukaemia tissues that had been subjected to potential toxicities during processing, in 
order to assess GFP/YFP/mCherry percentages accurately, live cells were gated for using cells negative 
for 7-AAD (Methods 2.4.1) detected on the 561 670/30 channel.  
 
2.5 Protein purification, detection and analysis 
2.5.1 Preparation of cell lysates for GSK343 inhibitor work 
As a similar set up for a time course (Methods 2.4.1), changes in H3K27me3 in the Kasumi AML cell line 
in the presence of GSK343 versus DMSO control were assessed in order to identify a time point of 
maximal inhibition of H3K27-trimethylation. The time points chosen were 24, 48, 96 and 144hr (D1, 
D2, D4 and D6 respectively). Two million Kasumi cells were cultured in 4ml media with either DMSO 
or GSK343 at 10µM concentration. Every 24 hours the cells were counted and media + drug/DMSO 
were refreshed if counts were greater than 1x106/ml, with cells being returned to a 0.5x106/ml 
concentration each time. At each time point, 0.5x106 cells were removed, washed and resuspended in 
1ml cold PBS containing Ca2+/Mg2+. They were then resuspended in 20ml of 2X Dithiothreitol (DTT) 
with repetitive pipetting up and down to shear DNA. Using a hot block, the cells were then boiled for 
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5 minutes at 100oC and spun at 8000rpm for 1 minute. The resulting lysates were then stored at -80oC 
until required for SDS-PAGE and protein transfer.  
 
2.5.2 Preparation of cell lysates for confirmation of overexpression of candidate genes 
Either 293T HEK cells that had been successfully transfected with the MSCV-IRES-mCherry vector 
containing the cloned candidate gene insert (Lin28b or Plag1) OR transduced wild-type murine c-kit 
selected bone marrow cells with the same were used to prepare cell lysates for an assessment of 
overexpression of the protein for each candidate gene. Approximately 106 transfected or transduced 
cells were washed and resuspended in 40µl Laemmli buffer (made as below) supplemented with 2µl 
of 5% β-mercaptoethanol (Sigma; Cat No: M6250) and 0.4µl of protease inhibitor (Sigma Cat No: 11 
873 580 001). These were transferred to 1.5ml TPX sonication tubes (Diagenode; Cat No: C30010009), 
secured into a precooled Diagenode Bioruptor Plus machine and sonicated on “high” setting for 10 
cycles (30seconds on; 45 seconds off) to break down DNA interfering with the sample processing. 
These were transferred on ice to a heat block at boiled at 100oC for 5 minutes and spun at 8000rpm 
for 1 minute. The resulting lysates were then stored at -80oC until required for SDS-PAGE and protein 
transfer. 
Laemmli buffer 
3.125ml 1M Trisma pH 6.8 
5ml 20% SDS 
10ml 50% glycerol 
5ml 0.1% bromophenol blue 
26.875ml Ultra-pure water 
 
2.5.3 SDS-PAGE and protein transfer  
A 12.5% Polyacrylamide gel was prepared between 1.5mm glass spacer plates: 
Lower 12.5% gel 
6.25ml Acrylamide 
3.75ml Lower gel buffer – containing 1.5M Tris and 0.4% SDS, pH to 8.8 (with HCl) 
5ml Water 
10µl TEMED 
50µl APS 
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1ml of isobutanol was overlayed on this gel to ensure an evenly horizontal upper gel surface. After the 
gel was set, the isobutanol was poured away and any excess dried with Whatman 3MM paper.  
The stacking gel was then prepared as follows: 
Upper gel 
400µl Acrylamide 
800µl upper gel buffer – containing 0.5M Tris and 0.4% SDS, pH to 6.8 (with HCl) 
1.9ml water 
3.13µl TEMED 
15.7µl 10% APS 
 
The stacking gel was set above the lower gel and wells were formed by placement of a 1.5mm plastic 
comb. Once solidified, the comb was removed and the gel assembled into an electrophoresis chamber 
(BioRad) filled with 1x Laemmli buffer (containing Tris pH 6.8, SDS, glycerol and bromophenol blue as 
above). Each lysate was diluted 1:5 with 5x Laemmli buffer, denatured at 95oC for 3-5 minutes and 
then loaded into the wells created on the gel following comb removal. Any spare wells/lanes were 
loaded with sample buffer to ensure even running across the gel, when run at a constant 30mA over 
an hour. 
A Polyvinylidene Difluoride (PVDF) membrane was then cut to match the size of gel and activated by 
immersion into 100% methanol for a few minutes (with subsequent washing with water). A large 
transfer container was then filled with CAPS transfer buffer in preparation for transfer. The gel and 
PVDF membrane were layered sequentially into a cassette, whilst submerged in transfer buffer, 
between sponge and Whatman 3MM paper and bubbles were removed using a roller. The cassette 
was transferred to the container with an ice box to prevent overheating, and run for 2 hours at a 
constant 200mA. After completion of wet transfer, the membrane was labelled to highlight the side 
opposed to the gel during transfer. 
 
2.5.4 Western Blotting 
The membrane was then immersed in blocking buffer composed of 5% dried milk powder in 1x 
PBS/0.1% Tween20 for 1 hour at room temperature.  Following this, it was stained overnight at 4oC 
with appropriate antibodies (e.g. for H3K27me3, Lin28b, Plag1 and β-Actin or GAPDH as loading 
controls) made to the appropriate dilution as per manufacturer’s instructions (in a Falcon tube placed 
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on a roller for constant agitation) in 5% milk powder and PBS/Tween (as above). It was then washed 
every 10 minutes with PBS/Tween for an hour, utilising a platform rocker. Secondary antibody 
conjugated to horseradish peroxidase was made up to the appropriate dilution in 0.5% milk powder 
and PBS/Tween and the membrane was submerged in this for 1 hour at room temperature. The blot 
was then washed as previously with excess buffer removal via filter paper and the membrane was 
immersed in Amersham ECL solution for 5 minutes.  
 
2.5.5 Developing Western blot 
Hypercassette method 
After drying, the membrane was encased in cling-film and taped inside a Hypercassette (Amersham 
Biosciences) with a marker attached for orientation and exposed to x-ray film for 2-10 seconds 
(dependent upon the strength of antibody, in order to achieve a good quality exposure) and 
developed. 
Licor Odyssey 
After secondary antibody staining for 30 minutes at room temperature with Donkey Anti-Rabbit: green 
or Goat Anti-Mouse: Red the membrane was washed with 5% milk powder and TBST as above and 
then developed on a Licor Odyssey instrument, with images of the Western Blot being captured 
directly to computer via the supplied ImageStudio software.  
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2.6 Mouse work and development of induction and maintenance in vitro / in vivo models 
2.6.1 Animal husbandry 
All regulated procedures were performed in accordance with Huntly group Project license numbers 
80/2454 and P86C400DB. Any procedures outlined in this report were completed under my personal 
Home Office licence and included irradiation, blood sampling, ear notching for identification purposes, 
intraperitoneal injections and humane sacrifice under Schedule 1. Direct supervision and 
training/assistance with these procedures was kindly provided by Dr George Giotopoulos (Huntly 
group) who also performed all tail vein injections required for the transplant experiments.  
2.6.2 Ezh2 fl/fl tissues 
Through collaboration with Dr George Vassiliou’s laboratory, Wellcome Trust Sanger Centre, Hinxton, 
Cambridge UK, the Huntly laboratory had access to existing Sanger C57/Bl6 strain mice engineered to 
have a loxp site flanking exon 9 of the Ezh2 sequence (“Ezh2 fl/fl” mice) in a homozygous fashion.2 
Breedings between these and mice homozygous for Mx1-Cre recombinase were set up courtesy of Drs 
Milena Mazan and Monika Dudek, Vassiliou group and subsequently litters of Ezh2 fl/fl; wild-type for 
Mx1-Cre (henceforth ‘Ezh2 fl/fl; wt’ or ‘wt’) or Ezh2 fl/fl; heterozygous for Mx1-Cre (henceforth ‘Ezh2 
fl/fl; Cre+’ or ‘Cre+’), mice were generated and selected for use following genotyping to confirm Mx1-
Cre status. Ezh2 fl/fl; Mx1-Cre homozygous mice were not used due to well documented issues with 
Cre-mediated toxicity.  
For both in vitro and in vivo induction experiments, 5-6 mice from each wt or Cre+ litter generated 
were used (ensuring animals were age and sex-matched) to provide bone marrow (BM).  
For maintenance in vitro experiments, 5-6 wt mice were used, and for the maintenance in vivo 
experiments 5-6 Cre+ mice were used to generate the primary leukaemias. 
2.6.3 Ezh2 Genotyping 
Due to this project being heavily dependent on accurately assessing Ezh2 excised vs unexcised states 
(and their intermediaries), it was very important able to quantify these accurately at various stages 
during setup and analysis of these experiments. In order to do this, a qPCR strategy was developed and 
optimised through guidance from Dr George Giotopoulos (Huntly group) in order to better 
quantify/estimate levels of excision. A standard PCR and gel method, though able to provide an 
assessment of “excised or unexcised”, was at best semi-quantitative.  
33 
 
Therefore, primers coding for a 150bp sequence within the loxp sites surrounding exon 9 of Ezh2 were 
designed and a similar pair of primers (with identical melting temperatures) for an equal length 150bp 
sequence very closely downstream of the loxp sites (that would be unaffected by excision and 
therefore maintained during PCR amplification) were created (Figure 2.2).  
 
 
 
 
  
 
 
 
 
 
Ezh2 fl/fl primers -    Forward sequence: TATGGGGGATGAAGTTCTGG 
    Reverse sequence: CCACTGTCATGGCAACAAGA 
 
Ezh2 unexcised primers -   Forward sequence: CTTCTTCCTCCGGGTCTCTC   
    Reverse sequence: GATCTTGGGGCATTGCAGTA 
 
 
 
In the Ezh2 unexcised state, these primers would amplify their respective sequences at an 
approximately 1:1 ratio given identical sequence sizes. In the Ezh2 excised state, the “Ezh2 fl/fl” 
primers would fail to amplify whilst the “Ezh2 unexcised” primer pair would amplify. All qPCR was done 
using a Stratagene MX3000P machine and data analysed through MxPro qPCR software. Each reaction 
used 10-20ng DNA and SYBR Green reagent (Ultrafast III, Agilent Technologies). 
Trialling these two pairs of primers on control DNA (where Ezh2 was known to be floxed but not excised 
i.e. “Ezh2 fl/fl”) showed almost identical amplification between both primer pairs as evidenced by very 
FIGURE 2.2 Primer design for assessing Ezh2 excision via qPCR 
In the unexcised state, both pairs of primers amplify at a 1:1 ratio by qPCR due to similar melting temperatures and identical 
sequence length. In the excised state, “Ezh2 fl/fl” primers are unable to amplify the region in relation to “Ezh2 unexcised” 
primers. This difference was consistent and when compared within the sample and then to a control sample subjected to the 
same qPCR reaction, the ratio of the difference in Ct values was used to provide an estimation of level of excision 
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similar average Ct values (average Ct: 23.27 for “Ezh2 fl/fl” primers vs average Ct: 23.795 for “Ezh2 
unexcised” primers), (Figure 2.3):  
 
 
 
When tested in an Ezh2 deleted scenario (“Ezh2 -/-”, Figure 2.4), as expected, amplification with the 
“Ezh fl/fl” primer pair was significantly decreased, therefore the average Ct value for this was typically 
higher when compared to the normal amplification attained by the “Ezh2 unexcised” primer pair 
(average Ct: 27.685 for “Ezh2 fl/fl” primers vs average Ct: 23.635 for “Ezh2 unexcised” primers):  
 
 
 
In both the control (Ezh2 fl/fl) and test sample (Ezh2 -/-), this change in average Ct value between both 
pairs of primers was calculated (∆Ct) (Figure 2.5):  
 
 
 
As seen in Figure 2.5, the ∆ Ct value for the Ezh2-/- sample (4.05) was considerably different to the ∆ 
Ct value attained in the control DNA (-0.525). This reflected the difference in Ezh2 states (unexcised in 
the control, and excised to an unknown proportion in Ezh2 -/-). Using the control DNA ∆ Ct value as 
the normal, the ∆ Ct value for Ezh2-/- was then subtracted from it, providing an estimation of the 
differences in amplification seen between the control and Ezh2-/- (∆∆Ct) (Figure 2.6): 
fl/fl Unexcised
Average  Average
EZH2 fl/fl 22.93 23.39 23.49 23.27 23.63 23.96 23.8 23.795 -0.525
Un. (3) ∆CtSample fl/fl (1) fl/fl (2) fl/fl (3) Un. (1) Un. (2)
fl/fl Unexcised
Average  Average
Ezh2 -/- 27.8 27.57 27.685 23.74 23.53 23.635 4.05
fl/fl (1) Un. (3) ∆CtUn. (2)Un. (1)fl/fl (3)fl/fl (2)Sample
fl/fl Unexcised
Average  Average
EZH2 fl/fl 22.93 23.39 23.49 23.27 23.625 23.96 23.8 23.795 -0.525
Ezh2 -/- 27.8 27.57 27.685 23.74 23.53 23.635 4.05
fl/fl (1) Un. (3) ∆CtUn. (2)Un. (1)fl/fl (3)fl/fl (2)Sample
FIGURE 2.3  Ct values on qPCR using Ezh2 fl/fl primers versus Ezh2 unexcised primers 
   “Ezh2 fl/fl” is Control DNA obtained from Ezh2fl/fl; wild-type for Mx1-Cre murine HSPCs.  
Mean average from triplicates 
FIGURE 2.4  Ct values on qPCR using Ezh2 fl/fl primers versus Ezh2 unexcised primers 
Ezh2 -/- is test DNA from Ezh2 fl/fl; Mx1-Cre+ murine HSPCs that have undergone pIpC to induce Ezh2 
deletion. 
    
FIGURE 2.5  ∆ Ct values for control and test samples 
“Ezh2fl/fl”: control unexcised DNA as above; Ezh2 -/- is test DNA (where Ezh2 deletion is expected, as 
above) 
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This ∆∆ Ct value reflected the number of additional cycles required by the primers to amplify in Ezh2 -
/- compared to the control sample and when this was resolved using 2^(∆∆ Ct), a final value was 
generated (termed “2nd Ct”), which reflected the proportion of unexcised DNA in the sample. Knowing 
that no excision had taken place in the control sample, the unexcised proportion was taken to be 100%. 
By comparison in Ezh2-/-, there was only 4.2% unexcised, therefore approximately 95.8% excision 
(Figure 2.7): 
 
 
 
Thus, by comparing test sample ∆ Ct values with control DNA ∆ Ct values (where 100% of Ezh2 was 
intact) each time, it was possible to generate an approximation of Ezh2 excision, expressed as a 
percentage.  
This assay was validated against a semi-quantitative PCR strategy developed separately, consisting of 
one forward primer upstream (F1) of the initial loxp site and two reverse primers (R1: within the loxp 
sites and R2: downstream of the second loxp site). The PCR products of F1+R1 and F1+R2 yield the 
following bands depending upon Ezh2 state (Figure 2.8): 
 
Ezh2 fl/fl unexcised   Ezh2 fl/fl excised   Wild-type 
F1+R1 = 533bp    F1+R1 = no band   F1+R1 = 316bp 
F1+R2 = 1254bp   F1+R2 = 407bp    F1+R2 = 955bp 
fl/fl Unexcised
Average  Average
EZH2 fl/fl 22.93 23.39 23.49 23.27 23.625 23.96 23.8 23.795 -0.525 0
Ezh2 -/- 27.8 27.57 27.685 23.74 23.53 23.635 4.05 -4.575
fl/fl (1) Un. (3) ∆Ct ∆∆CtUn. (2)Un. (1)fl/fl (3)fl/fl (2)Sample
Sample ∆Ct ∆∆Ct 2ndCT Unexcised proportion Excision efficiency
EZH2 fl/fl -0.525 0 1 100 0
Ezh2 -/- 4.05 -4.575 0.042 4.195539071 95.80446093
FIGURE 2.6  ∆∆Ct values for control and test samples 
“Ezh2fl/fl”: control unexcised DNA as above; Ezh2-/- is test DNA (where Ezh2 deletion is expected, as 
above) 
FIGURE 2.7  Calculation of Ezh2 excision in control and test samples 
“Ezh2fl/fl”: control unexcised DNA as above; Ezh2-/- is test DNA (where Ezh2 deletion is expected, as 
above) 
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F1: CCTGCAGCAGTTTCCTTTCTTA, R1: CCCATGTGGTAGGCAGAGAA, R2: CAGCGACACCCCAGAAAATT 
 
When known Ezh2 excised and unexcised DNA controls were run alongside four MOZ-TIF2 and four 
AML1-ETO9a DNA samples with an expected excised status, the qPCR strategy provided the following 
results (Table 2.3): 
 
 
 
Sample fl/fl primers Unexcised primers ∆ Ct ddCt 2ndCT Unexcised Excision efficiency
average average proportion
1 (Excised) 29.32 24.525 4.795 -4.533 0.043185 4.32 95.68
2 (Excised) 29.475 24.345 5.13 -4.868 0.034236 3.42 96.58
1 (unexcised) 24.68 24.235 0.445 -0.183 0.880666 88.07 11.93
2 (unexcised)** 24.56 24.30 0.26 0 1 100.00 0.00
1 (MOZ-TIF2) 26.635 24.39 2.245 -1.983 0.252905 25.29 74.71
2 (MOZ-TIF2) 26.695 24.91 1.785 -1.523 0.347881 34.79 65.21
3 (MOZ-TIF2) 26.53 24.61 1.92 -1.658 0.316805 31.68 68.32
4 (MOZ-TIF2) 25.605 24.255 1.35 -1.088 0.470304 47.03 52.97
1 (AML1-ETO9a) 26.18 24.595 1.585 -1.323 0.399611 39.96 60.04
2 (AML1-ETO9a) 28.02 24.36 3.66 -3.398 0.094842 9.48 90.52
3 (AML1-ETO9a) 26.015 24.26 1.755 -1.493 0.355191 35.52 64.48
4 (AML1-ETO9a) 26.67 24.39 2.28 -2.018 0.246843 24.68 75.32
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FIGURE 2.8  Primer design for assessing Ezh2 excision by PCR and Gel electrophoresis 
 
TABLE 2.3  Assessment of Ezh2 excision in unknown Ezh2 status samples using qPCR 
Samples indicated in Yellow are known excised controls and red are known unexcised controls.  
Levels of excision highlighting in bold (final column – “Excision efficiency”) 
(** control sample in which 1:1 amplification is expected. All other sample ∆Ct values compared to this 
control when calculating change in ∆Ct to assess excision efficiency) 
37 
 
 
When the same samples were run using the PCR and gel strategy (shown in Figure 2.9 - labels are 
colour matched to Table 2.3), the MOZ-TIF2 and AML1-ETO9a unknowns all demonstrated clear 
excision, with band intensities visually comparable to the percentages of excision calculated by the 
qPCR method.  
 
 
 
 
 
 
 
 
 
 
 
 
With successive repeats (data not shown), the qPCR method proved to be a reliable means of assessing 
levels of Ezh2 excision and was comparable to assessing bands on agarose gels after PCR using a 
traditional primer strategy as described above. It had the added advantage of being able to quantify 
levels of excision approximately in terms of percentages, thereby allowing a fairer comparison across 
in vitro and in vivo samples that required genotyping throughout this PhD project, therefore this 
method was used for genotyping and assessing Ezh2 deletion in all experiments described. 
 
 
 
FIGURE 2.9  Assessment of Ezh2 excision in unknown Ezh2 status samples using PCR & Gel 
F1+R1 and F1+R2 primers used for PCR 
 
Excised controls (yellow):  show intense 407bp band expected in excised state and less intense 533bp band reflecting 
a small proportion in the unexcised state 
Unexcised controls (red):   show a single 533bp band expected in unexcised state 
Test samples (blue/green): all demonstrate varying levels of excision (both 407/533bp bands of varying intensities) 
directly comparable to estimated percentage of excision by qPCR method 
 
*additional faint band seen across test samples at 316bp position reflects residual wild-type status, as samples were 
taken from primary transplants into wild-type recipients, therefore reflect chimerism   
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2.6.4 Ezh2 deletion and bone marrow harvesting 
 
2.6.4.1 Induction experiments 
At 6 weeks of age both Ezh2 fl/fl; wt and Ezh2 fl/fl; Cre+ mice were subjected to 
polyinosinic:polycytidylic acid (pIpC) injections to facilitate Cre-mediated excision in the Cre+ group. 
Four weeks following pIpC, peripheral blood samples from each animal from both groups were 
obtained for genotyping to ensure Ezh2 excision had occurred in the Cre+ group and that no excision 
had occurred in the wt group. After this, both cohorts were culled humanely and both femurs and tibia 
were harvested from each mouse. Both in vitro and in vivo induction experiments utilised bone marrow 
harvested from the above genotypes treated with pIpC in this way.  
2.6.4.2 Maintenance experiments 
For in vitro experiments only Ezh2 fl/fl; wt mice at 8-12 weeks of age were required. These were 
genotyped for Ezh2 status using peripheral blood samples prior to bone marrow harvesting. 
For in vivo experiments only Ezh2 fl/fl; Cre+ mice at 8-12 weeks of age were required. These were again 
genotyped for Ezh2 and Mx1-Cre status using peripheral blood samples prior to bone marrow 
harvesting. There was no pIpC treatment beforehand as the conditional knockout was required only 
at the secondary transplantation stage.  
2.6.4.3 Functional validation of candidate genes (Lin28b, Plag1) 
For these experiments, 5-8 wild-type C57/Bl6 mice aged 8-12 weeks were used to provide bone 
marrow. Harvesting of bone marrow cells was done as already described in this section. Their 
processing for c-kit selection, transduction and in vitro (Western blot, qPCR) and in vivo work 
(transplantation) is as described in the relevant sections. 
 
Under sterile conditions, the bones from each animal were flushed with 20-30ml sterile 1xPBS through 
a 70µm EASYstrainerTM (Greiner) into separate 50ml Falcon tubes on ice, centrifuged at 1200rpm, 4oC 
and the cell pellet resuspended in 5ml of RBC lysis solution (5 Prime GmbH, Cat No: 2301310) for 5 
minutes. Red cell lysis was stopped by addition of 45ml PBS and total BM cell number was counted via 
CASY Counter. At this stage 1x106 whole BM cells from each mouse were stored for genotyping.  
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2.6.5 c-kit selection 
All samples were centrifuged again and wt cells were pooled together separately from Cre+ cells by 
resuspending in FcR mouse blocking reagent (Miltenyi Biotec, Cat No: 130-092-575) as per 
manufacturer’s instructions and MACS buffer (500 ml PBS without Ca/Mg, 2.5 g BSA and 2 ml of 0.5 M 
EDTA, filter sterilised). Following this, CD117 (c-kit) mouse Microbeads (Miltenyi Biotec, Cat No: 130-
091-224) were added and incubated as per manufacturer’s instructions then passed through a pre-
separation 30µm filter and MACS LS separation column (Miltenyi Biotec, Cat No: 130-041-407 and 130-
042-401 respectively) attached to a midiMACS magnetic separator (Miltenyi Biotec, Cat No: 130-042-
301). C-kit selected cells were trapped in the column attached to the magnetic separator and the flow 
through contained c-kit negative cells. The column was then removed and flushed separately to release 
c-kit positive cells from both wt and Cre+ pools. Total cell numbers yielded were confirmed using a 
CASY counter. Typically, c-kit selection efficiency using this method was approximately 10% of total 
BM cells, with assessment of purity by flow cytometry following CD117-PE staining. 
Following this, c-kit positive cells were resuspended at 1x106 cells/ml in RPMI+20%FCS media, 
supplemented with mIL-3, IL-6 and mSCF cytokines, (PeprotechTM; final concentrations of 10ng/ml, 
10ng/ml and 100ng/ml respectively) and cultured overnight at 37oC in 12-well plates for retroviral 
transduction the following morning (Methods 2.6.7). 
 
2.6.6 Production of retroviral supernatant 
In accordance with Institution guidelines, all retroviral work was carried out under Category II 
laboratory conditions. The Huntly laboratory possesses MSCV-IRES-GFP/YFP backbone constructs 
harbouring MOZ-TIF2 (GFP marker) and MLL-AF9 (YFP marker) oncogenes and a MIGR1 construct that 
contains the AML1-ETO9a oncogene (GFP marker): 
1) MSCV-IRES-MLL-AF9-YFP (referred to as ‘MLL-AF9’ in Methods 2.6.6.1 and 2.6.7.2) 
2) MSCV-IRES-MOZ-TIF2-GFP 
3) MIGR1-AML1-ETO9a-GFP (https://www.addgene.org/12433/) 
These were used to transfect 293T cells as follows: 
293T cells were passaged, using Trypsin-EDTA (Thermo Scientific, Cat No: 25200056) to detach from 
plates, under standard tissue culture conditions in DMEM + 10% FCS medium + L-glutamine, on 10cm 
sterile plates. 2.5x106 cells were plated on Day 0 and incubated overnight. At Day 1, provided the cells 
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were 50-70% confluent, transfection was completed using an incubated mixture of 5µg ψ eco with 
47.5µl TranSIT LT1 reagent (Mirus, Cat No: MIR2300) added dropwise to 600µl Optimem media (Life 
Technologies, Cat No: 31985062) with 5µg of construct DNA. The mixture was added dropwise to the 
plates whilst rocking to ensure even mixing then incubated at 37oC overnight. At Day 2, the media was 
replaced with 6ml RPMI+20%FCS media and the cells were incubated at 32oC overnight. On Day 3 (48hr 
post transfection) retroviral supernatant was harvested and filtered through 45µm filters on ice to 
remove any detached 293T cells. Supernatant was stored in aliquots at -80oC.  A further 6ml media 
was added and again incubated overnight so that more supernatant could be harvested at Day 4 (as 
per Day 3).  
2.6.6.1 Functional validation of candidate genes (Lin28b, Plag1) 
For this experiment, retroviral supernatant from 293T cells either single or dual-transfected with the 
following constructs was collected: 
1) MLL-AF9 alone 
2) MLL-AF9 + MSCV-IRES-Lin28b-mCherry 
3) MLL-AF9 + MSCV-IRES-Plag1-mCherry  
The procedure for transfection was exactly as described above, with the only difference being in the 
dual-transfection, where 2.5µg of DNA of MLL-AF9 + 2.5µg DNA of candidate gene inside MSCV-IRES-
mCherry vector (as listed here) was used to generate retroviral supernatant containing both constructs 
at a 1:1 ratio. This was stored as described above. 
 
2.6.7 Retroviral transduction 
2.6.7.1 Induction and maintenance experiments 
Retroviral supernatant aliquots for each oncogene AML1-ETO9a, MOZ-TIF2, MLL-AF9 were thawed 
slowly on ice under sterile conditions, and the c-kit positive cells (wt or Cre+) were split into three 
portions depending on total viable cell number appropriate to an estimation of cells required for 
transplant per mouse for each oncogene. After resuspension in retroviral supernatant (1ml 
supernatant per 1x106 cells) supplemented with cytokines (as in Methods 2.6.5) and polybrene to a 
final concentration of 8ng/µl, the cells were distributed evenly across a 12 or 24-well plate and 
centrifuged at 2500rpm for 90 minutes at 30oC. Following this the plates were incubated for 3-4 hours 
at 37oC at which point the media was changed (after centrifugation and resuspension) to RPMI+20% 
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FCS + cytokines but lacking polybrene, as above. The cells were then incubated overnight. A second 
round of retroviral transduction (as described) was performed on the cells the following morning, after 
which they were washed three times in sterile PBS. 
2.6.7.2 Functional validation of candidate genes (Lin28b, Plag1) 
Retroviral supernatant for MLL-AF9 alone or MLL-AF9 + either a) MSCV-IRES-Lin28b-mCherry or b) 
MSCV-IRES-Plag1-mCherry was thawed as above. Following c-kit selection, the cells were split into 
three conditions and transduced with MLL-AF9 viral supernatant alone or MLL-AF9 + a) MSCV-IRES-
Lin28b-mCherry or b) MSCV-IRES-Plag1-mCherry. The transduction procedure is as described above. 
 
2.6.8 Assessment of transduction efficiency 
2.6.8.1 Induction and maintenance experiments 
Following two rounds of transduction and three washes, cell numbers were attained for wt and Cre+ 
c-kit positive cells for each oncogene and 105 cells were taken to assess transduction efficiency by flow 
cytometry (as per Methods 2.4.3) as each construct expressed GFP (MOZ-TIF2 or AML1-ETO9a) or YFP 
(MLL-AF9). The same channel (488 530/30) was used to detect both. On average there was a 1-5% 
transduction rate for MLL-AF9 and MOZ-TIF2 (due to larger construct size) and 15-25% rate for AML1-
ETO9a (smaller construct). Following this, cells were either plated into methylcellulose for assessment 
in vitro, or injected into C57/Bl6 wild-type sub-lethally irradiated mice and monitored for development 
of leukaemia.   
2.6.8.2 Functional validation of candidate genes (Lin28b, Plag1) – flow cytometry 
Following transduction, flow cytometry was used to assess efficiency using 488 530/30 filter for YFP 
(MLL-AF9) and 561 610/20 for mCherry (candidate genes). An assessment of percentage of single-
transduced YFP or mCherry cells and double-transduced YFP+mCherry cells was made. After this, it 
was possible to calculate the appropriate number of YFP positive cells for injection into each arm of 
the in vivo study to ensure an equal dose of MLL-AF9 transduced cells was given.  
2.6.8.3 Functional validation of candidate genes (Lin28b, Plag1) – quantitative RT-PCR 
Following transduction, RNA was isolated from 1x106 cells as per section 2.8.14.2 and cDNA was 
generated as per Section 2.7.1.1 to quantitate mRNA. A 20µl reaction was prepared in 96 well plates 
(using 10µl SYBRGreen master-mix, 1µl each of forward and reverse primers (to a final concentration 
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of 10µM), 1µl cDNA, ROX fluorescent reference dye 0.3µl of 1:500 dilution and 6.7µl RNase-free 
water). PCR amplification was performed with an initial step of 10 minutes at 95°C, followed by 40 
cycles of 15 seconds at 95°C and 1 minute at 60°C. All samples were measured in duplicate and the 
mean Ct values were used to calculate relative expression levels. The reference housekeeping genes 
used were β-actin and GAPDH.  
 
2.6.9 Irradiation and primary transplantations 
Where transduced c-kit positive wt or Cre+ cells were used for in vivo transplantation, the recipient 
C57/Bl6 wild-type mice had been ear notched prior for identification purposes, and given sub-lethal or 
lethal irradiation (a single 5.5Gy dose or two doses of 5.5Gy on consecutive days respectively). In order 
to reduce skewing of results due to variability in cell numbers injected per mouse, the transduction 
efficiency was used to calculate an approximate number successfully transduced cells, i.e. GFP/YFP-
positive (in the induction and maintenance experiments) or a ratio of YFP/mCherry to YFP positive cells 
(in the functional validation experiments) that were then resuspended in the correct volume of sterile 
PBS required for tail-vein injections. As a result, for example in the induction in vivo experiment, each 
mouse transplanted with wt cells received approximately the same number of GFP/YFP-positive cells 
as per the mice transplanted with Cre+ cells, ensuring a fair comparison between the two cohorts for 
each oncogene. The same process was applied when calculating appropriate cell numbers for 
transplantation in the functional validation experiments (MLL-AF9-YFP single-transduced vs MLL-AF9-
YFP + MSCV-IRES-Lin28b/Plag1-mCherry dual-transduced).  
Each mouse received cells in a 200µl volume via tail vein injection. Following injection all mice received 
enrofloxacin prophylaxis (BaytrilTM) for two weeks and were monitored closely for signs of disease, 
with serial peripheral bleeds and assessment of GFP/YFP expression and blood counts and clinically for 
signs of leukaemia. When mice showed clinical signs (piloerection, hunched posture, inactivity, 
inappetence, weight loss >20% compared to non-injected age-matched mice, dyspnoea) they were 
humanely sacrificed under Schedule 1 of the Animals Scientiﬁc Procedures Act 1986.  
 
2.6.10 Murine leukaemia tissue processing/storage 
Bone marrow and splenic tissues were processed under sterile conditions after flushing, filtering, red 
cell lysis and washing (as per Methods 2.6.4) and frozen in liquid nitrogen in FCS+10%DMSO aliquots. 
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For every animal, GFP/YFP expression in terminal peripheral blood, bone marrow and spleen was 
assessed by FACS and recorded. Other organs were stored in Formalin (heart, lungs, sternum, liver, 
kidneys, bowel) and later embedded in wax for sections to be made and stained. Cytospins of bone 
marrow, splenic tissue (2-4x105 cells/slide) were made and fixed along with a terminal blood film and 
stained using the Rapid Romanowsky stain (TCS Biosciences, Cat No: HS705). Histological preparations 
of murine tissues and staining were kindly performed by Dr George Giotopoulos (Huntly group). Images 
were taken using Olympus BX51 microscope with a Pixera 600ES camera and the software for image 
acquisition was Viewfinder Version 3.01 (Pixera). DNA was extracted from spleen or bone marrow for 
genotyping for each culled mouse (as per Methods 2.8.14.1). Peripheral blood counts were performed 
on a Woodley ABC blood counter (Woodley). 
 
2.6.11 Induction in vitro assays 
Following transduction of wt or Cre+ c-kit bone marrow cells from mice pre-treated with pIpC to induce 
Ezh2 deletion for each oncogene (MLL-AF9, AML1-ETO9a or MOZ-TIF2), 3.3-5x104 transduced cells 
were plated for every one millilitre of M3434 methylcellulose. These were then serially replated on a 
weekly basis, with an assessment of total colony and cell number being made at each stage. The overall 
experimental plan is depicted in Figure 2.10. 
 
2.6.12 Maintenance in vitro assays 
In order to set up this experiment, steps from harvesting bone marrow of Ezh2 fl/fl;wt Cre mice (aged 
8-12 weeks) through to generation of the three transformed cell lines were performed (as detailed 
above). GFP/YFP expression was measured by FACS and increased as expected with each successive 
replating. By week 4-5 all three cell lines had GFP/YFP levels consistently above 95%, and from 
assessment of colony appearance, number and rapid increase in total cell number per plate, appeared 
immortalised.  
In order to then excise Ezh2 in these established cell lines, they were taken into liquid culture (RPMI 
media + 20% FBS supplemented with cytokines initially and maintained at a concentration between 
0.5-1x106/ml. After 2-3 passages on alternate days, they were resuspended into RPMI + 20% FBS with 
mIL-3 alone (in order to reduce cellular differentiation). Using a p-babe-Cre-puro and p-babe-puro 
empty vector (already available in the Huntly lab) to generate retroviral supernatant, the cell line was 
split into two arms and then subjected to a second round of retroviral transduction with either vector. 
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The transduced cells were finally seeded into M3434 methylcellulose plates (at 3.3–5x104 per ml) with 
or without 1µg/ml puromycin (Thermo Scientific, Cat No: A1113803) and assessment of colony/total 
cell number was made at Day 7.  
Cells remaining in either conditions at Day 7 were replated into fresh M3434 at the same 
concentrations to allow further rounds of replating. At each weekly replating, an assessment of total 
colony number and cell number was made.  The overall experimental plan is depicted in Figure 2.11. 
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FIGURE 2.10 Experimental plan for assessing the role of Ezh2 in leukaemic induction in vitro 
Ezh2 fl/fl; wt or Ezh2 fl/fl;Mx1-Cre+ mice at 6 weeks of age were treated with pIpC to induce Ezh2 deletion in Cre expressing mice (confirmed by 
genotyping from peripheral blood at 4 weeks post treatment). BM from these two cohorts was then harvested and c-kit positive HSPCs selected and 
pooled as either Ezh2 non-excised or excised cells in liquid culture (with RPMI 1640+20% FCS supplemented with cytokines as detailed in main text). 
Following retroviral overexpression of the 3 oncogenes listed above in both groups of HSPCs, the cells were cultured in methylcellulose assays to 
assess clonogenic/proliferative function and compared with each other over subsequent weeks of replating as immortalisation took place. 
 
“wt” denotes wild-type for Mx1-Cre, “Mx1-Cre+” denotes heterozygous for Mx1-Cre, “c-kit+” denotes c-kit/CD117 positively selected HSPC’s 
M3434 = Methocult GF M3434 methylcellulose medium for mouse cells with cytokines (StemCell Technologies) 
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FIGURE 2.11  Experimental plan for assessing the role of Ezh2 in maintenance of AML in vitro 
1) Generate Ezh2 fl/fl leukaemia cell lines: Bone marrow from Ezh2 fl/fl; wt mice at 8-12 weeks of age was harvested and c-kit positive HSPCs were selected, pooled 
and divided into 3 arms. Each then underwent retroviral transduction of the 3 oncogenes listed above and was allowed to transform over successive methylcellulose 
replatings. GFP/YFP percentage and colony number/appearance assessments at each replating provided a clear assessment of when transformation had occurred.  
 
2) Excise Ezh2 in established leukaemic cell lines: Once established, these cells were taken into liquid culture (in RPMI 1640+20% FCS supplemented with cytokines as 
in main text), transduced either with a p-Babe-puro empty vector or a p-Babe-Cre-puro vector containing a Cre-recombinase (both vectors included puromycin as 
a selection marker) and cultured +/- puromycin in methylcellulose. Transduction with a retroviral Cre would lead to Ezh2 deletion and the inclusion of an empty 
vector arm would assist with assessing any Cre-mediated toxicity 
 
 
“wt” denotes wild-type for Mx1-Cre, “c-kit+” denotes c-kit/CD117 positively selected HSPC’s 
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2.6.13 Induction in vivo model  
wt (Ezh2+/+) or Cre+ (Ezh2-/-) cells from Ezh2fl/fl mice of either genotype (pre-treated with pIpC to 
induce Ezh2 deletion in the Cre+ arm) were transduced as described. After assessment of transduction 
efficiency, an equal number of transduced cells were transplanted into lethally irradiated C57/Bl6 wild-
type recipient mice, generating Ezh2+/+ and Ezh2-/- leukaemia arms for each oncogene. These were bled 
at Day 14-21 and their full blood counts assessed to ensure adequate engraftment. They were then 
followed through regular assessment and blood sampling for development of leukaemia as described 
above. The overall experimental plan is depicted in Figure 2.12. 
 
2.6.14 Maintenance in vivo model  
The overall experimental plan for this is depicted in Figure 2.13. 
 
2.6.14.1  Generation of primary leukaemias 
Generation of primary murine leukaemias for each oncogene (n=5 per oncogene) was performed as 
described in Methods 2.6.9. The only difference for this part was that Ezh2 fl/fl; Cre+ mice (without 
any Mx1-Cre prior activation i.e. pIpC treatment) exclusively were harvested to provide HSPCs for 
retroviral transduction. Five mice per oncogene were used to generate sufficient leukaemic tissue for 
secondary transplants.  
 
2.6.14.2  Maintenance in vivo model – secondary leukaemias and Ezh2 deletion 
Following generation of primary leukaemias, when mice were terminal, bone marrow and splenic 
tissues were harvested and GFP/YFP expression was assessed and recorded before freezing at -80oC. 
Immunophenotyping was performed to characterise and confirm the leukaemia with genotyping of 
spleen cells to assess for any spontaneous recombination. Secondary recipient animals chosen were 
wild type C57/Bl6 mice at the age of 8-12 weeks. Each secondary recipient underwent lethal irradiation 
as per Methods 2.6.9.  
Following this, for each of the three leukaemias to be tested (i.e. MLL-AF9 / AML1-ETO9a / MOZ-TIF2), 
1x106 spleen cells (in a volume of 200µl sterile PBS) were injected intravenously per animal (n= 20, 
divided into two arms), and close monitoring (via peripheral blood GFP/counts and clinical assessment) 
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was undertaken. The animals were maintained on prophylactic antibiotics as described above. After 
engraftment, at the earliest suggestion the animal was developing leukaemia (approximately Day 7 for 
MOZ-TIF2/MLL-AF9 and Day 15 for AML1-ETO9a from previous unpublished data in Huntly laboratory), 
the test arm (n= 10-12) received pIpC treatment via intraperitoneal (IP) injections (at a dose of 
10µg/gram of body weight) on five alternate day doses over eleven days, with the control arm (n= 10-
12) receiving IP PBS injections at equal frequency and number.  
In the pIpC treated cohort, Ezh2 deletion occurred (assessed by qPCR genotyping of DNA extracted 
from peripheral blood, spleen and bone marrow) with differences in survival and phenotypic outcomes 
being compared to the control treated (i.e. Ezh2 unexcised) arm.  
 
2.6.15 Functional validation of candidate oncogenes (Lin28b/Plag1) – in vivo model 
MLL-AF9 or MLL-AF9+candidate oncogene (as listed above) was transduced as described above into 
wild-type c-kit selected bone marrow cells harvested from wild-type C57/Bl6 mice (8-12 weeks age). 
These cells were transplanted into wild-type lethally irradiated C57/Bl6 recipient mice (8 weeks age) 
via tail-vein injections in four cohorts (n= 8 per arm) and monitored to ensure engraftment had 
occurred adequately via full blood count measurements at 14-21 days. Development of MLL-AF9 or 
MLL-AF9/candidate gene driven leukaemia was monitored through flow cytometry assessment of YFP 
percentage (in MLL-AF9 solo control arm) and dual YFP/mCherry percentages (in MLL-AF9/candidate 
gene test arms) from mononuclear cells isolated from peripheral blood sampling. Monitoring and 
culling of mice, processing and storage of tissues was performed as described above.  
The overall experimental plan for this is depicted in Figure 2.14. 
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FIGURE 2.12 Experimental plan for assessing the role of Ezh2 in leukaemia induction in vivo 
Ezh2 fl/fl; wt (wild-type for Mx1-Cre) or Ezh2 fl/fl; Mx1-Cre (heterozygous for Mx1-Cre) mice were treated with pIpC to induce Ezh2 deletion in the Cre-
expressing mice (confirmed by genotyping DNA extracted from peripheral blood samples 4 weeks post-treatment). BM from these two cohorts was 
then harvested and c-kit positive HSPCs selected and pooled in two groups (wt vs excised).  
Following retroviral transduction of these HSPCs with supernatant from the 3 oncogenes listed above, these cells were transplanted into sub-lethally 
irradiated wild-type C57/Bl6 recipient mice. Each oncogene being tested had two arms, Ezh2 wild type (Ezh2+/+) versus Ezh2 excised (Ezh2-/-). These 
were closely monitored for any signs of disease and outcomes were compared with each other.  
 
“wt” denotes wild-type for Mx1-Cre, “Mx1-Cre+” denotes heterozygous for Mx1-Cre, “c-kit+” denotes c-kit/CD117 positively selected HSPC’s 
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FIGURE 2.13  Experimental plan for assessing the role of Ezh2 in maintenance of AML in vivo 
1) Generate Ezh2fl/fl; Mx1-Cre+ primary leukaemias: Bone marrow from Ezh2 fl/fl;Mx1-Cre+ (heterozygous for Mx1-Cre) mice aged 8-12 weeks 
was harvested and c-kit/CD117 positive HSPCs selected, pooled and then divided into 3 experimental arms. Each arm then underwent retroviral 
transduction using supernatant generated from the 3 oncogenes listed above. The transduced cells were immediately transplanted into lethally 
irradiated, wild-type C57/Bl6 recipients (n=5 per oncogene). Once leukaemia developed, these were culled and bone marrow and spleen 
harvested and stored. Each was genotyped to assess for any spontaneous recombination 
 
2) Generate secondary leukaemias THEN excise Ezh2: Secondary transplantations into lethally irradiated wild-type C57/Bl6 recipients were then 
set up through tail vein injections of spleen cells from a single primary leukaemia representative of each oncogene. At the earliest sign of 
leukaemia, mice were given intraperitoneal pIpC injections to induce Ezh2 deletion (vs. intraperitoneal PBS as control). These were monitored 
clinically for disease and differences in survival outcomes were assessed 
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FIGURE 2.14 Experimental plan used to functionally validate Lin28b or Plag1 overexpression with MLL-AF9 in vivo  
  
C57/Bl6 wild-type recipient mice aged 8-12 weeks were harvested for whole bone marrow. c-kit positive HSPCs were then selected and placed into 
liquid culture, divided into three arms. Each arm was then transduced with a) MLL-AF9, b) MSCV-Lin28b-IRES-mCherry + MLL-AF9 or c) MSCV-Plag1-
IRES-mCherry + MLL-AF9 retroviral supernatant. After assessment of transduction efficiency by flow cytometry, cells numbers were then adjusted 
accordingly (as described in main text) and injected into lethally irradiated C57/Bl6 wild-type recipients. These were monitored clinically for disease 
and differences in survival outcomes were assessed 
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2.7 DNA protocols 
The 3 fusion oncogenes to produce immortalise in vitro and produce AML in vivo used in this project 
were already available in the Huntly lab. For an analysis of the oncogenic role of two candidate genes 
(Lin28b and Plag1) in the induction of leukaemia, the coding sequences of Plag1 were cloned from 
cDNA using the steps detailed below. For Lin28b, a GFP-tagged ORF clone containing Mus musculus 
Lin-28 homolog B (Lin28b) was purchased from OriGene (Cat No: MG225677). The vector that each 
candidate gene was cloned into was pMSCV-IRES-mCherry that was purchased from AddGene (Cat No: 
52114) through an MTA.  
 
The cloning strategies for each candidate gene were as follows: 
 
Lin28b - EcoRI and XhoI sites introduced at 5’ and 3’ ends 
Plag1 - EcoRI and XhoI sites introduced at 5’ and 3’ ends 
 
Both were then cloned into multiple cloning site (MCS) of MSCV-IRES-mCherry pre-digested with EcoRI 
and XhoI 
 
2.7.1 cDNA synthesis 
 
To amplify the coding sequences of Plag1, cDNA was prepared through reverse transcription of RNA 
extracted from wild-type murine tissues (bone marrow or testis).  
The Transcriptor One-Step RT-PCR kit (Roche, Cat No: 04655877001) was used for cDNA synthesis. 
Each reaction was set up as below: 
PCR grade water                    = 33µl 
5x Reaction buffer                = 10µl 
F primer (10µM dil.)             = 2µl 
R primer (10µM dil.)             = 2µl 
Transcriptor Enzyme            = 1µl 
RNA (50ng/µl dil.)                 = 2µl 
TOTAL                                        = 50µl 
 
The reaction was gently vortexed and placed into a BioRad thermal cycler with an initial denaturation 
step of 94°C of 10 seconds, followed by an annealing step of 55-62°C for 30 seconds and an elongation 
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step at 68°C for 1 minute per kilobase of size of PCR product. A further 25 cycles were undergone in 
the same format introducing an additional 5 seconds per kilobase to each elongation step. The primers 
used are detailed in Appendix A 2.1. 
 
 
2.7.1.1 First-Strand cDNA synthesis 
To synthesise first strand cDNA, the Superscript III Reverse Transcriptase Kit (Invitrogen, Cat No: 
18080093) was used as per manufacturer’s instructions. This method was used to isolate cDNA from 
transduced c-kit selected murine bone marrow cells to assess expression levels of candidate genes by 
qPCR. 500ng of RNA purified as per Section 2.8.14.2 was mixed with 1µl of oligo (dT) primers (50µM) 
and 300ng of random hexamer primers (provided in kit), 1µl dNTP (10mM) and sterile distilled water 
to 13µl. Samples were heated for 5 minutes at 65°C to denature the RNA secondary structure followed 
by a 1 minute incubation step on ice to allow the primers to anneal to RNA. After a brief centrifugation, 
4µl of 5X First-Strand Buffer, 1µl 0.1M DTT, 1µl RNAse OUT (recombinant RNase inhibitor at 40 
units/µl) and 1µl SuperScript III reverse transcriptase (200 units/µl) were added and gently mixed, then 
incubated for 5 minutes at 25°C. The reaction was then incubated at 50°C for 30-60 minutes to allow 
reverse transcription to take place. Finally, the reaction was inactivated at 70°C for 15 minutes.  
 
 
2.7.2 Agarose Gel electrophoresis 
1-2% (w/v) of agarose was mixed into 1xTAE (Tris-Acetate-EDTA buffer) in a glass jar and heated in a 
microwave oven to near boiling point until it had completely dissolved. It was then allowed to cool 
slightly and ethidium bromide was added to a final concentration of 0.1µg/ml. The gel was poured into 
a gel tank containing a gel comb and allowed to cool to room temperature thereby becoming set. It 
was then loaded into a Bio-Rad Sub-Cell compartment with the comb/top of the gel closest to the 
anode and submerged in 1xTAE buffer. The gel comb was then removed yielding empty wells for 
loading DNA samples/DNA ladder into.  
 
10-100µl DNA for analysis were mixed with 2-20µl 5x DNA loading buffer (Bioline, Cat No: Bio-37045) 
and loaded into the wells in the gel, with 5µl of DNA Hyperladder II (Bioline, Cat No: Bio-33053) in 
separate wells to assess DNA size and quantity. Application of 80-100 volts were applied to the gel via 
a Bio-Rad PowerPac power supply for 30 - 90 minutes depending on the percentage of agarose in the 
gel and the size of DNA fragments to be visualised.  
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When complete, the gel was viewed under a UV light source using a Transilluminator (Life 
Technologies, Cat No: TFX-35M). The appropriate sized band was cut and the DNA was then extracted 
from the gel.  
 
2.7.3 DNA gel extraction 
 
Once cut from the agarose gels, each piece of gel containing DNA was weighed. Using a MiniElute Gel 
extraction kit (QIAGen, Cat No: 28604), the DNA was purified from the gel. Briefly, 3 volumes of QG 
Buffer (provided in the kit) were used per one volume of gel, then incubated at 50°C for 10 minutes 
(with additional vortexing during incubation to assist with dissolving). Once the agarose had been 
solubilised completely, one gel volume of isopropanol was added to the mixture and the sample placed 
in a MiniElute column for centrifugation at 13000rpm for 1 minute.  The flow through was discarded 
and the column was washed through centrifugation with 500µl QG Buffer and 750µl of PE Buffer. 
Finally, DNA was eluted from the column into 30µl of provided EB Buffer after 1 minute of incubation 
at room temperature. This was quantified via a Nanodrop reader (Methods 2.8.14) 
 
 
2.7.4 Primer design 
Utilising software Primer 3 (http://primer3.ut.ee/) oligonucleotides were designed to have restriction 
enzyme (RE) recognition sites on both 5’ and 3’ ends, with 4-6 random nucleotides added 5’ to the RE 
site of the forward primer and 3’ to the reverse primer to ensure adequate enzymatic cleavage. 
 
Oligonucleotides used to clone the coding sequences from cDNA were designed to be approximately 
18-22 base pairs (bp) long, with a G-C content of 50-60% and a melting temperature of 55-65°C. 
All custom oligonucleotides were ordered from Sigma-Aldrich. 
 
2.7.5 PCR 
The appropriate coding sequence from the genes of interest above was then amplified through 
PCR.  Utilising the primers designed above the cDNA was subjected to PCR to amplify the coding 
sequences further. This was followed by separation using gel electrophoresis and extraction (as 
described above). Then a separate PCR was performed to introduce appropriate restriction sites to the 
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inserts using primers in order to facilitate cloning into the retroviral vector. Each PCR reaction was set 
up as follows: 
 
 
25µl   MyTaq HS 2x Mix (Bioline, Catalogue No: Bio-25045) 
0.5µl   Platinum Taq DNA Polymerase (Invitrogen, Catalogue No: 10966026) 
2µl   Fwd Primer (10mM) 
2µl   Rev Primer (10mM) 
10ng   DNA  
Rest to 50µl  PCR grade water 
 
The PCR was set in a Bio-Rad thermal cycler as follows: 
a.       96°C for 10mins (1 cycle) 
b.       96°C for 30s 
c.       60°C for 30s 
d.       72°C for 1min (35 cycles of b-d) 
e.       72°C for 10min 
f.        4°C hold 
 
Following the second PCR, the products were again run on gel electrophoresis and the appropriate 
sized band was cut and purified.  
 
2.7.6 Restriction enzyme digestion 
Once the PCR DNA or vector product had been purified, both were digested with the appropriate 
restriction enzymes (New England Biolabs). This was a double digest with a combination of two 
enzymes with a compatible reaction buffer. In a 50µl reaction, 2-5µg DNA was combined with 5µl of 
the appropriate 10X NEB restriction enzyme buffer (supplied with the enzyme), 2µl of enzyme and 
DEPC-treated water to 50µl. The reaction was then incubated at the recommended digestion 
temperature (usually 37°C) for a minimum of 2-12 hours. Digested PCR DNA products were purified 
using a QIAquick PCR Purification column based kit (QIAGen, Catalogue No: 28104) and eluted in water. 
Digested vectors or DNA were then run on an agarose gel (as described above) and the appropriate 
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sized band corresponding to the linearised vector was excised and purified using a MiniElute Gel 
extraction column based kit. Restriction enzymes used are detailed in Appendix A 2.3.  
 
2.7.7 DNA ligation 
Following restriction enzyme digestion, DNA inserts were ligated to plasmid vectors with the relative 
amounts calculated according to the formula: 
 
Insert mass (ng) = Molar ratio x [Insert Size (Kb) x Vector mass (ng)]/Vector Size (Kb) 
 
The molar ratio used was 3:1 insert:vector.  
Approximately 90ng of vector DNA was used per ligation as follows: 
 
1µl  T4 DNA Ligase (New England Biolabs, Cat No: M0202S) 
2µl  10X T4 DNA Ligase reaction buffer (0.5M Tris-HCl, 100mM MgCl2, 100mM DTT, 10mM ATP, pH 7.5) 
 Vector DNA  
 Insert DNA (as per formula above) 
to 20µl PCR grade water 
 
The reaction was then incubated at 16°C overnight. 
 
 
2.7.8 Transformation 
Chemically competent E. Coli cells (One Shot Stbl3, ThermoFisher, Cat No: C737303) were transformed 
for all cloning reactions. 20µl of ligation reaction was added to 100µl of bacteria that had been slowly 
thawed on ice. The cells and DNA were mixed by gently flicking the tube. This was incubated on ice for 
30 minutes. The cells were then heat-shocked for exactly 1 minute in a pre-heated waterbath at 42°C 
and immediately cooled on ice for another 30 minutes. Following this, 250µl of Luria Bertani (LB) broth 
media was added and the tubes were incubated for an hour in a 37°C shaking incubator. 30-100µl of 
transformed cells were evenly spread onto a pre-warmed (37°C) ampicillin containing agar plate and 
incubated overnight at 37°C 
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2.7.9 Miniprep plasmid DNA purification 
To assess for successful ligation and integration of insert into vector, single colonies were plucked from 
the plates and then expanded overnight in 3ml of LB broth containing 100µg/ml ampicillin in a 37°C 
shaking incubator. Plasmid DNA was then purified using a QIAGen Spin Miniprep kit (Qiagen, Catalogue 
no: 27104). This is a buffer/centrifugation column based system that uses a modified alkaline lysis 
method to yield 5-20µg plasmid DNA from the bacteria. All steps were carried out at room 
temperature. Briefly, 2-3ml of bacteria were centrifuged at 4000rpm and resuspended in 250µl of 
provided Buffer P1 (containing RNAse A). 250µl of Buffer P2 was then added with gentle mixing by 
inversion of the tube 4-6 times. These reactions allowed for lysis of bacterial cells and denaturation of 
dsDNA to ssDNA. 350µl of N3 Buffer was then added with inversion of the tube 4-6 times to neutralise 
the lysis reaction, allowing the plasmid DNA to renature whilst longer genomic DNA would fail to 
reanneal properly. This was centrifuged for 10 minutes at 13000rpm and the supernatant 
(approximately 750µl) was decanted into the provided QIAprep spin column. The column was 
centrifuged at 13000rpm for 1 minute, the flow-through discarded and the column then washed with 
500µl of PB Buffer to remove any trace nuclease activity. The column was then washed with 750µl PE 
Buffer, and a final centrifugation step at 10000rpm for 1 minute to dry was performed. The purified 
DNA was then eluted by transferring the column to a new 1.5ml microcentrifuge tube, adding 30µl EB 
Buffer.  The column was then incubated for 1 minute and centrifuged at 10000rpm for 1 minute.  
 
 
2.7.10 Sequence verification 
Upon completion of cloning, constructs containing DNA sequences inserted into retroviral vectors as 
detailed above were verified through sequencing at Cambridge Biosciences (Cambridge, UK). DNA 
from miniprep plasmid purification was sent at a concentration of 100ng/µl and sequencing primers 
at 3.2pmol/µl.  
 
 
2.7.11 Maxiprep plasmid DNA purification 
To amplify large quantities of sequence verified constructs maxipreps were performed using a Roche 
Genopure Plasmid Maxi Kit (Roche, Cat No: 03143422001) according to the manufacturer’s 
instructions. Single colony starter cultures (that had been sequence verified) were expanded as for 
minipreps and then diluted in 250ml LB broth containing 100µg/ml ampicillin and grown overnight in 
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a 37°C shaking incubator. The cultures were centrifuged at 4000rpm at 4°C and carefully resuspended 
in the provided Suspension Buffer (with added RNAse) and mixed gently through inversion 6-8 times. 
12ml of Lysis Buffer was added with incubation at room temperature for 2-3 minutes, then 12ml pre-
cooled Neutralisation Buffer was added to the suspension and mixed through inversion 6-8 times. The 
lysate was then cleared through centrifugation at 4000rpm for 45 minutes at 4°C. The supernatant was 
then passed through a provided filter paper that had been pre-folded and moistened with a few drops 
of Equilibration Buffer. The collected flow-through was then passed through a provided column pre-
equilibrated with 6ml Equilibration Buffer. The column was then washed with 10ml Wash Buffer twice 
and it was inserted into a 50ml Falcon tube. The plasmid DNA was then eluted from the column with 
15ml prewarmed (to 50°C) Elution Buffer. The eluted plasmid was precipitated with 11ml isopropanol 
and immediately centrifuged at 4000rpm for 30 minutes at 4°C. The plasmid pellet was then 
resuspended in 4°C 70% ethanol and centrifuged once more at 4000 rpm, 4°C for 15 minutes. The 
ethanol was carefully removed with a pipette tip and the DNA pellet allowed to air-dry for 10 minutes 
at room temperature. Finally, it was dissolved in 500µl double-distilled water and its concentration 
and quality measured with a Nanodrop reader.  
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2.8 Analysis of transcriptional programmes subverted by Ezh2 loss 
The induction and maintenance in vitro and in vivo Ezh2 genetic deletion experiments gave rise to 
interesting and varying stage-specific roles for Ezh2 that warranted further inquiry. Therefore, further 
genomic analyses of Ezh2+/+ and Ezh2-/- tissues (both normal and leukaemic) were undertaken. The 
following sections detail the methods used therein. 
2.8.1 Lineage depletion 
Murine bone marrow was extracted individually from Ezh2 fl/fl; wild-type (wt) or Ezh2 fl/fl; Mx1-Cre 
(Cre+) heterozygous mice (as already described), that had been pIpC treated at 6 weeks of age to cause 
Ezh2 genetic deletion in the Mx1-Cre heterozygous cohort. These had been previously genotyped prior 
to culling, using DNA extracted from peripheral blood samples taken four weeks after pIpC treatment, 
to ensure adequate deletion. Each mouse was processed individually throughout to ensure biological 
replicates were possible.  In order to obtain a single-cell suspension before magnetic separation, the 
cells were passed through individual Pre-Separation filters (Miltenyi Biotec, Cat No: 130-041-407).  
Utilising a Miltenyi Lineage Cell depletion kit (Miltenyi Biotec, Cat No: 130-090-858), following a wash 
step with MACS buffer, cells were resuspended in 40µl per 107 total cells and magnetically labelled 
with 10µl per 107 total cells of the provided Biotin-antibody cocktail containing lineage-marker 
antibodies for mature cells [CD5, B220, CD11b, Gr-1, Ter-119]. After an incubation period at 4°C for 10 
minutes, a further 30µl MACS buffer per 107 total cells was added. Finally, 20µl per 107 total cells of 
Anti-Biotin Microbeads were mixed into the sample and incubated for a further 15 minutes at 4°C. The 
cells were then washed by adding 2ml MACS buffer per 107 total cells and centrifuged at 1200rpm for 
10 minutes. They were then resuspended in 500µl of MACS buffer ready for magnetic separation. The 
cells were then loaded through into a MACS LS separation column (Miltenyi Biotec; Cat No: 130-042-
401) attached to a midiMACS magnetic separator (Miltenyi Biotec; Cat No: 130-042-301). Lineage 
positive selected cells were trapped in the column attached to the magnetic separator and the flow 
through contained the lineage negative HSPCs. The column was washed three times with 3ml MACS 
buffer to wash through the lineage negative HSPCs. The column was then removed and flushed 
separately with 5ml MACS buffer to release the lineage positive HSPCs.  
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2.8.2 Cell counting: haemocytometer 
In order to preserve cell numbers, 10µl from each lineage negative flow-through sample was taken 
and a total cell number was estimated using a glass ‘hemacytometer’ (Sigma-Aldrich, Cat No: Z359629). 
Following a careful 1:2 dilution with Trypan Blue dye (Thermo Scientific, Cat No: 15250061) 10µl of cell 
sample was carefully spread across the hemacytometer grid under a glass cover slip. The total number 
of viable cells (those that did not take up the Trypan blue dye) present in one corner (16 small squares 
of the grid) were counted. This was done across 2 to 4 such grids in each corner and then divided by 
the number of corners to yield an average cell number. After correcting for the initial 1:2 Trypan blue 
dilution, this number was multiplied by 104 to yield a final cell concentration of number of cells x 
106/ml.  
2.8.3 Lineage depletion: purity assessment by flow cytometry 
Once lineage negative HSPC’s had been isolated through the negative selection process as described 
above, 100µl volume of Lineage negative cells (from flow-through) and Lineage positive cells (isolated 
from the column) was kept aside. These were then stained for flow cytometry through the addition of 
5µl of APC Lineage Positive antibody cocktail (BD Biosciences, Cat No: 558074) and incubated at 4°C 
for 30 minutes. Following this, the staining was inactivated by adding 1ml of 1X PBS and the cells were 
centrifuged for 5 minutes at 1400rpm. Finally, they were resuspended in 400µl of 1X PBS and 
transferred to polystyrene FACS tubes (BD Biosciences, Cat No: 352058) for flow cytometry. Flow 
cytometry was performed in the Cambridge Institute for Medical Research (CIMR) Flow cytometry 
core, on a BD Biosciences LSRFortessa 4-laser machine, using a laser (640 670/14) to detect the APC 
fluorochrome in the antibody cocktail. Unstained live cells were used to set initial forward area (FSC-
A) and side scatter area (SSC-A) gates, to capture the cell populations. Cell doublets were excluded by 
gating FSC-W and FSC-H within this population. Finally, using APC cocktail stained lineage positive cells 
isolated from the column gates were set around the population that were negative. This was then used 
to calculate the percentage of Lineage negative cells isolated (i.e. negative for APC after staining) to 
determine the purity of the depletion. All flow analyses were done using FACSDiva analysis software. 
Data was then analysed further with FlowJo software (Tree Star Inc.) if required. 
2.8.4 Lineage depletion: DNA extraction and genotyping 
From the remaining bone marrow lineage positive fraction isolated from flushing through the LS 
column after magnetic selection, approximately 5x106 cells were removed and DNA was extracted for 
genotyping. DNA was extracted using the QIAGen AllPrep DNA/RNA Mini kit as described in Methods 
2.8.14. Genotyping was then performed as described in Methods 2.6.3. A comparison to the original 
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peripheral blood genotyping was made. As Mx1-Cre is predominantly expressed in haematopoietic 
tissues, Ezh2 deletion, as estimated on genotyping cells isolated from bone marrow through qPCR, was 
consistently higher that the level of deletion estimated from genotyping peripheral blood cells.  
 
2.8.5 Lineage depletion: Cross-linking for ChIP-sequencing 
Once the lineage negative fraction isolated in the flow-through had been checked to have high purity 
by flow cytometry (typically >90%) the cells were resuspended in 1ml of 1X PBS in 1.5ml Eppendorf 
tubes to attain a concentration of 0.5-1x106/ml. Inside an air-flow fume hood, 27µl of 37% 
formaldehyde (Sigma-Aldrich, Cat No: F8775) was added resulting in a final 1% formaldehyde 
concentration to facilitate histone/protein crosslinking to DNA. The samples were placed on a shaker 
at 30rpm, room temperature for crosslinking: 5 minutes for histones and 15 minutes for 
proteins/transcription factors. Following this, 62.5µl of 2M Glycine (Sigma-Aldrich, Cat No: G8898; 
7.5grams dissolved in 50ml ultra-sterile water) was added and mixed in to stop crosslinking. The 
samples were placed on a shaker at 30rpm, room temperature for 10 minutes. From this point, all 
samples were kept on ice or at 4°C. After crosslinking had been stopped by the addition of Glycine, the 
cells were centrifuged for at 1000rpm for 10 minutes at 4°C, washed in 1ml PBS and centrifuged once 
more at the same settings. Finally, the supernatant was aspirated, leaving the crosslinked cell pellet. 
This was snap frozen by submerging the Eppendorf containing the pellet into a mixture of dry ice and 
neat isopropanol (Sigma-Aldrich, Catalogue No: W292907) for approximately 30 seconds. All cross-
linked lineage negative bone marrow samples were then stored at -80°C for later use in chromatin 
immunoprecipitation (ChIP). 
 
2.8.6 Chromatin immunoprecipitation (ChIP) 
Lineage depleted bone marrow HSPCs that had previously been isolated, cross-linked and stored at 
1x10^6 – 5x10^6 cells at -80°C were thawed slowly on ice. For histone modifications, the ‘iDeal ChIP-
seq kit for Histones’ (Diagenode; Cat No: C01010050) was used, and for PRC2 complex member binding 
the ‘iDeal ChIP-seq kit for Transcription factors’ (Diagenode; Cat No: C01010055) was used. 1x106 cells 
in duplicate from each condition (wt or Cre+) were used for histone modification ChIP and 5x106 cell 
pellets in duplicate (from wt or Cre+) were used for PRC2 complex member ChIP. Unless indicated 
otherwise, all buffers used were supplied in the Diagenode kits. 
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2.8.7 ChIP for histone modifications 
Upon thawing, the cells were lysed sequentially using 1ml Lysis buffer iL1 for 1x106 cells and then 1ml 
Lysis buffer iL2 with pelleting by centrifugation at 1600rpm for 5 minutes at 4°C then discarding the 
supernatant between each lysis step. They were then sheared using a mixture of Shearing buffer iS1 
and protease inhibitor cocktail (100µl for 1x106 cells; 1:200 dilution of protease inhibitor cocktail). The 
cell suspension was then transferred into 1.5ml TPX sonication tubes (Diagenode; Cat No: C30010009) 
and incubated on ice for 10 minutes. These were then secured into a precooled Diagenode Bioruptor 
Plus machine for sonication. Sonication on “high” setting for 10 cycles (30 seconds on; 45 seconds off) 
was then performed. The samples were removed and subjected centrifugation up to 2000rpm for a 
few seconds and transferred to a new 1.5ml TPX sonication tube. They then underwent a further 10 
cycles of sonication at high setting (30 seconds on; 45 seconds off). Once shearing was complete, the 
samples were centrifuged at 13000rpm for 10 minutes and the supernatant containing sheared 
chromatin was collected for magnetic immunoprecipitation. At this point, 1/10th volume (10µl) of 
sheared chromatin was removed and kept aside at 4°C as "Input" for each sample, representing total 
chromatin that was not subjected to immunoprecipitation. 
20µl of Diamag protein-A coated magnetic beads were used per immunoprecipitation (IP) reaction. 
These were initially washed with 4 times with 40µl of 1x ChIP buffer iC1 by resuspending them 
manually using a Gilson pipette inside an Eppendorf tube. The tube was then placed into a 1.5ml 
Diagenode Magnetic Rack (Cat No: B04000003) and after one minute the beads were completely 
captured by the magnet against the inner side of the Eppendorf tube. The supernatant (wash) was 
removed, the Eppendorf then lifted from the Magnetic Rack and the beads resuspended with 40µl of 
the next wash. After the fourth wash the beads were suspended in 20µl 1x ChIP buffer iC1. 
The final immunoprecipitation reaction was prepared as below: 
ChIP reaction mix 
No of 
Immunoprecipitations 
5% BSA 
(µl) 
200x PI 
cocktail 
(µl) 
5x buffer 
iC1 (µl) 
Sheared 
chromatin 
(µl) 
Magnetic 
beads (µl) 
ChIP-seq 
grade 
water (µl) 
Antibody 
(µl) 
1 6 1.5 56 100 20 116.5 to x 1 
 
Each IP reaction was then incubated at 4°C overnight under constant rotation at 40rpm on a rotating 
wheel. After overnight incubation, the tubes were placed into the Magnetic Rack allowing the 
immunoprecipitated chromatin to be separated. This was then washed and eluted sequentially using 
Wash buffers iW1-4 at 4°C and Elution buffers iE1/iE2 at room temperature respectively. At this stage 
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the Input samples were also mixed with the same volume of Elution buffer iE2 and both Input and IP 
reaction were incubated at 65°C for a minimum of four hours in a thermomixer at 800rpm to facilitate 
de-crosslinking.  
Finally, each Input and IP reaction were purified using a QIAgen PCR purification kit. Purified IP samples 
were then frozen at -20°C for later analysis.  
 
2.8.8 ChIP for PRC2 complex members 
These steps were performed as per the iDeal ChIP-seq kit for Transcription factors kit and largely 
overlap with those described above. Cell lysis, chromatin shearing and magnetic immunoprecipitation 
were performed in a similar way as described, using the buffers provided. The same proportion of 
sheared chromatin from each reaction was kept aside as Input.  In this protocol the DiaMag Protein-A 
coated magnetic beads were pre-incubated for four hours with antibody at 4°C on a rotating wheel at 
40rpm before immunoprecipitation. Following overnight immunoprecipitation, the beads from each 
IP and Input were washed and antibody-protein-DNA complexes eluted in a similar way. After decross-
linking the samples were purified using a QIAgen PCR purification kit. Purified IP samples were then 
frozen at -20°C for later analysis.  
 
2.8.9 ChIP qPCR analysis 
To validate the ChIP reactions prior to sequencing, qPCR analysis was performed. As the repressive 
histone mark H3K27me3 and activating H3K27Ac and H3K4me3 histone marks were being assessed, 
qPCR to assess relative levels at control regions, including the first intron of HoxC10 (normally 
repressed and at low level expression) and the promoter of Gapdh (normally constitutionally active 
and present at high levels) was performed using primers detailed in Appendix A2.1.  
2.8.9.1 H3K27me3 ChIP 
The expectation was that HoxC10 would be enriched compared to Input in H3K27me3 ChIP in Cre- 
conditions and following Ezh2 loss (i.e. Cre+ condition) due to loss of H3K27me3 this enrichment would 
disappear. Gapdh would be undetectable compared to Input in both Cre- and Cre+ conditions.  
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2.8.9.2 H3K27Ac and H3K4me3 ChIP 
The expectation was that there would be no difference for HoxC10 enrichment between Cre- and Cre+ 
conditions compared to Input for H3K27Ac and H3K4me3 ChIP, and Gapdh would remain enriched at 
similar (high) levels for both histone marks between Cre- and Cre+ conditions.  
Each qPCR reaction was performed using Agilent Technologies 2X Brilliant III SYBR Green qPCR Master 
Mix (Agilent, Cat No: 600882-51) with the provided reference dye. The reactions were performed in 
duplicate for each condition on 96 well plates using a Stratagene Mx3000P PCR machine: 
 
1x Reaction 
SYBR Green   5µl 
Primers (F+R)         0.6µl (final concentration 6uM) 
Rox Ref Dye (1:500)       0.15µl 
H2O         3.75µl 
DNA (1:5 dilution)        0.5µl 
 
The PCR reaction was set at the following conditions: 
1 cycle   95°C, 03:00 minutes 
40 cycles  95°C, 00:10 seconds 
   60°C, 00:20 seconds 
1 cycle   95°C, 01:00 minute 
   95°C, 00:30 seconds 
 
The results were analysed in MxPro – Mx3000P software version 4.10, where the threshold 
fluorescence was set at 0.1 dRn. By including the Input for each ChIP condition as a comparator, it was 
possible to calculate the percentage enrichment compared to Input for each primer, in order to 
validate the ChIP performed before amplification prior to sequencing.  
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2.8.10 Amplification of ChIP products 
Utilising the Illumina TruSeq ChIP sample prep kit (Illumina, Cat No: IP-202-1012) the ChIP products 
containing fragmented DNA post sonication were subjected to an end repair process. The ChIP samples 
were mixed with a resuspension buffer and End-Repair mix and incubated in a pre-heated thermal 
cycler for 30 minutes at 30°C. Following this, the samples were purified using DNA Clean and 
Concentrator Kit (Zymo Research, Catalogue No: D4014) where the end repaired DNA fragments were 
bound to a column through centrifugation, washed twice and eluted to recover purified DNA. The 
addition of A-bases to 3' end of the DNA fragments was then performed by resuspending the DNA with 
Resuspension Buffer and A-Tailing Mix and incubating in a pre-heated thermal cycler as follows: 
  37°C 30 minutes 
  70°C  5 minutes 
  4°C Hold 
 
Libraries were then prepared through ligation of specific indexed Adapters to each sample using a 
Ligation Mix and diluted Adapter Index. Multiplex indices were chosen following manufacturer’s 
recommendation. The ligations were incubated in a preheated thermal cycler for 10 minutes at 30°C 
followed by the addition of Stop Ligation buffer to inactivate the ligation. Upon completion, the 
samples were purified once more using the DNA Clean and Concentrator Kit as described above.  
 
The A-tailed, indexed ChIP samples were then PCR amplified using PCR Primer cocktail and master mix 
supplied in the Illumina TruSeq kit using a thermal cycler at the following conditions: 
 
 
  98°C 30 seconds 
  98°C 10 seconds 
  60°C  30 seconds x18 cycles 
  72°C  30 seconds 
  72°C 5 minutes 
  4°C - Kept on hold 
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2.8.11 Size selection of Library 
In order to select the appropriate sized precipitated DNA fragments (250 - 450 base pairs), the samples 
were then loaded into a 2% agarose low melting gel (prepared by dissolving 2g Agarose low-melting 
Bio-Rad in 100ml 1XTAE buffer and Invitrogen SYBR-Green as a nucleic acid stain) in an electrophoresis 
device specifically used for ChIP-seq samples and run at 90-120 volts for 60 minutes. The 100bp 
Hyperladder II from BioLine was run at either end of the gel to characterise the size of the DNA 
fragments. Through UV light exposure the correct size range of fragments were identified compared 
to the DNA ladder, and cut out with a fresh scalpel, with care being taken to avoid contamination with 
adapter dimers (running at 126 base pairs in size).  
The cut-out gel pieces were then weighed and the DNA fragments (250 - 450 base pairs) within were 
extracted using a QIAgen MiniElute Gel Extraction Kit (QIAgen, Cat No: 28604). Utilising the column 
extraction system provided within the kit, a maximum of 400µg gel piece per column was dissolved 
using Buffer QG at 50°C for 10 minutes maintaining a pH of <7.5 using 3M sodium acetate and then 
loaded onto the column for centrifugation. DNA was adsorbed onto the silica membrane of the column 
during centrifugation and unwanted impurities, such as salts, unincorporated nucleotides, agarose and 
SYBR-Green were discarded in the flow through. Further wash and spin steps were performed before 
a final elution step with a 10µl of Elution Buffer containing 10mM Tris.Cl at pH 8.5 to yield the purified 
DNA libraries selected by gel electrophoresis.  
Appropriate size selection of these samples was then confirmed through usage of an Agilent 
Technologies 2100 Bioanalyzer system (Agilent, Catalogue No: G2940CA) and an Agilent DNA 1000 kit 
(Agilent, Catalogue No: 5067-1504). Briefly, a microfluidics chip within the Agilent DNA 1000 kit was 
prepared by loading the provided gel-dye mix and spreading evenly using the Chip Priming station. Five 
microlitres of DNA marker and 1µl ladder (provided in the kit) were then loaded and then 1µl of each 
gel purified sample were loaded. The chip was then vortexed for 1 minute at 2400rpm and inserted 
into the Bioanalyzer. Each microfluidics chip was able to analyse up to 12 samples.  The results were 
analysed in Agilent 2100 Expert software, generating both a gel electrophoresis trace for all the 
samples and individual electropherograms for each sample. It was then possible to ascertain the 
quality and average fragment length (in base pairs) of each sample after gel purification and identify 
any that had residual primer-dimer contamination and required a repeat size-selection.  
 
 
67 
 
2.8.11 Library Quantification 
KAPA Library Quantification kits (KAPA, Cat No: KK4824) were used to quantify each library. Each 
sample was diluted to 1:106 using PCR-grade water. The kit also provided a set of six DNA standards of 
dsDNA concentrations on a logarithmic scale to quantify against. Both samples and standards were 
loaded in duplicates into a qPCR reaction using KAPA SYBR FAST qPCR Master mix and PCR-grade water 
as follows: 
 
 
 
 
The qPCR reaction was run on a Stratagene Mx3000P PCR as follows:  
95°C 5 minutes 
  95°C 30 seconds 
  60°C  45 seconds x35 cycles 
 
Using MxPro software, the Ct values for each standard and sample were extracted. The mean Ct values 
for each standard (considering the logarithmic increases) were then plotted on a linear scale allowing 
a standard line of best fit curve to be constructed. The mean Ct values for each sample were then 
assessed against this allowing a concentration for each sample to be calculated after correction for the 
initial 1:106 dilution.  
 
Finally, a size adjusted concentration was calculated for each sample, to take into account the 
difference in size between the average fragment length of the library (as identified by the Bioanalyzer) 
and the DNA standard (452bp): 
 
Average Concentration of sample (pM) x  452          = Size adjusted concentration (pM) 
     Avg. fragment length (bp) 
  
 
KAPA SYBR FAST qPCR Master mix  12µl 
PCR-grade water    4µl  
Diluted DNA library or DNA standard (1-6) 4µl     
20µl 
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2.8.12 High throughput Sequencing 
Once the samples had been correctly quantified (according to size-adjusted concentrations) they were 
pooled for multiplexing for single-read sequencing on an Illumina HiSeq 4000 machine at the Genomics 
Core, CRUK Cambridge Institute. Each lane of sequencing was able to accept 4 pooled samples with a 
total amount of 225fmol in 15µl volume. Therefore, up to 56.25fmol of DNA from each labelled sample 
was used.  
 
2.8.13 Bioinformatics analysis 
All bioinformatics analysis was performed by Dr Eshwar Meduri in the Huntly lab. This included analysis 
of RNA-sequencing and ChIP-sequencing data.  
2.8.13.1 RNA sequencing results 
Paired end RNA-seq reads were quality filtered similar to Chip-Seq reads and were mapped using STAR3 
against the mouse genome (mm10). Read counts were quantified with HTSeq4 and Differential 
expression analysis was carried out with these counts using Bioconductor package DESeq2. 5  
The differential gene expression list generated for all RNA-sequencing experiments was rearranged by 
p adjusted values and filtered to include only p <0.05 results (for significantly down- or up-regulated 
genes). It was then sorted by Log2fold change and filtered to include only genes that had Log2fold 
changes in expression -0.5 < (x) > 0.5. Volcano plots to illustrate differences in gene expression 
between Ezh2+/+ and Ezh2-/- genotypes in different conditions were also provided by Dr Eshwar Meduri. 
2.8.13.2 ChIP-sequencing results 
Adapter sequences were trimmed for all paired end reads and mapped against mm10 reference 
genome using Bowtie2. 6 Uniquely mapped reads were retained and peaks were called using SICER 7 
with W200 and G600 for broad peaks (histone marks) and MACS28 for narrow peaks (Ezh2 and Eed) 
with –nomodel and –nolambda parameters. Motif analysis and peaks were annotated using HOMER. 
9 Peaks in intergenic regions were assigned to genes if they were within the 100kb window from the 
TSS. Differential binding analysis was performed using DiffBind. 10 Overlapping analysis of peaks was 
performed using intersectbed from bedtools. 11 
After peak calling, differentially bound histone and protein peak lists generated from Ezh2+/+ and Ezh2-
/- conditions were initially filtered to select all those peaks with a False Discovery Rate (FDR) of <0.01. 
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They were then rearranged in order of fold change and only those with Fold changes -1.5 < (x) > 1.5 
were selected. When comparing against gene expression changes from RNA-seq, all intergenic peaks 
further than 100kb from the transcriptional start site (TSS) were removed, yielding a final list of peaks. 
 
2.8.14 DNA/RNA extraction  
All DNA and RNA samples from a maximum of 5x106 cells (mouse bone marrow/spleen, in vitro 
cultured mouse bone marrow cells, in vitro cultured mouse spleen AML tumours, human AML cell lines 
and primary AML samples) were extracted through use of a QIAGen AllPrep DNA/RNA Mini kit (QIAGen 
Cat No: 80204). Briefly, this kit allowed for purification of genomic DNA and total RNA simultaneously 
from animal cells.  
2.8.14.1 DNA 
The cells were lysed and homogenised with 600µl RLT Lysis Buffer (QIAGen, Cat No: 79216) and 6µl 
14.3M β-mercaptoethanol, then placed into the DNA mini column provided. A high-speed 
centrifugation kit allowed DNA to bind to the column and the total RNA to pass into the flow-through. 
The DNA was then washed using the included wash buffers and finally eluted through centrifugation 
at high speed with the provided elution buffer.  
2.8.14.2 RNA 
Total RNA from the original flow-through was mixed with one volume of 70% ethanol and a maximum 
of 700µl was transferred to the RNeasy spin column provided. A centrifugation step allowed RNA to 
bind to the column. This was then sequentially washed using the provided RNA wash buffers and finally 
eluted in RNase-free water. 
 
All DNA and RNA samples were quantified using a Thermo Scientific NanoDrop 1000 
Spectrophotometer. One µl of sample was pipetted onto a pedestal on the instrument attached to the 
receiving fibre optic cable, with a second pedestal containing a source fibre optic cable being placed 
directly over this, causing the sample to bridge the gap between both ends. Using a pulsed xenon flash 
lamp, a light source was passed through the source cable through the sample and measured through 
the spectrometer to analyse the light. The instrument then provided a reading of DNA/RNA purity and 
concentration via supplied PC based software (NanoDrop 1000 v 3.8).  
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2.8.15 RNA-sequencing 
RNA was extracted from cells as described above. Purity and quantity were assessed using the 
Nanodrop 1000 instrument. Approximately 5 µg RNA was submitted for paired-end sequencing on an 
Illumina HiSeq 4000 machine at the Genomics Core, CRUK Cambridge Institute. Library preparation 
and processing of samples prior to sequencing was performed at the Institute as part of a Core Facility 
service.  
 
2.8.16 RNA-sequencing of MLL-AF9 tumours subjected to Ezh2 pharmacological inhibition 
A satisfactory time point for H3K27me3 reduction following GSK343 treatment of two MLL-AF9 spleen 
tumours in vitro was identified, from performing the time course flow cytometry experiment detailed 
above. RNA was then extracted from the remaining DMSO and GSK343 treated cells in culture, 
quantified and sent for sequencing as per Methods 2.8.16.  
 
 
2.9  Statistical Methods 
The results detailed in this thesis are expressed as mean ± standard error of the mean (SEM) with 95% 
confidence intervals in brackets (95% CI). Error bars on graphs represent SEM. A Student’s two-tailed 
t-test was used to compare colony formation in human and murine primary cells and cell lines treated 
with DMSO and GSK343. The Logrank test was used to compare survival outcomes for all in vivo 
experiments Prism 7 (GraphPad software). 
 
 
 
 
 
 
71 
 
References 
1) Daniel A. Arber, Attilio Orazi, Robert Hasserjian, Jurgen Thiele, Michael J. Borowitz, Michelle 
M. Le Beau, Clara D. Bloomfield, Mario Cazzola and James W. Vardiman. The 2016 revision to 
the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 
2016; 127(20):2391-2405. 
 
2) Skarnes, W. C. et al. A conditional knockout resource for the genome-wide study of mouse 
gene function. Nature. 2011; 474, 337–42. 
 
3) Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 
STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013 Jan 1;29(1):15-21. 
 
4) Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput 
sequencing data. Bioinformatics. 2015 Jan 15;31(2):166-9. 
 
5) Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq 
data with DESeq2. Genome Biol. 2014;15(12):550. 
 
6) Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nature methods. 
2012; 9, 357-9 
 
7) Xu, S., Grullon, S., Ge, K. & Peng, W. Spatial clustering for identification of ChIP-enriched 
regions (SICER) to map regions of histone methylation patterns in embryonic stem cells. 
Methods in molecular biology. 2014; 1150, 97-111. 
 
8) Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome biology. 2008; 9, R137. 
 
9) Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-
regulatory elements required for macrophage and B cell identities. Molecular cell. 2010; 38, 
576-589. 
 
10) Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical 
outcome in breast cancer. Nature. 2012; 481, 389-393. 
 
11) Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. 
Bioinformatics. 2010; 26, 841-842. 
 
 
 
 
 
 
72 
 
Appendix A 2.1  Oligonucleotide primers 
Cloning Primers 
 
cDNA synthesis primers 
Name Sequence 
Plag1 F primer ATGGCCACTGTCATTCCTG 
Plag1 R primer CAGGGCTACACAAGCACCTC 
 
Genotyping primers 
Name Sequence 
Ezh2 fl/fl primer F TATGGGGGATGAAGTTCTGG 
Ezh2 fl/fl primer R CCACTGTCATGGCAACAAGA 
Ezh2 unexcised primer F CTTCTTCCTCCGGGTCTCTC 
Ezh2 unexcised primer R GATCTTGGGGCATTGCAGTA 
Ezh2 F1 primer CCTGCAGCAGTTTCCTTTCTTA 
Ezh2 R1 primer CCCATGTGGTAGGCAGAGAA 
Ezh2 R2 primer CAGCGACACCCCAGAAAATT 
 
ChIP qPCR primers 
Name Sequence 
Hoxc10 int1 F ATATGCACTCTTTTGGCGCG 
Hoxc10 int1 R TCATCTCCACAAGCACAGCC 
Gapdh F TCATCCACCTCCCCACAGTA 
Gapdh R TTTCTTCTCCTGCAGCCTCG 
 
RT qPCR primers 
Name Sequence 
Lin28b F ATGGCACTTCTTTGGCTGAG 
Lin28b R ATAGGTGGAGACGGCAGGAT 
Plag1 F GACAAGGCCTTTAACAGTGTTG 
Plag1 R TCAGGAGAGTGAGTAGCCATG 
 
 
Name Sequence 
Lin28 Cloning F_EcoRI TATGGAATTCATGGCCGAAG 
Lin28 Cloning R_XhoI TATGCTCGAGACAGTCTTTTTCC 
Plag1cloneEcoRIF TATGGAATTCATGGCCACTGTCATTCCTG 
Plag1cloneXhoIR TATGCTCGAGCAGGGCTACACAAGCACCTC 
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Appendix A 2.2  Antibodies 
Name Clone/Catalogue Number Manufacturer 
H3K27me3 07-449 Millipore 
H3K4me3 C15410003 Diagenode 
H3K27Ac ab4729 Abcam 
Anti EZH2 D2C9 Cell Signaling Technology 
Anti EED CS204392 Millipore 
   
 
Total H3 Pacific-Blue 12167 Cell Signaling Technology 
H3K27me3 Alexa Fluor 647 ab205729 Abcam 
   
   
CD117 (c-kit) magnetic beads 130-091-224 Mitenyi 
APC Lineage Positive Cocktail 558074 BD Biosciences 
   
 
Annexin V-FITC kit 559763 Miltenyi Biotech 
7-AAD 51-68981E BD Bioscience 
   
   
LIN28B 37362 Signalway Antibody 
Anti PLAG1 TA335811 OriGene 
   
   
Anti β-Actin ab6276 Abcam 
Anti GAPDH ab9484 Abcam 
   
   
Donkey Anti-Rabbit Green 92632213 Odyssey 
Goat Anti-Mouse Red 92668070 Odyssey 
 
 
Appendix A 2.3  Restriction Enzymes & Buffers 
Name Catalogue Number Manufacturer 
EcoRI R0101S New England Biolabs 
XhoI R0146S New England Biolabs 
CutSmart Buffer B7204S New England Biolabs 
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Chapter 3 
Characterising the role of EZH2 in the induction of Acute Myeloid 
Leukaemia 
 
3.1  Aims 
This section details the results of experiments designed to investigate whether genetic loss of Ezh2 
prior to leukaemogenesis mediated by ectopic expression of three disparate driver oncogenes, serves 
to influence AML induction.  
 
3.2  Introduction 
This experiment was designed to test the genetic requirement of Ezh2 in the generation of leukaemia, 
using HSPC from existing mice possessing a conditional Ezh2 fl/fl (floxed) allele that were also 
heterozygous for the expression of the Mx1-Cre recombinase. By activation of Mx1-Cre with 
polyinosinic:polycytidylic acid (pIpC), recombination in vivo occurred resulting in Ezh2 excision. 
Through deletion of Ezh2 prior to immortalisation/transformation, an assessment of whether Ezh2 is 
a requirement for induction of leukaemia or not was made. Ezh2+/+ and Ezh2-/- HSPCs were harvested 
and retrovirally transduced with three specific AML-associated fusion oncogenes, representing several 
AML genotypes: 
 
 
MLL-AF9:  potent oncogene capable of producing short-latency AML. Human 
disease is associated with intermediate-poor prognosis. Transforms via 
gene activation. Positive control for maintenance experiments1,2 
AML1-ETO9a:   the t(8;21) is the commonest translocation seen in adult AML, associated  
with a repressive gene expression programme that transforms through  
the activation of oncogenic gene programmes. Typically associated with a  
good prognosis 
 
MOZ-TIF2:      a strong oncogene, associated with poor prognosis 
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Experimental designs similar to the above for assessing epigenetic regulators, have been previously 
performed in the Huntly lab, validating this strategy as a means to assess the role of Ezh2 in AML.3 
The importance of Ezh2 in the maintenance of MLL-AF9 leukaemias has been demonstrated in recent 
years.1,2 The mixed lineage leukaemia (MLL) gene is involved in translocations in AML cases which 
invariably have a poor outcome. MLL is a histone methyltransferase, containing a SET domain and is 
involved in post translational trimethylation of lysine 4 on histone 3 (H3K4me3), facilitating 
transcription. In MLL-rearranged leukaemias the N-terminus of MLL is fused to one of over 70 fusion 
partner genes, with all of these rendering loss of the SET domain. These fusions activate pro-leukaemic 
changes in gene expression. Many fusion partners of MLL are members of the super-elongation 
complex, which is a key regulator of transcriptional elongation. MLL-AF9 overexpression consistently 
immortalises haematopoietic progenitors and generates aggressive short-latency AML in vivo.4 
Characteristic pathological features of the disease included enlarged pale livers and spleens, pale 
femurs and marked peripheral white cell counts, anaemia and thrombocytopenia.  
 
The AML1-ETO9a transcript was shown to be an alternative spliced isoform of the AML1-ETO 
transcript, including an extra exon, exon 9a, of the ETO gene.5 The commonly known AML-ETO fusion 
transcript contains AML1 exons 1-5 and ETO exons 2-11, producing a 752-amino acid fusion protein 
AML1-ETO (AE). The addition of Exon 9a provides a stop codon after the last amino acid encoded by 
exon 8, resulting in a 575-amino acid protein AML1-ETO9a (AE9a). Both the larger form of AML1-ETO 
and AML1-ETO9a are expressed in patients with this leukaemia. Whilst its overexpression in murine 
bone marrow demonstrated increased self-renewal and a partial block in myeloid differentiation, 
AML1-ETO (via a MSCV-AML1-ETO-IRES-eGFP cDNA construct) was shown to be insufficient to 
generate leukaemia in murine overexpression and transplantation experiments on its own. 6 
Expression of AML1-ETO9a (via a MIGR1 cDNA construct) in murine foetal liver cells from C57/Bl6 mice 
however, lead to the development of leukaemia when these cells were transplanted into irradiated 
recipient mice. The median survival time was 25 weeks from transplantation. AML1-ETO9a 
overexpression in wild-type C57/Bl6 bone marrow has been shown to produce leukaemia when 
transplanted similarly, though these have a longer latency (30-65 weeks). 7 Mice typically showed pale 
femurs, enlarged liver/spleens but no abnormalities in thymuses or lymph nodes. Terminal blood 
counts typically demonstrated a raised white cell count, profound anaemia and mild 
thrombocytopenia. 
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The MOZ-TIF2 fusion is associated with AML with inv(8) (p11q13). MOZ belongs to the MYST family of 
histone acetyltransferases and TIF2 is a member of the p160 nuclear receptor transcriptional 
coactivator family that associates with CREB binding protein (CBP). MOZ-TIF2 (via a MSCV-MOZ-TIF2-
IRES-GFP construct) has transforming properties and reliably causes AML in murine bone marrow 
transplantation assays. 8 The original study described an aggressive leukaemia with a median latency 
of 90 days, with pathological findings of generalised lymphadenopathy, widespread infiltration into 
cervical nodes and salivary glands, enlarged spleens/livers and raised white cell counts.  
Thus far, no assessments of the role of Ezh2 in the induction of experimental AML have been described. 
As these oncogenes generate obvious leukaemic immortalisation and transformation in vitro and in 
vivo in normal HSPC, they were reliable and consistent tools to functionally assess the role of Ezh2 in 
the generation (and maintenance) of leukaemia, using: 
1) growth in methylcellulose and liquid culture in vitro and 
2) in vivo transplantation 
A comparison between Ezh2+/+ and Ezh2-/- cells transformed with the same oncogenes was made using 
the above assays. A broad schema of this plan is provided in Figures 2.10 (in vitro) and 2.12 (in vivo) 
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3.3  Results and discussion 
 
3.3.1  Ezh2 does not appear to be a requirement for induction of AML in vitro 
After retroviral transduction of wt (Ezh2+/+) vs Cre+ (Ezh2-/-) HSPCs with each of the three oncogenes, 
50,000 cells were plated into 1ml of methylcellulose M3434 in duplicate (as in Methods 2.3.2 and 
2.6.11) and their clonogenic/proliferative growth potential assessed with successive weekly replatings 
(for 4-5 replatings). The aim was to test whether Ezh2 excised clones would be rapidly outgrown by 
Ezh2 wt clones. Across all three subtypes of AML, transformation occurred between both study arms 
and there was no clear difference in clonogenic or proliferative potential in the Ezh2-/- transformed cell 
lines.  
The only modest difference seen in the first plating, where consistently (across all three AML subtypes) 
the total number of colonies and total cell number was markedly lower in the Ezh2-/- arm than in the 
Ezh2+/+ arm. However, this apparent disadvantage disappeared from Week 2 onwards and there was 
no noticeable difference between the two arms thereafter (Figure 3.1). 
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FIGURE 3.1 Clonogenic (colony number, left) and proliferative (total cell number, right) 
potential of AML1-ETO9a (a), MOZ-TIF2 (b) and MLL-AF9 (c) transformed Ezh2+/+ 
versus Ezh2-/- c-kit selected murine bone marrow cells on weekly replatings 
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However, within the first week (even for the very potent MLL-AF9 fusion oncogene) transformation 
and immortalisation would not be expected to occur. The Week 1 colonies that formed were not 
dense, round and with clear margins as would be expected from an established MLL-AF9 or MOZ-TIF2 
immortalised cell line. As each oncogene construct harboured a fluorescent marker readily detectable 
by flow cytometry (GFP for AML1-ETO9a and MOZ-TIF2 and YFP for MLL-AF9), it was possible to assess 
percentage of transduced cells expressing the fusion oncogene at each weekly replating and it was 
clear at Week 1 that only a minority were expressing the marker/fusion oncogene. With each 
successive replating, the proportion of cells positive for the marker (and hence fusion oncogene 
expression) increased and with MLL-AF9 and MOZ-TIF2, by week 3-4 90-100% cells (and by Week 5-6 
for AML1-ETO9a) were positive for marker, with colonies taking on the classical immortalised 
appearance.  
These data suggested that the Ezh2-/- c-kit selected bone marrow cells may have decreased inherent 
clonogenic and/or proliferative potential compared to the Ezh2+/+ cells before the effects of the 
oncogene would take over and drive them toward immortalisation.  
This prompted an assessment of the serial replating potential of untransduced Ezh2-/- vs Ezh2+/+ c-kit 
selected bone marrow cells through weekly replatings (Figure 3.2):  
  
 
 
 
 
 
 
 
 
 
 
FIGURE 3.2 Ezh2-/- HSPCs have a decreased clonogenic and proliferative potential 
Clonogenic (colony number) and proliferative (total cell number) potential of untransduced 
Ezh2+/+ versus Ezh2-/- c-kit BM cells on weekly replatings 
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This clearly demonstrated that untransduced Ezh2-/- bone marrow cells had a significant reduction in 
clonogenic and proliferative potential from as early as the first replating and totally exhausted by Week 
2, compared to Ezh2+/+ cells that replated to Week 3 and beyond. This was expanded to an assessment 
for 9 separate mice (all harvested at 8 weeks of age) across both genotypes, again demonstrating a 
clearly significantly lower clonogenic potential in the Ezh2-/- HSPCs (Figure 3.3): 
 
 
 
 
 
 
 
 
 
 
 
 
These results suggest at the early HSPC level at least, in adult murine BM cells Ezh2 deletion 
significantly reduces repopulation potential in vitro, however does not alter outcome of the 
transformation or immortalisation significantly in these three AML-associated oncogenes.  
To exclude differences in the size or frequency of specific progenitor populations within the HSPC 
compartment between untransduced Ezh2+/+ and Ezh2-/- genotypes, immunophenotyping designed to 
characterise these populations thoroughly was kindly performed by Dr George Giotopoulos, Huntly lab 
(data not shown). This was performed for 12 individual mice of the same age as used in these 
experiments, from each Ezh2+/+ (wt) or Ezh2-/- (Cre+) study arm to reduce phenotypic bias. There was 
no significant difference in numbers of long-term or short-term HSCs (LT-HSCs and ST-HSCs), lineage 
negative cells or early myeloid progenitors seen.  
FIGURE 3.3 Average clonogenic output at Day 7 from untransduced Ezh2+/+ (n=5) versus  
Ezh2-/- (n=4) c-kit selected murine BM cells 
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3.3.2 Loss of Ezh2 prior to induction of AML in vivo has dramatic subtype-dependent 
effects 
The in vivo experiments for each oncogene were performed next (set up as per Figure 2.12 and 
Methods 2.6.13). In addition, to assess the kinetics of disease induction, we performed serial 
peripheral blood counts to assess total white cell count (WCC) and for percentage of GFP (and 
therefore oncogene) expressing cells.  
 
3.3.2.1 Loss of Ezh2 retards MOZ-TIF2 AML induction in vivo 
In this experiment, peripheral bleeds as early as Day 21 post-transplant demonstrated a significant 
difference in WCC and GFP-expression, with lower levels of both seen in the Ezh2 excised cohort 
(Figure 3.4): 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.4  Ezh2-/- MOZ-TIF2 transplanted mice demonstrate lower white cell counts and 
peripheral blood GFP expression at Day 21 
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As the disease latency was relatively short due to the potency of MOZ-TIF2 as an oncogene, it was 
apparent that when assessed early i.e. just after engraftment, loss of Ezh2 was associated with 
significantly less GFP positive cells in peripheral blood. The inference from this early time point was 
that Ezh2 seemed to be required in leukaemic transformation or simply that Ezh2 may be required for 
efficient transplantation. Mice became visibly moribund as early as Day 45 post-transplant and all were 
terminal between Days 49 and 90. When terminal, they exhibited significant clinical deterioration with 
emaciation, piloerection, hunched posture and on occasion, marked dyspnoea. At necropsy, some 
exhibited enlarged cervical lymph nodes consistent with the original description. 8 
In the cohort of Ezh2+/+ (wt) versus Ezh2-/- (Cre+) MOZ-TIF2 transformed mice, the median survival 
differed significantly, from 51 (wt) to 76 (Cre+) days – a median increase of 50%, data shown in Figure 
3.5: 
  
 
 
 
 
 
 
 
 
 
 
 
 
Notably, there were no significant differences in terminal white cell counts, spleen or liver weights 
(Figure 3.6, below) nor in GFP distribution between haematopoietic compartments (Figure 3.7, 
overleaf) between the Ezh2+/+ and Ezh2-/- cohorts: 
FIGURE 3.5  Kaplan-Meier survival curve of Ezh2+/+ vs Ezh2-/- MOZ-TIF2 leukaemic mice 
 Ezh2-/- (Cre+) MOZ-TIF2 leukaemias demonstrate a significant increase in survival compared 
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FIGURE 3.6 Spleen/Liver weights and terminal white cell counts of Ezh2+/+ vs Ezh2-/- 
MOZ-TIF2 leukaemic mice 
 No significant differences are seen between wt and Cre+ mice 
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FIGURE 3.7  GFP expression in terminal blood samples, bone marrow and spleen of Ezh2+/+ vs 
Ezh2-/- MOZ-TIF2 leukaemic mice 
 No significant differences are seen between wt and Cre+ mice 
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Analysis of GFP expression within tissue compartments infiltrated by AML, revealed GFP expression 
between 20-90% in terminal peripheral blood, 49-97% in marrow and 20-75% in spleen (Table 3.1):  
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunophenotyping between the two cohorts (kindly performed by Dr George Giotopoulos, Huntly 
Lab) revealed no significant differences, with the following myeloid profile: Mac1+/Gr1+, c-kit positive 
leukaemia splenic tissues (also negative for CD4/B220 and Ter119). There were no differences in GFP 
distribution amongst haematopoietic compartments (Figure 3.7).  
These data suggested no difference between phenotypes of the leukaemias seen in the Ezh2+/+ and 
Ezh2-/- cohorts and are in keeping with described MOZ-TIF2 murine leukaemia models.8 Ezh2 clearly 
exhibited an oncogenic function in MOZ-TIF2 leukaemogenesis in this in vivo experiment, with its loss 
delaying onset of disease.  
 
 
 
TABLE 3.1  Terminal data for all MOZ-TIF2 leukaemic mice (Ezh2+/+ (wt) and Ezh2-/- (Cre+) arms) 
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3.3.2.2 Loss of Ezh2 accelerates AML1-ETO9a mediated leukaemogenesis in vivo 
The MOZ-TIF2 induction experiment produced results strongly favouring a role for Ezh2 as an 
oncogenic facilitator of disease. As with that experiment, an assessment of peripheral blood GFP and 
white cell counts was made at Day 21 for AML1-ETO9a transplanted mice. In contrast to MOZ-TIF2, 
there was no significant difference in GFP expression or total white cell count in the blood between 
AML1-ETO9a transduced; Ezh2+/+ (wt) versus Ezh2-/- (Cre+) mice (Figure 3.8), suggesting that loss of 
Ezh2 did not affect early AML1-ETO9a transformation. However, AML1-ETO9a transduced wild-type 
bone marrow cells that have been transplanted into healthy recipients have a significantly longer 
disease latency7 than wild-type MOZ-TIF2 transplants, so we considered it possible that this difference 
between these two subtypes of AML (at this early time point) reflected the disease latencies. 
 
 
 
 
 
 
 
 
 
 
 
Serial measurements of peripheral blood GFP percentage and WCC at regular intervals allowed us to 
monitor the kinetics of the disease (Figure 3.9): 
 
 
 
FIGURE 3.8  White cell counts and peripheral blood GFP expression between Ezh2+/+ (wt) and 
Ezh2-/- (Cre+) AML1-ETO9a mice at Day 21 post transplant 
AML1-ETO9a - White cell counts at Day 21
Ez
h2
+/+
 (w
t)
Ez
h2
-/- 
(C
re+
)
0
2
4
6
P value 0.9013
W
B
C
 (x
 1
09
/l)
AML1-ETO9a - Peripheral GFP expression at Day 21
Ez
h2
+/+
 (w
t)
Ez
h2
-/- 
(C
re+
)
0
10
20
30
40
50
P value 0.1714
G
FP
%
  e
xp
re
ss
io
n
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
FIGURE 3.9 Serial bleeds assessing GFP percentage in peripheral blood (PB) from (a) 
Ezh2+/+ (wt); AML1-ETO9a and (b) Ezh2-/- (Cre+); AML1-ETO9a cohorts over 
time (in days) 
  
 (a) Ezh2+/+ mice (#4437 - 4443, n=7) show similar levels of GFP expression in 
peripheral blood at Day 21 post transplantation to Ezh2-/- mice. This GFP 
expression then falls and remains low level (<20%) until significantly later, 
increasing rapidly just before mice become terminal 
 
(b) In contrast, Ezh2-/- (#4444 - 4450, n=7) mice display consistently higher GFP 
expression in peripheral blood across serial bleeds until they become terminal 
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Strikingly, whilst all Ezh2+/+ (wt) animals had a significant fall in GFP following the initial Day 21 bleed, 
only retaining a low level of peripheral GFP expression until disease onset close to a year later, this was 
not the case with the Ezh2-/- (Cre+) animals. As shown above, all mice retained a markedly high 
peripheral GFP percentage until time of death which was significantly accelerated compared to the 
wild-type cohort. This suggests that not only is disease accelerated in the Ezh2-/- cohort (as seen below), 
but that its early kinetics are also altered, with all animals constantly demonstrating a higher circulating 
GFP expression after engraftment than in the Ezh2+/+ cohort.  
The Ezh2-/- (Cre+) cohort became terminal as early as Day 86 of the experiment, with clinical signs of 
emaciation, piloerection, hunched posturing and noticeably pale extremities. By Day 138 the entire 
cohort had died of leukaemia. Each animal had a pancytopenia with marked anaemia and 
thrombocytopenia, with higher GFP expression in bone marrow than spleen or peripheral blood. In 
contrast, the Ezh2+/+ (wt) cohort, typically with the longer latency, began to develop GFP positive 
leukaemia at Day 323, at which point the experiment was terminated due to the clear significance of 
the result. A few of the Ezh2+/+ (wt) cohort died of other causes than leukaemia (GFP negative in PB, 
BM and spleen) – bilateral hydronephrosis, enlarged thymi and livers on necropsy). The survival 
outcomes are shown below (Figure 3.10): 
 
  
 
 
 
 
 
 
 
 
 
FIGURE 3.10 Kaplan-Meier survival curve of Ezh2+/+ (wt) vs Ezh2-/- (Cre+) AML1-ETO9a 
leukaemic mice 
 Ezh2-/- (Cre+) AML1-ETO9a leukaemias develop significantly quicker than Ezh2+/+ (wt) AML1-
ETO9a leukaemias 
Three notches for Ezh2+/+ (wt) curve (black) indicate 3 mice culled for reasons other than leukaemia as 
indicated in main text, excluded from survival curve 
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GFP percentages in bone marrow and spleen in both cohorts were typically high, varying from 32-91% 
and 45-77% respectively (Table 3.2). All mice had enlarged livers and spleens, with markedly low 
haemoglobins at time of culling, consistent with the original description of AML1-ETO9a transplanted 
mice. Immunophenotyping of leukaemic splenic tissues (Dr George Giotopoulos, Huntly lab) 
demonstrated a solely c-kit positive population (negative for Mac1/Gr1 myeloid markers and also 
negative for CD4/B220 and Ter119 lymphoid/erythroid markers), again consistent with the original 
study. 5 Cytospins of peripheral blood and spleen prepared freshly upon culling demonstrated 
leukaemic blasts in Cre+ mice. Histopathology of bone marrow and spleens showed dense infiltration 
in both with a monomorphic population of primitive blasts (Figure 3.11).  
 
 
      GFP%   
Mouse 
# 
Cre 
status 
Day 
culled 
WCC 
(x109/l) 
Hb 
(g/dl) 
Plts 
(x109/l) 
Periph 
Blood 
Bone 
Marrow Spleen 
Spleen 
wt (g) 
Liver 
wt (g) 
4449 Cre+ 86 5.6 36 122 29.1 85.5 56.0 0.28 1.16 
4450 Cre+ 100 3.4 ** 40 43.2 86.0 66.0 0.32 1.23 
4444 Cre+ 107 2.4 ** 22 36.9 43.5 45.8 0.31 1.11 
4447 Cre+ 123 3.1 44 15 43.0 76.9 76.7 0.40 1.10 
4448 Cre+ 127 3.1 30 73 46.0 76.8 77.0 0.26 1.39 
4446 Cre+ 130 7.4 35 37 55.0 91.0 67.5 0.39 1.33 
4441 wt 132 15.2 82 105 5.0 1.6 2.2 0.51 1.50 
4445 Cre+ 133 4.5 28 120 34.7 61.0 61.9 0.28 1.08 
4451 Cre+ 138 1.2 26 31 8.9 80.9 66.4 0.29 1.29 
4439 wt 204 N/A N/A N/A N/A N/A N/A 0.31 1.32 
4442 wt 323 27.4 53 273 75.6 32.1 66.5 0.59 2.88 
 
 
 
 
 
 
 
 
 
TABLE 3.2 Terminal data for AML1-ETO9a leukaemic mice (Ezh2+/+ (wt) and Ezh2-/- (Cre+) 
arms) 
 Rows in grey/italic indicate animals that died of non-leukaemia causes (GFP negative) – 
findings at necropsy included bilateral hydronephrosis, massive thymic enlargement, 
massive hepatomegaly 
** indicate haemoglobins lower than the lower limit of detection by blood analyser 
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotyping of two mice from each arm (Ezh2fl/fl; wt and Ezh2 fl/fl; Cre+ AML1-ETO9a leukaemic mice) 
from DNA extracted from spleen tissues, demonstrated 99-100% excision in the Cre+ group versus no 
excision in the wt group, confirming the leukaemias maintained the genotypes of the transplanted 
cells.  
This experiment resulted in the highly significant and surprising finding that Ezh2 loss prior to induction 
of AML1-ETO9a leukaemogenesis actually accelerated its development whilst showing no obvious 
phenotypic differences to the Ezh2 replete cohort, suggesting a potent tumour suppressive function, 
in stark contrast to the role of Ezh2 in transformation by MOZ-TIF2.  
 
 
 
 
 
 
FIGURE 3.11 Histopathology of bone marrow and spleen taken at time of death in Ezh2+/+ (wt) 
vs Ezh2-/- (Cre+) AML1-ETO9a murine leukaemias 
 Rapid Romanowsky stain. x40 magnification 
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3.3.2.3 Loss of Ezh2 accelerates MLL-AF9 mediated leukaemogenesis in vivo 
The same experimental setup was then applied to assessing the role of Ezh2 in MLL-AF9 mediated 
leukaemogenesis. As described above, the MLL-AF9 translocation is a particularly potent oncogenic 
driver of AML producing aggressive, short latency disease9, so the expectation here was that loss of 
Ezh2 prior to MLL-AF9 transformation in vivo was less likely to produce a significant effect on outcome, 
if at all any. Once again, leukaemia development was tracked by regular clinical monitoring of mice 
and peripheral blood sampling to assess whole blood count and GFP percentages. At Day 40, there was 
a significant increase in circulating GFP positive cells in the Ezh2-/- (Cre+) cohort compared to Ezh2+/+ 
(wt) (Figure 3.12): 
 
 
 
 
 
 
 
 
 
 
 
This translated into earlier development of terminal leukaemias in this cohort.  As early as Day 41, 
animals in the Ezh2-/- (Cre+) arm became terminal with emaciation, ruffled fur, reduced movements 
and marked dyspnoea. All animals exhibited marked hepatosplenomegaly, elevated white cell count, 
anaemia and strongly expressed GFP in peripheral blood, spleen and bone marrow tissues.   There was 
a significant acceleration of development of MLL-AF9 driven AML in the Ezh2-/- (Cre+) arm as seen in 
Figure 3.13:  
 
FIGURE 3.12 GFP expression in peripheral blood between Ezh2+/+ (wt) and Ezh2-/- (Cre+) MLL-
AF9 mice at Day 40 post-transplant 
 Ezh2-/- MLL-AF9 transplanted mice display a significantly higher level of GFP in peripheral 
blood prior to becoming terminal compared to Ezh2+/+ MLL-AF9 transplanted mice 
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Mice in the Ezh2+/+ (wt) arm survived significantly longer (median survival 60 days compared to 49 days 
in the Ezh2-/- (Cre+) group). GFP percentages in bone marrow and spleen in both cohorts were typically 
high, varying from 80-96% and 49-84% respectively (Table 3.3). Immunophenotyping of leukaemic 
splenic tissues was not different between genotypes (Dr George Giotopoulos, Huntly lab) confirming a 
significant myeloid population, strongly positive for Mac1 and c-kit (whilst negative for CD4/B220 and 
Ter119 lymphoid/erythroid markers).  
 
 
 
 
 
 
 
FIGURE 3.13 Kaplan-Meier survival curve of Ezh2+/+ (wt) vs Ezh2-/- (Cre+) MLL-AF9 leukaemic 
mice 
Ezh2-/- (Cre+) MLL-AF9 leukaemias develop significantly quicker than Ezh2+/+ (wt) MLL-
AF9 leukaemias 
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There were no significantly different phenotypic effects between the two cohorts. Average spleen and 
liver sizes and blood counts were similar as were distribution of leukaemic cells (assessed by GFP 
proportions) (Figures 3.14 and 3.15). 
 
 
 
 
 
 
 
 
 
 
       GFP%       
Mouse 
# 
Cre 
status 
Day 
culled 
WCC 
(x109/l) 
Hb 
(g/dl) 
Plts 
(x109/l) 
Periph 
Blood 
Bone 
Marrow Spleen 
Spleen 
wt (g) 
Liver 
wt (g) 
5329 Cre+ 41 32.7 136 113 45.90% 84.40% 57.00% 0.531 2.287 
5335 Cre+ 43 67.2 70 280 50.00% 80.30% 49.20% 0.8 2.88 
5336 Cre+ 43 36.1 96 496 52.80% 80.20% 63.60% 0.62 2.72 
5331 Cre+ 47 108.4 65 110 67.90% 87.00% 71.60% 0.61 2.71 
5333 Cre+ 51 20.4 40 59       0.7 3 
5326 wt 52                 
5334 Cre+ 54 142.4 69 379 78.60% 93.10% 69.60% 1.15 4.18 
5342 wt 54 22.6 46 69 50.30% 90.70% 71.50% 0.89 2.74 
5328 wt 56 51.9 78 157 60.40% 94.00% 60.50% 0.57 2.66 
5332 Cre+ 57 26.1 44 310 75.70% 93.60% 75.80% 1.01 3.89 
5340 wt 60 54.7 133 209 75.50% 96.20% 65.50% 0.75 2.86 
5338 wt 60 >80 160 449 72.50% 83.60% 77.80% 0.76 2.28 
5327 wt 63 126 89 88 65.60% 84.20% 57.50% 0.96 4.05 
5330 Cre+ 64 19.2 109 332 57.50% 93.50% 84.70% 0.89 2.89 
5339 wt 66             0.71 3.09 
5341 wt 69 107.1 146 212 56.20% 93.10% 59.50% 0.75 2.54 
TABLE 3.3 Terminal data for all MLL-AF9 leukaemic mice (Ezh2+/+ (wt) and Ezh2-/- (Cre+) arms) 
 Blank cells – data not available 
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FIGURE 3.14 Spleen/Liver weights and terminal white cell counts of Ezh2+/+ vs Ezh2-/- MLL-AF9 
leukaemic mice 
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FIGURE 3.15 GFP expression in terminal blood samples, bone marrow and spleen of Ezh2+/+ vs 
Ezh2-/- MLL-AF9 leukaemic mice 
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3.3.3 Discussion and future work 
Though Ezh2 loss in vitro failed to demonstrate any marked differences in immortalisation for each of 
the three oncogenes described above, its loss in vivo prior to transformation and leukaemia 
development resulted in profound phenotypic outcomes starkly contrasting each other, depending 
upon AML subtype. In vivo, in MOZ-TIF2 leukaemogenesis, Ezh2 appeared to have clear oncogenic 
function as its absence permitted a significant increase in survival. Surprisingly, the same experiment 
for AML1-ETO9a and MLL-AF9 demonstrated a clear synergism between Ezh2 loss and these 
oncogenes in driving AML generation, demonstrate a clear tumour-suppressive role. This was 
corroborated by the genotypes of Ezh2fl/fl; Cre+ leukaemic mice in both fusions being 99-100% Ezh2 
deficient via qPCR assessment at time of culling, suggesting that the Ezh2-/- transformed cells have a 
clear selective advantage. It is interesting that Ezh2 loss has the same acceleratory effect upon two 
very different subtypes of AML. MLL-AF9 is characteristically known to promote transformation 
through gene activation whilst AML-ETO (and AML1-ETO9a) progress through the repression of gene 
transcription. That loss of Ezh2, a transcriptional repressor itself, should facilitate the generation of 
both these AML subtypes that alone progress by contrasting mechanisms, is highly unusual. 
Furthermore, similar to MLL-AF9, the MOZ-TIF2 oncogene transforms through activation of genes, yet 
Ezh2 loss here led to a clearly opposite effect, with a pronounced increase in survival. The expectation 
would have been that any effect of Ezh2 loss would be similar between MLL-AF9 and MOZ-TIF2 which 
transform in similar ways, are more aggressive and are clinically associated with poorer prognosis, 
whilst being different in the less aggressive AML1-ETO9a setting. However, this is not the case and as 
the in vivo effects are clearly significant across all three subtypes, this is a surprising result that 
reinforces the idea that Ezh2 has varying roles during induction of leukaemia, in a subtype-dependent 
context.  
Though different diseases, the findings in these MLL-AF9 and AML1-ETO9a in vivo experiments align 
with recently published data supporting the tumour suppressive role of Ezh2 in myeloproliferative 
neoplasms,10,11 which conclude by suggesting caution when considering EZH2 inhibitors in clinical 
programmes.  
As this experiment assessed Ezh2 loss during the early stages of AML evolution, in view of the in vitro 
experiments suggesting an early clonogenic and proliferative disadvantage of Ezh2-/- cells, an 
assessment of functional and phenotypic differences between wild-type Ezh2+/+ and Ezh2-/- bone 
marrow was made. Functional assays in vitro demonstrated significantly diminished replating potential 
of Ezh2 deficient cells and this difference was confirmed across 5 biological replicates. Furthermore, 
there was no significant alteration of early progenitor or HSC compartments following Ezh2 loss that 
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could account for the stark differences in leukaemia outcomes seen following transformation and in 
vivo transplantation.  
Given the major function of Ezh2 is to mediate histone methyltransferase activity through its catalytic 
SET domain, thus facilitating transcriptional repression, the next logical step was to assess differences 
in gene expression following Ezh2 loss in the wild-type/non-transformed setting. In doing so, it would 
be possible to establish which transcriptional programmes are altered in these c-kit positive HSPCs 
when Ezh2 is deleted, with the suggestion that these would either hinder or co-operate in a subtype-
specific manner with the individual driver oncogene in this system once it was overexpressed. To 
further interrogate how Ezh2 loss might mechanistically alter transcriptional programmes and their 
outputs, it was also important to assess changes in histone modifications – particularly trimethylation 
of lysine 27 at Histone H3 (H3K27me3), which it is responsible for. We also wanted to align this with 
an assessment of acetylation of lysine 27 of histone H3 (H3K27Ac) and trimethylation of lysine 4 at 
histone H3 (H3K4me3) – both associated with activation of transcription, to search for any overlaps 
between this and a loss of a repressive mark and increased gene expression. Through interlinking 
altered gene expression and analysis of potential alterations of the epigenetic landscape following 
Ezh2 deletion in non-transformed HSPCs, we wished to identify potential candidate gene facilitators of 
leukaemia development in the AML1-ETO9a or MLL-AF9 setting. Given their opposing mechanisms of 
transformation, yet the same outcome following Ezh2 loss, we expected to find differences in 
transcriptional changes between these leukaemias. By comparison of gene changes following Ezh2 loss 
in the non-transformed setting with altered gene expression in these Ezh2-deficient leukaemias, we 
aimed to reveal key functional regulators that were possibly co-operating with these two oncogenes 
in producing the profound acceleration in disease. This is detailed further in Chapter 5.   
Additionally, we wished to compare and contrast this with any functional differences seen in the 
maintenance experiments detailed in the next section.  
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Chapter 4 
Characterising the role of Ezh2 in the maintenance of Acute Myeloid 
Leukaemia 
 
4.1  Aims 
This series of experiments was designed to examine the genetic role of Ezh2 in established leukaemia, 
and whether its loss, either in vitro or in vivo, would alter immortalisation by AML oncogenes and the 
maintenance of these aggressive tumours. 
 
4.2  Introduction 
Retroviral transduction followed by overexpression of MLL-AF9, AML1-ETO9a and MOZ-TIF2 within 
murine HSPCs consistently produces immortalisation of these cells in vitro under the appropriate 
murine cytokine conditions. Transplantation of these cells into lethally irradiated wild-type C57/Bl6 
recipient mice through tail-vein injection and then engraftment, eventually generates leukaemias with 
disease latencies reflective of potency of each oncogene. In vitro the immortalised cells continue to 
form colonies and proliferate indefinitely, whilst in vivo once leukaemic, mice will rapidly deteriorate 
clinically and show terminal signs such as weight loss, inappetence, ruffled fur and dyspnoea, with the 
leukaemias able to perpetuate disease through serial transplantation. Through retroviral 
overexpression of these oncogenes in c-kit positive HSPC’s harvested from Ezh2 fl/fl; wild-type, it was 
possible to conditionally delete Ezh2 at any stage of AML evolution. After immortalisation or 
engraftment had occurred, the role of Ezh2 in maintaining this state was then interrogated. 
To test the requirement of Ezh2 in maintenance of the immortalised state in vitro, Ezh2 fl/fl (wild-type 
for Mx1-Cre) c-kit selected HSPCs from mice were immortalised/transformed by retroviral 
transduction of the same three oncogenes. Once established in weekly methylcellulose replatings (i.e. 
clear colony formation with 100% GFP/YFP expression), these cell lines were transferred to liquid 
culture and retrovirally transduced a second time with a p-Babe-Cre-puro vector or p-Babe-puro empty 
vector (both containing a puromycin selection marker), allowing for excision of Ezh2 at a stage where 
immortalisation was already established. The readout from this assay was through methylcellulose 
replatings, again assessing clonogenic and proliferative potential post Ezh2-excision (Figure 2.11 in 
Methods). 
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For the maintenance in vivo assays, primary leukaemias were generated for the same three oncogenes 
from Ezh2 fl/fl mice (heterozygous for Mx1-Cre) and then transplanted into lethally irradiated wild-
type C57/Bl6 secondary recipients. Once the cells had engrafted, PBS (control) or pIpC was then 
administered intraperitoneally to activate Mx1-Cre and delete Ezh2, thus testing its requirement for 
the maintenance of the leukaemia (Figure 2.13 in Methods). 
As mentioned in Chapter 3, Ezh2 deletion during the maintenance stage of MLL-AF9 transformed 
granulocyte macrophage progenitors (GMPs), severely compromised growth in vitro and the 
progression of AML in vivo. 1 This was performed utilising a similar Ezh2flox/flox knockout system, though 
employing a Rosa: Cre-ERT. Having seen the opposite effect on MLL-AF9 AML induction in vivo, we 
were keen to demonstrate that we could also see a delayed progression of AML in vivo using our 
conditional knockout system, therefore we carried out the maintenance experiments using MLL-AF9 
(to serve as a positive control) as well as in AML1-ETO9a and MOZ-TIF2 leukaemias. Having seen 
varying effects dependent on subtype in AML induction, it was important to ascertain if Ezh2 played 
any oncogenic or tumour-suppressive role in maintenance, especially of the latter 2 subtypes. 
 
4.3  Results and discussion 
4.3.1 Ezh2 is an absolute requirement for the maintenance of multiple subtypes of AML in vitro 
As described in Methods 2.6.12, methylcellulose platings with or without puromycin selection 
following transduction of each transformed Ezh2 fl/fl cell line with either empty vector or p-babe-Cre-
puro were set up, with the intention of noting differences in colony formation, total cell numbers over 
successive weekly replatings, and subsequently assessing any differences in cellular phenotype. 
Colonies growing in the +puromycin plates were those that had successfully been transduced with 
either vector. Use of the empty vector (hereafter “EV transduced”) in tandem with p-babe-Cre-puro 
(hereafter “Cre-transduced”) was to provide a control and assess for Cre-mediated toxicity.  
For MLL-AF9, Ezh2 deletion following successful Cre-transduction resulted in no colonies and virtually 
no cells available to replate after 7 days in methylcellulose (Figure 4.1, right): 
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In contrast, successful empty-vector transduced Ezh2 fl/fl; MLL-AF9 cell lines (as evidenced by 
puromycin selection - indicated with red bars) produced less colonies than non-transduced at Week 1, 
indicating modest toxicity of the additional transduction process. However by Week 2, the clonogenic 
potential of both successfully and unsuccessfully transduced empty vector cells was restored to similar 
high levels. This was maintained through 4 weeks of replatings (Figure 4.1, left). Taken together, it 
therefore appeared that retroviral insertion and subsequent expression of the Cre- recombinase 
completely abolished growth of the already immortalised Ezh2fl/fl; MLL-AF9 cell line.  
The effects of Cre recombinase mediated toxicity to mammalian cells have been widely reported in the 
literature. 2,3 In order to ensure that the profound inhibitory effect on colony growth seen on expressing 
Cre- from p-babe-Cre-puro transduction in the Ezh2 fl/fl; MLL-AF9 cell line was due to loss of Ezh2 and 
not Cre-toxicity, the same experiment was performed on a separately generated wild-type; MLL-AF9 
immortalised cell line (this was generated using wild-type murine c-kit positive HSPCs and subjecting 
them to MLL-AF9 transduction and immortalisation through successive methylcellulose replatings – 
performed at the same time as developing the Ezh2fl/fl; MLL-AF9 cell line).  
If the effects were solely due to Cre-mediated toxicity, it was expected that in this wild-type; MLL-AF9 
immortalised cell line where no sites were floxed, the same abolishment of colony growth at one week 
would be seen. However, despite being transduced with p-babe-Cre-puro (confirmed through its 
growth in puromycin), the wild-type; MLL-AF9 cell line was able to produce colonies at Week 1 and 
beyond (Figure 4.2). This established that the effects seen were due to Ezh2 loss, suggesting its 
importance in maintenance of MLL-AF9 immortalised cells in vitro.  
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When the same experiment was performed for the Ezh2fl/fl; AML1-ETO9a transformed cell line, it 
showed the same outcome – inhibited growth in the Cre-transduced +puromycin arm (compared to 
normal growth in both +/-puro arms for the EV-transduced cells). A single colony was present at Week 
1 but when cells from this were harvested, washed and replated they did not re-establish clonogenic 
growth at Week2 onwards (Figure 4.3): 
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Similarly, an equivalent wild-type; AML1-ETO9a immortalised cell line was unaffected by p-babe-Cre-
puro transduction (similar to the MLL-AF9 experiment above) and established clonogenic growth 
under puromycin selection in a similar fashion to Figure 4.2 (data not shown).  
Finally, the same experimental outcome for the Ezh2fl/fl; MOZ-TIF2 transformed cell line was seen. 
Ezh2 loss following Cre-transduction (selected again through growth in puromycin) definitively 
abolished growth, whilst transduction with the empty vector did not significantly affect the cell line at 
all (Figure 4.4): 
 
 
 
 
 
 
 
 
 
 
 
The substantial effects of Ezh2 deletion in these established immortalised cell lines were so significant 
that due to a complete absence of cells after overexpression of Cre recombinase through a second 
retroviral transduction, a number of factors such as: 
a) percentage of Ezh2 excised (as per qPCR strategy) 
b) functional differences e.g. changes in cell cycle progression, apoptosis and differentiation  
could not be assessed. These in vitro data fit with the original hypothesis provided in this thesis and 
provide a compelling argument towards therapeutically targeting EZH2. However, it was important to 
assess whether this functional role was also maintained in vivo – this is explored in the next section. 
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4.3.2 Loss of Ezh2 interferes with maintenance of secondary MLL-AF9 leukaemias in vivo 
Primary transplants 
CD117 (or c-kit) magnetic selection was performed on red-cell lysed, washed whole bone marrow 
taken from 2-3 Ezh2 fl/fl; Cre+ mice (with no prior pIpC treatment) to yield HSPCs. A typical harvest 
was approximately 40-50x106 whole bone marrow cells per mouse (aged 8-12 weeks). Magnetic 
labelling and selection typically yielded in the order of 10% c-kit positive cells from whole marrow (data 
not shown). These c-kit positive cells were then stabilised in overnight liquid culture in RPMI 20% and 
cytokines (as per Methods 2.6.5), and were then subjected to two rounds of retroviral transduction 
with retroviral supernatant derived from transfection of 293T cells with MSCV-IRES-MLL-AF9-YFP 
construct. Following the second round of transduction, an assessment of transduction efficiency was 
made using flow cytometry to assess the percentage of YFP positive (i.e. transduced) cells. For MLL-
AF9 (in this and across all the other experiments detailed above) the typical transduction efficiency 
was 0.5-4%, an example of this is shown in Figure 4.5: 
 
 
 
 
 
 
 
 
 
 
The relatively low levels of transduction efficiency were expected, given the relatively large size of the 
construct. Despite this, due to the potency of the oncogene, small numbers of cells YFP positive cells 
only were required to produce leukaemia (in the order of 103-104 YFP positive cells transplanted per 
mouse). 
Non-transduced cells MLL-AF9 transduced 
FIGURE 4.5  Transduction efficiency of MLL-AF9 into c-kit positive HSPCs 
Cells gated initially by forward and side-scatter, doublets removed and then gated for YFP positivity 
P5 indicates cells gated for YFP expression (detected on same channel as GFP, i.e. 488 530/30) 
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Using the percentage transduced and the total number of cells isolated, it was possible to adjust the 
volume injected per mouse to ensure each animal received exactly the same number of YFP-positive 
cells (this type of calculation was also used in all of the induction experiments for transplantation, in 
order to ensure each arm could be compared directly). Five wild-type C57/Bl6 mice were lethally 
irradiated (5.5Gy in 2 fractions) then injected with these transduced c-kit positive cells and monitored 
for disease, through tracking YFP percentages in peripheral blood samples across time and through 
clinical monitoring. By Day 40 and 41, all of these primary transplants were exhibiting clear terminal 
signs, with very high white cell counts and YFP-positivity (example in Figure 4.6): 
 
 
 
 
 
 
 
 
 
All animals had high white cell counts, hepatosplenomegaly and strongly YFP positive tissues at the 
time of sacrifice. Leukaemic splenic tissues and bone marrow were isolated, processed and stored in 
liquid nitrogen. In generating these transplants, the idea was to have conditional Ezh2 fl/fl; Cre+ MLL-
AF9 leukaemic tissues that we could then transplant into lethally irradiated C57/Bl6 secondary 
recipients. Following engraftment there, PBS or pIpC would be administered, causing Ezh2 deletion in 
the latter to occur and thus to test our hypothesis of whether Ezh2 was important in MLL-AF9 
maintenance.  
Given the presence of Cre recombinase in the cells originally used to generate these primary 
leukaemias, even though it was not activated at that stage by design, we assessed whether any 
spontaneous Cre-mediated recombination of Ezh2 had taken place by the time the animals were 
terminal for MLL-AF9 leukaemia, using DNA extracted from splenic tissues and the qPCR method 
already described. Surprisingly, all of the 5 primary MLL-AF9 leukaemias had some degree of Ezh2 
FIGURE 4.6  FACS analysis to estimate percentage of YFP-positive cells in peripheral blood of 
Ezh2 fl/fl; Cre+ MLL-AF9 transplanted primary recipient mouse, Day 40 
P2 indicates cells positive for YFP (detectable on GFP channel 488 530/30) after red cell lysis of 
whole blood sample. This particular sample exhibited approximately 82% YFP positivity, with WCC 
of 76x109/L  
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excision (even though there was no prior pIpC treatment). This varied from 80-90% Ezh2 excision. We 
opted to choose splenic tissue from the least Ezh2 excised of these animals to act as donor material 
for secondary transplants. Though the level of spontaneous Cre-mediated excision was higher than we 
expected, we used the spleen from one mouse (with the lowest level of Ezh2 excision - approximately 
80%) to generate secondary transplants and test our hypothesis. With hindsight, as the activation of 
Mx1-Cre involves an interferon mediated immune/inflammatory response, it is reasonable to expect 
there to be some degree of activation during the significant events of leukaemogenesis, and this has 
been recently demonstrated in the transplant setting.6 This experimental design (i.e. generating 
primary leukaemias that are conditional for the gene under investigation followed by transplanting 
into secondary recipients and then conditionally deleting the gene to assess its effects) has been used 
in the literature before, though perhaps the exact level of excision is underestimated – as assessments 
of gene excision/genotype are usually performed via the gel method, which does not yield as precise 
results as the qPCR method.  
 
Secondary transplants and Ezh2 functional assessment 
Splenic tissues from a primary Ezh2 fl/fl; Cre+ MLL-AF9 leukaemic mouse with the lowest level of 
excision were thawed, washed and counted. This particular animal was 76% YFP positive in splenic 
tissue at the time of culling. From this, approximately 1x106 cells were transplanted via tail-vein 
injection into 24 wild-type C57/Bl6 sub-lethally irradiated recipient mice (12 per arm) in a secondary 
transplantation assay. Both arms were allowed 7 days for engraftment (7 days was chosen based on 
previous experiments in the Huntly lab, and also given the highly aggressive nature of secondary MLL-
AF9 leukaemias it was better to choose an earlier time-point), then one cohort was treated with 
intraperitoneal PBS injections (control) and the other pIpC injections (test arm). Five doses were given 
on alternate days. Through pIpC injection, the Mx1-Cre was activated through an inflammatory 
response, facilitating Ezh2 deletion. Mice in both arms were then tracked for clinical signs of 
deterioration, with the expectation that the latency (at least for the wild-type) arm would be much 
shorter than the primary transplants. 
As demonstrated in Figure 4.7, loss of Ezh2 in the pIpC arm delayed onset of leukaemia significantly: 
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FIGURE 4.7  Kaplan-Meier survival outcomes for Ezh2fl/fl; Cre+ MLL-AF9 secondary recipient 
mice treated with PBS or pIpC 
 Mice in the pIpC treated (i.e. Ezh2 excised) arm demonstrate a significant increase in survival 
compared to PBS treated 
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There were no significant differences seen between the PBS and pIpC treated arms in terms of YFP 
distribution, terminal white cell counts or organ size (Figure 4.8). The leukaemias were positive for 
myeloid antigens Mac-1 and Gr-1 and negative for CD4/B220/Ter-119 (lymphoid and erythroid 
antigens). Each animal was genotyped using DNA extracted from splenic tissues. Details of all 
secondary leukaemias (where available) are in Table 4.1:  
FIGURE 4.8  Spleen and liver weights, terminal white blood cell counts and YFP percentages for 
blood, bone marrow and spleen for secondary MLL-AF9 recipients treated with PBS 
or pIpC.  
 There were no significant differences seen between both treatment arms 
YFP detectable on same laser/channel as GFP 
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       GFP%        
Mouse 
# 
PBS/PIPC 
treated 
Day 
culled 
WCC 
(x109/L) 
Hb 
(g/dl) 
Plts 
(x109/L) 
Periph 
Blood 
Bone 
Marrow Spleen 
Spleen 
wt (g) 
Liver 
wt (g) 
Ezh2 
excision 
4851 PBS 33 19.1 158 508 44.0 55.0 45.0 0.46 2.32 69.36% 
4855 PBS 33 19.6 157 412 44.6 63.0 51.0 0.28 1.44 42.20% 
4841 PBS 39 108.0 49 85 90.80 94.8 79.7 0.92 3.03  
4853 PBS 39 18.4 46 154 55.8 88.3 58.8 0.52 2.72 81.50% 
4838 PBS 40 740.0 121 253 78.8 84.2 92.4 1.05 4.57 93.10% 
4843 PBS 46 25.5 61 223 63.7 93.1 74.3 0.82 3.15 74.70% 
4844 PIPC 47 11.3 36 197 68.6 95.6 76.7 0.78 2.71 81.40% 
4850 PBS 47 28.0 79 193 75.8 93.5 76.5 0.68 2.69 88.28% 
4832 PIPC 49  1.2 3.48  
4846 PIPC 49 13.4 45 193 86.3 97.9 75.2 0.84 3.06 77.70% 
4842 PBS 55 52.1 92 270 64.4 91.7 87.0 0.69 3.02 72.80% 
4848 PIPC 56  0.93 3.66 67.35% 
4835 PIPC 56 6.4 28 199 84.0 97.2 78.3 0.65 2.11 78.39% 
4839 PBS 56 26.3 114 295 80.4 95.4 77.6 0.55 3 70.17% 
4840 PBS 56 102 136 169 92.8 98.2 84.6 0.55 2.3 76.84% 
4854 PBS 56 87 132 229 92.5 97.5 82.8 0.69 3.6 58.82% 
4833 PIPC 57  Enlarged  
4847 PIPC 61 55 111 137 67 88.7 72.7 1.04 3.92 38.87% 
4836 PIPC 63 6.3 83 250 31.8 77.8 40.3 0.31 1.52 27.80% 
4845 PIPC 69 16.4 47 57 55.6 93.1 65.5 0.7 2.84 3.10% 
4852 PBS 70 48.3 150 374 30.5 78.2 55.5 0.49 1.98 0% 
4834 PIPC 70 28.6 124 304 30.9 74.5 51.6 0.49 1.42 3.50% 
4837 PIPC 70 43.7 118 164 53.4 79.4 51.6 0.63 2.68 0% 
4849 PIPC 83 34.1 108 184 45.2 76.9 56.3 0.59 2.88 0% 
 
 
 
Ezh2 excision was assessed in splenic tissue for all mice where it was available. This is shown in the 
final column of Table 4.1. Whilst there are variable levels of excision in both cohorts, particularly in the 
mice that succumbed quickly to the disease, for those mice with longer survival there was a very low 
level of recombination, even in the pIpC treated cohort, suggestive of selective growth of the Ezh2+/+ 
leukaemia cells. These results could potentially be explained by a slight degree of variance in the 
natural course of this secondary leukaemia in each animal. Some animals in the PBS treated arm had 
more aggressive, short latency leukaemias, presumably with a significant inflammatory response that 
was indirectly causing Cre mediated recombination. However the longest latency leukaemias, with 
virtually no excision of Ezh2 at time of death, suggested recapturing and proliferation of any initial Ezh2 
replete clones that harboured a selective advantage, and with the longer latency, competitively 
outgrew Ezh2 excised leukaemic cells, establishing their dominance at the time the animal became 
terminal. Having caused maximal excision with pIpC at the outset, this simply delayed this process and 
highlighted that Ezh2 was facilitating the transformed state.  
TABLE 4.1 Terminal data for all secondary MLL-AF9 leukaemia transplanted mice (Ezh2fl/fl; 
Cre+ treated with PBS or pIpC) 
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4.3.3 Ezh2 is required for the maintenance of secondary AML1-ETO9a leukaemias in vivo 
 
Primary transplants 
The same process outlined in Section 4.3.2 was used to generate primary Ezh2 conditional AML1-
ETO9a leukaemias. Retroviral transduction was performed on c-kit selected bone marrow HSPCs taken 
from 2-3 Ezh2 fl/fl; Cre+ mice using retroviral supernatant derived from HEK 293T cells transfected 
with the MIGR1-AML1-ETO9a-GFP construct. This reliably yielded, on average, a higher transduction 
efficiency of 15-25% per experiment given the construct size is considerably smaller than MLL-AF9 
(Figure 4.9). Given the lower potency of this particular oncogene, this also meant that more GFP 
positive cells were required per mouse for each transplant (in the order of 105 per mouse).  
 
 
 
 
 
 
 
 
After transduction, as above, the cell dosage was adjusted based on total cell number and percentage 
of GFP positivity, and an equal number of GFP positive cells were injected into five primary lethally 
irradiated C57/Bl6 recipients. These animals were then tracked with serial bleeds and GFP 
assessments, and clinically for the development of leukaemia. The expectation was that these animals 
would have a long latency (close to one year) as seen in previous studies. 4 However disease features 
became prominent at approximately 3 months, with significantly raised GFP in peripheral blood 
sampling and all 5 animals succumbed to leukaemia between Days 96 and 138 post transplantation. 
Each displayed hepatosplenomegaly, marked anaemia and thrombocytopenia as seen in the induction 
experiments. Splenic tissue and bone marrow was harvested and frozen in liquid nitrogen. Spleen cells 
were c-kit positive but negative for other myeloid antigens such as Mac-1 and Gr-1 (also negative for 
B220/CD4 and Ter119). Given the latency for these primary leukaemias was slightly shorter than 
  
FIGURE 4.9  Transduction efficiency of AML1-ETO9a into c-kit positive HSPCs 
Live cells gated initially by forward and side-scatter, doublets removed and then gated for GFP 
positivity. Population positive for GFP, reflecting AML1-ETO9a transduced cells seen in Q4, right 
(here ~21%) 
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expected, genotyping to assess Ezh2 recombination was performed, as with the MLL-AF9 primary 
leukaemias. Unsurprisingly given the presumably pro-inflammatory nature of leukaemogenesis it 
appeared once again that spontaneous Cre-recombinase activation had occurred, demonstrating 60-
90% Ezh2 excision had occurred using the qPCR method across the five animals (from DNA extracted 
from splenic tissues). This disease latency tallied with the acceleration and shorter disease latency seen 
in the Ezh2fl/fl;Cre+ pIpC pre-treated arm in the induction in vivo experiments, suggesting again even 
partial Ezh2 loss through spontaneous Cre effects was powerful enough to facilitate accelerated 
leukaemogenesis. Nonetheless, having seen this already happen with the MLL-AF9 primary transplants 
as described above, we decided to proceed with secondary transplants using splenic tissue from the 
mouse with the least Ezh2 excision (approximately 60%).  
 
Secondary transplants and Ezh2 functional assessment 
Splenic tissue from one of the primary Ezh2fl/fl;Cre+ AML1-ETO9a leukaemic mice with the lowest level 
of spontaneous Ezh2 excision was thawed. This had an approximately 60% level of Ezh2 excision. After 
washing the cells, approximately 1x106 cells were injected via tail-vein into 20 sub-lethally irradiated 
wild-type C57/Bl6 mice (split thereafter into two arms). The cells were allowed 7 days for engraftment 
and the mice were then treated with intraperitoneal injections of either PBS (control) or pIpC (test 
arm), to induce complete Ezh2 excision in the latter. Five doses were given on alternate days. They 
were then tracked for aggressive, short latency secondary leukaemias, through peripheral blood 
sampling, GFP assessment and clinical monitoring. Ezh2 excision in the pIpC treated arm lead to a 
significant increase in survival compared to PBS treated (Figure 4.10): 
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FIGURE 4.10  Kaplan-Meier survival outcomes for Ezh2fl/fl; Cre+ AML1-ETO9a secondary 
recipient mice treated with PBS or pIpC 
 Mice in the pIpC treated (i.e. Ezh2 excised) arm demonstrate a significant increase in survival 
compared to PBS treated 
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As early as Day 35 post transplant, PBS treated animals became pre-terminal and were sacrificed. By 
Day 126, all PBS treated animals had been culled due to leukaemia development. In the pIpC arm only 
three out of ten animals actually developed secondary leukaemias, in general significantly later than 
the PBS treated animals. The remainder died of GFP-negative other causes (likely secondary to the 
effects of irradiation and aging), with several having massive thymic enlargement on necropsy (but 
GFP negative throughout all organs and blood counts not indicative of leukaemia) (Figure 4.11): 
 
 
 
 
 
  
 
 
 
 
 
 
 
This suggested that maximal Ezh2 excision in primary AML1-ETO9a transplanted leukaemic tissues, 
rendered a significant delay in the development of secondary leukaemia allowing other effects such as 
aging/post-irradiation to come into play, and/or through inhibiting leukaemia development, was 
influencing the development of other disease processes (outside the scope of this study). Details of all 
mice in this experiment (where available) are provided in Table 4.2: 
 
 
PBS PIPC 
FIGURE 4.11  Marked thymic enlargement seen in non-leukaemic mice transplanted with 
Ezh2fl/fl;Cre+ AML1-ETO9a splenic tissues and treated with pIpC (right) 
compared to PBS treated secondary leukaemic mouse (heart and lungs with 
minimal thymus) 
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       GFP%        
Mouse 
# 
PBS/PIPC 
treated 
Day 
culled 
WCC 
(x109/L) 
Hb 
(g/dl) 
Plts 
(x109/L) 
Periph 
blood 
Bone 
marrow Spleen 
Spleen 
wt (g) 
Liver 
wt (g) Excision 
4818 PBS 35 15.6 42 42 35.6 43.2 84.1 0.9 1.4 90.09% 
4822 PBS 35 29.6 29 125 54.6 54.8 90.9 0.69 1.44 89.76% 
4825 PBS 35 4.2 ** 103 42.8 54.7 93.8 0.62 1.22 86.99% 
4830 PIPC 37 40.5 46 55 92.0 85.0 90.0 0.69 2.03 90.95% 
4821 PBS 43 74.0 54 165 94.7 30.6 82.8 1.01 2.77 84.63% 
4823 PBS 56 15.6 36 134 41.8 50.1 82.5 1.02 2.45 79.17% 
4826 PBS 57 176.0 40 115 93.9 58.8 84.2 0.74 3.18 83.43% 
4817 PBS 64 26.1 73 95 53.6 53.4 55.5 1.02 3.16 41.49% 
4820 PBS 73  0.64 1.95 75.51% 
4814 PIPC 75 220 40 135 97.7 49.6 88.3 1.09 3.55 89.96% 
4819 PBS 126 37.1 84 91 90.1   0.84 2.64 86.08% 
4813 PIPC 134 75 56 171 39.4 77.0 66.9 1.52 3.22 90.70% 
4812* PIPC 170    <10% <10% <10%  
4815* PIPC 170    <5% <5% <5%  
4816* PIPC 175 13.8 102 209 <2% <2% <2% 0.83 5.46  
4831* PIPC 186     
4827* PIPC 203     
4829* PIPC 219    <1% <1% <1% 0.46 2.77  
4824 PBS 281 N N N <1% <1% <1%    
4828 PIPC 290 7.7 158 172 <1%  <1% 1.28 3.24  
   
 
        
 
 
 
Ezh2 excision was assessed in splenic tissue for only leukaemic mice where tissue/DNA was available. 
This is shown in the final column of Table 4.2. There were varying levels of excision seen (between 41-
90%) and did not follow a particular treatment arm. In view of the aggressive nature of these secondary 
leukaemias, we assumed that this level of excision was likely due to sustained Cre-activation caused 
by ongoing inflammation/interferon responses in the face of leukaemia progression in the PBS treated 
arm, though the phenotypic effects on survival clearly favour the pIpC treated arm (i.e. maximally Ezh2 
deleted after engraftment), producing a profound survival advantage. This again suggests that Ezh2 
appears to be a facilitator of the transformed state, with its complete removal at an early phase of 
leukaemia progression either blocking leukaemia completely (seven of ten pIpC treated mice did not 
develop GFP-positive leukaemia) or delaying it sufficiently to allow other disease processes to occur. 
Finally, there were no significant phenotypic effects on GFP distribution (though GFP percentage was 
marginally higher in bone marrow in the pIpC treated arm), peripheral blood counts or terminal organ 
size for all leukaemic mice between both arms (where available) (Figure 4.12): 
 
TABLE 4.2 Terminal data for all secondary AML1-ETO9a leukaemia transplanted mice 
(Ezh2fl/fl;Cre+ treated with PBS or pIpC) 
 Mice identified in Bold indicate those with GFP negative disease at time of culling 
*indicates mice with massive thymic enlargement at death. qPCR assessment of Ezh2 excision not 
performed in these latter cases as no evidence of leukaemia as determined by GFP expression 
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FIGURE 4.12  Spleen and liver weights, terminal white blood cell counts and GFP percentages 
for blood, bone marrow and spleen for secondary AML1-ETO9a recipients 
treated with PBS or pIpC 
 pIpC treated mice limited to those that developed leukaemia (n=3) 
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4.3.4 Loss of Ezh2 during maintenance of MOZ-TIF2 leukaemias in vivo does not significantly alter 
outcome 
 
Primary Transplants 
As per MLL-AF9 and AML1-ETO9a, primary leukaemias were generated using c-kit positive bone 
marrow transduced from Ezh2fl/fl; Cre+ mice with retroviral supernatant produced from HEK 293T 
cells transfected with the MSCV-IRES-MOZ-TIF2-GFP vector. As with MLL-AF9, transduction efficiencies 
were typically low, ranging from 1-5%, assessed by GFP expression through flow cytometry (Figure 
4.13): 
 
 
 
 
 
 
 
 
 
After transduction, as above, the cell dosage was adjusted based on total cell number and percentage 
of GFP positivity, and an equal number of cells were injected into five primary lethally irradiated 
C57/Bl6 recipients. These animals were then tracked with serial bleeds and GFP assessments, and 
clinically for the development of leukaemia. The expectation was that these animals would have a 
relatively short latency as seen in previous studies.5 As expected, animals developed leukaemia as early 
as Day 47 post-transplant and by Day 83 all five had been culled with splenic tissues and bone marrow 
harvested. Through immunophenotyping these were confirmed to be Mac-1, Gr-1 and c-kit positive 
(myeloid), and again DNA from spleen was extracted to assess for any Ezh2 excision due to 
spontaneous Cre-mediated recombination for the reasons described above. Once again this was 
present, with a range from 65-74% Ezh2 excision seen across the five mice.  
Non-transduced cells MOZ-TIF2 transduced 
FIGURE 4.13  Transduction efficiency of MOZ-TIF2 into c-kit positive HSPCs 
Live cells gated initially by forward and side-scatter, doublets removed and then gated for GFP 
positivity.  
Population positive for GFP, reflecting MOZ-TIF2 transduced cells seen in Q4, right (here ~1%) 
117 
 
Secondary transplants and Ezh2 functional assessment 
Splenic tissue from one of the primary Ezh2fl/fl; Cre+ MOZ-TIF2 leukaemic mice with the lowest level 
of spontaneous Ezh2 excision was thawed. This had an approximately 65% level of Ezh2 excision. After 
washing the cells, approximately 1x106 cells were injected via tail-vein into 20 sub-lethally irradiated 
wild-type C57/Bl6 mice (split thereafter into two arms). The cells were allowed 7 days for engraftment 
and then the mice were treated with intraperitoneal injections of either PBS (control) or pIpC (test 
arm), to induce complete Ezh2 excision in the latter. Five doses were given on alternate days. They 
were then tracked for aggressive, short latency secondary leukaemias, through peripheral blood 
sampling, GFP assessment and clinical monitoring. 
 
 
 
 
 
 
 
 
 
 
 
Though there appeared to be an initial early survival advantage of pIpC treated Ezh2fl/fl; Cre+ MOZ-
TIF2 leukaemia secondary recipients, this was negated by around Day 140 post transplantation, with 
the final outcome being statistically non-significant (Figure 4.14). Furthermore, there was a 
considerable delay in some of the pIpC treated mice developing leukaemia, therefore the experiment 
was terminated at Day 320 in view of the outcome.  
There was no significant difference between organ size, terminal blood counts or GFP distribution 
across haematopoietic compartments (where data available) (Figure 4.15): 
FIGURE 4.14  Kaplan-Meier survival outcomes for Ezh2fl/fl; Cre+ MOZ-TIF2 secondary recipient 
mice treated with PBS or pIpC 
 Though there was an initial trend toward survival advantage in the pIpC treated (i.e. Ezh2 
excised) arm, this was not statistically significant by the conclusion of this experiment 
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FIGURE 4.15 Spleen and liver weights, terminal white blood cell counts and GFP percentages 
for blood, bone marrow and spleen for secondary MOZ-TIF2 recipients treated 
with PBS or pIpC 
 
119 
 
 
In view of the non-significance attained between the study arms in this experiment, Ezh2 excision 
status was not checked. As the experiment was prematurely terminated at Day 320, not all mice were 
analysed. Table 4.3 summarises the data for the secondary MOZ-TIF2 transplants: 
 
       GFP%       
Mouse 
# 
PBS/PIPC 
treated 
Day 
culled 
WCC 
(x109/L) 
Hb 
(g/dl) 
Plts 
(x109/L) 
Periph 
Blood 
Bone 
Marrow Spleen 
Spleen 
wt (g) 
Liver 
wt (g) 
4803 PBS 47 13.1 173 275 45.4 96.0 49.5 0.34 1.25 
4806 PBS 61 16.4 78 176 46.4 94.4 57.8 0.45 1.53 
4805 PBS 65 22.7 95 109 31.5 91.3 49.3 0.64 1.86 
4798 PBS 66 26.2 123 103 43.4 97.3 61.2 0.55 2.21 
4807 PIPC 103 6.9 133 223 28.5 94.2 44.3 0.45 1.48 
4800* PBS 111 75.1 149 419 <10% <10% <10% 0.33 2.46 
4794 PIPC 113 59.1 167 372 54.1 83.4 30.8 0.37 1.8 
4793 PIPC 126 3.5 142 279 36.5 96.0 65.9 0.67 1.77 
4799* PBS 126 29.2 115 169 <1% <1% <1% 0.81 2.77 
4808 PIPC 133 274 110 101 54.5 62.8 59.4 0.89 3.1 
4797 PBS 145 11.4 142 286 10.0 25.7 45.4 0.51 4.9 
4796 PIPC 154 4.5 154 915 34.0 42.9 14.4 0.93 1.08 
4792* PIPC 175 9.5 154 915 <5% <2% <2%   
4801* PBS 205 64.6 131 194 0.0 0.0 0.0 0.64 2.54 
4804* PBS 232 12.7 94 189 7 4.7 2.2 0.66 3.22 
4809 PIPC 232 6.2 137 386 26.8 93.7 47.5 0.349 1.4 
4802 PBS 237 3.8 124 265 72.2 86.6 60.2 0.99 2.14 
4811 PIPC 318 2.7 144 597 62.9 96.1 40.2 0.33 1.7 
 
 
 
 
 
 
 
 
 
 
TABLE 4.3 Terminal data for all secondary MOZ-TIF2 leukaemia transplanted mice 
(Ezh2fl/fl;Cre+ treated with PBS or pIpC) 
*indicates mice with that died of causes other than leukaemia (i.e. GFP negative with no 
other phenotypic features) 
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4.4  Discussion and future work 
The experiments detailed in this chapter showed striking effects of Ezh2 loss during maintenance of 
AML. In vitro, Ezh2 was clearly an absolute requirement across two aggressive subtypes (MLL-AF9, 
MOZ-TIF2) and a third, less aggressive subtype (AML1-ETO9a), with its genetic loss in already 
transformed cell lines completely stopping growth of these. These very prominent results translated 
generally into the in vivo studies, which demonstrated Ezh2 loss interfered with maintenance of MLL-
AF9 and AML1-ETO9a leukaemias, with its loss causing a significant improvement in survival in both 
cases. Furthermore, our results for the MLL-AF9 experiments were in alignment the previously 
published data. 1 With the inference being that Ezh2 is a general facilitator of the transformed state, 
this provided strong support towards an oncogenic role for Ezh2 in AML maintenance. However, 
common to both the primary and secondary leukaemias in this chapter, where characterised, was the 
problem of spontaneous Cre-mediated recombination occurring during leukaemia development. The 
experiment was deliberately designed in such a way so as to delete Ezh2 only at the maintenance stage 
i.e. disease propagation in the secondary leukaemias, however it was hampered by early deletion 
during the development of the primary leukaemias and possible selection for the Ezh2 deficient cells 
during leukaemia induction, and quite possibly further enhanced during progression of the secondary 
leukaemias, even in the absence of pIpC treatment. Spontaneous Mx1-Cre recombinase activation 
when modelling haematopoietic disease has recently been reported in the literature and highlights 
potential pitfalls in utilising this in conditional knock-out experiments.6 However, in these maintenance 
in vivo experiments, whilst we accept the eventual comparison was not strictly between Ezh2+/+ versus 
Ezh2-/-, it was instead a comparison of a baseline of partially excised Ezh2 (in the PBS arm) versus wholly 
excised Ezh2 (in the pIpC treated arm) which clearly significantly influenced survival outcomes and still 
provides functional relevance and evidence of Ezh2’s oncogenic role in AML maintenance. In this 
respect, the prediction is that the requirement of Ezh2 is actually underestimated. 
Interestingly, the maintenance study findings were in stark contrast to the findings in the induction in 
vivo experiments detailed in the previous chapter, where early loss of Ezh2 clearly favoured MLL-AF9 
and AML1-ETO9a driven leukaemogenesis. This diametrically opposite effect of Ezh2 loss during 
different stages of AML evolution (and also variance in induction, dependent upon AML subtype) 
serves to highlight how complex this epigenetic regulator is, playing two very different roles as tumour-
suppressor and oncogenic facilitator in specific contexts. Having seen varying effects dependent upon 
AML subtype in the induction experiments, from a therapeutic perspective, it was reassuring to see a 
uniform absolute inhibitory effect of Ezh2 loss upon maintenance of the all three subtypes in vitro and 
a similar, though less absolute effect upon secondary leukaemia progression in vivo. This suggests that 
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there may be an overlap in programmes controlled by Ezh2 that are relevant to AML maintenance 
across these three subtypes and would be interesting to explore further. Furthermore, it supports an 
argument towards pharmacologically targeting EZH2 in AML.  
As alluded to in the previous chapter, to try and explain this oncogenic effect, the next steps in these 
maintenance experiments (as per the original aims of this thesis) were to assess for any differences in 
gene expression through RNA-sequencing of AML tumours from mice that were Ezh2 replete versus 
Ezh2 deplete. In doing so, we would be able to characterise which transcriptional programmes were 
being subverted by loss of Ezh2 during maintenance of disease, to account for the oncogenic effect it 
was clearly producing when present. An additional aim was to assess differences in H3K27 
trimethylation between the representative tumours from the two maintenance arms to determine if 
any gene expression differences were in part due to loss of histone methyltransferase activity. As a 
result of the higher than expected levels of spontaneous recombination in both PBS treated MLL-AF9 
and AML1-ETO9a partially Ezh2-deleted arms, we felt that comparing gene expression and histone 
marks from our experiments designed to genetically ablate Ezh2 in vivo would provide relatively 
modest differential results due to the modest differences in Ezh2 expression. This would therefore not 
be a direct comparison of complete Ezh2+/+ against a fully Ezh2-deficient state as it was in the induction 
experiments.  
To bypass this issue and still assess which transcriptional programmes were being governed by Ezh2 in 
the maintenance of these AML murine tumours, we utilised a novel EZH2 inhibitor or its vehicle control 
(described in Chapter 7) against established Ezh2fl/fl; wt MLL-AF9 tumours cultured in vitro to draw 
out any differences in gene expression. This is detailed in Chapters 5 and 7.  
Having completed the Induction and Maintenance experiments, it was possible to conclude that Ezh2 
had markedly opposite roles during these stages of AML evolution, serving to highlight the complexity 
of this epigenetic regulator. By moving on to analyse the genomic alterations produced by Ezh2 loss in 
either stage, our hypothesis was that Ezh2 loss de-repressed a completely different gene expression 
set in either cellular context, and we hoped to demonstrate this. In doing so, we would then be able 
to identify downstream oncogenic facilitators that were de-repressed in AML induction, and tumour-
suppressive candidates that were de-repressed in AML maintenance as a result of Ezh2 loss/Ezh2 
inhibition.  
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Chapter 5 
Genomic analysis of transcriptional programmes subverted by Ezh2 
during AML induction and maintenance 
 
5.1  Aims 
This section details the genomic analysis performed with the aim of characterising the mechanisms by 
which Ezh2 has opposing effects in induction and maintenance of AML. A significant proportion of the 
data discussed in this section was analysed and referenced with the help of Dr Eshwar Meduri, a 
bioinformatician within the Huntly group. 
 
5.2  Introduction 
Having established the completely contrasting role of Ezh2 between AML induction and maintenance, 
the next step was to analyse the transcriptional programmes manipulated and altered by Ezh2 loss in 
either phase of disease. The stark contrast in Ezh2 functioning as a tumour-suppressor during induction 
of MLL-AF9 and AML1-ETO9a leukaemia in vivo when compared to its oncogenic role in the 
maintenance of these leukaemias in vivo, provided a substantial challenge to explain. As Ezh2 is an 
epigenetic regulator, we employed both differential gene expression analysis (through RNA-
sequencing) and histone modification / PRC2 complex member binding analysis (through ChIP-
sequencing) to provide answers to this question.  
We initially chose to focus more on the most unexpected finding (and contrary to the original 
hypothesis) that Ezh2 loss accelerated MLL-AF9 and AML1-ETO9a leukaemia induction. Both leukaemia 
models are well characterised in the literature and have direct clinical relevance, particularly with the 
human equivalent of AML1-ETO fusion – the t(8;21) (q22;q22.1) or RUNX1-RUNX1T1 translocation 
being the most common fusion oncogene seen in AML. Two recent studies have extensively profiled 
the genomic landscape of the core-binding factor leukaemias (RUNX1-RUNX1T1 or CBFB-MYH11 
rearrangements) through whole genome or whole-exome sequencing of paediatric and adult cases.1,2 
Both have demonstrated that not only are there an array of relatively underappreciated co-operating 
mutations with these translocations with remarkably different spectra between the two, but that there 
appeared to be a clear enrichment for certain mutations in the RUNX1-RUNX1T1 cases, particularly the 
cohesin complex members and a number of important epigenetic regulators. Surprisingly, and highly 
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relevant to our finding with the induction experiments, was that in both studies, EZH2 was exclusively 
mutated (all putative loss-of-function mutations) in a reasonable proportion of RUNX1-RUNX1T1 cases 
compared to all CBFB-MYH11 cases analysed. In the first study, there were 7 EZH2 mutated cases in a 
total of 106 cases (~7%, p-value 0.006) and in the second there were 7 EZH2 mutated cases from a 
total of 85 cases. The inference from this, particularly considering the cooperative nature of Ezh2 loss 
and AML1-ETO9a induction in the in vivo experiment, might be a functional association between EZH2 
mutations and RUNX1-RUNX1T1 driven leukaemias in humans. It would be interesting to characterise 
variant allele frequencies in larger human AML datasets of EZH2 mutations in t(8;21) cases to see if 
this could firstly corroborate a link between EZH2 mutations in t(8;21) leukaemias and then inform 
regarding order of mutation, and the tantalising possibility that EZH2 mutations might occur before or 
at the time of the translocation and co-operate to drive leukaemogenesis.   
 In the induction experiments, Ezh2 had been clearly deleted in the Ezh2 fl/fl; Mx1-Cre heterozygous 
arm (whilst it was impossible to excise in the Ezh2 fl/fl; wt arm by design due to lack of Mx1-Cre) prior 
to retroviral overexpression of and transformation by MLL-AF9 or AML1-ETO9a. This suggested that 
Ezh2 loss may have fostered an altered epigenetic and/or transcriptional state, by virtue of its role as 
a transcriptional repressor, resulting in the de-repression of genes in the non-transformed state that 
would potentially co-operate with the driver oncogene in hastening leukaemia development. The 
initial focus therefore was to characterise differentially expressed genes in HSPCs following Ezh2 loss 
in the non-transformed setting (i.e. Ezh2+/+ vs Ezh2-/-) and to then compare this with the same analysis 
performed in the Ezh2+/+ and Ezh2-/- MLL-AF9 and AML1-ETO9a leukaemias. In triangulating these 
datasets, we aimed to find common genes that were de-repressed following Ezh2 loss that would 
functionally prioritise those able to augment the process of transformation by the fusions.  
To enhance the analysis in the non-transformed setting further, we then sought to assess whether loss 
of Ezh2 had genome-wide effects upon its repressive H3K27me3 mark and also whether there were 
any associated changes in other linked local histone activating marks – specifically H3K27Ac and 
H3K4me3. We additionally pursued binding of the PRC2 complex in the Ezh2+/+ setting, through ChIP-
sequencing analysis of Ezh2 and Eed binding. We hypothesised that genes de-repressed and activated 
by Ezh2 loss would feature a significant reduction in H3K27me3 at their cis-regulatory promoters and 
enhancers, and reduced PRC2 binding in the absence of Ezh2 (as directed by Eed localisation). At the 
same time, we were keen to see whether these regions also had the presence of H3K27Ac/H3K4me3 
facilitating transcriptional activation and whether there was any change in these marks to further 
explain increased gene expression. From this comprehensive analysis, we aimed to identify any 
candidate drivers of disease and functionally validate them.  
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To address the maintenance in vivo experiments, we adopted a different strategy from the original 
aim, given the unexpected interference of spontaneous Cre-recombination activity in the primary and 
secondary leukaemias. Despite showing a clear effect on survival, we felt these would only allow a 
comparison between partially and completely Ezh2 excised leukaemias, meaning that any differential 
effects at the genomic level would be relatively diluted. We were able to establish effective liquid 
culture growth of thawed and washed Ezh2fl/fl; wt MLL-AF9 spleen tumour cells from two separate 
mice with relative ease, allowing us to utilise chemical inhibition of Ezh2 to abrogate its function. We 
then used GSK343 (a novel EZH2 inhibitor available to us through collaboration with GlaxoSmithKline) 
or vehicle control (DMSO) against these tumours in liquid culture to impede growth (full details in 
Chapter 7). Furthermore, we demonstrated a clear reduction in H3K27me3 of these cells following 
GSK343 treatment, as early as 24 hours. Having seen the growth inhibitory effects on these MLL-AF9 
tumours, we used this pharmacological ‘knockdown’ of Ezh2 as a system to assess which 
transcriptional programmes were being affected, through RNA-sequencing of the tumours +/- GSK343 
inhibitor. Given the opposite effect of Ezh2 loss (i.e. delaying leukaemia progression) in maintenance, 
we expected to find a different gene-set altered in maintenance when compared to induction, to 
account for the phenotypic effects.  
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5.2  Differential gene expression analysis between Ezh2+/+ and Ezh2-/- states in the non-
transformed setting reveals an altered transcriptional programme that may facilitate 
leukaemia induction 
 
As described in Methods 2.8.1, lineage negative selection was performed on whole bone marrow from 
pIpC pre-treated Ezh2 fl/fl; wt and Ezh2 fl/fl; Mx1-Cre+ mice, to isolate early HSPCs of each genotype. 
A yield of approximately 1x106 lineage marker negative cells per mouse on average was attained. The 
purity (typically 85-95% pure) of these was confirmed by flow cytometry analysis (example in Figure 
5.1): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstained Lineage negative Lineage positive 
a) b) c) 
FIGURE 5.1 FACS analysis of Lineage marker depleted murine bone marrow cells 
Live cells firstly gated by forward and side-scatter, doublets then removed. Lineage 
antibody cocktail stained cells gated on side-scatter and 640 670/14-A channel 
a) Unstained cells (control) 
b) Lineage depleted cells in flow-through (~92% of events in this example) 
c) Lineage positive (mature cells) isolated from column after selection 
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DNA was extracted from flow-through lineage positive cells and used for genotyping by qPCR to 
confirm both presence of Mx1-Cre and adequate Ezh2 excision in the Ezh2 fl/fl; Mx1-Cre+ arm 
(compared to lack of Mx1-Cre and no excision in the Ezh2 fl/fl; wt arm). Ezh2 excision was typically as 
high as 90-98% in these bone marrow cells.  
Having established the correct genotypes after pIpC treatment, lineage negative cells were pooled 
together from 2-3 mice within each genotype and RNA was extracted (as described in Methods 
2.8.14.2). This was then quantified using a Nanodrop Spectrophotometer and approximately 5µg per 
condition were submitted for paired-end sequencing on an Illumina HiSeq 4000 machine at the 
Genomics Core, CRUK Cambridge Institute (Methods 2.8.15).  
 
Once sequencing data returned, it was processed as described in Methods 2.8.13. Through this a 
filtered list of significantly differentially expressed genes was generated. Significant gene expression 
results were those with a p-value adjusted for multiple hypothesis testing of <0.05 with a log2 fold 
change of greater or less than 0.5.  
Consistent with its role as a transcriptional repressor, there were considerably more significantly 
upregulated genes (n= 476) following Ezh2 deletion than those downregulated (n= 48). A list of the top 
25 genes de-repressed following Ezh2 loss is given in Table 5.1 (genes were ranked in order of log2 fold 
change). The full list of differentially expressed genes (both up- and downregulated) is given in 
Appendix A5.1. 
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TABLE 5.1  Top 25 differentially upregulated genes in Ezh2-/- lineage negative HSPCs 
Arranged in order of log2 fold change (highest first) 
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Notably, Ezh2 appears in the downregulated list, aligning with its confirmed deletion by qPCR 
genotyping prior to RNA-sequencing. The whole list is presented in the form of a volcano plot (Figure 
5.2): 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within the top 25 were several potentially interesting candidate genes (exhibiting a significant log2fold 
increase). Lin28b, a negative regulator of the let-7 micro-RNA tumour-suppressor family, was 
maximally upregulated, featuring at the top of this list. As discussed in Chapter 1, this candidate (along 
with Igf2bp3 – also present in the top 25) was recently implicated as a potential downstream oncogenic 
effector following Ezh2 loss in cooperation with JAK2-V617F in driving myelofibrosis. 3 Other candidates 
such as Igf2bp3 – another oncogenic driver in solid malignancies4, and a target of let-7 repression, 
were also upregulated. Additionally, the tyrosine kinase Yes1, which has recently been shown to play 
a facilitator role in AML1-ETO leukaemia maintenance was also upregulated. 5 A number of other 
candidates overlapped between this and the top 10 upregulated genes following Ezh2 loss in the 
myeloproliferative disorder study, such as Pcolce2, Ddah1, Bmpr1a, Spats2 etc., suggesting their roles 
in facilitating myeloid leukaemogenesis. 3  
476 48 
Lin28b 
Yes1 Ezh2 
FIGURE 5.2 Volcano plot representing differentially expressed genes determined by RNA-
sequencing between Ezh2+/+ and Ezh2-/- lineage negative HSPCs 
The plot shows both negative and positive log2fold changes in gene expression (x-axis) 
and their adjusted p-value demonstrating significance (y-axis) 
Certain genes of interest, e.g. Lin28b, Igf2bp3, Yes1 and Plag1 are highlighted 
Ezh2 appears in the downregulated (blue) 
 
Igf2bp3 
Plag1 
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Gene ontology analysis (via http://www.geneontology.org/) of the 476 upregulated genes following 
Ezh2 loss revealed enrichment within biological processes for positive regulation of calcium ion 
transport, cell-cell adhesion, immune responses and negative regulation of cell proliferation. Analysis 
by molecular function demonstrated enrichment particularly for cytokine receptor activity and 
binding, catalytic activity and receptor activity suggesting Ezh2 plays a role in regulating these 
processes (Figure 5.3): 
 
 
 
 
 
 
 
FIGURE 5.3 Gene ontology analysis of genes deregulated following Ezh2 loss 
Molecular functions shown 
Panther overrepresentation test (release Apr 2017) 
  GO Ontology database (release Aug 2017) 
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5.3  Differential gene expression analysis between Ezh2+/+ and Ezh2-/- in the MLL-AF9 and 
AML1-ETO9a induction leukaemias divulges key potential downstream mediators of AML 
induction 
 
Having established a clear gene set differentially regulated by Ezh2 in the non-transformed setting, the 
same process was applied to the leukaemias that had accelerated upon Ezh2 loss in the induction 
experiments. Two representative tumours (Ezh2+/+ and Ezh2-/-) from each of the MLL-AF9 and AML1-
ETO9a induction in vivo experiments had DNA and RNA extracted from spleen cells (previously frozen) 
after thawing and washing. The DNA was used to confirm that levels of Ezh2 excision were >95% in 
both Cre+ tumours (as expected) and that there was no excision in the wt arm (Figure 5.4): 
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FIGURE 5.4 Percentage of Ezh2 across Ezh2fl/fl; wt Cre (wt) and Ezh2fl/fl; heterozygous Cre 
(Cre+) AML1-ETO9a and MLL-AF9 murine leukaemias as assessed by q-PCR 
WT (blue) = Ezh2fl/fl wild-type DNA (control) 
AML1-ETO9a leukaemias in light/dark green 
MLL-AF9 leukaemias in light/dark red 
Numbers indicate identity of mouse. Data represent the mean and SEM of two 
independent experiments 
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Once confirmed, RNA was extracted from the same splenic tissues and after quantifying, and sent for 
paired-end sequencing on an Illumina HiSeq 4000 machine at the Genomics Core, CRUK Cambridge 
Institute. The sequencing data was again processed as per Section 5.2 and filtered to yield a list of 
significantly differentially expressed genes with a p-value adjusted for multiple hypothesis testing of 
<0.05 with a log2 fold change of greater or less than 0.5. 
For the MLL-AF9 leukaemias, differential expression was more balanced than in the non-transformed 
setting suggesting a possible interaction with Ezh2’s repressive role, with 368 genes upregulated and 
278 downregulated following Ezh2 loss. This may also correlate with the aggressive nature of MLL-
translocated leukaemias driven by different transcriptional programmes that are likely capable of 
overwhelming other programmes. For the AML1-ETO9a leukaemias, the balance was similar to the 
non-transformed setting with 388 genes upregulated and 55 genes downregulated following Ezh2 loss 
(again consistent with AML1-ETO9a being a less aggressive leukaemia and the possibility that there is 
less interaction between AML1-ETO9a and Ezh2). The top 25 genes upregulated following Ezh2 loss in 
both these induction leukaemias are listed in Table 5.2 (with the entire lists in Appendices A 5.2 and A 
5.3 respectively). Figure 5.5 shows these in volcano plot format for a direct comparison: 
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TABLE 5.2  Top 25 differentially upregulated genes in Ezh2-/- MLL-AF9 and AML1-ETO9a 
leukaemias 
Arranged in order of log2 fold change (highest first) 
Left (red) – MLL-AF9 leukaemias, Right (green) – AML1-ETO9a leukaemias 
MLL-AF9 AML1-ETO9a 
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Strikingly, the gene most significantly upregulated in the Ezh2-null MLL-AF9 leukaemias was also 
Lin28b, as per the non-transformed setting. Other genes of interest, further down the list, were also 
present such as transcription factor Plag1 and Yes1. The AML1-ETO9a leukaemias, whilst also having a 
significant number of upregulated genes, had a lesser degree of overlap with interesting candidates 
identified in the non-transformed differential gene expression analysis. However, Plag1 was notably 
present and significantly upregulated, and was common to all three groups. A triangulation 
overlapping all genes differentially upregulated following Ezh2 loss in the non-transformed, MLL-AF9 
and AML1-ETO9a leukaemias was made (Figure 5.6): 
 
Ezh2
+/+
 vs Ezh2
-/-
 
MLL-AF9 
368 278 
Lin28b 
Yes1 
Plag1 
Ezh2
+/+
 vs Ezh2
-/-
 
AML1-ETO9a 
388 55 
Plag1 
FIGURE 5.5 Volcano plots representing differentially expressed genes determined by RNA-
sequencing between Ezh2+/+ and Ezh2-/- MLL-AF9 (a) and AML1-ETO9a 
leukaemias (b) 
 Certain genes of interest, e.g. Lin28b, Yes1 and Plag1 are highlighted.  
Upregulated (red), downregulated (blue) 
The plot shows both negative and positive log2fold changes in gene expression (x-axis) 
and their adjusted p-value demonstrating significance (y-axis) 
(a) (b) 
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Though previously noted in the upregulated list for non-transformed, it was only after analysis of the 
differential gene expression data for both leukaemias that demonstrated a very small number of 
genes, including Plag1, that were common to all three conditions. Plag1 is a transcription factor, and 
has been previously described as an oncogene which augments Cbfb-MYH11 driven leukaemias.6,7 The 
other 5 genes common to all three groups were Bmpr1a, Perp, Ptk7, Cacnb2, and Tjp2, which appeared 
to have no functional significance in the literature as potential drivers of AML. Lin28b, and to a lesser 
extent Yes1, were commonly upregulated between the WT and MLL-AF9 Ezh2-null leukaemias, 
suggesting these may also be important mediators of the co-operation between Ezh2 loss and 
leukaemia induction.  
 
 
 
 
FIGURE 5.6 Integration of upregulated genes in wild-type (non-transformed or ‘WT’ setting) 
with upregulated genes in MLL-AF9 and AML1-ETO9a leukaemias occurring 
after Ezh2 deletion 
136 
 
5.4  Loss of Ezh2 in the non-transformed state results in a significant reduction in H3K27 
trimethylation at multiple sites across the genome 
 
Having characterised the effects of Ezh2 loss at the gene expression level in the non-transformed 
setting, where a significant number of genes were upregulated (some of whom were putative 
candidates for facilitating MLL-AF9 and AML1-ETO9a leukaemia induction), it was then imperative to 
determine whether this degree of upregulation was mechanistically as a direct result of loss of 
canonical Ezh2 function. As discussed at length in the introduction, EZH2 is the core catalytic 
component of the PRC2 complex, and contains the requisite SET domain necessary to methylate the 
lysine 27 residue of histone H3. Ezh1 containing PRC2 complexes (in the absence of Ezh2) have been 
shown have little methyltransferase activity, and our expectation was to see a relatively significant loss 
of H3K27me3 following Ezh2 deletion.  
As described in Section 5.2, lineage marker negative murine HSPCs for both Ezh2+/+ and Ezh2-/- 
genotypes were harvested and isolated and adequate Ezh2 excision was confirmed. For each ChIP-seq 
experiment two mice i.e. biological replicates were used per condition. Following this, the cells were 
lysed and nuclei were crosslinked with formaldehyde to allow histone modifications and proteins 
interacting with DNA to be preserved. Chromatin immunoprecipitation (ChIP) for H3K27me3 was then 
performed and samples were prepared for high-throughput sequencing (as per Methods 2.8.6 to 
2.8.12). Each sample was ratified for adequate enrichment through ChIP-qPCR (as detailed in Methods 
2.8.9). Once the sequencing data was available it was analysed as per Methods 2.8.13, and a SICER 
based peak-calling method was used to call differentially bound H3K27me3 peaks. Peaks were called 
using a p-value of significance at 1x10-10 and there was reasonable concordance in total numbers of 
peaks called between biological duplicates for each condition (wt vs Cre+). Following the generation 
of this list, it was filtered to select all those peaks with a False Discovery Rate (FDR) of <0.01. They were 
then rearranged in order of fold change and only those with Fold changes -1.5 < (x) > 1.5 were selected. 
All intergenic peaks further than 100kb from the transcriptional start site (TSS) were removed, yielding 
a final list of peaks which were then referenced to genes, when comparing with RNA-seq changes.  
Following Ezh2 loss, there was a large number of H3K27me3 peaks whose differential binding was 
downregulated (n= 3821). In comparison, only a handful of peaks (n=4) were identified whose 
differential binding was significantly increased. The downregulated peaks were distributed primarily 
across intergenic and intron sites, with some also present at promoter and transcriptional start sites 
(TSS) (Figure 5.7): 
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FIGURE 5.7 Distribution of significantly downregulated H3K27me3 peaks following Ezh2 
deletion in lineage negative murine HSPCs (n=3821) 
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5.5  Reduction of H3K27me3 occurs strictly at promoters/TSS of a narrow subset of all 
genes that are upregulated after Ezh2 loss 
 
Once aligned to the reference genome (‘mm10’ - the Mus musculus assembly (Genome Reference 
Consortium Mouse Build 38 [GCA_000001635.2])), the regions where H3K27me3 binding was 
significantly reduced following Ezh2 deletion could be associated with 2706 genes. This list of genes 
was then overlapped with the list of 478 upregulated genes following Ezh2 deletion (Appendix A5.1) 
to determine which were being directly upregulated as a result of H3K27me3 loss. Approximately 20% 
of all genes (91 of 478) upregulated on Ezh2 loss were associated with a significant reduction in 
H3K27me3 (Figure 5.8): 
 
 
 
 
 
 
 
When the genomic location of these 91 overlapping regions was determined, unlike the global pattern, 
there was a striking enrichment for promoter/TSS regions (75 genes out of 91, i.e. 82%). 
2615
374
91
H3K27me3
(↓ peaks)
Expression
(↑ genes)
p = 1.314 e-6
FIGURE 5.8 Overlap of all upregulated genes and genes at which H3K27me3 peaks were 
significantly downregulated following Ezh2 loss 
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This overlap identified a narrow subset of 91 upregulated genes that were associated with a reduction 
in H3K27me3, suggesting that loss of Ezh2 function at their promoters/TSS regions directly contributed 
to their increased expression. This list of 91 genes is provided in Table 5.3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within this subset of genes are some of the key candidates (highlighted in red) also present in the 
leukaemia gene expression datasets. It is interesting to note that around 80% of genes upregulated 
following Ezh2 loss did not have an associated reduction in H3K27me3, suggesting alternative and 
possibly indirect mechanisms for upregulation. Additionally, the smaller subset of genes 
downregulated after Ezh2 loss (n=48) had no overlap with changes in H3K27me3.  
Gene ontology analysis of these 91 genes demonstrated an enrichment in metabolic, developmental 
and regulatory processes. Molecular functions predominantly included binding, catalytic and receptor 
activity (Figure 5.9). These data imply that in particular, Ezh2 enzymatic function is directly related to 
these processes and functions. 
 
 
TABLE 5.3  Genes whose expression is significantly upregulated following Ezh2 loss that are 
also associated with a significant reduction in H3K27me3 binding 
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FIGURE 5.9 Gene ontology analysis of genes upregulated via direct loss of H3K27me3 
following Ezh2 loss 
Enriched biological processes and molecular functions shown 
Panther overrepresentation test (release Apr 2017) 
  GO Ontology database (release Aug 2017) 
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Visualisation of the H3K27me3 changes in a Genome Browser (UCSC Bioinformatics, University of 
California Santa Cruz) following Ezh2 loss at these selected genes showed a clear loss of H3K27me3 
peaks at the promoter regions (example in Figure 5.10): 
 
 
 
  
 
 
 
 
For Lin28b the reduction in the H3K27me3 peak was 5.06 fold, whilst it was 1.95 fold for Plag1, both 
with adjusted p-values of < 1x10-6. There were similar changes in H3K27me3 across all 91 genes 
selected in this overlap.  
FIGURE 5.10 Change in H3K27me3 peaks at (a) Plag1 and (b) Lin28b genes before and after 
Ezh2 loss 
 Data presented in UCSC Genome Browser on Mouse Dec. 2011 (GRCm38/mm10) 
Assembly 
 
(a) 
(b) 
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Having established that a number of these genes are upregulated in association with a loss of the 
H3K27me3 repressive mark, we rapidly moved to assess the presence of, and any alterations in 
potentially interrelated histone activating marks – H3K4me3 and H3K27Ac. 
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5.6  Analysis of H3K27Ac changes does not reveal any additional mechanistic insight into 
associated gene expression changes following Ezh2 loss 
 
ChIP-sequencing of the activating histone modification H3K27Ac was also performed on chromatin 
derived from lineage negative HSPCs isolated from murine bone marrow of pIpC pre-treated Ezh2+/+; 
wt and Ezh2-/-; Cre+ mice (in biological duplicates). The data was analysed as detailed above and a 
filtered list of differentially bound H3K27Ac peaks was generated using the same FDR and fold change 
criteria detailed above. Following the application of these filters, 846 genes were revealed to be 
differentially H3K27 acetylated. Twenty-four of these were associated with significant upregulation of 
H3K27Ac mainly at intergenic sites (Table 5.4), consistent with the fact that H3K27 acetylation primarily 
occurs at enhancer regions at some distance away from promoters or TSS. However, the majority - 822 
genes had a significant downregulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 5.4 Genes at which H3K27Ac is significantly upregulated following Ezh2 loss 
 ‘Fold’ represents log2fold change 
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This latter finding was somewhat surprising and unexpected. Overlaps between either up or 
downregulated H3K27Ac genes and genes increased in expression following Ezh2 loss failed to show 
any specific correlation (for example there was no overlap in the genes identified in Table 5.4 and all 
genes upregulated after Ezh2 loss). When a more targeted approach was adopted in scrutinising 
specific genes, such as some of the candidates discussed above, there was no differential change in 
H3K27Ac for either Plag1 or Yes1. Counterintuitively, there appeared to be a reduction in H3K27Ac for 
Lin28b and Igf2bp3. As this particular dataset did not reveal a significant influence of changes in this 
histone modification on gene expression following Ezh2 loss, no further analysis was undertaken.  
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5.7  Analysis of H3K4me3 localisation reveals bivalent domains that are subject to 
alteration following Ezh2 loss, favouring transcriptional activation 
 
As discussed earlier, the H3K4me3 mark is a histone modification associated with transcriptional 
activation. Its colocalization with H3K27me3 at promoters has been recognised in embryonic stem cells 
and this combination is widely considered to poise the expression of developmental genes, with its 
resolution in favour of H3K4me3 allowing rapid induction of differentiation programmes.8 This then 
allows for timely activation, whilst maintaining repression in the absence of differentiation signals. In 
mammals, the SET1A, SET1B and mixed lineage leukaemia (MLL) proteins 1-4 are the enzymes 
responsible for laying the H3K4me3 mark, using additional subunits to form complexes for their 
activity.  
Using an orthogonal dataset of H3K4me3 peaks across the genome in wild-type C57/Bl6 murine 
derived lineage negative HSPCs in duplicate, available in the Huntly lab (courtesy of Dr Haiyang Yun), 
we were able to gain a cursory glance at the presence or absence of H3K4me3 peaks at the previously 
identified H3K27me3 laden genes described in Section 5.4. Interestingly, of the 91 genes upregulated 
AND having a significant downregulation in H3K27me3 after Ezh2 loss, 79 (~87%) also had a clear 
H3K4me3 peak from this dataset, at the same promoter. An example is shown in Figure 5.11: 
 
 
 
 
 
FIGURE 5.11 H3K4me3 is present at the Lin28b promoter, also marked by H3K27me3 
 Data presented in UCSC Genome Browser on Mouse Dec. 2011 (GRCm38/mm10) 
Assembly 
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This suggested bivalency (i.e. the presence of both an activating and repressive mark) at these genes, 
and the tantalising possibility that in the wild-type scenario at the HSPC level, these genes were being 
held in a poised transcriptional state by the presence of the conflicting histone marks. With the loss of 
Ezh2, causing a significant reduction of H3K27me3 at these gene promoters, we hypothesised that the 
balance would resolve towards transcriptional activation due to the presence of H3K4me3, facilitating 
increased gene expression.  
 
Additionally, overlapping the remainder of the genes (n=2561) at which H3K27me3 was 
downregulated without any changes in gene expression with this H3K4me3 dataset showed that only 
24% (n=562 genes), i.e. the minority had a co-existing H3K4me3 peak. This strongly suggested the 
possibility that the selected subset of 91 genes were being regulated by both H3K27me3 and H3K4me3 
and loss of Ezh2 was resulting in the resolution of a conflict between the opposing marks in favour of 
facilitating transcription. 
 
In order to test the hypothesis made upon this observation, we proceeded to perform ChIP-sequencing 
of H3K4me3 (in biological duplicates) of both genotypes, using lineage negative HSPCs derived from 
pIpC pre-treated Ezh2+/+ (wt) and Ezh2-/- (Cre+) mice (as per H3K27me3). The sequencing data was 
analysed in the same way as detailed above, generating a list of differentially bound H3K4me3 peaks. 
Peaks with a False Discovery Rate (FDR) of <0.01 and fold changes -1.5 < (x) > 1.5 were selected. In 
total, there were 75 genes at which significantly differential H3K4me3 peaks were seen between 
Ezh2+/+ and Ezh2-/- states – 45 upregulated and 31 downregulated following Ezh2 loss. Importantly, this 
gain of H3K4me3 at these genes included the promoter regions of Lin28b and Plag1 (example shown 
in Figure 5.12):  
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The differentially upregulated H3K4me3 peaks corresponding to the 45 genes are listed in Table 5.5: 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.12 H3K4me3 is upregulated at the Lin28b promoter following Ezh2 loss 
 Data presented in UCSC Genome Browser on Mouse Dec. 2011 (GRCm38/mm10) 
Assembly 
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TABLE 5.5 Genes at which H3K4me3 is significantly upregulated following Ezh2 loss 
 ‘Fold’ is log2fold change, n = 45 genes 
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The overlap between differentially upregulated H3K4me3 genes and H3K27me3 downregulated genes 
that exhibited increased gene expression (n=91) was relatively small – only 4 genes were common to 
all three criteria – and these included Lin28b and Plag1.  
However, a comparison between H3K4me3 peaks present at genes in the Ezh2+/+ (wt) state and this 
selected subset of genes, revealed the majority (80 out of 91, i.e. 88%) at least had a recognisable 
H3K4me3 peak at the same promoter region as they had appeared to in the initial observation from 
the orthogonal dataset.  
Combining these datasets suggested that Ezh2 loss could in fact alter both H3K27me3 and H3K4me3 
at a highly-selected set of upregulated genes leading to their increased expression. These included two 
candidate oncogenes, Lin28b and Plag1, which had both been identified as being significantly 
increased in expression in the non-transformed Ezh2-null state AND in Ezh2-null MLL-AF9 and AML1-
ETO9a leukaemias. In addition, most of the upregulated genes that were associated with 
downregulated H3K27me3 peaks were also associated with the presence of a H3K4me3 mark at their 
promoters.  
Taken together, these integrated data suggested that Ezh2 loss would result in a resolution of conflict 
between these two competing histone modifications at the bivalent domains, favouring (or in the case 
of some important candidates, e.g. Lin28b and Plag1 increasing) H3K4me3, providing an additional 
mechanistic explanation for why these genes were upregulated.  
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5.8 Assessment of PRC complex localisation in the absence of Ezh2 
As discussed above, one of the other aims of this genomic characterisation was to delineate where 
Ezh2 itself was binding in the non-transformed state (in the Ezh2+/+; wt condition) through ChIP-
sequencing. In doing so, we posited seeing a substantial overlap where H3K27me3 was reduced 
following Ezh2 loss, and an association with upregulated genes. Additionally, we sought to characterise 
PRC2 complex differential binding in the non-transformed state in the absence of Ezh2, through ChIP-
seq profiling the binding of another core PRC2 complex member (Eed) in both Ezh2+/+ and Ezh2-/- states.  
 
Ezh2 binding 
The same methods were used to obtain chromatin from lineage negative HSPCs isolated from murine 
bone marrow of pIpC pre-treated Ezh2+/+; wt mice (in biological duplicates). In view of them being wild-
type i.e. lacking Mx1-Cre expression, there was no excision expected and this was confirmed through 
qPCR genotyping before continuing. A total of 5x106 cells were used per replicate with a longer 15-
minute cross-linking time than for histones, given the relatively lower abundance of proteins when 
compared to the above histone modifications. Following this ChIP-sequencing of Ezh2 was performed 
and data analysed as already described. Peaks were called at a p-value of 1x10-5 (considerably less 
stringent than that used to call the histone modification peaks detailed above) due to the poorer 
quality of antibody binding and non-specific binding. The initial results showed an immediate problem 
between biological replicates themselves, with a marked difference in the total number of significant 
peaks called between identical duplicates (2900 peaks in replicate 1 and 4300 peaks in replicate 2). 
There was a limited overlap of 1280 genes between these two duplicates (<50%) and therefore it was 
felt that due to poor concordance between these two datasets (most likely for technical reasons such 
as poor specificity of the antibody) further analysis of this dataset was unlikely to reveal meaningful 
results.  
 
Eed binding 
As per Ezh2, 5x106 lineage negative HSPCs per replicate were used for ChIP-sequencing to track Eed 
binding and PRC2 localisation both in the presence and absence of Ezh2. The cells were obtained as 
described above, from pIpC pre-treated Ezh2+/+; wt and Ezh2-/-; Cre+ mice (whose excision in the Cre+ 
arm had been confirmed prior to use). ChIP-qPCR for control positive and negative regions did appear 
to show enrichment as expected between the two conditions (data not shown). Following sequencing, 
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data was analysed as already described. Peaks were called at a p-value of 1x10-5. Unfortunately, (likely 
for the same technical reasons as described above), there was again a significant variance in numbers 
of peaks between biological replicates in both wt and Cre+ conditions (e.g. 1801 peaks for replicate 1 
and 10191 peaks for replicate 2 in the Cre+ setting and 1741 peaks for replicate 1 and 7841 peaks for 
replicate 2 in the wt setting). Additionally, when visualised on a UCSC genome browser session, these 
peaks were of poor quality and not readily distinguishable from the baseline (example shown in Figure 
5.13), with poor concordance between replicates. It was therefore decided not to attempt further 
analysis of this dataset.  
 
 
 
 
 
 
Both these ChIP-sequencing datasets highlighted technical difficulties in obtaining adequate results 
when using antibodies against a protein marker as opposed to those against a histone modification. 
There was a reasonable degree of heterogeneity between biological replicates and even when the 
stringency of peak calling was relaxed (relative to that used for the histone modifications datasets 
above), it was still not possible to have a reliable filtered set of results for either Ezh2 or Eed binding 
that we could use to compared to the gene expression and histone modification datasets.  
 
 
 
FIGURE 5.13 Eed binding between Ezh2+/+ and Ezh2-/- genotypes 
 Data presented in UCSC Genome Browser on Mouse Dec. 2011 (GRCm38/mm10) 
Assembly 
 Lin28b is shown (centre-right) 
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5.9 Analysis of differential gene expression resulting from pharmacological Ezh2 
inhibition in MLL-AF9 murine leukaemias in vitro reveals an entirely different gene 
expression set involved in their maintenance 
 
As discussed at the beginning of this chapter, the profoundly different functional outcomes of Ezh2 
loss in MLL-AF9 and AML1-ETO9a leukaemia induction versus their maintenance led us to hypothesise 
that different transcriptional programmes were being altered by Ezh2 loss, or that, at the very least, 
there would be minimal overlap between these two programmes. Having compared the transcriptional 
and epigenetic differences between a 100% Ezh2 replete (wt) and 95%+ Ezh2 deleted (Cre+) scenarios 
through genetic excision in the induction in vitro experiments, we felt it would be an unfair comparison 
to any differential gene expression analysis to compare the partially Ezh2 excised ‘wild-type’ 
leukaemias and their completely Ezh2 deleted counterparts in the maintenance experiments. 
Differences at the genomic level would likely be diluted by the relative lack of genotype extremes (as 
the induction experiments had cleanly provided) in the maintenance in vivo experiments, due to 
spontaneous Cre-mediated Ezh2 excision.   
We therefore sought a different approach to characterise the altered transcriptional programmes that 
were possibly leading to abrogation of the leukaemias following complete Ezh2 excision. Instead of 
further genetic manipulation, we employed pharmacological inhibition of Ezh2 in established 
leukaemia tumours to produce a more pronounced Ezh2 deficiency that we could compare to vehicle 
control treatment alone. As MLL-AF9 tumours tend to proliferate more aggressively in liquid culture 
than AML1-ETO9a tumours do, we decided to conduct this experiment utilising the former. After 
thawing and washing spleen cells from two separate Ezh2fl/fl; wt MLL-AF9 primary leukaemia mice 
whose tissues had been processed and stored in liquid nitrogen during the induction in vivo 
experiment, we were able to culture and expand these reliably and consistently in vitro using sterile X-
Vivo 20 culture medium, as they were already established leukaemias (as described in Methods 2.2.2). 
Full details of the following are provided in Chapter 7, but briefly, both spleen tumours showed an 
almost equal sensitivity to GSK343 (dissolved in DMSO as vehicle) in liquid culture in vitro, with an 
inhibitory effect on liquid culture growth as early as 24 hours and IC50 inhibition as low as 
concentrations of 10µM. Having established sensitivity, both tumours were treated with DMSO 
(Control) or GSK343 in liquid culture and cells harvested at every 24 hours for up to 72 hours to assess 
reduction in H3K27me3 by flow cytometry (Methods 2.4.2). Biological and technical replicates 
demonstrated that a near total loss of H3K27me3 was seen in each tumour as early as 24 hours of 
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treatment with GSK343 (Figure 5.14). Therefore, this time point was chosen and cells were harvested 
from both tumours in liquid culture at 24 hours from both DMSO and GSK343 treated conditions.  
 
 
 
 
 
 
 
 
 
 
 
RNA was extracted from these cells and after quantification, 5µg from each sample was sent for library 
preparation and sequencing (Methods 2.8.15). Through this, a filtered list of differentially expressed 
genes of significance between DMSO and GSK343 treated tumours was generated. Significant gene 
expression results were those with a p-value adjusted for multiple hypothesis testing of <0.05 with a 
log2 fold change of greater or less than 0.5. With the application of these criteria, a total 91 genes were 
differentially regulated – considerably less than in the MLL-AF9 induction programme. Of these, likely 
as a result of Ezh2 inhibition, 79 genes were significantly upregulated. These are listed in Table 5.6: 
 
 
 
 
 
 
H3K27me3 Total H3 
GSK343 treatment of  
MLL-AF9 spleen tumour in vitro at 24 hrs 
DMSO 
GSK343 
FIGURE 5.14 Loss of H3K27me3 at 24hours following Ezh2 inhibition with GSK343 in MLL-AF9 
spleen tumour #5340 in vitro 
 Comparisons made to DMSO (vehicle control treated) cells and Total Histone H3 of the 
same cells 
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TABLE 5.6 Genes upregulated following Ezh2 inhibition with GSK343 in established MLL-
AF9 murine leukaemia 
 ‘padj’ is adjusted p-value for multiple hypothesis testing 
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Albeit that there are significant differences between genetic loss and reversible inhibition of Ezh2, this 
set of de-repressed genes involved in the maintenance of these MLL-AF9 leukaemias is almost mutually 
exclusive with the de-repressed gene set seen in the both the non-transformed and MLL-AF9 
leukaemia induction in vivo setting. Overlapping these datasets revealed very few common candidates, 
none of which had immediate obvious relevance to either phase of AML evolution (Figure 5.15): 
 
 
 
 
 
 
This analysis suggested that the significantly opposing functional differences seen in the in vivo 
induction and maintenance experiments subsequent to Ezh2 loss could be explained by the de-
repression of a completely different gene expression set in either cellular context. At the time of 
submission, further work such as gene set enrichment analysis on these datasets is being performed 
to see if there is any alignment with specific cellular programmes.   
 
FIGURE 5.15 Overlap of genes de-repressed following Ezh2 loss in MLL-AF9 leukaemia 
induction and genes de-repressed following Ezh2 inhibition in MLL-AF9 
leukaemia maintenance 
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5.10  Discussion and future work 
 
The genomic analysis described in this chapter served to provide a better mechanistic understanding 
of the different outcomes seen in leukaemia induction and maintenance, particularly in the previously 
described in vivo experiments. It also allowed for the identification of certain genes that were de-
repressed following Ezh2 loss that could potentially co-operate with MLL-AF9 and AML1-ETO in 
accelerating leukaemia induction.  
Through comparison of the non-transformed state in both the presence and absence of Ezh2, a 
detailed characterisation of differential gene expression and relevant histone modifications was made. 
When these datasets were compared, it was apparent that a number of genes that were de-repressed 
following Ezh2 loss were associated with a significant reduction in H3K27me3 (the direct output of 
Ezh2 enzymatic function). Interestingly, a number of these genes were also populated with the 
activating H3K4me3 mark at their promoters (79 out of 91), suggesting bivalency and a possible shift 
in balance towards transcriptional activation due to the resolution of the conflict between these two 
histone marks in favour of H3K4me3 upon Ezh2 loss. Strikingly, a few select candidate genes (Lin28b 
and Plag1 amongst others) also demonstrated a significant increase in H3K4me3 following Ezh2 loss, 
potentially explaining why they were so significantly upregulated. It is highly interesting that Ezh2 loss 
does not only downregulate H3K27me3, but also in some way is modulating H3K4me3 upregulation, 
particularly at a limited set of genes where the level of upregulation is incredibly marked. A recent 
study characterising the role of the histone demethylase UTX (responsible for demethylation of the 
H3K27me3 mark – effectively the opposite role of EZH2) in the epigenetic regulation of invariant 
natural killer T cells, identified that UTX knock-out led to the downregulation of a number of genes. 
Genes that were most downregulated in the UTX knock-out scenario were revealed to have an 
accumulation of H3K27me3 at their promoters (consistent with repression), but also a marked 
decrease in H3K4me3 when both histone marks were assessed by ChIP-sequencing.9 The deficiency in 
UTX appeared to affect the chromatin state around a particular subset of downregulated genes. Whilst 
a completely separate enzyme with canonically the opposite function to EZH2, UTX loss in this study 
appears to be demonstrating a clear effect on H3K4me3. The common link between fluxes in EZH2 and 
UTX status is centred around changes in H3K27me3. Alterations in H3K27me3 resulting from changes 
in these two, particularly at the promoters of certain subsets of genes (both in this study and in our 
data above), appear to directly influence significant changes in their H3K4me3 state (in the opposite 
direction), providing a valid mechanism for the changes seen in transcriptional output. However, the 
mechanisms that underlie this are not entirely clear and would be very interesting to further 
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characterise. Taken together and particularly supported by the opposing effects of EZH2 and UTX and 
their diametrically opposite effects on the H3K4me3 mark at highly specific genes, this suggests a 
significant and active ‘cross-talk’ between H3K27me3 and H3K4me3 in gene regulation.  
Having compared the gene expression changes resulting from Ezh2 loss in the non-transformed setting 
to those seen in MLL-AF9 and AML1-ETO9a during leukaemia induction, further evidence was provided 
for some of these candidate genes facilitating a functional role in accelerating leukaemogenesis. We 
hypothesised that early Ezh2 loss in the non-transformed state led to the de-repression of a number 
of genes, of which Lin28b and Plag1 were plausibly at the forefront in co-operating with MLL-AF9 
and/or AML1-ETO9a to accelerate leukaemia induction. Lin28b was maximally upregulated in both the 
non-transformed and MLL-AF9 gene expression sets (appearing at the top of both lists in order of 
log2fold change), and with its general role in tumour induction and recent implication as a mediator of 
Ezh2 loss synergising with JAK2-V617F myeloproliferative neoplasms3 warranted further inquiry into 
its functional role in AML induction.  
The evidence implicating Plag1 as a facilitator of Ezh2 loss in AML induction was potentially even 
stronger. Despite it not appearing in the top 25 upregulated genes for each of the three conditions, it 
was the only known oncogene common to all three groups, and has also been implicated in the 
accelerated development of Cbfb-Myh11 murine AMLs.4,5 Both candidates had a reduction in 
H3K27me3 and increase in H3K4me3 to explain the mechanism behind their upregulation. Having 
established these as potential candidates, the next step was to attempt to functionally validate these 
through overexpression of either of these genes in tandem with MLL-AF9 or AML1-ETO9a, ideally in 
vivo, with the aim of phenocopying Ezh2 loss to accelerate leukaemia induction.  
Finally, we identified a largely different transcriptional programme altered by Ezh2 loss to potentially 
explain the opposite and negative effects seen in the maintenance in vivo MLL-AF9 leukaemia 
experiments, albeit that we utilised reversible inhibition of Ezh2 rather than genetic ablation. It is also 
arguable that the lack of overlap seen between the gene sets is in part due to experimental differences 
(genetic versus pharmacological inhibition) and that the two are not directly comparable. However, 
we maintain that this is a better comparison than that between partially Ezh2-excised versus 
completely Ezh2-excised states.   
The induction experiments had brought up valid concerns that use of EZH2 inhibitors mandated 
caution (also exhibited in the myeloproliferative studies), considering that Ezh2 loss in the murine 
experiments was clearly accelerating leukaemia development. However, this latter characterisation of 
genes altered in maintenance has allayed these fears largely because they are almost mutually 
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exclusive gene sets. For the maintenance phase, these findings reassured regarding the use of EZH2 
inhibitors, especially as they are currently in clinical trials, and the next step then was to test GSK343 
further in murine and human leukaemia cell lines and in primary AML samples.  
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Chapter 6 
Functional analysis of candidate genes identified by genomic analysis 
 
6.1 Aims 
This chapter addresses the following question: 
1. Does overexpression of Lin28b or Plag1 phenocopy loss of Ezh2 in accelerating MLL-AF9 
leukaemia induction in vivo? 
 
6.2 Introduction 
LIN28 
Lin28 was initially characterised in the Caenorhabditis elegans nematode as being an important 
regulator of developmental timing1, and is highly conserved across evolution. Its mammalian 
homologues Lin28a and Lin28b are RNA-binding proteins that bind to the terminal loops of the let-7 
microRNA tumour-suppressor family and prevent their post-translational processing into functional 
mature miRNAs.2 The let-7 microRNAs in turn negatively regulate LIN28B expression as well as many 
other genes such as HMGA2, c-Myc and K-Ras, normally promoting cell differentiation. 3,4 LIN28 has 
been described as an important reprogramming factor in concert with KLF4, SOX2 and NANOG during 
the induction of pluripotency in adult human fibroblast cells. 5 In murine haematopoiesis, the Lin28b 
protein, let-7 and its target gene Hmga2 have been identified as important determinants of enhanced 
self-renewal characteristics that foetal haematopoietic stem cells (HSCs) display. 6 Reintroduction of 
Lin28b into purified adult HSCs resulted in a nearly 10-fold greater numerical expansion and increased 
lineage reconstitution following transplantation into recipient mice, suggesting the reacquisition of 
foetal-like self-renewal capacity. The overexpression of Lin28b in adult HSCs reactivated Hmga2, a key 
let-7 miRNA target. Hmga2 has been demonstrated to regulate growth and metabolism pathways 
through important regulators such as insulin-like growth factor (IGF) and the oncogenic Myc pathway 
and is well described as a downstream mediator of oncogenic function associated with the Lin28b-let-
7 pathway.7 LIN28 and LIN28b have been shown to be overexpressed in a number of primary human 
tumours and human cancer cell lines and this overexpression was linked to de-repression of let-7 
targets. 8 Elevated LIN28/LIN28B expression across many cancer types (including advanced breast, lung 
and liver) correlate with poorer prognosis and clinical outcomes. 9  
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Recently, Ezh2 was characterised as a regulator of the Lin28b-let-7 pathway in adult murine HSCs 
through H3K27me3, with its loss resulting in the re-activation of foetal-like gene signatures, through 
ectopic expression of Lin28b. 10 The suggestion here was that Ezh2 co-operated with let-7 microRNAs 
to silence foetal-like gene signatures in adult bone marrow HSCs, potentially restricting their 
propensity to transformation.  
Ectopic expression of Lin28b in a transgenic mouse model on a C57/Bl6 strain (via a HS 21/45-vav 
vector for targeted expression in haematopoietic tissues) resulted in aberrant T-cell development and 
invariably led to the development of aggressive peripheral T-cell lymphoma with associated systemic 
inflammatory changes, with a latency as early as 10 months. 11 In the recent study describing Ezh2 loss 
cooperating with JAK2-V617F to drive myelofibrosis, the Lin28b-let-7-Hmga2 axis was suggested as a 
key candidate pathway mediating this process. 12 
 
PLAG1 
The PLAG family comprises 3 members (PLAG1, PLAGL1 and PLAGL2), all of which function as 
transcription factors. They are highly conserved in structure and function and the PLAG1 gene 
(pleomorphic adenoma gene) has been associated with benign tumours harbouring 8q12 
translocations including pleomorphic adenomas of the salivary glands, lipoblastomas and 
hepatoblastomas. 13,14 Plag1 was identified (through a retroviral insertional mutagenesis screen) as a 
potential co-operative gene with Cbfb-MYH11 leukaemias in vivo. 15 In a successive study by the same 
group, co-expression of Plag1 and Cbfb-MYH11 in a bone marrow transduction and transplantation 
assay caused the development of AML in 100% of recipient mice, with a latency of 3-12 weeks, whilst 
expression of Plag1 or Cbfb-MYH11 alone was insufficient to cause leukaemia. 16 In vitro, Plag1 
overexpression also caused expansion of murine haematopoietic progenitors. In the same study, 5% 
of primary AML samples had significantly elevated levels of the PLAG1 transcript across all cytogenetic 
groups, suggesting PLAG1’s promiscuity in co-operating with other mutations associated with AML.  
 
The gene expression and epigenetic analysis of the induction in vivo leukaemia experiments 
documented thus far revealed several plausible downstream effectors of Ezh2 loss whose de-
repression was potentially capable of augmenting MLL-AF9 or AML1ETO9a leukaemogenesis. After 
detailed genomic analysis the most striking candidates were Lin28b and Plag1 (for the reasons 
discussed in Chapter 5), and coupled with clearly supportive data from other studies in the literature 
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as discussed above, we felt these two candidates specifically warranted further functional 
investigation. 
 
6.3 Functional assessment of a retroviral overexpression system for Lin28b and Plag1 
The retroviral vectors MSCV-Lin28b-IRES-mCherry and MSCV-Plag1-IRES-mCherry were generated for 
this experiment through cloning each insert into the MSCV-IRES-mCherry vector as described in 
Methods 2.7. Having established these, the aim was to utilise them to overexpress each of the putative 
co-operating oncogenes with MLL-AF9 in c-kit selected HSPCs harvested from the bone marrow of 
wild-type C57/Bl6 mice. These transduced cells would then be immediately transplanted into 
irradiated wild-type C57/Bl6 recipients to determine whether either would co-operate to cause 
acceleration of MLL-AF9 induction in vivo, thus phenocopying the loss of Ezh2. This would be compared 
against a single transduced MLL-AF9 control arm. The MLL-AF9 leukaemia model was chosen to assess 
these two candidate genes over AML1-ETO9a as its latency on the bone marrow transplantation 
experiments described in Chapter 3 described was significantly shorter (6-10 weeks), to enable a faster 
readout. This was balanced against the potential pitfall that the MLL-AF9 leukaemia programme is so 
aggressive that it risked overwhelming or diluting any additional co-operative function we were aiming 
to demonstrate through the overexpression of either of these single candidate genes. 
Prior to commencing the functional in vivo transplantation experiment, it was imperative to assess the 
function of each newly generated construct. Firstly, retroviral supernatant was generated from dual 
transfection of 293T cells with equal amounts of MSCV-MLL-AF9-IRES-YFP and either a) MSCV-Plag1-
IRES-mCherry or b) MSCV-Lin28b-IRES-mCherry (Methods 2.6.6.1). To confirm co-expression of YFP 
and mCherry within 293T cells (indicating successful dual transfection), these were assessed by flow 
cytometry and compared to single MSCV-MLL-AF9-IRES-YFP transfected 293T cells (Figure 6.1) 
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Having demonstrated the presence of dual transfected 293T cells in similar proportions for both MLL-
AF9+ Plag1- or Lin28b- conditions, and importantly that it did not deviate in favour of singly transfected 
MLL-AF9 cells, the next step was to determine whether the retroviral supernatant produced from each 
would provide appropriate transduction. Retroviral transduction was performed as detailed in 
Methods 2.6.7.2. The expectation was that transduction of c-kit positive bone marrow cells with 
supernatant from conditions (b) and (c) in Figure 6.1 above, would result in four populations: (1) non-
transduced cells, (2) single MLL-AF9 (YFP+) transduced cells, (3) single Plag1- or Lin28b- (mCherry+) 
transduced cells and (4) double transduced MLL-AF9 + Plag1 OR Lin28b (dual YFP/mCherry positive) 
cells.  
Ideally, the double transduced population (4) would form the majority of the sum of (2), (3) and (4) 
and would allow for a fair functional assessment of overexpression of either candidate gene in the 
presence of MLL-AF9. 
Given the potency of the MLL-AF9 oncogene, a major concern was whether there would be the 
presence of a significant sized population (2), i.e. single MLL-AF9 (YFP+) transduced cells. If present, 
alone these could potentially override any additive functional effect either candidate gene may 
b) c) 
FIGURE 6.1 Flow cytometry of (a) single (MLL-AF9), and (b) or (c) dual (Plag1+MLL or 
Lin28b+MLL) transfected 293T cells 
Live cells firstly gated by forward and side-scatter, doublets then removed (not shown). YFP 
detected on 488 530/30A channel (x-axis), mCherry detected on 561 610/20A channel (y-axis) 
a) 293T cells transfected with MSCV-MLL-AF9-IRES-YFP alone 
b) 293T cells transfected with MSCV-MLL-AF9-IRES-YFP AND MSCV-Plag1-IRES-mCherry 
c) 293T cells transfected with MSCV-MLL-AF9-IRES-YFP AND MSCV-Lin28b-IRES-mCherry 
MLL transfected 293T Plag1+MLL transfected 293T Lin28b+MLL transfected 293T 
a) 
YFP m
Ch
er
ry
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demonstrate. As the experimental design was to transplant bulk transduced cells and not flow sort 
population (4) for each condition (to avoid further stress to the cells being transplanted), this concern 
required addressing before any in vivo transplants utilising these could be set up.  
To test the retroviral supernatants, mock transductions were performed with these in duplicate 
(Methods 2.6.7.2) utilising c-kit selected HSPCs isolated from the bone marrow of 2 wild-type C57/Bl6 
recipient mice. A representative example of this is shown in Figure 6.2: 
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MLL-AF9 transduced 
ckit+ BM 
  
Non-transduced ckit+ 
BM 
  
Plag1+MLL-AF9 
transduced ckit+ BM 
  
Lin28b+MLL-AF9 
transduced ckit+ BM 
  
FIGURE 6.2 Flow cytometry analysis of single (MLL-AF9) and dual (Plag1+MLL-AF9 or 
Lin28b+MLL-AF9) transduced c-kit selected BM HSPCs shows dual transduction 
without a significant single MLL-AF9 transduced population 
Live cells firstly gated by forward and side-scatter, doublets then removed (not shown).  
YFP detected on 488 530/30A channel (x-axis), mCherry detected on 561 610/20A channel (y-axis) 
 
a) Non-transduced bone marrow (Control) 
b) MLL-AF9 transduced bone marrow (P6 approximately 4-5% in this case) 
c) Plag1 and MLL-AF9 transduced – dual transduced cells in P4 (~1%), P6 (~0.5%) 
d) Lin28b and MLL-AF9 transduced – dual transduced cells in P4 (8-10%), P6 (~0.5%) 
(a) (b) 
(c) (d) 
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For Plag1 + MLL-AF9 transduced cells (Figure 6.2c), dual transduction was lower than anticipated (P4), 
but perhaps reflected the larger insert size of Plag1 (1500bp). There were, however, a reasonable 
proportion of single Plag1 transduced cells (as indicated by single mCherry expression), but virtually 
no single MLL-AF9 transduced cells (as indicated in P6). Plag1 overexpression alone did not induce 
disease in the CBFB-MYH11 study with 100% of single Plag1 transplanted C57/Bl6 mice remaining alive 
and well through the entire experiment, so this was not a particular concern.16  
For Lin28b + MLL-AF9 transduced cells (Figure 6.2d), dual transduction was reasonably high (P4), and 
higher than with Plag1 + MLL-AF9, perhaps owing to the smaller insert size of Lin28b (800bp). There 
was a significantly higher proportion of single-transduced Lin28b cells (as indicated by single mCherry 
expression), but only a small number of single MLL-AF9 transduced cells. Whilst there have been no 
reports of the effects of Lin28b retroviral overexpression in the haematopoietic system in the 
literature, as mentioned before, a transgenic mouse model employing Lin28b enforced expression led 
to the development of peripheral T cell lymphoma, with a disease latency considerably longer than 
that of MLL-AF9 transplanted mice, so we were not unduly concerned that these single-transduced 
Lin28b cells would influence the development of AML in this experiment or affect outcome.  
These mock transductions allayed concerns regarding any interference of additional single MLL-AF9 
transduced cells and each batch of retroviral supernatant was tested in this way prior to use in the 
final in vivo assessment.   
 
6.4 Assessment of Lin28b and Plag1 overexpression in c-kit+ transduced HSPCs 
The presence of mCherry following transduction was a surrogate marker for adequate expression of 
the retroviral construct. However, to ensure the constructs were leading to an overexpression of both 
candidate genes appropriately at the transcript and protein level, it was imperative to assess this 
appropriately.  
RNA was extracted from the c-kit positive HSPCs following their transduction with Lin28b or Plag1 in 
the assessments described above.  This was then used to quantitatively assess expression using qPCR 
(as described in Methods 2.6.8.3).  The housekeeping gene used as a reference was Gapdh and for 
each condition being assessed, the other was used as a negative control (Figure 6.3): 
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FIGURE 6.3 RT qPCR demonstrating overexpression of (a) Lin28b following transduction with 
MSCV-Lin28b-IRES-mCherry construct and (b) Plag1 following transduction with 
MSCV-Plag1-IRES-mCherry construct in c-kit selected wild-type HSPCs normalised to 
Gapdh control 
 
a) Lin28b is significantly overexpressed following single transduction of c-kit selected HSPCs with 
its construct. Note Plag1 expression is also modestly increased when normalised to Gapdh 
control (discussed further in main text) 
b) Plag1 is significantly overexpressed following single transduction of c-kit selected HSPCs with 
its construct compared to Gapdh control and Lin28b 
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Both qPCR assays demonstrated that each construct was able to produce an appropriately significant 
increase in expression of the gene at the transcript level within the c-kit selected HSPCs when 
compared to control. Interestingly, Lin28b overexpression appeared to be unexpectedly causing a 
modest degree of Plag1 overexpression (Figure 6.3a), suggesting the possibility that it may exert some 
control over Plag1 expression independent of Ezh2 status. A cursory glance at a publicly available micro 
RNA database (www.mirdb.org) reveals the Plag1 gene in Mus Musculus is a predicted target of 180 
miRNA’s in order of interaction, amongst which three of the let-7 family appear in the top ten. Though 
speculative, this suggests Lin28b may exert a direct positive regulatory effect on Plag1 through 
releasing let-7 mediated suppression and would warrant further investigation.   
 
Cell lysates were prepared from Lin28b or Plag1 transduced c-kit selected HSPCs for protein extraction 
(as described in Methods 2.5.2). Western blotting was then performed to assess for overexpression of 
each candidate at the protein level within these cells (Figure 6.4): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lin28b 
β-Actin 
M
LL
-A
F9
 
Li
n2
8b
 +
 M
LL
-A
F9
 
Plag1 
Gapdh 
M
LL
-A
F9
 
Pl
ag
1 +
 M
LL
-A
F9
 (a) (b) 
FIGURE 6.4 Western blot demonstrating overexpression of (a) Lin28b protein after 
transduction with Lin28b and MLL-AF9 constructs, (b) Plag1 protein after 
transduction with Plag1 and MLL-AF9 constructs, compared to single-transduced 
MLL-AF9 control 
 
a) Lin28b protein is significantly overexpressed following transduction with viral supernatant 
from dual- Lin28b and MLL-AF9 construct transduced cells. β-actin used as loading control 
b)  Plag1 protein is overexpressed following transduction with viral supernatant from dual- 
Plag1 and MLL-AF9 construct transduced cells. Gapdh used as loading control 
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Both Lin28b and Plag1 were overexpressed at the protein level compared to minimal expression in 
single MLL-AF9 transduced c-kit positive HSPCs (Plag1 to a slightly lesser extent than Lin28b as 
evidence by blot).  
Having demonstrated that both constructs were capable of causing adequate overexpression of Lin28b 
and Plag1 at both the transcript and protein level (following transduction within the same c-kit HSPC 
population we intended to use for the transplantation experiments to validate either candidate gene), 
we proceeded to the functional in vivo experiment.  
 
6.5 Overexpression of Plag1 phenocopies Ezh2 loss in synergizing with MLL-AF9 to 
accelerate leukaemia induction 
Four wild-type C57/Bl6 mice aged 8-12 weeks were culled and whole bone marrow was harvested as 
previously described. From this, c-kit+ HSPCs were selected (as described in Methods 2.6.5) and 
cultured overnight in appropriate culture medium. The cells were then divided into three conditions 
and transduced with retroviral supernatant: 
a) MSCV-MLL-AF9-IRES-YFP 
b) MSCV-MLL-AF9-IRES-YFP + MSCV-IRES-Lin28b-mCherry 
c) MSCV-MLL-AF9-IRES-YFP + MSCV-IRES-Plag1-mCherry  
As described in Section 6.3, an estimation of transduction efficiency for each arm was made through 
flow cytometry so that the total number of cells injected per lethally irradiated C57/Bl6 wild-type 
recipient mouse could be adjusted to ensure that equal numbers were being injected per animal and 
that the ratio of double transduced m-Cherry/YFP+ cells to single YFP+ cells was noted. For the Lin28b 
test arm, the ratio injected per mouse was approximately 3:1 and for the Plag1 test arm the ratio 
injected per mouse was 1:1 (this was expected as the number of dual-transduced cells were always 
lower in the Plag1 mock transductions than the Lin28b mock transductions as described above). The 
control arm (i.e. MLL-AF9 alone) also had the same number of YFP+ cells injected as per the two test 
arms. An overview of the experiment is depicted in Figure 6.5: 
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FIGURE 6.5 Experimental design used to functionally validate Plag1 or Lin28b overexpression with MLL-AF9 in vivo  
 
 BONE MARROW TRANSDUCTION AND TRANSPLANTATION ASSAY:  
C57/Bl6 wild-type recipient mice aged 8-12 weeks are harvested for whole bone marrow. c-kit positive HSPCs are then selected and 
placed into liquid culture divided into three arms. Each arm is then transduced with a) MLL-AF9, b) MSCV-Lin28b-IRES-mCherry + 
MLL-AF9 or c) MSCV-Plag1-IRES-mCherry + MLL-AF9 retroviral supernatant. After assessment of transduction efficiency by flow 
cytometry, cells numbers are then adjusted accordingly (as described in main text) and injected into lethally irradiated C57/Bl6 wild-
type recipients. These are monitored clinically for disease and differences in survival outcomes are assessed 
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Mice transplanted with Plag1 + MLL-AF9 transduced c-kit+ HSPCs became moribund as early as Day 35 
post transplantation and overall developed leukaemia significantly quicker than those transplanted 
with MLL-AF9 transduced c-kit+ HSPCs (Figure 6.6): 
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Mice exhibited elevated white cell counts and anaemia as they became terminal. The median survival 
differed significantly from 37.5 days in the Plag1 + MLL-AF9 group to 53.5 days in the MLL-AF9 control 
group. Analysis of both spleen and bone marrow from Plag1 + MLL-AF9 transplanted mice 
demonstrated an increase in the ratio of double transduced m-Cherry/YFP+ cells to single YFP+ cells 
from approximately 1:1 at the start of transplant to as high as 5:1 in BM and 3.1:1 in spleen (averaged 
across 5 animals), clearly indicating that dual overexpressing Plag1 and MLL-AF9 cells had a selective 
advantage over single MLL-AF9 transduced cells alone, and were accelerating disease. At the time of 
writing these animals are being further characterised, but there are no apparent significant phenotypic 
differences.  
 
Mice transplanted with Lin28b + MLL-AF9 transduced c-kit HSPCs failed to show any significant 
acceleration of AML induction compared to those transplanted with MLL-AF9 transduced c-kit+ HSPCs 
alone (Figure 6.7): 
FIGURE 6.6  Plag1 co-operates with MLL-AF9 to accelerate the induction of AML in mice 
Kaplan-Meier survival curve of mice that were transplanted Plag1 + MLL-AF9 transduced  
c-kit+ HSPCs or MLL-AF9 transduced c-kit HSPCs alone 
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Though animals transplanted with Lin28b + MLL-AF9 transduced c-kit HSPCs did develop disease 
slightly earlier, becoming moribund as early as Day 36, the overall survival trend did not demonstrate 
a significant alteration in outcome. Median survival was 48 days in the Lin28b + MLL-AF9 transplanted 
group compared to 53.5 days in the MLL-AF9 control group. There was also no significant expansion in 
the ratio of double transduced m-Cherry/YFP+ cells to single YFP+ cells in haematopoietic tissues of 
terminal mice suggesting no functional advantage for dual overexpressing Lin28b and MLL-AF9 cells. 
Again at the time of writing, the leukaemias are being further characterised but there are no obvious 
phenotypic differences.  
 
 
 
 
 
FIGURE 6.7 Lin28b overexpression with MLL-AF9 does not significantly accelerate the 
induction of AML in mice 
Kaplan-Meier survival curve of mice that were transplanted with Lin28b + MLL-AF9 
transduced c-kit+ HSPCs or MLL-AF9 transduced c-kit HSPCs alone 
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6.6 Discussion and future work 
The loss of Ezh2 prior to leukaemia induction with MLL-AF9 and AML1-ETO9a dramatically accelerated 
leukaemogenesis. Through detailed characterisation of the genomic changes resulting in Ezh2 loss we 
were able to discover that the overexpression of a few select genes resulted from a loss of repression 
by H3K27me3 and an upregulation of the activating histone mark H3K4me£ at their promoters. From 
this select group both Lin28b and Plag1 were identified as possible oncogenic mediators of Ezh2 loss 
in augmenting disease development. 
Having established and validated a retroviral overexpression system for either candidate gene, we 
demonstrated that overexpression of Plag1 co-operated with MLL-AF9 in clearly accelerating the 
development of AML (compared to MLL-AF9 driven AML) without any notable changes in phenotype. 
Haematopoietic tissues were infiltrated by an increased ratio of dual Plag1/MLL-AF9 expressing 
leukaemia cells, on cursory analysis by flow cytometry. Overexpression of Plag1 was able to phenocopy 
loss of Ezh2 in accelerating the induction of MLL-AF9 leukaemia. This significant result was further 
corroborated by the fact that the Plag1/MLL-AF9 combination resulted in a marked expansion of the 
cells over single MLL-AF9 expressing cells. The ability of a single gene to be able to augment and drive 
as aggressive a leukaemia programme as MLL-AF9 is remarkable. In its role as a transcription factor, it 
is possible that overexpression of Plag1 may be driving another transcriptional programme that 
synergizes with MLL-AF9 and facilitates transformation. PLAG1 regulates gene expression through DNA 
binding at promoters. The insulin like growth factor gene (IGF2) is known to contain multiple PLAG 
binding sites within its promoter. 17 The Cbfb-MYH11 and Plag1 study proposed the possibility that 
Plag1 may expand haematopoietic precursors through driving the Igf2 pathway and found that Igf2 
transcript levels in bone marrow cells overexpressing Plag1 were increased. Furthermore, loss of 
imprinting at the IGF2 locus resulting in overexpression of IGF2 has been described in AML cases. 18  
Though the genomic analysis provided evidence of its role as a downstream mediator of Ezh2 loss, the 
overexpression of Lin28b did not significantly accelerate MLL-AF9 driven disease. Whilst also being 
repeatedly identified as a potential co-operator with JAK2-V617F following Ezh2 loss in the MPN study, 
when functionally assayed in vivo, Lin28b did not produce a significantly synergistic effect - rather this 
was borne out by Hmga2, which Lin28b potentially exerts control over (through suppression of let-7 
microRNAs). 12 
 
Though speculative at present, it is not unreasonable to propose that there are multiple pathways 
through which Ezh2 loss in haematopoietic progenitors may facilitate transformation and drive the 
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MLL-AF9 leukaemia programme. Whilst the overexpression of Lin28b described above did not 
demonstrate a significant acceleration in MLL-AF9 disease induction, following Ezh2 loss, Lin28b was 
clearly the most upregulated gene in both the non-transformed setting and MLL-AF9 leukaemias from 
the gene expression datasets, suggesting it may still contribute. As discussed above, the Lin28b protein 
blocks normal maturation of inhibitory let-7 microRNAs. One of the downstream targets of the let-7 
miRNA suppressor family is the insulin-like growth factor binding protein Igf2bp3, and following Ezh2 
loss, this gene was also noted to be significantly upregulated in both the non-transformed and MLL-
AF9 induction leukaemias as described in Chapter 5.  IGF2BP3 is known to facilitate translation of an 
IGF2 transcript variant through direct binding to its 5’UTR sequence. 19  
The synergism between Ezh2 loss and MLL-AF9 is likely to be mediated by the concerted action of 
several genes and this data indicates that Plag1 is clearly one of these downstream targets. A possible 
sequence of events following loss of Ezh2 in haematopoietic progenitors might be that, firstly through 
direct chromatin effects, the upregulation of a number of genes including Plag1 and Lin28b occurs. 
Plag1 may then facilitate transformation potentially through an expansion of progenitors by driving 
the Igf2 pathway (as also proposed in the Cbfb-MYH11 study). The concurrent upregulation of Lin28b, 
whilst not driving MLL-AF9 leukaemia forwards directly on its own, may also facilitate the proposed 
Plag1-Igf2 pathway in a number of ways. Firstly, through directly increasing the expression of Plag1 as 
surprisingly noted in the qPCR assessments in Figure 6.3, and secondly through releasing let-7 
mediated suppression of Igf2bp3. (Interestingly, Ezh2 loss itself may also fuel the upregulation of 
Igf2bp3 as observed in our gene expression datasets, where there was an associated reduction in 
H3K27me3 at its promoter). As described, IGF2BP3 is known to increase the translation of IGF2 mRNA 
transcripts. For these reasons, a plausible common pathway between Plag1 and to a lesser extent 
Lin28b, following Ezh2 loss might be through the Igf2 pathway, promoting an environment conducive 
to MLL-AF9 mediated leukaemic transformation. A summary of these pathways is shown in Figure 6.8.  
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Though all of this is highly speculative, it would be interesting to examine some of these hypotheses 
further, potentially starting by assessing any functional changes induced in murine HSPCs following 
Plag1 overexpression and whether these were related to components of the Igf2 pathway. It would be 
interesting to assess and compare any differences in expression of Igf2 between MLL-AF9 and Plag1 + 
MLL-AF9 leukaemic tissues.  
Finally, whilst demonstrating that Plag1 is able to copy Ezh2 loss in synergizing with MLL-AF9 in 
accelerating leukaemogenesis, it would be important to assess (ideally in vivo) if it has the same 
capabilities in driving AML1-ETO9a leukaemogenesis, which canonically drives AML in a different 
fashion to MLL-AF9 through repression of multiple pathways. At the time of writing, an in vitro 
characterisation of this is being performed through retroviral transduction and overexpression of Plag1 
together with AML1-ETO9a versus AML1-ETO9a alone in c-kit+ HSPCs.  
FIGURE 6.8 Proposed molecular model of Ezh2 loss and downstream effects  
Ezh2 loss leads to direct upregulation of Plag1 and Lin28b through loss of H3K27me3 and 
an increase in H3K4me3 at their promoters. Lin28b overexpression negatively regulates 
maturation of the let-7 miRNA family, releasing let-7 inhibition on Igf2bp3 and on Plag1. 
Plag1 and Igf2bp3 co-operate to potentially drive the Igf2 axis through increased 
transcription and translation of Igf2 mRNA respectively 
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Chapter 7 
Pharmacological inhibition of EZH2 in the context of AML 
 
7.1  Aims 
This chapter details the preclinical in vitro activity of GSK343, an EZH2 inhibitor, and aims to answer 
the following: 
1. Is EZH2 a plausible therapeutic target (as informed by work in previous chapters) and does 
pharmacological inhibition with an EZH2 inhibitor have a role in AML? 
 
7.2 Introduction 
Abnormal regulation of chromatin modifiers is a common and recurrent theme in the pathogenesis of 
AML. As discussed above, recent studies have consolidated the significant number of epigenetic 
regulators that are mutated and potentially implicated as drivers of AML. 1,2 The plasticity and potential 
reversibility of chromatin modifications makes them tantalising targets for therapeutic intervention. 
EZH2 has histone methyltransferase activity through its catalytic SET domain, which is potentially 
druggable for therapeutic benefit. However, based on its contrasting roles in various malignancies (as 
detailed in Chapter 1) and the phase and subtype of disease as demonstrated in this thesis thus far, 
the context in which this is proposed is clearly of significant importance. In mice, Ezh2 is essential for 
normal foetal haematopoiesis with Ezh2 deficient murine embryos dying of severe anaemia.3 In the 
same study, Ezh2 deletion in adult murine bone marrow did not significantly compromise 
haematopoietic stem cell function, importantly highlighting its potential as a target in haematological 
disease without predicting disastrous toxicities for normal haematopoiesis. Following extensive 
preclinical work in the lymphoma arena, EZH2 has emerged as a potential therapeutic target in DLBCL 
and FL with gain-of-function EZH2 mutations4 and EZH2 inhibitors GSK126, EPZ-6438, and CPI-1205 
have been in Phase I Clinical trials for the past 2-3 years [NCT Trial numbers: NCT02082977, 
NCT01897571, NCT02395601 for compounds GSK2816126, EPZ-6438 and CPI-1205 respectively].  
In functional assessments of the role of Ezh2 in AML, we have identified markedly disparate outcomes 
following genetic loss of Ezh2 at various stages of leukaemia evolution. The finding and subsequent 
molecular characterisation of Ezh2 loss accelerating MLL-AF9 driven leukaemogenesis in vivo (and 
similar observations in AML1-ETO9a leukaemogenesis), raised concerns that EZH2 inhibition in AML 
may be an issue. However, upon assessment of Ezh2’s role in maintaining established AML in vivo (for 
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both the same models) we found the stark opposite – that genetic loss delayed leukaemia progression 
considerably. We were able to characterise this further mechanistically and demonstrate that a 
different transcriptional programme was being subverted in AML maintenance to that during 
induction, providing some reassurance that targeting EZH2 in established AML might be a viable 
option. Taking this forward, we aimed to assess sensitivity of murine and human AML cell lines as well 
as human AML primary samples to another EZH2 inhibitor, GSK343 to see if it was possible to further 
consolidate the hypothesis that EZH2 has an oncogenic role in the maintenance of AML.  
Through the specifications of an MTA between the Huntly laboratory and GlaxoSmithKline, the active 
small molecule inhibitor of EZH2, compound GSK343, and its inactive homolog GSK669 were provided. 
GSK343 is a specific inhibitor of the histone H3-lysine 27 (H3K27) methyltransferase EZH2. It inhibits 
EZH2 enzymatic activity with an IC50 of 4nM. 5 A schematic of its structure is shown in Figure 2.1 
(Methods 2.1.2). The compound displays 60 fold selectivity for EZH2 over EZH1, and 1000 fold or 
greater selectivity against other histone methyltransferases (Figure 7.1). EZH1 is highly homologous to 
EZH2 with 76% sequence identity overall and 96% sequence identity within the catalytic SET domain. 
The structural factors responsible for the selectivity over EZH1, and for the different levels of selectivity 
for EZH2 over EZH1, are presently unclear. GSK343 is available as a chemical probe as part of the 
Structural Genomics Consortium epigenetics initiative and commercially available through Sigma-
Aldrich.  
 
 
 
 
 
 
 
 
 
Its inactive homolog GSK669 was also provided to the Huntly laboratory and served as a control, 
demonstrating no efficacy or significant cellular toxicity. 
FIGURE 7.1  GSK343 displays marked selectivity for EZH2 over other histone 
methyltransferases (Adapted from GSK/SGC) 
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7.3 GSK343 demonstrates efficacy against human AML cell lines 
GSK343 was initially tested against a panel of human AML cell lines available in the Huntly lab (Table 
2.1, Methods 2.2.2.1). Of these, the Kasumi and KG1 cell lines exhibited sensitivity above the others. 
Unresponsive cell lines included K562, MV4-11 and U937 (which harbour the BCR-ABL, MLL-AF4 and 
CALM-AF10 translocations respectively). A titration of different concentrations was used (assessed 
concurrently with GSK669 as a control) to roughly determine what concentration could be used for 
further assessments (Figure 7.2): 
 
 
 
 
 
 
 
 
 
This established the 10µM concentration as an appropriate starting point for assessing sensitivity to 
GSK343. Kasumi and KG1 cells were then expanded in liquid culture over a 12-day time course (as 
described in Methods 2.3.1) in the presence of DMSO (vehicle control), GSK343 at 10µM and GSK669 
at 10µM (Figure 7.3): 
 
 
 
 
 
FIGURE 7.2  The KG1 cell line is most sensitive to GSK343 at 10µM following 6 days in liquid 
culture growth 
y-axis: Cell count is x106 
 
 
181 
 
0
5
10
15
20
25
30
35
40
D0 D3 D6 D9 D12
To
ta
l c
el
l c
ou
nt
 (1
06
)
KASUMI + DMSO
KASUMI + 343 (10uM)
KASUMI + 669 (10uM)
0
5
10
15
20
25
30
D0 D3 D6 D9 D12
To
ta
l c
el
l c
ou
nt
 (1
06
)
KG-1 + DMSO
KG-1 + 343 (10uM)
KG-1 + 669 (10uM)
 
 
   
  
 
 
 
  
   
 
  
 
 
 
 
 
This was highly interesting given the Kasumi cell line harbours the t(8;21) RUNX1-RUNX1T1 
translocation, and corroborated with the clear disruption we had seen following Ezh2 loss in the 
maintenance experiments (detailed in Chapter 4), where in vitro Ezh2 loss completely abolished 
established AML1-ETO9a driven immortalisation, and in vivo Ezh2 loss clearly led to the disruption of 
AML1-ETO9a leukaemia progression. This suggested that pharmacological inhibition of the AML-ETO 
programme was similar to genetic disruption of Ezh2 in the murine experiments.  
A colony formation assay utilising methylcellulose (as described in Methods 2.3.2) to assess clonogenic 
and proliferative potential of Kasumi and KG1 cells was then performed. Both cell lines exhibited 
sensitivity and reduced colony formation and cell proliferation in the presence of GSK343 at 10µM 
when total colony and cell number were assessed at weekly replatings (Figure 7.4, data shown for KG1 
as an example): 
 
 
Kasumi KG1 (a) (b) 
FIGURE 7.3  GSK343 at 10µM concentration markedly impedes liquid culture growth of AML 
cell lines (a) Kasumi, (b) KG1 
Total cell count measured across a 12-day period in the presence of DMSO (blue), GSK343 
(red) and GSK669 (green) 
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The results for the Kasumi cell line were similar. Both the liquid culture and colony formation assay 
experiments suggested that GSK343 has efficacy against the Kasumi and KG1 cell lines and the next 
step was to perform some functional assays to verify this.  
 
 
(a) (b) 
(c) 
DMSO GSK343 (10µM) 
FIGURE 7.4  GSK343 significantly reduces the clonogenic and proliferative potential of 
the KG1 cell line in a colony formation assay 
(a) Total colony numbers at weekly replatings for DMSO, GSK669 and GSK343 (at 
10µM) treatment. A significant reduction in colony numbers following GSK343 
treatment is seen (drugs added at the first round only). 104 cells plated each week 
(b) Total cell numbers at weekly replatings for DMSO, GSK669 and GSK343 (at 10µM) 
treatment. A significant reduction in colony numbers following GSK343 treatment 
is seen (drugs added at the first round only). 104 cells plated each week 
(c) Morphology of KG1 colonies treated with DMSO (control) left, and GSK343 (10µM) 
right (x10 magnification). Colonies are dense and well formed in DMSO, but barely 
present in GSK343 
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7.4 GSK343 treatment is accompanied by modest late apoptosis and G1 cell cycle arrest 
Upon staining, apoptotic cells are Annexin V positive and 7AAD negative. When the Kasumi cell line 
was treated with GSK343 in liquid culture, though modest, the maximal level of apoptosis (as assessed 
according to Methods 2.4.1) was consistently seen at 96 hours (with some initial degree noted as early 
as 72 hours, data not shown) as shown in Figure 7.5. The response was similar for KG1 (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
FIGURE 7.5  GSK343 treatment of the Kasumi cell line in liquid culture causes induction of 
apoptosis at 96 hours (over 4 replicates) 
(a) Flow cytometry analysis of DMSO, GSK343 and GSK669 treated cells at 96hrs post 
treatment. Live cells gated by forward and side-scatter, doublets removed and then 
gated for 7-AAD (y-axis) and Annexin FITC (x-axis) 
(b) Percentage of Kasumi cells undergoing apoptosis at 96hrs (DMSO vs GSK343).  
Average of 4 replicates 
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Cell cycle analysis was also performed and this demonstrated G1 cell cycle arrest for both cell lines, 
most prominent at 96hrs for the KG1 cell line (Figure 7.6). Similar G1 cell cycle arrest was seen at 96hrs 
with Kasumi cells (data not shown). The data suggested an antiproliferative effect on Kasumi/KG1 at 
72-96 hours post treatment, suggesting that any methylation related changes were occurring before 
this time point.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMSO 
GSK343 
GSK669 
48hr 24hr 72hr 96hr 
53.9% 
64.3% 
50.7% 
Propidium iodide 
FIGURE 7.6  GSK343 treatment of the KG1 cell line in liquid culture causes modest G1 cell 
cycle arrest and is most pronounced at 96 hours 
Flow cytometry analysis of DMSO, GSK343 and GSK669 treated cells at 96hrs post 
treatment. Live cells gated by forward and side-scatter, doublets removed and then 
assessed for total cell counts propidium iodide stain.  
Though modest, an increase consistent with G1 cell cycle arrest is seen at 96 hours following 
GSK343 treatment (highlighted). GSK343 decreases progression from G0/G1 to S and G2M 
phases. In GSK343 treated cells at 96 hours, 64.3% of cells are in G0/G1 phase compared to 
50.7-53.9% in GSK669 and DMSO treated conditions respectively.  
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7.5 GSK343 demonstrates efficacy at micromolar concentrations 
Through employing a cell proliferation assay (as described in Methods 2.3.3), the efficacy of GSK343 
against cell proliferation of Kasumi and KG1 was tested to determine the optimal concentration of 
GSK343 required to reduce proliferation by 50% (IC50). The results shown in Figure 7.7 suggest an IC50 
of 10-20µM for these two cell lines, corroborating the concentrations used previously:  
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FIGURE 7.7  GSK343 inhibits cell proliferation of (a) Kasumi and (b) KG1 cell lines at IC50’s 
of 17µM and 11.4µM respectively 
The [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] MTS compound was used to assay cell proliferation at 72 hours across a 
range of different GSK343 concentrations (from 100nM to 100µM, represented on a 
logarithmic scale, x-axis). The proliferation reduced in a sigmoid manner as the 
concentration of drug was increased. Each assay was repeated in triplicate.  
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7.6 H3K27 trimethylation is inhibited as early as 48 hours by GSK343 
Lysates of Kasumi cells treated with DMSO/GSK343 were prepared and processed for Western blotting 
as described in Methods 2.5. Figure 7.8 shows a time course of progressive H3K27me3 changes with 
EZH2 inhibition, with a noticeable reduction in H3K27me3 as early as 48hrs.  
 
 
 
 
 
 
 
 
 
By Day 6 (144hrs) both Kasumi and KG-1 (and NB4 to a lesser degree) show a considerable reduction 
in H3K27me3 as demonstrated in Figure 7.9: 
 
 
 
 
 
 
 
 
 
FIGURE 7.9  At 144hrs GSK343 treatment results in a significant reduction of H3K27me3 
in Kasumi, KG1 and NB4 human AML cell lines  
DMSO/GSK343/GSK669 against sensitive KG1, Kasumi, partially sensitive NB4 and 
resistant K562 AML cell lines, at 144 hours post treatment 
 
FIGURE 7.8  GSK343 treatment of the Kasumi cell line results in a reduction of 
H3K27me3 as early as 48 hours  
 Western blot showing decrease in H3K27me3 with GSK343 treatment compared 
to DMSO at 24hr, 48hr, 96hr and 144hr 
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As epigenetic modifications and their downstream effects tend to occur over several days, these 
findings of EZH2 inhibition leading to a decrease in H3K27me3 from 48 hours onwards in the sensitive 
AML cell lines were expected, and were compatible with the modest functional effects of apoptosis 
and cell cycle arrest that were demonstrated to occur at 96 hours and beyond.  
 
 
7.7 Transformed Ezh2fl/fl;wt murine cell lines exhibit sensitivity to GSK343 
 
The immortalised cell lines generated through transduction of Ezh2fl/fl;wt c-kit selected HSPCs with 
oncogenes MLL-AF9, AML1-ETO9a and MOZ-TIF2 (detailed in Chapter 4) were maintained in 
methycellulose replatings on a weekly basis. After a second transduction with a separate retroviral 
Cre-recombinase, the resulting Ezh2 deletion resulted in complete abolishment of clonogenic growth.   
To gauge whether pharmacological Ezh2 inhibition had any similar effect to genetic Ezh2 deletion in 
these cell lines, a clonogenic assay was performed using established Ezh2fl/fl;wt MLL-AF9 and 
Ezh2fl/fl;wt MOZ-TIF2 cells treated with either DMSO (control) or GSK343 (at 10µM). The assay was 
set up as described in Methods 2.3.2 seeding an initial 5x104 cells per millilitre of methylcellulose. 
GSK343 treatment resulted in a significant decrease in clonogenic growth assessed by total colony 
number and a marked decrease in colony size and density (Figure 7.10) in both murine cell lines. The 
effects were more marked in the MOZ-TIF2 cell line, with a dramatic reduction in colony size as 
demonstrated. Though not absolute, as was genetic deletion of Ezh2, this assay provided further 
evidence to suggest that pharmacological inhibition of Ezh2 was capable of exerting a negative effect 
on established leukaemia.  
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FIGURE 7.10 GSK343 significantly inhibits clonogenic growth of transformed murine  
(a) MLL-AF9 and (b) MOZ-TIF2 cell lines in vitro 
(a) LEFT: Immortalised Ezh2 fl/fl;wt MLL-AF9 cells exhibit reduced colony formation 
at 1 week in the presence of GSK343 (10µM) compared to DMSO control. (n=3) 
RIGHT: Reduction in colony size and density on GSK343 treatment (x20 
magnification) 
 
(b) LEFT: Immortalised Ezh2 fl/fl;wt MOZ-TIF2 cells exhibit reduced colony formation 
at 1 week in the presence of GSK343 (10µM) compared to DMSO control. (n=3) 
RIGHT: Reduction in colony size and density on GSK343 treatment (x20 
magnification) 
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7.8 Murine Ezh2fl/fl;wt MLLAF9 spleen tumours exhibit sensitivity to GSK343 when 
cultured in vitro 
 
Having established that the t(8;21) RUNX1-RUNX1T1 translocated Kasumi AML cell line (and KG1)  and 
murine transformed MLL-AF9 and MOZ-TIF2 cell lines were both exhibiting a degree of sensitivity to 
EZH2/Ezh2 inhibition with GSK343 at the same concentration, it was important to assess whether 
murine leukaemic tissues generated in vivo were also affected by Ezh2 inhibition. Genetic deletion of 
Ezh2 in established Ezh2 conditional MLL-AF9 and AML1-ETO9a leukaemias in vivo had demonstrated 
a disruption in leukaemia progression in the transplantation assay described in the maintenance 
experiments (Chapter 4). We speculated that pharmacological inhibition of Ezh2 through GSK343 
treatment of these tumours (in the absence of any Ezh2 deletion) would also cause impaired growth 
and proliferation.  
To assay this, the splenic tumour tissues from two Ezh2fl/fl; wt MLL-AF9 leukaemia (also referred to as 
Ezh2+/+ MLL-AF9 tumours) were placed into liquid culture in sterile conditions and expanded as 
described in Methods 2.2.2. Two tumours of the same genotype were used to provide biological 
replicates. Both behaved aggressively in liquid culture, expanding rapidly and requiring passage 
frequently, showing no signs of exhaustion or morphological differentiation. To establish whether 
these tumours were sensitive to GSK343, an initial titration of varying concentrations (from 5uM to 
250uM) was carried out. Equal numbers of cells from both tumours were cultured in the presence of 
DMSO or GSK343 at concentrations of 5µM, 10µM, 50µM, 100µM and 250µM for 24 hours and total 
cell numbers were established at the end of this period. Both tumours (henceforth #5340 and #5342) 
were inhibited considerably from concentrations of 10µM and upward (data not shown).  
Having established this as a starting point, a more precise assessment utilising the cell proliferation [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] MTS assay 
was performed for each tumour (Figure 7.11): 
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FIGURE 7.11 IC50 assay demonstrating that GSK343 inhibits proliferation of two murine 
Ezh2+/+ MLL-AF9 tumours (a) #5340 and (b) #5342 cultured in vitro with IC50’s 
of approximately 10µM 
The [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] MTS compound was used to assay cell proliferation of Ezh2+/+ MLLAF9 
spleen leukaemia cells cultured in vitro at 72 hours across a range of different GSK343 
concentrations (from 5µM to 500µM, represented on a logarithmic scale, x-axis).  
The proliferation reduced in a sigmoid manner as the concentration of drug was 
increased. Each assay was repeated in triplicate 
(a) 
(b) 
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Strikingly, both tumours #5340 and #5342 were inhibited at 9.2µM and 9.6µM respectively – 
approximate to the 10µM concentration that the AML cell lines and transformed murine cell lines 
exhibited sensitivity at.  
To test this further, colony forming assays in methylcellulose were performed (as per Methods 2.3.2). 
Cells from both tumours #5340 and #5342 were taken from liquid culture into methylcellulose treated 
with either DMSO (control) or GSK343 at 10µM. At Day 7, the total number of colonies produced in 
each condition for each tumour was assessed, along with a record of colony morphology. Both tumours 
exhibited a significant reduction in colony formation and size with GSK343 treatment compared to 
DMSO (Figure 7.12, representative data shown for tumour #5340): 
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FIGURE 7.12 GSK343 significantly inhibits clonogenic growth of murine Ezh2+/+ MLL-AF9 
spleen tumour in vitro 
(a) The total number of colonies formed following treatment with GSK343 at 10µM 
is significantly reduced compared to DMSO treatment at Day 7 in methylcellulose 
colony forming assay (data is normalised to total colonies produced in DMSO), 
performed in triplicate 
(b) Reduction in colony size and density on GSK343 treatment (x20 magnification) 
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7.9 Murine Ezh2fl/fl;wt MLLAF9 spleen tumours demonstrate loss of H3K27me3 as early 
as 24 hours post GSK343 treatment 
 
In order to further characterise the sensitivity of these murine Ezh2+/+ MLL-AF9 tumours (#5340 and 
#5342) to GSK343 and to assess whether it was due direct inhibition of Ezh2 enzymatic function, an 
assessment of changes in H3K27me3 following GSK343 treatment of each tumour in liquid culture was 
made using flow cytometry. Briefly, both tumours were maintained in liquid culture in sterile 
conditions in the presence of either DMSO or GSK343 at 10µM. At 24, 48 and 72 hours, cells were 
harvested from each condition for fixation and permeabilization. Following permeabilization, each 
condition (DMSO or GSK343 from each tumour #5340 and #5342) was divided into two further 
conditions and stained for H3K27me3 or total histone H3 (control) using fluorochrome conjugated 
antibodies (as described in Methods 2.4.2 and 2.4.2.1). As early as 24 hours, there was a near total loss 
of H3K27me3 with no changes in total histone H3 (a representative example is shown in Figure 7.13): 
 
 
 
 
 
 
 
 
 
 
 
 
 
H3K27me3 Total H3 
24hrs GSK343 treatment of  
Ezh2+/+ MLL-AF9 spleen tumour in vitro 
DMSO 
GSK343 
FIGURE 7.13 GSK343 significantly reduces H3K27me3 in Ezh2+/+ MLL-AF9 spleen tumour 
in vitro as early as 24 hours (tumour #5340) 
 Histogram representing changes in H3K27me3 with GSK343 treatment 
LEFT: Total H3K27me3 (detected on 640 670/14 channel) – Following GSK343 
treatment (blue) a near total loss is seen compared to DMSO treatment (red) 
RIGHT: Total histone H3 (control, detected on 405 450/50 channel) – no changes seen 
between DMSO (red) and GSK343 (blue) treatment 
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This reduction in H3K27me3 demonstrated GSK343 cellular inhibition correlated with and appeared to 
be functioning through direct inhibition of Ezh2 catalytic function. Both MLL-AF9 tumours exhibited 
marked sensitivity to the inhibitor, having a significant reduction in total cell number within 24 hours 
when treated with GSK343 as already described. Therefore, it was not surprising to see that the 
reduction in H3K27me3 was taking place as early as 24 hours post treatment, though it was earlier 
than that seen in the Kasumi cell line where H3K27me3 reduction occurred from 48 hours and beyond. 
This demonstrated that the murine leukaemias were even more sensitive to GSK343 than the human 
AML cell lines or that the flow cytometric assay was more sensitive to levels of H3K27me3.  
As described in Chapter 5, having established that this sensitivity at 24 hours was possibly secondary 
to an active reduction in H3K27me3, it was felt that any resultant gene expression changes would 
become apparent as early as this time point. Therefore, RNA was harvested from both tumours treated 
with DMSO and GSK343 at 24 hours and sent for RNA-sequencing to analyse which transcriptional 
programmes or tumour suppressive genes were potentially being de-repressed through this 
pharmacological Ezh2 inhibition and H3K27me3 loss, to account for this marked sensitivity.   
It would be useful to adopt the same technical approach and test Ezh2+/+ AML1-ETO9a murine tumour 
cells in the same way to corroborate the same level of sensitivity and loss of H3K27me3 and this work 
is being planned. 
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7.10 Clonogenic growth of AML patient samples is inhibited by GSK343 treatment  
 
GSK343 was tested against primary AML samples collected by the Huntly lab (Methods 2.2.3). 80,000 
mononuclear cells were plated in duplicate in methylcellulose containing appropriate human cytokines 
plus either DMSO or GSK343 (10µM) and incubated for 7-10 days, following which colony numbers 
were counted (Methods 2.3.2). Colony numbers in GSK343 treated samples were normalised to paired 
DMSO samples. Despite being a relatively small sample size (n=14), there was a significant reduction 
in average colony numbers when treated with GSK343 compared to DMSO (Figure 7.14): 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the brittle nature of colonies (even when supported in methylcellulose specifically optimised 
to support human HSPCs) formed from mononuclear cells isolated from whole blood or bone marrow 
of newly diagnosed AML patients, it was only possible to assess this effect at 7-10 days post seeding – 
multiple weekly replatings were not possible. The 14 cases that this assay was performed against were 
unselected, in order to contain a range of ages and variety of karyotypes across both sexes (Table 7.1): 
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FIGURE 7.14 GSK343 significantly inhibits clonogenic growth of primary human AML 
samples in vitro 
Colonies counted D7-10 after seeding 80,000 cells/ml in methylcellulose.  
The total number of colonies formed following treatment with GSK343 at 10µM is 
significantly reduced compared to DMSO treatment at Day 7 in methylcellulose colony 
forming assay (data is normalised to total colonies produced in DMSO), performed in 
duplicate for each sample (n=14). 
  An average reduction in colony production of ~75% is seen in GSK343 treated samples 
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TABLE 7.1 Primary AML samples treated with GSK343 - patient characteristics  
Sex, age and karyotype or cytogenetic abnormality associated with each case is 
detailed. ‘N/A’ indicates samples where karyotyping failed. 
Clonogenic assay results for these patient samples is shown in Figure 7.12 
 
 
 
196 
 
Interestingly, Patient 14 had the MLL-AF9 translocation detected on cytogenetic testing and its colony 
formation assay showed an approximately four-fold reduction in colony numbers when treated with 
GSK343 compared to DMSO. This was in keeping with the sensitivity we had seen of the murine MLL-
AF9 tumours to GSK343. Examples of reduction in colony size seen in primary AML samples following 
GSK343 are shown in Figure 7.15: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMSO GSK-343 
FIGURE 7.15 Marked reduction in colony size and density seen in the when unselected 
primary human AML samples are treated with GSK343 in colony formation 
assay (compared to DMSO) 
 x20 magnification. 3 patient samples shown 
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7.11 GSK343 does not significantly eliminate colony formation by normal CD34+ control 
cells 
 
Although other EZH2 inhibitors are now in Phase I clinical trials, we wanted to assess whether the 
effect of EZH2 inhibition by GSK343 was leukaemia specific as opposed to secondary to general toxicity 
to primary haematopoietic cells in vitro. Primary human CD34+ cells were used as a control. These 
were harvested through GCSF-stimulated apheresis from patients with non-Hodgkin’s 
lymphoma/myeloma in clinical remission prior to autologous stem cell transplantation (with consent 
as per Methods 2.2.3). Following harvesting these samples were subjected to magnetic bead 
separation to further purify and obtain in the order of >90% pure CD34+ cells. These purified CD34+ 
samples were already present in the Huntly lab and were used, amongst other things, to assess 
haematopoietic toxicity to novel inhibitor compounds.  
An assessment of toxicity secondary to GSK343 was made at 10µM and 20µM. Though a very small 
sample size (n=2), the results suggest that at 10µM no significant toxicity is present, though 
considerable toxicity is seen at 20µM (Figure 7.16): 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.16 GSK343 at 10µM does not exhibit a significant effect on normal CD34+ cells 
GSK343 versus normal CD34+ HSPCs, results normalised to GSK669 colony numbers. 
Colonies counted D7-10 after seeding 50,000 cells/plate in methylcellulose 
At 10µM, GSK343 treatment does not significantly reduced colony growth in the first and 
second round of replating. 
** = p-value indicates no significance between GSK669 and GSK343 at 10µM 
Error bars represent the SEM. (n=2 samples) 
 
 
 
** ** 
GSK669 10µM 
GSK343 10µM 
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7.11 Discussion and future work 
These data demonstrate that GSK343 appears to have a wide range of efficacy against some human 
AML cell lines, but a larger number of murine cell lines immortalised with AML driver oncogenes, 
murine MLL-AF9 leukaemias cultured in vitro and, most importantly, unselected primary AML samples. 
Having demonstrated that loss of Ezh2 was capable of accelerating AML1-ETO9a and MLL-AF9 
leukaemogenesis in vivo we felt there were valid concerns about the use of EZH2 inhibitors in AML. 
However we were greatly reassured by our genetic data that Ezh2 loss antagonised the maintenance 
of the same leukaemias in vivo. We used this as a surrogate to postulate that EZH2/Ezh2 
pharmacological inhibition with GSK343 would be efficacious and inhibitory toward leukaemic cell 
line/tumour growth and expansion in vitro.  
We were able to formally demonstrate that GSK343 caused effective inhibition of expansion of the 
Kasumi and KG1 cell lines, with the effect on the former being very interesting given it is driven by the 
AML-ETO RUNX1-RUNX1T1 translocation. This corroborated our demonstration that genetic Ezh2 loss 
was inhibitory to AML1-ETO9a transformed cells in vitro and AML1-ETO9a driven secondary 
leukaemias in vivo. At no point did we see an acceleration or augmentation of cellular growth and 
expansion in the Kasumi cell line when treated with GSK343. We were able to demonstrate that 
GSK343 was causing a clear reduction in total H3K27me3 in the Kasumi (and KG1/NB4) cell line. This 
again demonstrated the oncogenic effect that EZH2 was likely exerting in the maintenance of this AML-
ETO driven cell line, further strengthening our argument that intrinsic EZH2 expression (through the 
maintenance of the repressive H3K27me3 mark) likely has negative influence over a different and 
presumably tumour-suppressive transcriptional programme in the maintenance of AML. 
Importantly, Ezh2fl/fl;wt MLL-AF9 (and MOZ-TIF2) transformed murine cell lines exhibited marked 
sensitivity to GSK343, exhibiting a clear reduction in clonogenic potential, and two Ezh2+/+; MLL-AF9 
murine primary leukaemias whose spleen tumour tissues were cultured in vitro demonstrated a 
distinct sensitivity to GSK343 at a consistent 10µM concentration. We were able to demonstrate the 
reduction in clonogenic potential, liquid culture expansion as early as 24 hours and that this appeared 
to be secondary to a near total loss of H3K27me3 as early as 24 hours following GSK343 treatment. 
This suggested that GSK343 was exerting its effects through direct epigenetic changes, making a formal 
assessment of differentially regulated genes in the MLL-AF9 leukaemias following Ezh2 inhibition 
possible (Chapter 5). As well as doing this, it provided insight and corroborated our demonstration that 
genetic Ezh2 loss in established MLL-AF9 leukaemias delayed their progression in vivo. Once again 
there was no indication that Ezh2 inhibition had any positive effect on the expansion of these MLL-AF9 
transformed murine cell lines and tumours in vitro. 
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Pharmacological inhibition of Ezh2 therefore appears pre-clinically effective in AML-ETO and MLL-AF9 
driven leukaemias, albeit that we have not demonstrated this in vivo. It is remarkable to see that 
EZH2/Ezh2 appears to be exerting an oncogenic function in the maintenance of two very different 
subtypes of AML. MLL-AF9 is a very aggressive leukaemia model in vitro and in vivo that transforms 
through the activation of genetic programmes and in humans the translocation is associated with an 
intermediate-poor prognosis. In contrast the AML1-ETO9a is a less aggressive leukaemia model both 
in vitro and in vivo that is described to function through the repression of genetic programmes. 
Additionally, its translocation in human AML is associated with a good prognosis. Why two such 
disparate drivers of AML, acting through differing programmes, behave in the same way following 
genetic or pharmacological targeting of Ezh2/EZH2 is of considerable interest and warrants further 
characterisation. A starting point would be the comparison of differential gene changes following 
pharmacological Ezh2 inhibition of the MLL-AF9 murine leukaemias in vitro (already performed) and 
that of AML1-ETO9a murine leukaemias similarly cultured and treated in vitro (not yet performed), 
which we suggest would provide further mechanistic insights into this sensitivity. Additionally, in the 
genetic and pharmacological experiments of in vitro MOZ-TIF2 maintenance and in vitro MOZ-TIF2 
immortalised cells maintenance respectively, Ezh2 deletion / Ezh2 inhibition clearly antagonised the 
maintenance of the leukaemia. Though clinically less common, the MOZ-TIF2 leukaemia programme is 
also an aggressive one, associated with poor prognosis and acts, as MLL-AF9, through the activation of 
genes.  
Taken together, these results demonstrate that, in the maintenance phase of disease for a wide range 
of AML, targeting Ezh2/EZH2 is a viable therapeutic option.  
When this assessment was extrapolated to primary human AML samples in vitro, we saw a pronounced 
inhibitory effect on clonogenic potential across a wide variety of AML samples that appeared 
independent of sex, age and cytogenetic abnormality. Once again, following EZH2 inhibition, at no 
point did we see any augmentation of clonogenic or proliferative ability across any of these primary 
samples. Though this cohort did not include any t(8;21) RUNX1-RUNX1T1 or inv(8)(p11q13) MOZ-TIF2 
translocated samples, it did include a primary sample from a patient with MLL-AF9 translocation, which 
exhibited marked sensitivity to GSK343. It would be useful to expand this further using more AML 
samples especially ones from patients with the aforementioned translocations (currently ongoing at 
time of writing). Additionally, we saw only low levels of toxicity from GSK343 to normal haematopoietic 
cells, though this was in a very limited number and ideally requires further work in more normal CD34+ 
samples to consolidate this. 
 
200 
 
Taken together all this data, as discussed above, provides preclinical evidence that EZH2 inhibition in 
established human AML (i.e. the maintenance phase of the disease) is a plausible therapeutic option 
and should be free of concerns that disease may be accelerated as the latter occurs in a different and 
independent phase (induction) of disease.  
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Chapter 8 
Summary and conclusions 
 
The unifying theme of the work detailed in this thesis is the multifaceted, heavily context-dependent 
role that EZH2, a key epigenetic regulator, plays in acute myeloid leukaemia.  
The dysregulation of epigenetic mechanisms across AML is a widely-recognised feature and as more 
detailed functional and genomic analyses are being performed to better characterise these, the 
greater the potential for further classifying disease and developing novel therapies to treat this 
aggressive cancer will become.  The molecular processes that govern haematopoiesis are controlled 
by lineage-specific transcription factors which are, in turn, regulated by and contribute to a higher level 
of epigenetic control. Through direct surveillance and modification of chromatin, epigenetic readers, 
writers and erasers are able to control changes in chromatin structure and gene transcription. 
Mutations in histone modifiers are increasingly implicated in haematological malignancies, especially 
across AML, and examining these closely at the molecular level allows for a better understanding of 
how epigenetic dysregulation may be targeted for therapeutic benefit.  
In this thesis, data addressing the role of EZH2 in various phases of AML evolution with perturbations 
performed both genetically and pharmacologically, have been presented. Through the use of three 
markedly different AML driver oncogenes, via retroviral transduction/overexpression and bone 
marrow transplantation assays on the backdrop of a conditional Ezh2 knock-out murine model, it was 
possible to clearly demonstrate that Ezh2 has entirely opposite roles dependent upon subtype and 
phase of disease. The purposeful use of three separate models of AML, clinically associated with a 
range from good and intermediate to poor prognosis, each with markedly different mechanisms of 
leukaemic transformation, allowed for a better experimental representation of the considerable 
heterogeneity seen at the cytogenetic and molecular level within human AML. Moreover, the 
characterisation of Ezh2’s role in the early stages of leukaemogenesis – a critical period of disease 
development - provided a better understanding of specific transcriptional programmes that were 
being de-repressed in its absence and contributing to the significant alterations in disease outcome. 
By thoroughly examining this and then contrasting to its function in AML maintenance – the 
therapeutically significant phase of disease – an additional layer of understanding into the complexities 
of how this transcriptional repressor exerts a variety of effects was provided.  
In Chapter 3 it was demonstrated that whilst not providing any strong influence in vitro, Ezh2 loss led 
to unexpected and varying outcomes in the induction of leukaemia in vivo across three subtypes of 
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AML. Whilst attaining a significant 50% increase in median survival in the MOZ-TIF2 experiment, Ezh2 
loss served to considerably accelerate the functionally repressive and less aggressive AML1-ETO9a 
leukaemia programme and accelerate the considerably more aggressive, short-latency MLL-AF9 
leukaemia programme in vivo. How the manipulation of one gene is able to induce such disparate 
outcomes between three heterogenous subtypes of AML in vivo, serves to portray how remarkably 
complex this epigenetic modifier is. Whilst not examined further in this thesis, due to focusing on the 
concern that Ezh2 loss clearly accelerated the induction of the more clinically relevant MLL-AF9 and 
AML1-ETO9a leukaemias, the observation that following Ezh2 loss dramatic slowing of MOZ-TIF2 
leukaemogenesis (whose mechanisms of transformation are felt to be similar in some ways to MLL-
AF9) was also important, suggesting it has an oncogenic role within this subtype, but a tumour-
suppressive role within the other two, during the same phase of disease. This clearly warrants further 
investigation, perhaps with the starting point of assessing changes in gene expression in these 
induction MOZ-TIF2 leukaemias and comparing with the non-transformed, MLL-AF9 and AML1-ETO9a 
gene changes. The hypothesis would be (as per the maintenance experiments) that the continued 
presence of Ezh2 is required for efficient transformation by MOZ-TIF2.  
The recent recognition of mutations of epigenetic regulators, including chromatin modifiers such as 
EZH2, as being associated more exclusively with the t(8;21) RUNX1-RUNX1T1 translocated subset of 
core-binding factor leukaemias, suggests a plausible co-operative and mechanistic link between the 
two, as it did in the AML1-ETO9a induction experiment. It would be important to examine larger AML 
datasets for the co-occurrence of EZH2 mutations in t(8;21) mutated cases, and ideally, an assessment 
of variant allelic frequencies to inform regarding order of mutation. Additionally, a comparison of 
differences in survival outcomes of EZH2 mutated versus EZH2 wild-type cases and the same 
assessment specifically within AML1-ETO rearranged cases (to determine if EZH2 status alters 
outcomes) would be highly interesting. The suggestion from the in vivo work was clearly that Ezh2 loss 
was a co-operative event in AML1-ETO9a murine leukaemogenesis and adds weight towards 
speculation that EZH2 mutation in t(8;21) translocated human leukaemias may occur preceding or at 
the time of transformation. The tumour suppressive effect of Ezh2 in the induction of JAK2-V617F 
driven MPN has been well characterised recently (with some of its downstream mediators), and its 
loss led to a synergism with JAK2-V617F in accelerating disease development, supporting the data in 
this thesis that Ezh2 has a tumour suppressive role in myeloid malignancy, perhaps more so in its 
development than its maintenance or progression.  
Ezh2 loss in established, immortalised murine haematopoietic cell lines for all three driver oncogenes 
assessed in the induction experiments, led to a complete abolishment of growth in vitro. The possibility 
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that this impressive outcome was secondary to Cre-recombinase toxicity was subsequently excluded. 
In vivo experiments assessing loss of Ezh2 during the maintenance of AML, whilst showing no 
significant effect on secondary MOZ-TIF2 leukaemia progression, demonstrated a clear increase in 
survival for both AML1-ETO9a and MLL-AF9 secondary leukaemias. This suggested Ezh2 was exhibiting 
an oncogenic role in AML maintenance, facilitating the transformed state, through potentially 
repressing tumour-suppressive elements via its role as a transcriptional repressor. This was backed up 
by preceding studies that had demonstrated similar findings in the maintenance of MLL-AF9 driven 
AML in mice. Additionally, in demonstrating Ezh2 had oncogenic function in AML maintenance, further 
evidence for pursuing EZH2 as a therapeutic target in AML was provided, leading to functional 
experiments with an EZH2 inhibitor to assess efficacy against murine and human AML cell lines, murine 
leukaemias and primary AML samples. Importantly, the outcomes in the maintenance experiments 
were in stark contrast to its apparent tumour-suppressive function in the same two AML subtypes 
during leukaemogenesis. The realisation that one gene was able to have such pronounced and 
opposing effects at two different phases of the same two subtypes of disease was an incredibly 
interesting one and prompted a detailed genomic analysis to explain this ‘Jekyll and Hyde’ behaviour.  
Initially focusing on the tumour suppressive nature of Ezh2, with its loss facilitating progression from 
the normal state to overt AML1-ETO9a or MLL-AF9 leukaemia, a characterisation of differential gene 
expression changes before and following Ezh2 loss in the normal state was made. Consistent with its 
role as a transcriptional repressor, deletion of Ezh2 in normal HSPCs led to the upregulation of 
significantly more genes than those downregulated (in the order of 9:1). When gene expression 
changes between both Ezh2+/+ and Ezh2-/- AML1-ETO9a and MLL-AF9 leukaemias were characterised in 
the same way, a similar though less pronounced shift in balance towards de-repressed genes was 
revealed, suggesting in the transformed state, the effects of Ezh2 loss were being diluted and 
overridden by the leukaemia programmes themselves. This change was least marked in the 
differentially expressed genes for the MLL-AF9 leukaemias, where the balance between upregulated 
and downregulated genes was close to 1.5:1, perhaps reflecting the more aggressive nature of this 
disease or the effects of an activating oncogenic programme. Given these changes appear to vary 
depending upon the oncogene, it would be interesting to examine changes in binding patterns of each 
of these in the context of Ezh2 loss or reduced H3K27me3. Nonetheless, a number of potential 
oncogenic candidate drivers of disease presented themselves when the upregulated genes for all three 
cohorts were overlapped. LIN28B, a well-documented candidate known to repress the let-7 microRNA 
tumour-suppressor family, with a clear correlation to poor prognosis and outcomes across a range of 
malignancies was highlighted in these gene expression datasets. It was the gene with the highest 
ranked log2fold change between the normal and MLL-AF9 leukaemia states. The recent documentation 
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of Lin28b and its potential downstream regulators, including Hmga2, Igf2bp3 as oncogenic facilitators 
of Ezh2 loss in collaborating with JAK2-V617F mediated MPN further served to fuel interest in exploring 
this candidate. Whilst not quite as highly upregulated as Lin28b, this overlapping analysis also revealed 
Plag1 as another plausible oncogenic mediator of Ezh2 loss. Plag1 is a zinc-finger transcription factor 
that has been implicated as a collaborator in the pathogenesis of Cbfb-MYH11 translocated murine 
AML in vivo – the equivalent of the inv(16) CBFβ-MYH11 core-binding factor leukaemias in human AML. 
PLAG1 has been documented as being associated with a number of other benign tumours and has 
been demonstrated to have increased levels of expression across AML subtypes. In these analyses, 
Plag1 stood out (from a limited group of six genes) as being the most likely potential oncogene 
mediator de-repressed upon Ezh2 loss and was commonly upregulated in all three groups – non-
transformed, AML1-ETO9a and MLL-AF9.  
Mechanistically, further genomic analyses informed the potential regulation of these genes by Ezh2. 
Through characterising global changes in H3K27me3 following Ezh2 deletion utilising ChIP-sequencing 
in the normal non-transformed state, it was possible to identify genes that were being directly 
upregulated as a result of loss of Ezh2 enzymatic activity. Approximately 20% of all genes upregulated 
were associated with a reduction in H3K27me3, suggesting alternative unexplored and potentially 
indirect mechanisms by which the remaining 80% were being upregulated. However, within this 
smaller subset again were Lin28b, Plag1 and Igf2bp3 amongst others. Characterisation of changes in 
the H3K27Ac activating mark, generally present at enhancer regions, did not reveal any significant 
insights into the upregulation of these genes. However, genome wide analysis of the H3K4me3 
activating mark, associated primarily with promoter regions, revealed a significant proportion of the 
subset of genes upregulated after Ezh2 loss AND which demonstrated a loss of H3K27me3 at their 
promoter, also demonstrated the presence of H3K4me3 at their promoter – suggesting these were 
bivalent domains – held in a poised transcriptional state by two conflicting histone marks, and that 
Ezh2 loss was shifting the balance in favour of gene activation at least through loss of H3K27me3. 
When probed further however, it became apparent that Ezh2 loss was also causing a significant 
upregulation of H3K4me3 at these bivalent domains for some, but not all of this subset of genes – 
including the promoters of Lin28b and Plag1. This surprising finding, that changes in H3K27me3 
resulting directly from alterations in the enzyme responsible for its deposition were also capable of 
either directly or indirectly modulating H3K4me3 was highly interesting, and warrants further work to 
determine what is unique about these particular genes and how Ezh2 loss might mechanistically lead 
to an upregulation of H3K4me3 at their promoters. A recent study assessing the UTX protein, which 
functions as a histone demethylase for H3K27me3 (the opposite function to EZH2), has shown that its 
loss, although in the different context of variant natural killer cells, results in increased H3K27me3 and 
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the downregulation of H3K4me3 again at particular subsets of genes, corresponding to the 
downregulation of those genes. This suggests that changes in H3K4me3 status are being directly 
regulated in some way by fluxes in H3K27me3. The complex interplay or ‘cross-talk’ between these 
conflicting histone marks and the enzymes controlling their deposition and removal is highly 
interesting, even in the normal state, and unravelling this might further inform how Ezh2 loss fosters 
an epigenetic state that is co-operative for AML transformation. Analysing changes in H3K27me3 and 
H3K4me3 in the Ezh2+/+ and Ezh2-/- AML1-ETO9a and MLL-AF9 leukaemias and comparing with that in 
the normal state would be a starting point.  
Having identified plausible downstream effectors of Ezh2 loss and building a strong case that either or 
both of these were potentially facilitating leukaemogenesis, it was then imperative to functionally 
validate them in vivo. Through cloning, both Lin28b and Plag1 were inserted into the murine stem cell 
virus (MSCV) retroviral construct under the control of the IRES promoter, and therefore could be 
overexpressed upon retroviral transduction. Whilst potentially contributing to both AML1-ETO9a and 
MLL-AF9 leukaemogenesis, it was decided that they would be functionally validated in the MLL-AF9 
setting, given the shorter latency of wild-type MLL-AF9 disease in vivo. Through co-expression of 
Lin28b or Plag1 with MLL-AF9 using the same retroviral transduction / overexpression and bone 
marrow transplantation assays used in the preceding Ezh2 induction and maintenance experiments, it 
was possible to address the question of whether either of these oncogenes would accelerate MLL-AF9 
leukaemogenesis in vivo. Whilst ectopic expression of Lin28b failed to accelerate MLL-AF9 compared 
to the wild-type arm (even though there was an early trend that it was doing so), strikingly, 
overexpression of Plag1 in concert with MLL-AF9 led to a dramatic increase in the rate of leukaemia 
development, with an almost 30% reduction in median survival, without obviously altering phenotype 
(currently being analysed at time of writing). The fact that overexpression of a single gene, amongst 
the potent milieu of transcriptional changes driven by such an aggressive leukaemia programme, was 
able to exert its effect enough to phenocopy Ezh2 loss and significantly alter survival outcome, was 
extremely striking. Speculation as to how these two might collaborate to induce AML faster potentially 
implicates the IGF2 pathway – a known target of PLAG1, though requires further studies to confirm 
this hypothesis. Though Lin28b overexpression alone was unable to phenocopy Ezh2 loss, given its 
profound upregulation in both normal and MLL-AF9 settings after Ezh2 deletion and the fact that it in 
turn influences the upregulation of a number of potential oncogenic candidates (surprisingly including 
Plag1 itself, from the qPCR analysis following Lin28b transduction), it remains likely to play a role. The 
synergism between Ezh2 loss and MLL-AF9 or AML1-ETO9a likely results from the concerted action of 
several genes that are altered in their expression, with this data indicating, for MLL-AF9 at least, that 
Plag1 is one of these downstream targets. Further work is required to assess if overexpression of Plag1 
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is capable of augmenting AML1-ETO9a leukaemogenesis as well as MLL-AF9, ideally in vivo, though 
given the long latency of wild-type disease, it would be more feasible to initially attempt this in vitro - 
and therefore this is being done at the time of writing. If borne out across both leukaemia subtypes, 
given their significant differences in mode of leukaemia induction, this Ezh2-Plag1 axis has the 
potential to be examined in other AML models.  
To explain the disparity in roles between induction and maintenance of MLL-AF9 leukaemias, a 
comparison of differential gene expression, following Ezh2 pharmacological inhibition in established 
murine MLL-AF9 spleen tumours cultured in vitro, was made to the induction differential gene 
expression dataset. MLL-AF9 spleen tumours were markedly sensitive to the EZH2 inhibitor in vitro and 
this was associated with a significant downregulation of H3K27me3 (as seen in the genetic 
experiments). Given the opposite outcomes seen in either phase of disease, the prediction was that 
Ezh2 was exerting control over different, and likely mutually exclusive, transcriptional programmes. 
Analysis of RNA-sequencing data in this scenario demonstrated differential regulation of a narrower 
set of genes than in induction, and that again more genes were upregulated than downregulated 
following Ezh2 inhibition. Despite this, comparing this dataset to genes upregulated following Ezh2 loss 
in induction of MLL-AF9 leukaemias revealed virtually no overlap, strongly suggesting that the 
opposing effects of Ezh2 loss or inhibition in either scenario could be explained by the fact that Ezh2 
loss was resulting in the de-repression of a completely different gene expression set in either context. 
This demonstration provided reassurances that inhibition of EZH2 in the context of established AML – 
which is therapeutically more relevant –  was unlikely to be associated with adverse effects on 
leukaemia progression. It should be noted however, that these two experimental conditions cannot 
be fully compared, in that they represent Ezh2 perturbation in the context of different cellular states 
with one utilising full genetic ablation (induction), whilst the other utilises reversible chemical inhibiton 
(maintenance). 
To address the question of whether EZH2 might be a valid target in AML, experiments designed to 
preclinically test the EZH2 inhibitor GSK343 further were performed. Both the Kasumi and KG1 human 
AML cell lines exhibited sensitivity to GSK343 in liquid culture growth and demonstrated reduced 
clonogenic and proliferative potential in colony formation assays in the presence of drug. Further 
analysis revealed that in both cell lines, GSK343 treatment resulted in a modest increase in apoptosis, 
as late as 96 hours post treatment, and that there was a mild induction of G1 cell cycle arrest at around 
the same time point. The sensitivity displayed by the Kasumi cell line to GSK343 was of particular 
interest, given it harbours the t(8;21) RUNX1-RUNX1T1 translocation – equivalent to the AML1-ETO9a 
translocation oncogene employed in the murine experiments that demonstrated a clear sensitivity to 
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Ezh2 loss both in vitro and in vivo. Having established a link between the murine equivalent and human 
t(8;21) sensitivities to Ezh2 loss/EZH2 inhibition respectively, this fortified the idea that, whilst 
detrimental in the leukaemogenesis/induction pathway, EZH2 inhibition may play a role in established 
t(8;21) translocated leukaemias.  
Ezh2 inhibition with GSK343 appeared to have similar inhibitory effects on established immortalised 
MLL-AF9 and MOZ-TIF2 murine cell lines in vitro, and when taken further by assessing this efficacy on 
in vivo generated MLL-AF9 leukaemias whose spleen tumours were cultured in vitro, once again a clear 
sensitivity to Ezh2 inhibition was demonstrated. GSK343 reduced expansion of these tumours in liquid 
culture, decreased clonogenic and proliferative potential, and was associated with a clear loss of 
H3K27me3 at a relatively early time point after treatment. As with AML1-ETO9a, these findings were 
consistent with the maintenance in vitro and in vivo experiments demonstrating MLL-AF9 sensitivity 
to Ezh2 loss.  
Finally, extending this work further, the effects of EZH2 inhibition on human AML were modelled 
through assessing the sensitivity of a number of primary human AML samples to GSK343 in colony 
formation assays. Across a range of unselected AML cases, including one case harbouring the MLL-AF9 
translocation, it was possible to demonstrate a considerable degree of sensitivity through reduced 
clonogenic and proliferative potential. Interestingly the sensitive AML cell lines, immortalised murine 
cell lines, MLL-AF9 murine tumours had IC50 measurements in the 10-20µM range and the sensitivities 
demonstrated across these range of samples (including the primary samples) were all at the 10µM 
concentration. At no point did GSK343 appear to exert a positive effect on growth or expansion across 
these murine and human samples. No significant toxicity was seen when GSK343 was tested against a 
limited number of normal human CD34+ cells in the same assay. Further testing against more normal 
and AML samples (ideally with the latter containing t(8;21) or MOZ-TIF2 translocated cases) are 
warranted and will be conducted in the near future. Furthermore, it would be interesting to consider 
a drug trial in mice either with MLL-AF9 or AML1-ETO9a driven leukaemia to see if the effects of 
pharmacological inhibition could mimic that seen with genetic deletion in the maintenance 
experiments.  
The work set out in this thesis answers its initial aim through demonstrating that Ezh2 is differentially 
required for the induction and maintenance of AML in vitro and in vivo. This novel finding appears to 
be the first description of a single gene possessing significantly disparate behavioural requirements 
(i.e. tumour suppressor versus oncogenic roles) between different phases of the evolution of subtypes 
of a single disease. Given its role as an epigenetic regulator, controlling transcription at a potentially 
genome-wide level, this dramatic difference in role is inherently plausible. The work herein provides 
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mechanistic explanations for how loss of this gene is capable of accelerating AML induction, through 
detailed analysis of alterations in transcription and at the chromatin level, providing some novel 
observations regarding changes in histone modifications that result in the de-repression of genes. It 
then furthers this by functionally assessing plausible candidates and validating a single target, 
establishing a novel axis to explain the tumour suppressive behaviour seen in AML induction. To 
explain the reversal in role regarding the phenotypic outcomes seen in the maintenance of AML in 
vitro and in vivo, it then provides an assessment of transcriptional changes in this setting, 
demonstrating that they are clearly different from that seen in the induction programmes, allaying 
concerns regarding the therapeutic targeting of EZH2. Finally, through preclinical studies, this work 
provides uniform evidence that suggests there is scope in therapeutically targeting EZH2 in established 
AML. It will be interesting to see if further preclinical data to support these observations appears, and 
whether future Phase I/II clinical trials of EZH2 inhibitors would subsequently expand their scope from 
solid tumours and B-cell lymphomas to include AML cases.  
The data presented in this thesis has been a detailed characterisation of the role of EZH2 in AML and 
whilst fulfilling the aims set out in the Introduction chapter, has also created new questions that 
require further exploration: 
Is it possible to reconcile the increase in survival seen following Ezh2 loss in the induction of MOZ-TIF2 
leukaemias with the opposite reduction in survival seen in MLL-AF9 and AML1-ETO9a leukaemia during 
the same phase of disease evolution? Is there any overlap with changes in transcriptional programmes 
in this setting for MOZ-TIF2 induction to that seen in the maintenance experiments?  
Does the Ezh2-Plag1 axis also play a similar role in AML1-ETO9a leukaemogenesis? Through which 
pathways does Plag1 mechanistically act to accelerate MLL-AF9 leukaemia development? In larger 
patient datasets is there a direct link between EZH2 mutations and t(8;21) or MLL-AF9 translocated 
human leukaemias with any influence on survival outcomes? Do PLAG1 or LIN28B expression levels 
have any association with this? 
Through what mechanisms does Ezh2 loss in normal HSPCs lead to an upregulation of H3K4me3 at a 
limited set of gene promoters, and why are these restricted? Is this directly dependent upon changes 
in H3K27me3? Do changes in these facilitate a state that is more prone to transformation in AML? 
What are the associated changes in H3K27me3 and H3K4me3 in the AML-ETO9a and MLL-AF9 
induction leukaemias in the absence of Ezh2, and do they overlap those seen in the non-transformed 
state? 
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Answering these questions (with some experiments to address these being performed at the time of 
writing) would further this work and provide important insights into EZH2’s direct link to human AML, 
better defining its enigmatic and apparent dual nature that is so context-specific. Therefore, in 
summary, this work highlights the importance and inherent complexities of epigenetic dysregulation 
in AML, through defining the role of the epigenetic regulator EZH2 in different phases of AML 
evolution, and concluding that despite its dual nature, it remains a viable therapeutic target. Through 
further preclinical and clinical characterisation, EZH2 inhibition will hopefully be added to a growing 
repository of therapies in acute myeloid leukaemia, with the intent of impacting upon this aggressive 
disease whose outcomes continue to remain unacceptable in this era.  
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Appendix A 5.1  
Genes differentially expressed between Ezh2+/+ and Ezh2-/- lineage negative murine HSPCs in the non-
transformed setting. Significant gene expression results were those with a p-value adjusted for 
multiple hypothesis testing of <0.05 with a log2 fold change of greater or less than 0.5.  
Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Lin28b 7.2612 1.10E-10 Klra4 3.2902 2.01E-11 
Scn4b 5.9047 8.96E-28 Fbxo2 3.2685 0.001512777 
Pawr 5.7497 1.52E-29 Cdkn2a 3.2671 0.022365402 
Bmpr1a 5.6969 3.95E-59 1700001O22Rik 3.2592 0.004042759 
Pcolce2 5.5429 1.66E-13 Lta 3.2571 0.005009866 
Ackr3 5.0924 0.016653374 Fbln1 3.2571 0.005967392 
Spats2 4.9315 3.50E-44 Fgf13 3.2471 0.000167925 
Cttnbp2 4.5789 0.010903684 Ddx43 3.2413 2.23E-06 
Cma1 4.5477 2.32E-21 Klra8 3.2194 1.94E-08 
Cx3cl1 4.5347 0.002186949 A930004D18Rik 3.2137 0.010015884 
Fjx1 4.4137 3.02E-07 Zswim5 3.2083 1.23E-10 
Adamts20 4.3240 6.76E-05 Mcpt4 3.1720 0.009652117 
Thbs4 4.3219 0.001302677 D030025P21Rik 3.1520 6.54E-05 
Syt14 4.2766 0.002186949 Mpped2 3.0310 8.89E-10 
Yes1 4.2602 0.000247669 Cd109 3.0233 0.000128851 
Igf2bp3 4.2270 1.05E-30 6330403A02Rik 2.9847 8.23E-05 
Trnp1 4.2021 0.022904117 Igkv13-84 2.9838 0.000119993 
Vpreb1 4.0931 3.86E-21 Wtip 2.9444 0.042280005 
Gfra2 4.0801 8.25E-06 Homer2 2.9347 0.002498901 
Dsp 4.0644 0.008409518 Fbln1 2.9300 0.041344594 
Ddah1 4.0147 8.07E-13 Gm30948 2.8837 3.34E-07 
Cnn1 3.9225 0.001753485 Jph1 2.8431 3.82E-06 
Igll1 3.8967 1.51E-18 Usp44 2.8349 1.87E-12 
Itga7 3.8774 0.037784092 Myom3 2.8263 0.048648156 
Dscam 3.8103 0.000287645 Kank1 2.7940 0.001439296 
Dock3 3.7397 1.85E-19 Hspa12a 2.7916 0.003136277 
Bex2 3.7122 1.35E-11 Gfra4 2.7791 0.001970539 
Elfn1 3.6790 0.011629161 Plppr4 2.7776 0.000542065 
Penk 3.5996 8.18E-16 Pacsin1 2.7347 2.71E-05 
Ttc9 3.5696 2.88E-06 Nkain1 2.7187 0.026991604 
Adcyap1r1 3.5625 8.23E-06 Zfp462 2.7166 2.64E-14 
Snhg11 3.4513 2.16E-13 Arxes2 2.6878 9.46E-11 
Sntg2 3.4200 8.39E-06 Aif1l 2.6876 8.93E-07 
Rab15 3.4024 0.029712934 Slc1a3 2.6861 0.000298674 
Lhfpl4 3.3341 0.016653374 2600014E21Rik 2.6685 0.004625159 
Tmeff1 3.3174 0.002742996 Ptprm 2.6614 1.07E-07 
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Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Ank2 2.6589 2.86E-11 Otoa 2.1525 0.008985433 
Hmgcs2 2.6524 0.000173767 Ric3 2.1421 0.000173075 
Fam149a 2.6502 0.001314767 Mkx 2.1415 0.000746497 
Rtn1 2.6471 3.24E-05 Ptchd2 2.1392 2.20E-08 
Alpl 2.6256 3.07E-11 Spred3 2.1383 2.50E-07 
Syt13 2.5665 2.24E-12 Laptm4b 2.1180 1.84E-13 
Cyyr1 2.5662 3.34E-07 Grb7 2.1110 0.018499526 
Susd5 2.5409 1.40E-07 Plag1 2.1060 5.04E-16 
Rhbdf1 2.5352 4.97E-05 Ar 2.1046 0.001491956 
9630013D21Rik 2.5337 7.25E-15 Raver2 2.0966 0.0022645 
Gzma 2.5272 4.03E-16 Perp 2.0956 1.08E-05 
Cd5l 2.5127 0.000207577 Ncam1 2.0890 1.58E-18 
Bfsp2 2.5081 1.11E-05 Klrc2 2.0870 0.000204548 
Plekhh2 2.4946 2.23E-06 Slc35f2 2.0810 1.48E-11 
Ppm1e 2.4920 5.53E-27 Nid2 2.0792 2.88E-06 
Cadm3 2.4834 1.16E-07 E330013P04Rik 2.0773 0.047818044 
Efna5 2.4223 0.009652117 Dusp9 2.0733 2.43E-06 
Hap1 2.4164 0.018211409 Fzd3 2.0190 4.31E-07 
Olfml2a 2.4120 0.009652117 Slamf8 2.0028 0.036496196 
Unc13b 2.4116 0.00016128 Slc30a4 2.0007 0.00021033 
Enpep 2.4114 4.77E-05 Zfp503 1.9989 0.019232312 
Zfp105 2.4107 2.86E-11 Gfpt2 1.9927 0.000267527 
Bex1 2.4094 0.000287645 Clip4 1.9876 0.003359541 
Ighv3-8 2.3872 3.22E-13 Tln2 1.9855 0.019433058 
Stc2 2.3864 1.58E-05 Lonrf2 1.9850 3.29E-06 
Gm43194 2.3740 0.008088538 Cd3g 1.9811 9.55E-05 
Pydc4 2.3709 0.000708895 Pamr1 1.9700 1.30E-05 
Uchl1 2.3671 0.001386665 Msrb3 1.9696 1.17E-05 
Egfr 2.3653 0.018211409 Mar-09 1.9661 0.001491956 
Cplx2 2.3512 8.36E-22 Uaca 1.9630 5.50E-11 
Ndn 2.3471 0.000512003 Eomes 1.9598 0.000424129 
Ppp4r4 2.3368 0.033494793 Nlgn2 1.9564 0.013049867 
Zfp827 2.3143 1.19E-08 C1qb 1.9509 1.84E-05 
Neo1 2.3087 1.31E-07 Tmem178 1.9498 3.07E-11 
Hba-x 2.3057 0.000131138 Ptprn 1.9457 2.50E-12 
5730559C18Rik 2.2968 0.031561786 Hs3st3b1 1.9416 3.55E-06 
Tnfsf11 2.2924 0.045938796 H2-Q7 1.9410 0.000419471 
Klri2 2.2703 3.12E-11 Lrch2 1.9383 0.000791065 
Plcd3 2.2493 0.006047599 Ptprf 1.9336 0.00052296 
Ebf1 2.2219 2.40E-05 Ngfr 1.9210 0.007828262 
Klk1 2.1897 0.002768636 H2afy2 1.9125 6.14E-08 
Lingo3 2.1850 0.020288823 Bik 1.9121 9.55E-05 
Adamts14 2.1795 0.000424625 Camk2n1 1.9076 0.036456706 
Kdelr3 2.1732 0.006669568 Adam33 1.9026 0.000234465 
Lpl 2.1714 2.95E-18 Stk39 1.8891 1.05E-07 
Cnnm1 2.1708 3.57E-07 Trdc 1.8834 1.29E-07 
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Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Acsbg1 1.8796 4.97E-05 Vpreb3 1.6490 0.049110172 
Gzmb 1.8751 5.15E-12 Ccl5 1.6466 1.05E-07 
Gpc3 1.8682 0.001331854 Dcbld2 1.6465 0.032053258 
Mapk11 1.8586 0.009306334 Gbp4 1.6457 0.041343784 
Rag2 1.8451 0.018982672 BC023719 1.6443 0.029669006 
Dmc1 1.8358 0.014469499 Sdc3 1.6418 5.04E-10 
Zfp9 1.8331 4.88E-06 Ptprk 1.6405 0.003660368 
Klrb1c 1.8326 0.000356514 Plekhd1 1.6381 0.008619841 
Lysmd2 1.8260 1.43E-07 Sdc4 1.6357 0.015288254 
Prf1 1.8241 0.00030616 Tcf7 1.6293 3.30E-06 
Samd3 1.8207 0.000915544 Arhgap5 1.6263 2.26E-09 
Nrbp2 1.8133 0.000275601 Sh2d1b1 1.6222 0.001142403 
Zfp618 1.7978 0.04306599 Gjb2 1.6198 0.000124505 
Hes1 1.7888 5.97E-05 Pcsk9 1.6129 0.014568168 
Ppp3cc 1.7876 8.05E-11 Slamf6 1.6088 0.020520932 
Rras2 1.7851 3.62E-11 Dok4 1.6069 0.029304498 
Hist3h2ba 1.7844 0.002857106 Hmox1 1.5985 0.015148933 
Pde8a 1.7735 7.50E-11 Ctsf 1.5956 1.16E-07 
Olfml2b 1.7695 0.018277837 H2-Q6 1.5908 9.37E-10 
Prune2 1.7666 3.73E-06 Rundc3b 1.5836 0.049958762 
Id3 1.7662 0.00447536 Ptk7 1.5816 0.001418362 
Fzd4 1.7645 4.64E-06 Plcl1 1.5811 0.043948923 
Cbr3 1.7634 0.00735573 Lifr 1.5796 2.40E-05 
Hoxa10 1.7450 0.029669006 Dmxl2 1.5780 1.05E-07 
Hpgds 1.7450 0.003095991 Chst1 1.5750 1.19E-08 
Blnk 1.7448 0.000405842 Hotairm1 1.5722 0.015629399 
Slfn5 1.7350 0.0009039 C1qc 1.5722 0.001620482 
Btn1a1 1.7324 2.32E-05 Trbv13-2 1.5661 0.000560947 
Bmi1 1.7298 3.49E-13 Klre1 1.5595 4.82E-05 
Arl4d 1.7197 0.001275814 Nbea 1.5568 4.25E-05 
Fmn2 1.7194 0.015763733 Il22ra1 1.5538 0.049497332 
Nkx1-2 1.7184 0.01979553 Pbx3 1.5492 0.003984213 
4933440M02Rik 1.7184 6.43E-06 Oasl2 1.5473 2.07E-06 
Gkap1 1.7166 1.72E-12 Cacnb2 1.5473 0.006592219 
Fcna 1.7100 8.06E-05 Kcnc1 1.5472 0.005380876 
Gcat 1.7075 0.003382588 Notch3 1.5471 0.033494793 
C1qa 1.7066 0.009768013 Adra2a 1.5324 0.017969399 
Sorcs2 1.6944 1.67E-06 C4b 1.5314 0.001313899 
Zfp580 1.6801 2.71E-05 Dip2c 1.5309 3.32E-07 
Abcg3 1.6763 0.010944972 Xcl1 1.5291 0.003136277 
Mlph 1.6756 0.022207452 Rapgef5 1.5255 0.000507638 
Slc16a2 1.6672 0.002710722 Chd7 1.5225 6.25E-05 
Prkg1 1.6633 0.006355029 Zbtb10 1.5185 2.44E-07 
Kcnj10 1.6614 0.018794747 Bend5 1.5180 0.032730211 
Spic 1.6566 0.038273745 Ccr5 1.5171 3.34E-07 
Gimap7 1.6513 0.000195244 Mreg 1.5068 0.005319185 
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Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Jam3 1.5028 0.005167454 Stx1a 1.3400 0.029712934 
Prrg4 1.4973 3.08E-06 Cxcr3 1.3350 0.001626747 
Gimap3 1.4945 0.001696653 Zdhhc2 1.3291 3.94E-05 
Tbc1d30 1.4929 0.003468624 H2-Aa 1.3270 0.017831065 
Cd247 1.4850 0.022402666 Gimap8 1.3229 0.019886567 
Pmaip1 1.4818 0.003123615 Klrk1 1.3227 0.000497758 
Ubtd2 1.4796 9.92E-06 Sep-10 1.3194 8.34E-05 
Tmem151b 1.4794 0.006355029 Gm37795 1.3149 0.012298401 
Pkia 1.4739 0.044988956 Il7r 1.3126 0.005396486 
Klrc1 1.4739 0.000675351 Thy1 1.3123 6.27E-07 
Lix1l 1.4716 0.000187107 Tgtp1 1.3116 0.00735573 
Fam184a 1.4662 1.25E-05 Cpne7 1.3112 0.004594572 
Gmfg 1.4651 0.038345424 Atp8b5 1.3107 0.002606342 
Il2rb 1.4617 1.14E-06 Prkcdbp 1.3054 0.027902112 
Eml5 1.4555 0.000544739 Arhgef5 1.3021 5.30E-05 
Afp 1.4537 0.029712934 Gimap3 1.2992 8.70E-05 
Dtna 1.4529 0.045496728 Tox 1.2966 0.005009866 
Fam212b 1.4517 0.045309023 Ciita 1.2929 0.003272852 
Mllt4 1.4469 8.00E-06 Cd4 1.2920 0.009404166 
H1f0 1.4388 1.42E-06 A430105I19Rik 1.2881 0.005801168 
Abca5 1.4370 0.001504638 Lrrc16b 1.2805 0.000279419 
Tdrkh 1.4352 3.42E-05 Tmc3 1.2780 0.004037481 
Selm 1.4287 2.44E-07 Parp12 1.2776 6.50E-07 
Reep1 1.4254 0.00204637 Cdkl5 1.2765 0.000961543 
Rora 1.4239 0.026093987 Trbc1 1.2738 0.001312081 
Tbx21 1.4221 0.001642171 Fkbp11 1.2708 1.70E-05 
Chic1 1.4133 0.005955875 Gprin3 1.2703 0.001439296 
B3galnt1 1.4127 0.022365402 Tjp2 1.2694 8.23E-08 
Shisa2 1.4097 0.003660368 Prss16 1.2667 9.90E-06 
Wdr54 1.4031 0.041832986 Maf 1.2640 0.012634679 
Kif19a 1.4003 0.005657275 Cdkn1a 1.2534 0.00832091 
E130012A19Rik 1.3970 2.41E-07 H2-Q5 1.2462 1.49E-06 
Mpzl3 1.3954 0.008831026 Trbc2 1.2355 0.006304986 
Lrig3 1.3951 0.000665237 Irf2bpl 1.2329 0.000242105 
Tgfa 1.3869 0.033494793 Pou6f1 1.2301 0.042280005 
Myh7b 1.3855 0.013585246 Jazf1 1.2242 0.005611335 
Mageh1 1.3843 0.042542979 Trpc1 1.2206 0.025239268 
Gbp9 1.3813 0.016530871 Sapcd1 1.2156 0.033494793 
Pbx3 1.3797 0.018277837 Col27a1 1.2146 0.0315174 
Rasal2 1.3678 1.05E-06 Ptpru 1.2133 0.005628872 
Rtp4 1.3643 0.000191433 Ptpdc1 1.2021 1.18E-05 
Ccdc85c 1.3618 0.033494793 Lamc1 1.1934 1.05E-06 
Tcrg-C4 1.3576 0.00408088 Mn1 1.1841 0.00509308 
Arhgap29 1.3545 5.10E-06 Ppp2r3a 1.1827 0.003984213 
H2-Ab1 1.3507 0.003660368 Fkbp9 1.1800 1.67E-06 
Ctsw 1.3491 4.23E-06 Aldh5a1 1.1781 0.001384499 
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Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Gene ID Log2 Fold 
Change 
Adjusted p-
value 
Kbtbd11 1.1704 1.19E-05 Il2ra 1.0067 0.0276757 
Cd96 1.1699 0.002354766 Dusp23 1.0062 0.041427634 
Plxna2 1.1660 0.008831026 Rbp1 0.9910 0.032475731 
Ckb 1.1654 0.000915544 Myo1e 0.9887 0.005861915 
Fam174b 1.1623 6.19E-06 Hpgd 0.9886 0.049275679 
Ccnd1 1.1607 9.03E-06 Ldhb 0.9850 0.020288823 
Sema7a 1.1597 0.008198811 B4galnt4 0.9822 0.016747744 
Socs3 1.1503 0.006725463 Tnfrsf10b 0.9784 0.032652245 
Socs1 1.1500 0.006592219 Parm1 0.9524 0.003290689 
Cacna1e 1.1488 0.000915544 Camk1d 0.9515 0.000278543 
Degs2 1.1386 0.008619841 Cers4 0.9514 0.04306599 
Pik3c2a 1.1329 3.21E-06 Neto2 0.9499 0.041902127 
Abtb2 1.1274 0.001446088 Tmem98 0.9499 0.003473129 
Camk4 1.1256 0.009472597 Sall2 0.9497 0.013068533 
Adgra3 1.1247 2.25E-05 Cmtm4 0.9458 0.001983469 
Setbp1 1.1210 0.034485601 Nlrc5 0.9435 0.000250821 
Pde3b 1.1199 2.91E-06 Pkd2 0.9430 0.000708073 
Itm2a 1.1183 0.008583215 Slc22a21 0.9408 0.035918809 
Cysltr1 1.1141 0.014568168 Slc9a5 0.9360 0.004467257 
Myo10 1.1139 0.025581518 Car13 0.9312 0.001512777 
2700081O15Rik 1.1129 7.33E-06 Rxra 0.9310 0.005367173 
Slc26a3 1.1106 0.034485601 Pvrl1 0.9290 0.016530871 
Ncs1 1.1093 0.000371582 Adora2a 0.9186 0.013230002 
Fas 1.1068 0.036902743 Mybl1 0.9098 0.022207452 
Zap70 1.1053 0.027902112 Pycr1 0.9079 0.046847181 
Cecr2 1.1042 5.37E-05 Pik3c2b 0.9023 0.001826211 
Tcrg-C1 1.1030 0.027902112 Basp1 0.9017 0.032475731 
Zbp1 1.1029 0.008052666 Rhobtb3 0.8997 0.002891349 
Ifnlr1 1.1023 0.009306334 Plekha5 0.8919 0.002887594 
Glis3 1.1014 0.038273745 Tspan3 0.8881 0.000675351 
Slc39a14 1.1013 0.000608477 Ptk2 0.8881 0.015109867 
Id2 1.0968 1.85E-05 Rbm44 0.8828 0.03164704 
Ppp1r9a 1.0881 0.000138188 Sv2a 0.8793 0.047558474 
Plekhh1 1.0774 0.046681042 Tulp3 0.8788 0.006685678 
Syde1 1.0761 0.048842368 Armcx4 0.8786 0.02468981 
Coro2a 1.0689 0.022365402 Alox12e 0.8726 0.018677664 
Perm1 1.0673 0.038477979 Drc7 0.8684 0.047818044 
Peg12 1.0604 0.00693804 Phlpp1 0.8647 0.002810651 
Epb41l5 1.0571 0.005427571 1700025G04Rik 0.8603 0.011839211 
Tanc2 1.0516 0.000356514 Adgrl1 0.8516 0.003227465 
Pdia5 1.0487 5.21E-05 Slc7a6 0.8491 0.005861915 
Grap2 1.0449 2.84E-05 Afap1l1 0.8423 0.002367104 
Zfhx3 1.0390 0.009152793 Nusap1 0.8390 0.016653374 
Gimap6 1.0386 0.039978028 Homer1 0.8383 0.021022149 
Khdrbs3 1.0299 9.21E-05 Zbtb16 0.8365 0.008985433  
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Change 
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Mfsd6 0.8314 0.009306334 Emc9 -0.8110 0.011212359 
Prkch 0.8284 0.029712934 Sphk1 -0.8124 0.03164704 
Faah 0.8255 0.014568168 Spon2 -0.8170 0.007828262 
Cdc42bpb 0.8171 0.005409736 Pklr -0.8197 0.007234536 
Slc2a1 0.8135 0.009306334 Serinc3 -0.8238 0.000770619 
Foxd2os 0.8107 0.016654582 Igkv4-57 -0.8277 0.033494793 
Ada 0.8100 0.008271908 Ifi30 -0.8495 0.008746739 
Kif1b 0.8000 0.018677664 Fads3 -0.8984 0.006669568 
H2-Q4 0.8000 0.002158617 1700006J14Rik -0.9028 0.000785826 
Plcg1 0.7984 0.013230002 Ntn4 -0.9166 0.003229724 
Crim1 0.7983 0.018651241 Atp1b2 -0.9430 0.000374676 
Celsr2 0.7979 0.036496196 Cela1 -0.9481 0.00038049 
Hdgfrp3 0.7965 0.018677664 Cpt1c -0.9503 0.011008918 
Ms4a4b 0.7944 0.021695541 Hpn -0.9906 0.015425655 
Lama5 0.7917 0.012965366 Aqp11 -0.9939 0.027248364 
Ptrf 0.7837 0.040389149 Ighm -1.0285 5.58E-06 
Gmds 0.7805 0.016530871 C1qtnf6 -1.0345 0.015109867 
Ighv2-2 0.7473 0.036456706 Ighv1-19 -1.0504 0.002584592 
Hspa2 0.7442 0.030045938 Enpp3 -1.0761 0.030714021 
St8sia6 0.7442 0.031677663 Ccdc74a -1.0851 0.002186949 
Hipk2 0.7416 0.02048884 Ighv7-1 -1.1167 0.00255965 
Lax1 0.7405 0.036653999 Ighv2-6 -1.1303 0.016184476 
Serpine2 0.7384 0.008957346 Gm15915 -1.1501 0.013230002 
Foxo1 0.7383 0.025460628 Slc26a1 -1.2826 2.04E-05 
Bmp1 0.7327 0.021025807 Ighv7-3 -1.5705 3.07E-11 
Plekha8 0.7303 0.032475731 Ighv1-78 -1.6593 2.93E-05 
Lgalsl 0.7253 0.013310215 Igkv14-100 -1.6679 0.005628872 
Sep-06 0.7246 0.014195588 Ighv1-81 -1.6871 3.81E-09 
Npl 0.7202 0.033765948 Hddc3 -1.7055 5.74E-10 
Lacc1 0.7191 0.048648156 Ighg1 -1.7190 4.31E-07 
Gca 0.7095 0.029712934 Igkv4-61 -1.7474 0.003406732 
Klf7 0.6965 0.036496196 Nuf2 -1.7540 0.016654582 
Mboat1 0.6888 0.04479626 Otogl -1.8386 0.002034566 
Bbx 0.6750 0.03567193 Nuf2 -2.0160 0.000287645 
Ptprcap 0.6514 0.032052391 Ighv8-12 -2.1654 6.45E-06 
Prkar2a 0.6428 0.049685333 Ighv1-18 -2.1684 0.000234465 
Casp3 -0.6045 0.043459246 Ezh2 -2.3631 0.024614917 
Shkbp1 -0.6261 0.051042526 Igfn1 -3.6222 0.0276757 
Nxpe4 -0.7026 0.017969399 Igkv9-123 -4.3084 8.36E-22 
Setd6 -0.7153 0.018848593 Eif3j2 -4.3162 2.40E-46 
Fzd7 -0.7251 0.015052321 D430041D05Rik -4.3998 0.001202676 
Spire2 -0.7732 0.036902743 Pcna-ps2 -4.7606 6.86E-77 
Ctse -0.8034 0.0325769 
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Appendix A 5.2  
Genes differentially expressed between Ezh2+/+ and Ezh2-/- lineage negative murine HSPCs in the 
MLL-AF9 leukaemias. Significant gene expression results were those with a p-value adjusted for 
multiple hypothesis testing of <0.05 with a log2 fold change of greater or less than 0.5. 
 
 
Gene ID Log 2 Fold 
Change 
Adjusted p-
value 
Gene ID Log 2 Fold 
Change 
Adjusted p-
value 
Lin28b 8.3571 0.000409407 Asprv1 3.6325 2.75E-05 
Spag6 7.8819 1.39E-20 Gm14327 3.6317 0.000331242 
Cacnb2 6.2302 1.31E-32 Gm42632 3.6274 2.15E-05 
2900092N22Rik 6.1739 4.48E-27 Gm37240 3.5931 0.024579692 
Prg2 6.0452 0.003174392 Gm20407 3.5920 0.001311807 
Hist1h2al 5.8225 0.025360131 Nxnl2 3.5829 0.022219115 
Gm37437 5.6912 8.53E-12 Zcchc11 3.5457 4.10E-05 
C330013J21Rik 5.6301 2.15E-07 Kbtbd12 3.5427 3.88E-05 
Gm13269 5.3726 3.78E-11 Thbs1 3.5343 2.55E-08 
Gm37891 5.3422 3.02E-09 Yes1 3.5098 4.13E-09 
Gm38273 5.3385 1.29E-10 Tcf24 3.5073 3.37E-08 
Retnla 5.3260 2.97E-21 P2ry14 3.5025 0.004047245 
Gm44246 5.2468 2.83E-05 Gm26603 3.5001 8.10E-19 
Gm37006 5.2299 5.79E-19 Bmi1 3.4840 8.31E-08 
A1cf 5.0160 0.034048087 Pax5 3.4226 2.03E-06 
Gm4969 5.0027 7.34E-06 Epha7 3.4150 4.51E-07 
Gm38105 4.9686 4.85E-08 P2rx3 3.4039 1.36E-07 
Col19a1 4.8757 0.000120183 P2ry14 3.3568 0.008757237 
Sorcs2 4.5664 3.05E-18 C79798 3.3476 1.26E-17 
C330013J21Rik 4.5477 0.001277686 6720464F23Rik 3.3472 1.47E-06 
Slc22a3 4.4833 1.21E-14 Ptpn13 3.3420 0.009865244 
Gm20539 4.3688 0.000573742 Gm37524 3.3274 0.030624084 
9430087J23Rik 4.3135 2.19E-05 Bcl2a1b 3.3259 1.68E-05 
Ikzf3 4.1700 0.000295085 P2ry14 3.3200 0.000259914 
Tmem178 4.1529 1.35E-18 Oaf 3.3196 0.038098799 
Gm17110 4.1371 1.84E-06 Tns1 3.3179 0.001284206 
Gm8730 4.0936 4.97E-32 Epha7 3.2927 2.16E-05 
Bmpr1a 4.0751 2.42E-20 Tiam1 3.2920 0.01747164 
Gm11915 4.0618 6.77E-20 Krt18 3.2745 6.90E-07 
Retnlg 4.0438 8.95E-08 4933406I18Rik 3.2605 2.35E-08 
Ppnr 4.0289 5.49E-06 Zbtb16 3.2512 0.011131775 
Adgre4 4.0087 0.01081153 Gm25436 3.2466 0.01199519 
Gm37215 3.8372 0.00192646 Rspo1 3.2356 1.21E-09 
Aff3 3.8082 0.022634083 Col19a1 3.2129 7.74E-12 
Aspa 3.6819 5.38E-18 Lrrc1 3.1815 0.000559847 
Hoxc6 3.6605 0.001521857 A430093F15Rik 3.1722 0.001060425 
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Change 
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Gene ID Log 2 Fold 
Change 
Adjusted p-
value 
Unc5cl 3.1637 0.002625895 Trpv3 2.5561 2.59E-07 
Atp8a2 3.1576 1.02E-09 Cep126 2.5499 0.011624178 
E330040D14Rik 3.1553 0.000143898 Hcar2 2.5424 0.012134889 
Emid1 3.1533 4.16E-07 Clcf1 2.5405 0.037779742 
Gm25831 3.1159 3.14E-07 Gm29438 2.5005 0.004019465 
Plag1 3.1094 2.15E-18 Rras2 2.4875 3.16E-06 
9530036M11Rik 3.0905 0.001298601 Ankrd22 2.4740 0.007639463 
Dach1 3.0738 0.014048442 Nrarp 2.4721 0.034682741 
Stfa2 3.0646 6.24E-19 Csnk1e 2.4682 0.040427544 
4933406I18Rik 3.0631 3.88E-05 Pbx3 2.4675 0.000191321 
Gm14399 3.0493 0.008757237 Grb7 2.4660 0.003016624 
Cdkn2a 3.0402 0.024021077 Skida1 2.4574 0.0001055 
Fam135a 3.0352 1.77E-08 Fam135a 2.4431 0.002189662 
Gm37212 3.0069 0.000612244 Gm25465 2.4419 0.036858362 
Bmi1 3.0000 8.61E-17 Clic5 2.4286 8.74E-06 
Sema7a 2.9938 0.0003334 Pik3c2g 2.4281 0.044364482 
Slc14a2 2.9749 0.005013363 Dclk2 2.3902 0.001484416 
Gm14420 2.9102 0.00183369 Dapk2 2.3864 8.30E-10 
Gm38126 2.8776 0.001802243 Gm37310 2.3668 0.007304068 
Ankrd13b 2.8758 0.000717807 Adgrl4 2.3653 1.04E-07 
Heg1 2.8680 1.87E-10 Mir7655 2.3651 0.000449367 
Gm38125 2.8652 0.037256199 Ppp1r42 2.3307 2.05E-06 
Ly6g 2.8590 0.001827815 Gm38302 2.3232 0.014923603 
Faah 2.8567 1.48E-07 Eml5 2.3069 1.06E-06 
Akt3 2.8559 7.05E-06 Erc2 2.3013 7.34E-06 
Perp 2.8501 0.003190598 Tbc1d10c 2.3007 9.97E-10 
Slc25a23 2.8392 0.033823473 Ica1 2.2749 0.037009516 
Gm11655 2.8253 0.012578366 Ddx43 2.2649 0.004734003 
Gm37199 2.8115 0.005997471 Ighd 2.2645 0.002012049 
A930004D18Rik 2.8101 2.54E-08 Gm38235 2.2599 0.000859248 
Tet1 2.8078 0.014341187 Mmp9 2.2553 0.000194374 
Ptk7 2.7687 2.29E-07 Gm13371 2.2450 7.33E-05 
Stau2 2.7541 0.006885773 AI854703 2.2383 0.025360131 
Crtac1 2.7456 0.047914637 Pard6b 2.2218 0.002026092 
Rfx3 2.7415 3.46E-09 Calcrl 2.2192 5.11E-09 
Gm26756 2.7404 0.005997471 Mir1927 2.2149 0.040219402 
Pbx3 2.7246 1.42E-09 Dennd3 2.2017 1.42E-09 
Ldlrad4 2.7115 2.25E-11 Gm16158 2.1990 0.030778582 
Gramd2 2.7111 0.016320984 Gm5483 2.1982 0.005257418 
Ccdc8 2.7106 0.005239955 Add3 2.1975 0.000133328 
Cmya5 2.6839 0.000581586 Lrrc1 2.1963 0.011999887 
Gm25180 2.6672 0.00100639 Elovl7 2.1936 0.000245282 
Sh3bp5 2.6443 0.016480515 Galnt3 2.1880 4.22E-08 
Tacstd2 2.6391 8.21E-05 Ssbp2 2.1848 0.032830254 
Slain1 2.6053 0.021404084 Med12l 2.1739 0.003654687 
Coro2a 2.5600 8.17E-06 Gm15818 2.1539 0.001269854 
220 
 
Gene ID Log 2 Fold 
Change 
Adjusted p-
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Change 
Adjusted p-
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BC100530 2.1350 0.003285881 Flt3 1.7897 0.032343751 
Sh3bp4 2.1250 7.05E-06 6330409D20Rik 1.7851 0.000204552 
Fam169b 2.1240 1.15E-06 Cd33 1.7804 1.84E-06 
Tln2 2.1113 1.11E-07 Ppm1e 1.7771 2.51E-06 
Glis2 2.1012 3.88E-05 Fgr 1.7740 0.004402726 
Stfa2l1 2.0952 0.036015993 Zfp831 1.7355 9.14E-05 
Ipcef1 2.0781 0.0353509 Sgms1 1.7254 0.029047921 
Klhl41 2.0721 0.033869367 Mapk4 1.7241 0.000478668 
Prss30 2.0639 0.007035403 Stfa3 1.7187 0.009973649 
Fam73a 2.0614 0.015684058 Ear2 1.7128 0.047376298 
Sesn1 2.0610 0.041278046 Smim5 1.7125 0.026427153 
Agpat4 2.0585 3.56E-05 Gm26522 1.7080 0.027652291 
Gm22883 2.0534 0.037633378 Gp1bb 1.7064 0.002701185 
Gm5416 2.0348 3.69E-05 Gm42571 1.7055 0.000925419 
Phlpp1 2.0094 7.32E-08 Gm17207 1.7047 0.007503325 
Tnik 2.0053 0.016766204 Mfsd6 1.7032 0.000191321 
Add3 1.9945 7.34E-06 Cxadr 1.7002 0.00054897 
Gm15356 1.9934 0.002479963 Gm16059 1.6974 0.002625895 
Slc1a3 1.9914 0.005941906 Spns3 1.6966 0.039333199 
Smpd3 1.9841 0.000229904 Gm36975 1.6955 0.001069895 
Six5 1.9606 0.003151284 Tspan13 1.6903 0.023961069 
Bcas1os2 1.9556 0.000977746 Gm28373 1.6800 0.001060242 
Gm37802 1.9361 0.002974898 Hip1r 1.6740 2.44E-05 
Slpi 1.9345 0.047535854 Klf5 1.6737 0.018984682 
Gphn 1.9320 7.05E-06 Alcam 1.6600 0.00088187 
Fmnl2 1.9246 0.003175948 Adcy4 1.6571 0.004385005 
Pde3b 1.9225 2.01E-07 Klrb1f 1.6560 0.038098799 
Epb41l4b 1.9199 0.01083626 Gm15880 1.6469 0.029769008 
Prkca 1.9092 0.014256054 Sh2d3c 1.6203 0.004683723 
Ntng2 1.9085 0.002029901 Tbc1d16 1.6148 0.040219402 
Gm37334 1.9076 0.013686056 Gm43430 1.6011 0.002446865 
Sox13 1.9031 0.014836458 Tjp2 1.5998 0.004786272 
C030034L19Rik 1.8795 0.021996195 Nrip1 1.5959 0.00088187 
Gm37465 1.8786 0.034964156 Mar-01 1.5947 0.015152184 
Gkap1 1.8758 2.92E-05 Map3k9 1.5942 1.79E-05 
Il1b 1.8703 0.020617799 Spns2 1.5925 5.97E-05 
Hoxaas2 1.8685 0.020379532 Pik3cb 1.5913 0.002607396 
Zfp599 1.8656 0.001542566 Ddx3y 1.5889 2.37E-05 
Col4a1 1.8623 8.61E-05 Csnk1e 1.5875 0.004265588 
Gcnt2 1.8561 0.002385479 Slc7a8 1.5837 0.000190855 
Col5a1 1.8465 1.06E-06 Kdm5b 1.5833 0.017430509 
Thbd 1.8309 0.004636264 Parp3 1.5823 0.030624084 
Syne1 1.8223 0.000459336 Itgb3 1.5820 0.025360131 
Trib1 1.8096 0.008227053 Caskin2 1.5815 0.022896818 
Gm43999 1.8003 0.009445025 Ralgps2 1.5788 0.028031315 
Ralgps2 1.7964 0.019679195 Hsh2d 1.5728 0.022219115 
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Gm5751 1.5723 0.012596437 A330023F24Rik 1.3141 0.024183645 
Chrnb1 1.5613 0.023699414 Scmh1 1.3051 0.034048087 
Rltpr 1.5593 0.00331841 Pde7a 1.2992 0.016840344 
Sycp2 1.5589 0.031830631 Syne1 1.2984 0.000973551 
Tmem216 1.5535 0.008368056 Gm44292 1.2890 0.016768979 
Smim5 1.5520 0.000527932 Ssh1 1.2862 0.021996195 
Hipk2 1.5480 5.12E-05 A430046D13Rik 1.2832 0.002673331 
Cebpe 1.5288 0.032343751 Runx2os2 1.2809 0.008368056 
Vipr1 1.5254 0.023983074 Gm42463 1.2778 0.045349683 
2700081O15Rik 1.5132 0.019960492 Adpgk 1.2767 0.024892656 
Csnk1e 1.5119 0.000516684 Inpp5j 1.2690 0.003151284 
Lurap1 1.5082 0.004603258 Gm10612 1.2684 0.009471129 
9830107B12Rik 1.5058 0.034816645 Acox3 1.2664 0.024431725 
Ppp3cc 1.5030 0.016651481 Acss1 1.2572 0.003175948 
Anxa11os 1.4972 0.011855976 Abcb9 1.2545 0.011667527 
Chil5 1.4870 0.02308857 Srgap3 1.2433 0.040452683 
Myadml2 1.4826 0.008117382 Btbd11 1.2250 0.030209302 
Neo1 1.4685 0.048810554 6030400A10Rik 1.2236 0.034045645 
Ccdc85c 1.4667 0.021196459 Carns1 1.2111 0.025551012 
Lrrk2 1.4615 0.022543245 Dsp 1.2065 0.005359344 
Ranbp17 1.4594 0.021692373 Ap1s3 1.2040 0.021485406 
B630019K06Rik 1.4526 0.018016455 Gm17552 1.1988 0.037633378 
Pdlim1 1.4512 0.000911926 Ccdc102a 1.1947 0.037633378 
Mbp 1.4371 0.031074368 Ugcg 1.1922 0.025159991 
Fndc9 1.4304 0.001181623 9530085L11Rik 1.1899 0.027232914 
Gm44001 1.4167 0.04778651 Gm43274 1.1805 0.014883992 
Map3k5 1.4159 0.036496618 Gm42572 1.1753 0.015684058 
Igf1r 1.4151 0.000177284 Tmco3 1.1718 0.01083626 
Kif21b 1.4130 0.00020904 Itgb5 1.1712 0.019753071 
2310001H17Rik 1.3992 0.007353507 Ptprcap 1.1529 0.023459094 
Samd9l 1.3962 0.004393371 Cd84 1.1462 0.015975805 
Gm20721 1.3946 0.016177947 Socs6 1.1421 0.022075368 
Olfm4 1.3944 0.011257381 A130048G24Rik 1.1363 0.018723227 
Rere 1.3792 0.002259632 Ccl6 1.1329 0.010968802 
9530077C05Rik 1.3661 0.008614204 Gm10097 1.1326 0.029510447 
Olr1 1.3642 0.000432923 Lilr4b 1.1257 0.022889331 
Cd5 1.3552 0.021692373 Fgd6 1.1204 0.015482829 
Plxnc1 1.3496 0.003471371 Ell2 1.1201 0.02699617 
Hmgn1 1.3438 0.0007259 Ltb4r1 1.1167 0.010410422 
Sep-01 1.3424 0.015852596 Raph1 1.1148 0.014632041 
Prex1 1.3329 0.001698042 Zfp318 1.0950 0.017430509 
Gpr18 1.3317 0.006211376 A630072L19Rik 1.0948 0.047573494 
Tmem71 1.3314 0.039757716 Arhgap27 1.0907 0.044291239 
Gnas 1.3267 0.00705825 Phtf2 1.0880 0.033070808 
Cyp4f18 1.3202 0.048812272 Gm37159 1.0865 0.035350682 
Chn2 1.3151 0.021544955 Gm20632 1.0843 0.029047921 
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Gene ID Log 2 Fold 
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Adjusted p-
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Gm43982 1.0790 0.029313718 Il3ra -1.1983 0.005342288 
9630013D21Rik 1.0746 0.022219115 Btbd19 -1.2289 0.029103733 
Kdm6b 1.0623 0.01897076 Galc -1.2434 0.004317886 
Ric1 1.0600 0.019960492 Cyp27a1 -1.2511 0.005212461 
Pik3ap1 1.0515 0.029999353 Tlr6 -1.2526 0.005013363 
Trp53bp2 1.0282 0.040219402 H2-Ab1 -1.2558 0.015391194 
Clec2i 1.0239 0.032319532 Gm16104 -1.2660 0.022488475 
Prrc2b 1.0201 0.039567406 Lpcat1 -1.2807 0.002860596 
Wipi1 1.0177 0.048810554 Phyh -1.2850 0.0015981 
Dennd1c 1.0141 0.028031315 Pyhin1 -1.2924 0.001213877 
Crtc3 1.0130 0.028282334 Dhrs9 -1.3028 0.008113507 
Zbtb10 1.0073 0.044314642 Mllt4 -1.3070 0.001829311 
Rabgap1l 1.0056 0.045556763 C3 -1.3085 0.000752295 
Mylk 0.9860 0.02872854 Hs6st1 -1.3200 0.00365675 
Cd2ap 0.9854 0.039775258 Oas1c -1.3242 0.013546745 
Xylt1 0.9838 0.039775258 Atp10a -1.3273 0.001150452 
Strbp 0.9592 0.047090629 Tfec -1.3304 0.003938258 
Rabgap1l 0.9559 0.044088806 Ptger2 -1.3447 0.018016455 
Gfod1 0.9553 0.044769427 Adam3 -1.3455 0.008757237 
Arsb 0.9421 0.044291239 Ldhb -1.3455 0.004079882 
Stom -0.9416 0.043399503 Chpt1 -1.3504 0.004603258 
Calr -0.9648 0.0338262 Pyroxd2 -1.3543 0.001542566 
Mt1 -0.9727 0.039449055 Rexo2 -1.3625 0.000753803 
Tax1bp1 -0.9866 0.028524483 Zfp217 -1.3859 0.016768979 
Limd1 -0.9944 0.030624084 Tmem38b -1.3922 0.000512489 
Tmx4 -0.9996 0.027583885 Chpt1 -1.4004 0.023680887 
Tlr4 -1.0113 0.038663847 Gpr65 -1.4194 0.0010031 
Top1mt -1.0126 0.048670386 Plpp5 -1.4238 0.049400656 
Vps13c -1.0325 0.018632515 1810011H11Rik -1.4371 0.000331242 
B2m -1.0403 0.015781075 Sema6b -1.4467 0.015545321 
Ppp1r21 -1.0406 0.019571318 Rps2 -1.4526 0.003260338 
4930503L19Rik -1.0455 0.047028515 Egln3 -1.4545 0.000225606 
Deptor -1.0500 0.037009516 Praf2 -1.4570 0.018209427 
Grn -1.0970 0.008827397 Dnajc12 -1.4595 0.008757237 
Tmem150b -1.1092 0.023699414 Glce -1.4695 0.035183671 
Serp1 -1.1253 0.006210509 Layn -1.4700 0.034816645 
Dpp7 -1.1359 0.015391194 Smad1 -1.4806 0.011201557 
Tspan31 -1.1364 0.010130058 Asns -1.4923 0.016122878 
Ogfrl1 -1.1393 0.023699414 Fam114a1 -1.5018 0.000889241 
App -1.1537 0.028524483 Gm13881 -1.5039 0.000911926 
Hspa13 -1.1614 0.015100438 Ptch2 -1.5070 0.037256199 
Pkd2 -1.1724 0.024813193 Lonrf3 -1.5116 0.00032763 
Dhx58 -1.1747 0.011841109 Zfp948 -1.5124 0.005331053 
Ifih1 -1.1763 0.019002737 Trem3 -1.5247 4.93E-05 
D5Ertd605e -1.1816 0.019429285 Arhgap31 -1.5464 0.018718378 
Oas1a -1.1832 0.020892644 Cmtm3 -1.5674 0.000255641 
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Adjusted p-
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Prdx4 -1.5715 7.81E-05 C1qb -1.8355 0.001031584 
Gpr179 -1.5768 0.004378766 Gbp2 -1.8362 0.004019465 
Mrc1 -1.5800 0.002489643 Mfap3l -1.8525 0.006140216 
Slc6a13 -1.5801 0.007798183 9330159M07Rik -1.8596 0.035681842 
Ppm1f -1.5866 0.034380078 Adamts2 -1.8716 1.81E-05 
1810008I18Rik -1.5868 0.003471371 Slc28a2 -1.8974 0.002320235 
C1qc -1.5886 0.015391194 Gm29395 -1.9138 0.024545915 
Gm38244 -1.5950 0.001838628 Cndp2 -1.9256 0.005307977 
Gm15232 -1.6052 0.005076312 Afap1 -1.9265 0.022543245 
Gm11685 -1.6056 0.037256199 Gm11505 -1.9278 2.59E-07 
Tlr1 -1.6099 0.029139505 AI429214 -1.9322 0.001838628 
Celsr1 -1.6122 0.039449055 Lmo1 -1.9396 0.000401478 
Akap17b -1.6289 0.003031951 Ces2g -1.9460 0.040219402 
Copz2 -1.6307 0.009511636 Prtn3 -1.9503 1.54E-08 
Gstm7 -1.6323 0.044291239 Gstm1 -1.9600 0.008687739 
Pafah2 -1.6565 6.17E-05 Chst1 -1.9622 0.036015993 
Gm13431 -1.6591 0.039775258 Ldlrad3 -1.9625 1.23E-07 
Cfp -1.6607 3.36E-06 Bhlha15 -1.9644 0.000442066 
Mmp19 -1.6628 1.50E-05 Mcf2l -1.9654 0.000111053 
Gm37233 -1.6673 0.00322379 9430069I07Rik -1.9697 0.006289198 
Adhfe1 -1.6688 0.009700028 0610038B21Rik -1.9731 0.003446389 
Srxn1 -1.6707 0.000169352 Endod1 -1.9864 1.44E-07 
Man1a -1.6792 7.54E-06 Otogl -1.9920 3.40E-06 
Mrgpra2a -1.6887 0.007144454 Lgals3bp -1.9947 0.002496489 
Mgst2 -1.7024 0.004986334 Gm16619 -1.9963 0.00331841 
F10 -1.7101 9.30E-06 Cyp39a1 -1.9967 0.000118406 
Ptgir -1.7179 0.026297264 Slc36a3os -2.0011 0.008780287 
Gm37261 -1.7218 0.000596947 Gm9898 -2.0069 0.048331067 
Ptprm -1.7291 9.68E-05 Vat1 -2.0095 2.38E-05 
Zdhhc2 -1.7350 0.015836166 9330159M07Rik -2.0584 1.25E-08 
Mgam -1.7470 0.02872854 Ms4a6d -2.0606 0.0003334 
6330562C20Rik -1.7479 0.014836458 Nid2 -2.0689 0.000226246 
Cebpa -1.7509 1.21E-06 Fam20c -2.0711 0.007258212 
Slc46a1 -1.7598 0.000250224 Mpo -2.0980 1.16E-06 
F10 -1.7624 0.0010031 Sntb1 -2.1010 0.03386502 
Il1rl2 -1.7700 0.035350682 Pla2r1 -2.1128 0.00331841 
C3ar1 -1.7775 0.005907562 Dab2 -2.1275 0.000166664 
Jag1 -1.7854 0.0093633 Rassf10 -2.1580 2.35E-08 
Scamp5 -1.7860 0.011131775 Ifi27 -2.1725 0.029739338 
Rhoj -1.7938 0.028770254 D430019H16Rik -2.1856 0.001822599 
Il1f9 -1.8023 3.78E-05 Ms4a3 -2.1922 0.003446389 
Baiap3 -1.8036 0.046418775 A930033H14Rik -2.2336 0.01177775 
Hal -1.8119 0.008227053 Guca1a -2.2373 0.0330242 
Car2 -1.8240 0.000100645 Esr1 -2.2384 4.92E-06 
Spry2 -1.8313 1.86E-06 Gm15658 -2.2390 0.000629931 
Tubb6 -1.8342 0.025879577 Sec24d -2.2452 5.09E-10 
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Gm16193 -2.2618 1.86E-06 S1pr3 -2.7882 9.35E-13 
Mertk -2.2630 3.62E-07 Gm38399 -2.7906 0.042090255 
Six1 -2.2668 7.54E-05 Tnfsf13os -2.7952 0.009629654 
Mpo -2.2677 0.000957854 1810006J02Rik -2.8030 0.008033807 
Fstl1 -2.3089 5.05E-05 Slfn4 -2.8454 0.000326946 
Tnr -2.3131 0.001802243 Pm20d1 -2.8523 9.46E-07 
Mfsd7a -2.3145 5.31E-09 Prps1l1 -2.8847 8.60E-10 
Soga1 -2.3385 6.90E-09 Il22ra2 -2.9168 1.69E-08 
Elane -2.3526 0.009940874 Amot -2.9212 0.023354938 
Rassf8 -2.3789 2.57E-06 Slfn4 -2.9270 9.35E-13 
Kcnip3 -2.3846 0.000227241 Gm15401 -2.9298 0.008143725 
Slamf9 -2.3976 0.002356368 Ube2l6 -2.9299 4.56E-09 
Gstm1 -2.4287 0.002078787 Col6a6 -2.9463 5.16E-08 
Six4 -2.4393 0.024892656 2210010C04Rik -2.9526 0.022543245 
4933406C10Rik -2.4437 0.026493429 Muc13 -2.9813 2.89E-07 
Six4 -2.4491 9.64E-05 Tg -2.9830 4.68E-16 
Slc13a3 -2.4560 0.001525379 Mok -3.0091 1.07E-05 
F13a1 -2.4562 5.04E-05 2210417A02Rik -3.0690 0.022543245 
2510009E07Rik -2.4740 0.000260618 5930430L01Rik -3.0829 3.00E-07 
Spocd1 -2.4744 0.038983543 Tslp -3.1442 0.004930889 
Atp6v0d2 -2.4961 1.69E-08 Gm12498 -3.1614 0.021826097 
Pou4f1 -2.5218 0.02169934 Slc4a8 -3.1792 1.42E-07 
Clec4b2 -2.5305 3.70E-12 Mamdc2 -3.2085 0.000129356 
Adgrb1 -2.5647 2.08E-09 Muc13 -3.2241 0.023680887 
Atp6v0c -2.5697 0.015482829 Gm44107 -3.2265 0.000644778 
Gpnmb -2.6210 2.34E-09 Fmn1 -3.2362 0.021198775 
1810006J02Rik -2.6440 6.02E-14 C4b -3.2448 0.024545915 
Hfe -2.6495 1.69E-11 Mgl2 -3.2533 6.20E-18 
Arhgef38 -2.6828 6.83E-10 Cd4 -3.3012 3.68E-10 
Mcpt8 -2.6893 0.04298596 Mgl2 -3.3611 6.24E-19 
Mxi1 -2.7072 0.012569999 Trf -3.4025 1.23E-14 
Col6a3 -2.7131 0.004786272 Pde7b -3.4124 1.09E-09 
Tnfsf13b -2.7235 0.00147448 Gm13391 -3.4381 0.016768979 
Gm33370 -2.7252 1.13E-05 A730036I17Rik -3.5060 1.58E-05 
Rasgef1a -2.7258 0.000227407 Oas1h -3.6116 0.000400577 
Aox1 -2.7266 2.89E-06 Tspan10 -3.6921 0.008045858 
Tuba8 -2.7337 2.11E-14 Ctsg -3.6947 0.000335796 
Igfbp4 -2.7356 5.12E-14 Serpinf1 -3.7255 2.55E-21 
Ccno -2.7372 1.60E-09 Gja5 -3.7456 0.017866928 
4930403O15Rik -2.7463 0.021928008 Trim29 -3.7524 0.011269432 
F3 -2.7495 0.003557965 Sdc1 -3.7871 0.001326144 
Rnf186 -2.7496 0.006912851 Oas1g -3.7985 1.29E-09 
Gstm2 -2.7521 0.00350006 Tmem37 -3.8149 0.00350006 
Far2 -2.7551 0.000327591 Pvrl1 -3.8692 1.46E-06 
Slc26a9 -2.7610 0.01194795 Mtus1 -3.9265 0.000401478 
4933440M02Rik -2.7619 0.0121059 4933415J04Rik -4.0628 2.04E-06 
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Slc32a1 -4.1723 1.88E-22 Dsel -5.1182 2.65E-19 
Enpep -4.1915 0.004273077 Gm14204 -5.2199 3.91E-09 
Nr1i2 -4.2885 0.001624286 Clec11a -5.2832 0.003016624 
5830416I19Rik -4.3164 0.000227407 Grid1 -5.4359 1.23E-18 
Spink2 -4.3694 0.000228138 Cfap57 -5.5802 6.83E-10 
8430423G03Rik -4.3783 0.041665883 Wdr66 -5.7590 0.001997299 
Ces1d -4.4945 1.29E-05 Vmn2r96 -6.1210 1.30E-14 
Ccl9 -4.6210 0.000149592 F7 -6.2165 1.95E-57 
Pcdhb5 -4.8523 0.008227053 BC018473 -6.3030 0.000217409 
Gm26569 -4.9763 5.34E-06 BC018473 -7.7651 5.38E-18 
Colec12 -5.0789 0.015741546 St6galnac1 -8.3590 0.000527932 
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Appendix A 5.3  
Genes differentially expressed between Ezh2+/+ and Ezh2-/- lineage negative murine HSPCs in the 
AML1-ETO9a leukaemias. Significant gene expression results were those with a p-value adjusted for 
multiple hypothesis testing of <0.05 with a log2 fold change of greater or less than 0.5. 
 
 
Gene ID Log 2 Fold 
Change 
Adjusted p-
value 
Gene ID Log 2 Fold 
Change 
Adjusted p-
value 
Retnla 9.6530 1.44E-18 Retnlg 5.0326 1.55E-07 
Fbp1 8.1861 6.59E-12 Strc 4.9783 3.69E-06 
Perp 6.8145 7.72E-10 Bmpr1a 4.9762 0.021598398 
Cygb 6.7721 0.035404506 Pglyrp1 4.9567 2.21E-07 
Ceacam10 6.4928 2.11E-10 Sycp2 4.8865 0.008703859 
BC018473 6.3207 0.011154342 Gm13152 4.8595 0.008801495 
Flt1 6.2741 0.026791608 Spats2 4.8577 4.71E-05 
Csgalnact1 6.0371 6.91E-06 Slco3a1 4.8352 0.000141954 
Nat8l 5.9729 0.023345235 Dmxl2 4.8183 0.00110084 
Slc35d3 5.8415 2.66E-09 C4b 4.8152 1.55E-07 
Stfa2l1 5.8361 0.030335267 Ccnjl 4.8054 6.27E-05 
Gm5483 5.8153 0.032768258 Lcn2 4.7325 8.01E-07 
Trpv3 5.7963 0.000799199 Ptk7 4.7171 0.001259817 
Mmp8 5.6479 4.08E-09 Lrg1 4.6977 8.53E-07 
Glrp1 5.6026 0.021156303 4933431E20Rik 4.6962 0.015731238 
Ighv1-23 5.5947 0.002173496 P2ry2 4.6951 0.012546359 
Crispld2 5.5663 1.30E-08 Tmtc2 4.6434 0.000409001 
Gm2895 5.5628 0.000814866 Lbp 4.6241 2.47E-06 
Chil3 5.5373 6.28E-09 Gpr84 4.6224 0.000523592 
Plcb4 5.5205 1.68E-07 Peli2 4.5327 1.01E-05 
Gm16031 5.5128 1.66E-05 Cxcr2 4.5267 3.08E-06 
Mcam 5.4957 0.000409001 Serpine2 4.5194 6.91E-06 
Hif3a 5.4893 3.67E-08 Prkg1 4.5144 1.30E-05 
Prune2 5.4747 0.000538379 Cd33 4.5132 0.000966345 
Gp1bb 5.3697 1.30E-05 Ctsg 4.5075 2.91E-06 
Mdga1 5.3479 1.62E-07 Bmx 4.5033 0.010339075 
Serpinb10 5.3467 0.011815172 Slco3a1 4.4927 8.40E-06 
AI838599 5.3064 0.000713284 4930438A08Rik 4.4904 5.77E-06 
P3h2 5.2869 4.51E-07 Vegfc 4.4748 0.000131329 
Flt1 5.2794 0.000197457 Amica1 4.4534 0.027996315 
Plekhg1 5.1845 0.031026582 Cd177 4.4457 3.91E-06 
Ms4a3 5.1059 2.93E-06 Gm37297 4.4202 0.000311294 
Dgat2 5.0958 1.55E-07 Fam101b 4.4197 3.91E-06 
Scrg1 5.0916 2.29E-06 Gng11 4.4166 0.001029411 
Mgam 5.0799 4.51E-07 Pi16 4.3868 6.91E-06 
Gm11827 5.0371 0.048643768 Mapk13 4.3865 0.000579374 
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Slco4c1 4.3808 0.016352668 Plekhf1 3.9438 0.003977234 
Slc44a1 4.3706 1.70E-05 Osgin1 3.9418 0.038397449 
Mpo 4.3532 1.30E-05 Lmo1 3.9323 0.000965573 
Gk5 4.3498 0.000505877 Wfdc21 3.9320 6.32E-05 
Il1r2 4.3235 6.84E-06 Clec5a 3.9280 8.84E-05 
Ctla2b 4.2909 0.005502957 Gp6 3.8775 0.026099589 
G0s2 4.2880 0.002281246 Gm26512 3.8741 0.029023903 
Amer2 4.2779 0.001200592 Hk3 3.8695 0.000252546 
Ctbp2 4.2729 0.006939604 C3 3.8365 8.04E-05 
Thbs1 4.2698 0.004389357 Krba1 3.8338 0.001627021 
Orm1 4.2692 0.017656814 Cebpe 3.8303 0.000129641 
Cacnb2 4.2628 0.000804811 Elane 3.8286 8.04E-05 
Fpr2 4.2410 1.30E-05 Mpo 3.8233 0.044634913 
Olr1 4.2299 2.84E-05 Tarm1 3.8203 0.000409001 
Ppp1r3d 4.2186 4.14E-05 Mcemp1 3.8119 0.000125006 
Vnn3 4.2110 0.000995779 Foxd4 3.8089 0.007485866 
Itih5 4.2042 1.37E-05 Prtn3 3.7885 0.000110839 
Dio2 4.1940 4.25E-05 Kcnj2 3.7789 0.00019597 
Akt3 4.1816 0.025193588 Arsb 3.7746 0.000114626 
Zfp800 4.1805 0.01591885 Smoc2 3.7731 0.001696001 
Clec4a2 4.1781 0.037880126 Ngp 3.7428 0.000129641 
Itgb2l 4.1718 8.46E-05 Slfn1 3.7413 0.000409001 
Gcsam 4.1645 0.004210085 Aatk 3.7380 0.031161065 
Fpr1 4.1571 1.52E-05 S100a9 3.7360 0.00012773 
Crtac1 4.1443 0.023230866 Atp11a 3.7226 0.000945457 
Cldn1 4.1359 0.010687937 Dnph1 3.7104 0.003681518 
Gm38001 4.1284 0.021598398 S100a8 3.7100 0.000129005 
Prrt4 4.0996 0.000221127 Wwc2 3.7066 0.000314124 
Gpc1 4.0906 2.10E-05 Ctbp2 3.7028 0.003977234 
Scmh1 4.0810 0.000804811 Capns2 3.6632 0.006264829 
Mtus1 4.0538 0.000162994 Olfml2b 3.6607 0.000286963 
Ccpg1 4.0379 0.02214357 Arhgef28 3.6530 0.03186035 
Mylk 4.0376 5.15E-05 Adgrl4 3.6467 0.000422333 
Adgrb1 4.0340 0.036545179 Mogat2 3.6423 0.001573232 
F5 4.0323 0.001696001 Tgfbr3 3.6333 0.000177671 
Cdc42bpa 4.0219 0.000456102 Pdia5 3.6205 0.003277539 
Rnd1 4.0181 0.000176966 Egln3 3.6179 0.000456102 
Prss16 4.0034 0.000123335 Gm38215 3.6100 0.002008633 
Phactr2 4.0027 0.005144036 Ceacam18 3.6083 0.011720032 
Tacstd2 3.9811 0.01896859 Afap1l1 3.5993 0.000153426 
Cd300lf 3.9797 0.006939604 Dock5 3.5991 0.008505266 
Msrb2 3.9771 0.000286963 Clec12a 3.5975 0.006811352 
A530064D06Rik 3.9693 0.000416172 Cers6 3.5902 0.001256239 
Slc28a3 3.9662 0.007423496 B430306N03Rik 3.5868 0.002761282 
Bst1 3.9622 4.22E-05 Pls1 3.5864 0.005519174 
C1rl 3.9501 0.000109172 Siglece 3.5842 0.000149575 
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Nucb2 3.5603 0.003691292 Anxa1 3.2801 0.000981415 
Abcd2 3.5586 0.000305445 Rab32 3.2728 0.001054663 
Fam217b 3.5447 0.000605649 Gm13375 3.2718 0.025889705 
Ccr1 3.5342 0.000409001 Card9 3.2711 0.003622805 
Sgms2 3.5338 0.00049831 Aph1b 3.2640 0.00182194 
Rhobtb3 3.5324 0.002833777 Ckap4 3.2593 0.002368454 
Ccdc122 3.5296 0.002708803 Arl11 3.2544 0.004229527 
B4galt6 3.5270 0.000505877 Rgcc 3.2483 0.003480985 
Ltf 3.5173 0.000409001 Kctd1 3.2451 0.003640933 
Zfp449 3.5079 0.032352251 Cped1 3.2347 0.005800464 
Fam92a 3.5028 0.008541462 Sep-05 3.2344 0.002362986 
Ric3 3.4940 0.034241133 Gatm 3.2330 0.001128954 
Pira2 3.4848 0.000682284 Gapt 3.2320 0.002637033 
Zfp820 3.4836 0.006861602 Galc 3.2294 0.001744978 
Pram1 3.4828 0.000799199 Gm29125 3.2278 0.020108289 
6330403L08Rik 3.4825 0.017491763 Lpcat2 3.2228 0.001256239 
Atp8b4 3.4781 0.000678839 Plppr3 3.2221 0.002433827 
Afap1 3.4746 0.000523592 Gm26510 3.2143 0.012067299 
Bicd1 3.4591 0.006962375 Actn1 3.2135 0.009854763 
Fgd4 3.4529 0.00110084 Il1b 3.2089 0.047454967 
Agap1 3.4451 0.00161913 Serpina3i 3.1939 0.036725086 
Tnfrsf1a 3.4364 0.000563048 Mctp1 3.1803 0.001706699 
Acpp 3.4323 0.000830293 Bcl6 3.1759 0.039790742 
Il13ra1 3.4308 0.000523592 F730035M05Rik 3.1745 0.043548421 
Panct2 3.4237 0.012454234 Ldhb 3.1685 0.008382869 
Them7 3.4216 0.019695097 Hgf 3.1627 0.03997003 
Hp 3.4177 0.000606731 Sorl1 3.1509 0.001449066 
Neurl1b 3.4160 0.002362986 Tarm1 3.1444 0.017656814 
Tns1 3.4098 0.040503919 Gpr65 3.1329 0.001611033 
Clec5a 3.4076 0.012067299 Laptm4b 3.1315 0.005902668 
Hsd11b1 3.3973 0.003274721 Tlr2 3.1301 0.002637764 
Megf9 3.3916 0.000765291 Cass4 3.1262 0.044634913 
Igsf6 3.3704 0.000713284 Gk5 3.1169 0.033287325 
Cyp4b1 3.3672 0.030082072 Ptprc 3.1129 0.008541462 
Anxa3 3.3590 0.000942723 Fgr 3.0981 0.002250867 
Ndrg1 3.3565 0.000814866 App 3.0920 0.00244345 
Ano10 3.3379 0.000966345 Cebpb 3.0892 0.00411519 
Fcnb 3.3356 0.00110084 Slc35f2 3.0887 0.030410259 
Rhou 3.3320 0.003640933 Neto2 3.0865 0.007134391 
Enah 3.3281 0.016578309 Vwf 3.0835 0.025833008 
Hspa12a 3.3249 0.024307674 Abcc2 3.0807 0.04544032 
Lyz2 3.3249 0.000960005 Hvcn1 3.0792 0.041780018 
Chd7 3.3194 0.00417792 Pla2g7 3.0710 0.001482345 
Hook1 3.3080 0.042300222 F13a1 3.0702 0.004366123 
Ptges 3.3059 0.006962375 Ltbr 3.0653 0.003274721 
Slc2a9 3.2986 0.040141191 Ccdc8 3.0477 0.002761282 
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Ldlrad3 3.0461 0.003622805 Sla 2.8281 0.008580213 
Zik1 3.0454 0.033287325 Sell 2.8233 0.006962375 
Synm 3.0407 0.040815551 Fkbp11 2.8171 0.019725533 
Selp 3.0397 0.015894177 Clec4e 2.8132 0.008433658 
Itm2a 3.0326 0.006962375 E130012A19Rik 2.8124 0.026121203 
Slc25a24 3.0283 0.039189302 Plac8 2.8073 0.017875682 
Nfil3 3.0192 0.005533167 Ctla2a 2.7896 0.004056424 
Lpgat1 3.0189 0.002498172 Eif4e3 2.7831 0.009764698 
Ighv1-5 3.0100 0.018185192 Rxra 2.7761 0.01223428 
Fut4 3.0079 0.005902668 Anxa2 2.7692 0.008540913 
Znrf3 3.0066 0.037157487 Slc23a2 2.7654 0.00754827 
Gm14548 3.0046 0.004229527 Rgs18 2.7382 0.012676074 
Slc36a4 3.0034 0.033533276 Vsir 2.7382 0.012873361 
Gramd2 3.0007 0.046062404 Tlr4 2.7325 0.009243087 
Gbe1 2.9704 0.021728494 Trim30b 2.7322 0.024028463 
Reck 2.9646 0.01358965 Asrgl1 2.7313 0.008433658 
Gca 2.9640 0.006124391 Cybb 2.7311 0.008721279 
Ralb 2.9621 0.00411519 Ccl6 2.7310 0.042102606 
Rasgrf2 2.9474 0.020983308 Apobr 2.7278 0.014997163 
Glrx 2.9454 0.003561523 Lrp5 2.7211 0.011888345 
Gm38146 2.9452 0.045892593 Il6ra 2.7187 0.019725533 
Gm9949 2.9412 0.042102606 Nedd4l 2.7173 0.045086469 
Antxr2 2.9362 0.007637767 Reep3 2.7143 0.009764698 
Slc26a9 2.9357 0.022610022 B3gnt7 2.7073 0.01731534 
Dscam 2.9354 0.010751171 4930539E08Rik 2.6978 0.030697474 
Scel 2.9338 0.025989497 Atp10a 2.6957 0.011575935 
Prrg4 2.9249 0.042709665 Pstpip1 2.6936 0.013946069 
Slc22a21 2.9206 0.043972032 Gstm1 2.6908 0.018430476 
Dhrs7 2.9135 0.006124391 Nid2 2.6827 0.020983308 
Trim30b 2.9134 0.035160413 Ebi3 2.6619 0.020108289 
Mctp2 2.9077 0.018185192 Nadk 2.6611 0.030335267 
Sort1 2.9021 0.040436889 Rap2a 2.6608 0.018185192 
Pak1 2.9006 0.025193588 Scarb2 2.6604 0.010322684 
Adgra3 2.9004 0.037157487 Nfam1 2.6573 0.020134486 
Ltf 2.8941 0.033287325 Emb 2.6489 0.01591885 
1700020L24Rik 2.8810 0.039189302 Clec4d 2.6409 0.01896859 
Svip 2.8804 0.010222274 Slc31a2 2.6371 0.018797177 
Pygl 2.8642 0.007558363 Slc15a3 2.6326 0.011998272 
Treml1 2.8642 0.004542927 1700025G04Rik 2.6208 0.028370788 
Fam134b 2.8599 0.005636077 Gm9733 2.6024 0.033287325 
Sox6 2.8563 0.024601538 Msrb1 2.6002 0.024124491 
Mmp9 2.8538 0.007357828 Arhgef6 2.5995 0.014680924 
Iqgap2 2.8478 0.007619683 Slpi 2.5976 0.015894177 
Chst12 2.8466 0.007651711 Ptafr 2.5976 0.024524194 
Myo5a 2.8440 0.025193588 Fgl2 2.5916 0.012537033 
Tjp2 2.8347 0.00914445 Cd9 2.5899 0.018748591 
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Alcam 2.5867 0.029385461 Sphk1 -2.6058 0.047454967 
As3mt 2.5856 0.031384956 Fgf2 -2.6134 0.025833008 
Ltb4r1 2.5759 0.018430476 Gm16565 -2.6807 0.020987633 
Dhrs9 2.5528 0.037157487 Padi3 -2.6814 0.025833008 
Ifngr1 2.5507 0.017656814 Hdac11 -2.6895 0.033967631 
Arhgap18 2.5456 0.020509598 Gm43429 -2.7102 0.040141191 
Tst 2.5376 0.044634913 G530011O06Rik -2.7236 0.027506243 
Plcg2 2.5360 0.020983308 Slc25a21 -2.7651 0.020983308 
Trem3 2.5186 0.021336137 Mast4 -2.7709 0.03997003 
Gng12 2.5121 0.025368605 F830212C03Rik -2.8080 0.025989497 
Plag1 2.4945 0.028756058 Car1 -2.8263 0.012552935 
Fam114a1 2.4808 0.046228659 Gdpd1 -2.8345 0.022610022 
Trem1 2.4798 0.023856314 Atp2b4 -2.8448 0.006264829 
Fam84b 2.4793 0.044634913 Cnnm1 -2.8679 0.017873672 
Dram1 2.4790 0.029627535 Trbv13-2 -2.8715 0.018455669 
Tyrobp 2.4663 0.028511836 Mid1 -2.9279 0.035181044 
Pik3r5 2.4567 0.026791608 Hkdc1 -2.9379 0.011575935 
Timp2 2.4536 0.039832362 Abcb4 -2.9419 0.043621415 
Arrdc4 2.4493 0.040436889 Gm15726 -2.9923 0.008541462 
Itga5 2.4454 0.040436889 Gm37368 -3.0007 0.009481421 
Tlr13 2.4446 0.025889705 4933401H06Rik -3.0634 0.040436889 
Abtb2 2.4395 0.030335267 Rbm20 -3.0824 0.005260718 
Ncf4 2.4380 0.036876071 Gm21817 -3.0884 0.040794683 
Gda 2.4358 0.020983308 Sowaha -3.0888 0.008967509 
Tlr6 2.4317 0.038891244 Spin4 -3.1353 0.043666066 
Msra 2.4312 0.033287325 Nmnat2 -3.1534 0.004702454 
Tmem55a 2.4105 0.040819144 Crnde -3.2790 0.025540735 
Plxnd1 2.4083 0.039832362 Acp5 -3.4981 0.014635565 
S100a11 2.4079 0.039790742 1700063H04Rik -3.5109 0.002121898 
Hip1 2.3967 0.031557115 Pmfbp1 -3.5572 0.001147118 
Cd52 2.3820 0.024524194 Maob -3.6657 0.000701274 
Itga2b 2.3646 0.022039622 Gm38059 -3.7000 0.020346609 
Entpd1 2.3555 0.044634913 Tspan8 -3.7644 0.013784324 
Qser1 2.3487 0.043365654 Gata3 -3.7965 0.000126706 
Napsa 2.3401 0.036510638 P4htm -3.8678 0.009278296 
Ncoa1 2.3347 0.040815551 Gm10825 -3.9527 0.040436889 
Aldh3b1 2.3343 0.047454967 Slc30a2 -3.9719 0.030697474 
Pik3ip1 2.3021 0.044781897 C1qtnf4 -4.0384 0.00248504 
Ipcef1 2.2913 0.039823027 Sphk1 -4.0883 0.045913063 
Ddx60 2.2735 0.049341605 Gm42784 -4.3317 0.003248461 
Scd1 -2.3459 0.049341605 Zfp185 -4.5258 0.008106877 
Naaladl1 -2.4453 0.045987471 Arhgef25 -4.5347 0.003569835 
Samd11 -2.4876 0.033287325 Fgf2os -4.7687 0.033287325 
Dtx3 -2.5085 0.026717686 Nags -4.7690 2.36E-05 
Fgf10 -2.5171 0.039790742 Stard13 -4.9495 0.00239471 
Il1rl2 -2.5854 0.041139826 Magi1 -5.6302 0.036840441 
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P4ha3 -6.2278 0.007676119 Dbx2 -6.5337 3.06E-10    
Lonrf2 -8.1378 7.72E-10 
 
 
 
 
 
 
 
 
 
 
 
 
